L2

FILE 'HOME' ENTERED AT 07:56:44 ON 18 NOV 1999)

FILE 'REGISTRY' ENTERED AT 07:58:07 ON 18 NOV 1999

E AL-OBEIDI F. C
E SAFAR P
E LEBL M
E OSTREM
E STIERANDOVA
E STROP P
E WALSER A

FILE 'USPATFULL' ENTERED AT 08:06:07 ON 18 NOV 1999

0 S FACATOR (3A) "XA" (3A) INHIBITOR
0 S TRP-CHG-ARG-LEU PRO

FILE 'HOME' ENTERED AT 16:01:32 ON 08 NOW 2002

=> index chemistry pharmacology bioscience patents polymers

FILE 'DRUSMONOG' ACCESS NOT AUTHORIZED

COST IN U.J. DOLLARS

SINCE FILE ENTRY SESSION

FULL ESTIMATED COST

INDEX 'AGRICOLA, ALUMINIUM, ANABSTF, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ... ENTERED AT 16:02:03 ON 08 NOV 2002

108 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

- => s (Xa (s)(inhibitor or inhibition)) and peptide and arginine
  - FILE AGRICULA
  - FILE BABS
  - FILE BIOTECHNO \_4
  - 1 FILE CABA
  - 37 FILE CAPLUS
  - 1 FILE CEN
  - 0\* FILE FEDRIP
  - 26 FILES SEAPCHED...
    - 1 FILE INVESTEXT
    - FILE JICST-EPLUS

    - FILE PASCAL
    - FILE PROMT
    - FILE SCISEARCH
      - FILE ADISALERTS
  - 46 FILES SEAFCHED...
    - 0 FILE BIOBUSINESS
    - FILE BIOSIS
    - FILE CANCERLIT
    - FILE DDFU
    - 20 FILE DRUGU
  - 61 FILES SEAFCHED...
    - 35 FILE EMBASE
    - FILE ESBIORASE
      - FILE IFIPAT
    - FILE LIFESCI -1
    - 29 FILE MEDLINE
    - FILE PHIN 1
    - FILE SYNTHLINE l
    - FILE TOXCENTER
    - 614 FILE USPATFULL
    - FILE USPAT2 1.4
      - FILE AQUASCI
      - FILE BIOTECHABS
        - FILE BIOTECHDS
  - 79 FILES SEAPCHED...
    - 1 FILE VETU
    - FILE WPIDS
      - FILE WPINDEK
    - # FILE CASREAGT
  - 93 FILE: SEARCHED...
    - -9 FILE EUROPATFULL
    - 3.7 FILE POTFULL
  - 36 Files have one or more Answers, 109 Files searched in Sthindex
- QUE (MA 'S)/INHIBITOR OF INHIBITION) AND PETTIDE AND AFGININE

=> file hits COST IN U.S. IDLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 4.24 4.45

FILE 'USPATFULL' ENTERED AT 16:06:37 ON 08 NUM 1000 DA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMIDAL SOCIETY (ACS)

FILE 'POTFULL' ENTERED AT 16:06:27 ON 08 NOV 2002 COPYRIGHT (C) 2002 Univentie

FILE 'EUROPATFULL' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYPIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'CAPLUS' ENTERED AT 16:06:37 ON 08 NOV 0000 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 0000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:06:37 ON 08 NOV 2002

FILE 'EMBASE' ENTERED AT 16:06:37 ON 09 NOV 0000 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:06:37 ON 08 NOV 00000 COPYPIGHT (C) 0000 Institute for Scientific Information (ISI) (R)

FILE 'BIOSIS' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'DRUGU' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 NeV 2002 COPYFIGHT (3) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'USPAT2' ENTEFED AT 16:06:37 ON 08 NOV 0000 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'FASCAL' ENTEPED AT 16:06:37 ON 08 NOV 2002 Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYFIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 16:06:37 ON 08 NOV 0000 COPYFIGHT (C) 0000 ACS

FILE 'ESBIOBASE' ENTERED AT 16:06:37 ON DR NOV 2002 COPYFIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DDFU' ADDESS NOT AUTHORIZED

FILE 'IFIPAT' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYFIGHT (C) 2002 IFI CLAIMS(R) Fatient Services (IFI)

FILE 'WPIDS' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (6) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACRESS NOT AUTHORIZED

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 09 NOV 1962 COPYRIGHT 10, 2002 Cambridge Scientific Abstracts (CSA) FILE 'BABS' ENTEPED AT 16:06:37 CN 08 NOV 2002 COPYRIGHT 5: 2012 Beilstein-Institut zur Flerderung der Chemischen Wissenschaften libersed to Beilstein Chemiedaten & Zoftware GmbH and MDL Information Systems GmbH

FILE 'JICST-EPLUS' ENTERED AT 18:06:37 DN 06 NOV 2002 COPYFIGHT (C) U002 Japan Science and Technology Componation (UST)

FILE 'CANCERLIT' ENTERED AT 16:08:37 ON 08 NOV 106.

FILE 'BIOBUSINESS' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYFIGHT (2) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'CASREACT' ENTERED AT 16:06:37 ON 08 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 MOV 2002

FILE 'CABA' ENTERED AT 16:06:37 DN 08 NOV 2002 COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CEN' ENTERED AT 16:06:37 ON 03 NOV 2002 COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'INVESTEXT' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'PROMT' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 Gale Group, All rights reserved.

FILE 'ADISALERTS' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYFIGHT (3) 2003 Adis International Ltd. (ADI3)

FILE 'PHIN' ENTERED AT 16:06:37 ON 06 MOV 2002 COPYRIGHT (C' 2002 PJB Publications Ltd. (PJB.

FILE 'SYNTHLINE' ENTEPED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 Prous Science

FILE 'AQUASCI' ENTERED AT 16:06:37 ON 08 NOV 2002 (c) 2002 FAO (on behalf of the ASFA Advisory Board: All rights reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:06:37 CM 08 NOV 2002 COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'VETU' ENTERED AT 16:06:37 ON 08 NOV 2002 COPYRIGHT (C) 2002 THOMSON DERWENT

= s 11 614 FILE USPATFULL 367 FILE POTFULL L3 L480 FILE EUPCPATFULL 37 FILE CAPLUS L539 FILE MEDLINE Lő 17 25 FILE EMBASE 13 23 FILE SCISEARCH 21 FILE BIGSIS 19 20 FILE DRUGU 119 Lii 14 FILE BISTECHNO 14 FILE USPAT2 9 FILE PASCAL 113 9 FILE TOXIENTER 114

```
7 FILE ESBIOBASE
116
             5 FILE IFIFAT
1.7
             5 FILE WPIDS
118
             4 FILE LIFESCI
119
              3 FILE BABA
              3 FILE JICST-EPLUS
L.. )
              3 FILE CAMCERLIT
Ţ...
              1 FILE BIOBUSINESS
T ...
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OFERATOR ASSUMED 'XA (S) (INHIBITOR'
Lis
             2 FILE CASREAGT
<u>5. i</u>
             I FILE AGFICULA
100
             1 FILE DABA
LJ \circ
             1 FILE CEN
L27
             1 FILE INVESTEXT
L23
             1 FILE PROMT
L3.4
             1 FILE ADISALERTS
L_{3,1}
             1 FILE PHIN
L : :
             1 FILE SYNTHLINE
L30
             -1 FILE AQUASCI
L33
             I FILE BIOTECHOS
L34
             1 FILE VETU
TOTAL FOR ALL FILES
L35
          1306 L1
= s 135 and (selectivity or specificity) and analogue#
             98 FILE USPATFULL
L36
L37
            81 FILE PCTFULL
L33
            17 FILE EUROPATFULL
L3^{\circ 4}
             0 FILE CAPLUS
L40
             1 FILE MEDLINE
L4L
             1 FILE EMBASE
             2 FILE SCISEARCH
L42
             2 FILE BIOSIS
L43
             0 FILE DRUGU
L44
             0 FILE BIOTECHNO
L45
L4.6
             1 FILE USFATE
L47
             1 FILE PASCAL
L48
             0 FILE TOXOENTER
L49
             1 FILE ESBIOBASE
L50
             0 FILE IFIEAT
L \cap L
             0 FILE WPIDS
             1 FILE LIFESCI
L52
L^{5/3}
            0 FILE BABS
L5-4
             0 FILE JICST-EPLUS
            0 FILE CANCERLIT
L \subseteq \mathbb{S}
             0 FILE BIOBUSINESS
L^{(j,j)}
            O FILE CASREACT
L5.7
L^{z, z}
             0 FILE AGRICOLA
L^{\epsilon, \beta}
             0 FILE CABA
             0 FILE CEN
\mathbf{L}_{\mathbf{U}^{(1)}}
             0 FILE INVESTEXT
Lr 1
L60
             O FILE PROMT
L \odot 3
              1 FILE ADISALERTS
1,64
              FILE PHIN
<u>_</u>....
              D FILE SYNTHLINE
1. 4
              3 FILE AQUASCI
1.7
              0 FILE BIOTECHOS
L. 8
              0 FILE VETU
TOTAL FOR ALL FILES
1-9
          207 L35 AND 'SELECTIVITY OR SPECIFICITY, AND ANALOGUE#
```

=> s 169 factor 'w. Ma

MISSING OPERATOR '169 FACTOR' The search profile that was entered contains terms or nested terms that are not separated by a logical operator. => s L69 and !factor (w Ka L70 96 FILE USPATFULL 171 71 FILE POTFULL 172 17 FILE EURSPATFULL E FILE CAFLYS 173 1 FILE MEDLINE L74 1 FILE EMBASE L75 2 FILE SCISEARCH L7.5 2 FILE BIDSIS L77 0 FILE DRUGU L73 L7 + C FILE BIOTECHNO L80 1 FILE USPAT2 1 FILE PASCAL L81 L82 0 FILE TOXCENTER L83 - 1 FILE ESBIOBASE L84 0 FILE IFIPAT L85 0 FILE WRIDS L36! FILE LIFESCI L37 0 FILE BABS L33 0 FILE JIOST-EPLUS L39 0 FILE CANCERLIT  $L^{00}$ 0 FILE BIOBUSINESS L910 FILE CASREACT 0 FILE AGRICOLA 193L93 0 FILE CABA 0 FILE CEN L940 FILE INVESTEMT L95 L960 FILE PROMT 1 FILE ADISALERTS L97 L98 0 FILE PHIN L99 0 FILE SYNTHLINE L1000 FILE AQUASCI L101 0 FILE BIDTECHUS L1020 FILE VETU TOTAL FOR ALL FILES L103 195 L69 AND (FACTOR (W) KA) => dup rem 1103 DUPLICATE IS NOT AVAILABLE IN 'INVESTEXT, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE PROCESSING COMPLETED FOR L103 189 DUP REM L103 (6 DUPLICATES REMOVED) L104 = d 1104 1-189 ibib abs L104 ANSWER 1 OF 189 USPATFULL 2001:272801 USPATFULL ACCESSION NUMBER: Commositions and methods for the therapy and diagnosis TITLE: of dolon dancer Stolk, John A., Bothell, WA, UNITED STATES INVENTOR(S): Mu, Jiangchun, Bellevue, WA, UNITED STATES Chenault, Fith A., Seattle, WA, UNITED STATES Meagher, Madeleine Joy, Seattle, WA, UNITED STATES Jorixa Corporation, Seattle, WA, UNITED STATES, 98184 PATENT ASSIGNEE(S): 'U. .. corporation)

	NUMBER	KIND	PATE	
PATENT INFORMATION:	WS 1002150922	Al	20021017	
APPLICATION INFO.:	US 2001-998598	Al	20011116	14;

NUMBER DATE 
 US 0001-304037P
 20010710 (80)

 US 1001-279670P
 20010328 (80)

 US 1001-267011P
 20010306 (80)

 US 000-252022P
 20001120 (80)
 PRIGRITY INFORMATION: Ttility DOGUMENT TYPE: APPLICATION FILE SEGMENT: LEGAL REPRESENTATIVE: SEED INTELLECTUAL FROMERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 93194-7092

NUMBER OF CLAIMS: EXEMPLARY CLAIM: LINE COUNT: 9233

 Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more color tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells empressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L104 ANSWER 2 OF 189 USPATFULL

ACCESSION NUMBER: 2000:272761 USPATFULL

TITLE:

INVENTOR(S):

Directed evolution of novel binding proteins Ladner, Robert Charles, Ijamsville, MD, UNITED STATES Guterman, Sonia Rosow, Belmont, MA, UNITED STATES Roberts, Bruce Lindsay, Milford, MA, UNITED STATES Markland, William, Milford, MA, UNITED STATES Ley, Arthur Charles, Newton, MA, UNITED STATES Kent, Rachel Baribault, Boxborough, MA, UNITED STATES

KIND DATE NUMBER ......

PATENT INFOFMATION: APPLICATION INFO .: RELATED APPLN. INFO .: US 2002150981 Al 20021017 US 2001-781933 Al 20010214 (9) Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED Continuation

of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED Division of Ser. No. US 1991-564989, filed on 1 Mar 1991, PATENTED Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED

Continuation-in-part of Ser. No. US 1988-240160, filed

on 3 Sep 1988, ABANDONED

NUMBER DATE \_\_\_\_\_

PRIORITY INFORMATION: WO 1989-U83731 19890301

DOCUMENT TYPE: Utility File SEGMENT: APPLICAT FILE SEGMENT:

AFFLICATION

LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W.,

Washington, DC, 20001

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 16 Drawing Page(s) LINE COUNT: 18646

CAS INDEMING IS AVAILABLE FOR THIS PATERIT.

AB In order to obtain a novel binding protein against a chosen target, DMA molecules, each emording a protein comprising one of a family of similar potential kinding domains and a structural signal calling for the hisplay of the protein on the outer surface of a chosen hacterial cell, bacterial spore or phage genetic package, are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The bells or viruses rearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of ottential binding domains is related to be parameteric trypsin inhibitor, the genetic package is MIR phage, and the protein includes the cuter surface transport signal of the MIR gene III brotein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 3 OF 189 USFATFULL

ACCESSION NUMBER: 2000:243051 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis

of ovarian cancer

INVENTOE(3): Algate, Paul A., Issaguah, WA, UNITED STATES

Tones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corina Corporation, Seattle, WA, UNITED STATES, 98104

(U.S. corporation)

NUMBER DATE

PRIORITY INFORMATION: US 2000-207484P 20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REFFESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVE, SUITE 6300, SEATTLE, WA, 99104-7092

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian bander, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleatides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 4 OF 189 USPATFULL

ACCESSION NUMBER: 2002:242791 USPATFULL

TITLE: Commositions and methods for the therapy and diagnosis

of solen sancer

INVENTOR(S): Fing, Gordon E., Shoreline, WA, UNITED STATES

Meather, Madeleine Joy, Seattle, WA, UNITED STATES

Mu, Jiangthum, Bellevue, WA, UNITED STATES Jecrist, Heather, Seattle, WA, UNITED STATES

PATENT ASSIGNEE'S): Cirixa Corporation, Seattle, WA, UNITED STATES (U.S.

ocrporation)

NUMBER KIND BATE

PATENT INFORMATION: US 2002131971 A1 20020919 APPLICATION INFO.: US 2001-32529 A1 20011226 110

RELATED APPLM. INFO.: Dontinuation-in-part of Ger. No. US 2001-920300, filed

on 31 Jul 2001, PENDING

NUMBER DATE 

PRIDRETY INFORMATION:

 US 1001-302051P
 20010029 (60)

 US 1001-279763P
 20010328 (60)

 US 2000-223283P
 20000033 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION:
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AME, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: NUMBER DE DELITE
EXEMPLARY CLAIM: 1 9083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells empressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 5 OF 139 USPATFULL

ACCESSION NUMBER: 2002:221957 USPATFULL

Use of dendroaspin as a scaffold for non-dendroaspin TITLE:

domains

INVENTOR(S): Lu, Kinjie, London, UNITED KINGDOM

Kakkar, Vijay Vir, Landon, UNITED KINGDOM

NUMBER KIND DATE PATENT INFORMATION: US 2002120102 A1 20020829 APPLICATION INFO.: US 2001-773054 A1 20010205 (9) APPLICATION INFO .:

DATE NUMBER ---------

PRIORITY INFORMATION: GB 0000-2625 20000005 PRIORITY INFORMATION:

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL PEPRESENTATIVE:

FUEHR HOHBACH TEST ALBRITTON & HERBERT LLP, Suite 3400,
Four Embardadero Center, San Francisco, CA, 94111-4187

NUMBER OF CLAIMS:

56

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF PRAWINGS: 1 Drawing Page(s) LINE COUNT: 1277

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The use of dendroasp:n as a scaffold for one or more non-wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-hinding amino acid sequence other than RGD which contains

aspartic acid 'D) or glutamic acid (E).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 6 OF 189 USPATFULL

ACCESSION NUMBER: 2002:221018 USPATFULL

TITLE: Antibody conjugate formulations for selectively inhibiting VEGF

Thorne, Philip E., Pallas, TM, UNITED STATES INVENTORIS : Brekken, Rolf A., Seattle, WA, UNITED STATES

Board of Regents, The University of Texas System 'U.S. PATENT ASSIGNEE'S :

corporation)

NUMBER. KIND DATE \_\_\_\_\_\_

US . (0.119153 A1 .00020829 US . (0.-998831 A1 .00011130 (9) PATENT INFORMATION: APPLICATION INFO.:

RELATED AFFLM. INFO.: Continuation of Ser. No. US 2000-561109, filed on 28

Apr 2000, PATENTED

NUMBER DATE \_\_\_().\_().\_\_

PRIORITY INFORMATION: US 1999-131432P 19990428 (60)

PRIORITY INTEGRAL.

DOCUMENT TYPE: Utility

APPLICATION

LEGAL REPRESENTATIVE: Shelley P.M. Fussey, WILLIAMS, MORGAN & AMERSON, P.C., Suite 250, 7676 Hillmont, Houston, TX, 77040 NUMBER IF CLAIMS: 47

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 4 Drawing Page(s) LINE COUNT: 10502

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 7 OF 139 USPATFULL

2001:201009 USPATFULL ACCESSION NUMBER:

Methods and compositions for treating platelet-related TITLE:

disorders using MPL pathway inhibitory agents

Hanson, Stephen R., Stone Mountain, GA, UNITED STATES INVENTOR(S):

KIND DATE NUMBER: \_\_\_\_\_\_ PATENT INFORMATION: US 0000119144 A1 20020829 APPLICATION INFO.: US 0000-117837 A1 00020408 (10)

RELATED APPLN. INFD.: Division of Ser. No. US 2000-666224, filed on 21 Sep

2000, GRANTED, Pat. No. US 6376242

NUMBER DATE \_\_\_\_\_

PRIORITY INFORMATION: US 1999-154929P 19990921 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Maria A. Trevisan, Wolf, Greenfield & Sacks, F.C.,

Federal Reserve Plaza, 600 Atlantic Avenue, Bistin, MA,

02210

NUMBER OF CLAIMS: -5-5 EXEMPLARY CLAIM: LINE COUNT: 262

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embalism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations

comprising such agents are provided.

CAS INCEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 8 OF 189 USPATFULL

ACCESSIC: NUMBER: 200.:206239 USPATFULL

TITLE: Arrays of proteins and methods of use thereof Wagner, Peter, Belmont, CA, UNITED STATES INVENTOR S.:

Ault-Riche, Iana, Palo Alto, CA, UNITED STATES Nock, Steffen, Redwood City, CA, UNITED STATES Itin, Christian, Menlo Park, CA, UNITED STATES

NUMBER KIND DATE NUMBEF.

PATENT INFORMATION: US 0000110933 Al 20020815
APPLICATION INFO.: US 0000-113964 Al 20020329 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-353215, filed on 14

Tal 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-115455, filed in 14 Jul 1998, GRANTED, Pat. No. US

6406921

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: 2yomym, 36101 Research Road, Hayward, CA, 94545

33 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 2275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Protein arrays for the parallel, in vitro screening of biomolecular activity are provided. Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different proteins, such as different members of a single protein family, are immobilized on one or more organic thinfims on the substrate surface. The protein arrays are particularly useful in drug development, proteomics, and clinical diagnostics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 9 OF 139 USPATFULL

ACCESSION NUMBER: 0000:185871 USEATFULL Pharmaceutical combinations TITLE:

INVENTOR(3): Brearley, Christopher John, Sandwich, UNITED KINGDOM

Butler, Paul, Sandwich, UNITED KINGDOM

Chahwala, Suresh Babubhai, Sandwich, UNITED KINGDOM

Chopp, Michael, Sandwich, UNITED KINGDOM Krams, Michael, Sandwich, UNITED KINGDOM Looby, Muchael, Sandwich, UNITED KINGDOM MacIntyre, Fiona, Sandwich, UNITED KINGDOM McElroy, Andrew Brian, Sandwich, UNITED KINGDOM McHarg, Aileen Dorothy, Sandwich, UNITED KINGDOM

	NUMBER	HIND	DATE	
PATENT INFORMATION:	U3 200.10481 <b>7</b> 9	AI	30020725	
APPLICATION INFO.:	US 2001-969271	A1	.:0011001	(3)

		NUMBEE.	DATE	
		· - ·		
PRIORITY	INFORMATION:	GB 11000-116 <b>47</b> 3	20001017	
		ms 2010-253847P	20001129	(60)
DO-CUMENT	TYPE:	Thility		

APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: Paul H. Ginskurg, Pfizer Inc., 20th Floor, 235 East

42nd Street, New York, MY, 10017-5705

NUMBER OF CLAIMS: 4.9 EMEMPLARY CLAIM:

NUMBER OF DRAWINGS: 9 Drawing Page's LINE COUNT: 9339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates, inter alia, to methods of treating

patnophysiological conditions involving neutrophils, comprising administering to a patient in need of such treatment a combination therapy comprisin: at least one Meutrophil Inhibitory Factor (MIF) and at least one other agent that protects neurons from toxic insult, innibits the inflammatory reaction after brain damage or promotes

perebral reperfusion (i.e. neuroprotective or thrombolytic/fibrinolytic agents), or a pharmareutically appentable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 10 OF 189 USPATFULL

ACCESSION NUMBER: 0000:171946 USEATFULL

Kunitz-type protease inhibitor polynucleotides, TITLE:

polypeptides, and antibodies

Ruben, Steven M., Olney, MD, UNITED STATES INVENTOR(S::

Mi, Juan, Germantown, MD, UNITED STATES

NUMBER KIND DATE 

PATENT INFORMATION: US 2002090695 Al 20020711 APPLICATION INFO.: US 2001-958718 Al 20010517 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2000-US31917, filed

on 21 Nov 2000, UNKNOWN

NUMBER DATE .\_\_\_\_

PRIORITY INFORMATION: US 1999-166751P 19991122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

DEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC. 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 32 EXEMPLARY CLAIM: 1 LINE COUNT: 12006

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to novel human KTPI polypeptides and isolated nucleic acids containing the coding regions of the genes

entoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KTPI

polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related

to these novel human KTPI polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 11 OF 189 USPATFULL

2002:37526 USPATFULL ACCESSION NUMBER:

TITLE: Profiling of protease specificity using

combinatorial fluorogenia substrate libraries INVENTOR(3):

Harris, Jennifer L., San Diego, CA, UNITED STATES Backes, Bradley J., San Diego, CA, UNITED STATES Ellman, Jonathan A., Cakland, CA, UNITED STATES Oralk, Charles S., San Francisco, CA, UNITED STATES

NUMBER KIND DATE PATENT INFORMATION: MS 2002023343 A1 20020221 APPLICATION INFO.: MS 2001-866132 A1 20010525 9.

NUMBER DATE

PRIORITY INFORMATION: US 2000-209274P 20000602 (60)

rtility LOCUMENT TYPE:

APPLICÂTION FILE SEGMENT:

LEGAL REPRESENTATIVE: TIWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER,

EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIM: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
TIME COUNT: 2990
TIME FOR THIS PATENT NUMBER OF CLAIMS:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A method is presented for the preparation and use of fluorogenic peptide substrates that allows for the configuration of general substrate libraries to rapidly identify the primary and extended specificity of enzymes, such as proteases. The substrates contain a fluorogenic-leaving group, such as 7-amino-4-carbamoylmethylcommarin (ACC). Substrates incorporating the ACC leaving group show comparable kinetic profiles as those with the traditionally used 7-amino-4-methyl-boumarin (AMC) leaving group. The bifunctional nature of ACC allows for the efficient production of single substrates and  $% \left( 1\right) =\left( 1\right) +\left( 1\right) =\left( 1\right) =\left( 1\right) +\left( 1\right) =\left( 1\right)$ substrate libraries using solid-phase synthesis techniques. The approximately 3-fold increased quantum yield of ACC over AMC permits reduction in enzyme and substrate concentrations. As a consequence, a greater number of substrates can be tolerated in a single assay, thus enabling an increase in the diversity space of the library. Soluble positional protease substrate libraries of 137,180 and 6,859 members, possessing amino acid diversity at the P4-P3-P2-P1 and P4-P3-P2 positions, respectively, were constructed. Employing this screening method the substrate specificities of a diverse array of proteases were profiled, including the serine proteases thrombin, plasmin, factor Xa, uFA, tPA, granzyme B, trypsin, chymotrypsin, human neutrophil elastase, and the cysteine proteases papain and cruzain. The resulting profiles create a pharmacophoric portrayal of the proteases allowing for the design of selective substrates and potent inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 12 OF 189 USEATFULL

ACCESSION NUMBER: 2002:32572 USPATFULL

TITLE: Bicyclic sulfanyl amino inhibitors of

factor Xa

INVENTOR(S): Li, Wenhao, South San Francisco, CA, UNITED STATES

> Marlowe, Charles K., Redwood City, CA, UNITED STATES Scarbbrough, Robert M., Half Moon Bay, CA, UNITED

STATES

NUMBER KIND DATE .\_\_\_\_\_ PATENT INFORMATION: US 2002019394 A1 20020214 APPLICATION INFO.: US 2001-816781 A1 20010326 (9)

> NUMBEF: DATE

PRIGRITY INFORMATION: US 2000-191715P 20000324 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REFRESENTATIVE: MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON,

DC, 20036-5869

NUMBER OF CLAIMS: EKEMPLARY CLAIM: LINE COUNT: 151 "

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of formulae I or Ia: ##STR1##

including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The commounds and compositions are useful in vitro or in vive for preventing or treating conditions in mammals characterized by undesired thrombosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 13 OF 189 USPATFULL

ACCESSION NUMBER: 1000:290738 USPATFULL

TITLE: Arrays of proteins and methods of use thereof Wagner, Peter, Belmont, CA, United States INVENTOR(S :

Ault-Riche, Dana, Palo Alto, CA, United States Mock, Steffen, Redwood City, CA, United States Itin, Christian, Menlo Park, CA, United States

Dyomyx, Incorporated, Hayward, CA, United States (U.S. PATENT ASSIGNEE(S):

derperation)

NUMBER KIND DATE

PATENT INFORMATION: US 6475808 B1 20021105
APPLICATION: INFO.: US 1999-358215 19990714 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-115455, filed

on 14 Jul 1998

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chin, Christopher L.

LEGAL REPRESENTATIVE: Hager, Alicia J., Heinkel, Gregory L. NUMBER OF CLAIMS: 3

NUMBER OF CLAIMS: EKEMPLARY TLAIM:

NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s) LINE COUNT: 0339

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

Protein arrays for the parallel, in vitro screening of bicmolecular activity are provided. Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different proteins, such as different members of a single protein family, are immobilized on one or more organic thinfilms on the substrate surface. The protein arrays are particularly useful in drug development, proteomics, and clinical diagnostics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 14 OF 189 USPATFULL

ACCESSION NUMBEF: 2002:283394 USPATFULL

N-granidinoalkylamides, their preparation, their use, TITLE:

and pharmaceutical preparations comprising them

Klingler, Otmar, Rodgau, GERMANY, FEDERAL REPUBLIC OF INVENTOR(3:: Toller, Gerhard, Schoneck, GEFMANY, FEDEFAL REPUBLIC OF

Defossa, Elisabeth, Idstein, GERMANY, FEDERAL REPUBLIC

Al-Obeidi, Fahad A., Tucson, AZ, United States

Walser, Armin, Tucson, A2, United States Ostrem, James, Tucson, A3, United States Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY,

PATENT ASSIGNEE(S):

FEDERAL REPUBLIC OF 'non-U.S. corporation,

KIND DATE NUMBER PATENT INFORMATION: 18 6472562 B1 20021029 APPLICATION INFO.: US 2000-697188 20061027 20001027 19.

NUMBER DATE

PRIORITY INFORMATION: EP 1999-121623 19991030

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kumar, Shailencra

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Bunner, L.L.P.

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 0 Drawing Figure s.; 0 Drawing Page s LIME COUNT: 2136

The present invention relates to compounds of the formula I, ##STRl##

in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable

tharmappliqueally active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.

They are reversible inhibitors of the blood clotting enzymes

factor Xa and/or factor VIIa and can in general be

applied in conditions in which an undesired activity of factor

Xa and/or factor VIIa is present or for the cure or prevention

of conditions in which an inhibition of factor

xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

L104 ANSWER 15 OF 189 USPATFULL

ACCESSION NUMBER: 2002:167884 USPATFULL

Antibody conjugate kits for selectively inhibiting VEGF TITLE:

Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
Board of Regents, The University of Texax System, INVENTOR(3):

PATENT ASSIGNEE(S):

Austin, TX, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6416758 B1 20020709 APPLICATION INFO.: US 2000-561526 20000428 (9)

NUMBER DATE \_\_\_\_\_\_\_

PRIORITY INFORMATION: US 19994131432P 19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong

LEGAL REFRESENTATIVE: Williams, Morgan and Amerson NUMBER OF CLAIMS: 50

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s) LINE COUNT: 10439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFEL) of the two VEGF receptors. The antibodies effectively

inhibit andiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus

provides new antibody-based compositions, methods and combined protocols

for treating cancer and other angiogenic diseases. Advantageous

immunoconjugate and predrug compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 16 OF 199 USPATFULL

ACCESSION NUMBER: 2002:144299 USPATFULL

Conjugates of dithiocarbamates with pharmacologically TITLE:

active agents and uses therefor

Lai, Thing-Pan, Encinitas, CA, United States Wang, Tingmin, San Marcos, CA, United States INVENTOR S::

Medinox, Inc., San Diego, CA, United States (U.S. PATENT ASSIGNEE'S :

corporation.

NUMBER KIND DATE ------

PATENT INFORMATION: US 6400131 B1 20020618
APPLICATION INFO:: US 1999-453608 19991203 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1998-US10295, filed

on 19 May 1998 Continuation of Ser. No. US 1997-869158,

filed on 4 Jun 1997, now patented, Pat. No. US 5916910

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davemport, Avis M.

LEGAL REPRESENTATIVE: Reiter, Stephen E., Foley & Lardner NUMBER OF CLAIMS: 21

EMEMPLARY CLAIM:

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s) LINE COUNT: 5.157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric exide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 17 OF 189 USPATFULL

ACCESSION NUMBER: 2002:143940 USPATFULL

TITLE: Cancer treatment methods using antibodies to

aminophospholipids

Thorpe, Philip E., Dallas, TX, United States INVENTOF(S):

Pan, Sophia, Dallas, TX, United States

PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,

Austin, TX, United States (U.S. corporation)

NUMBER KIND DATE \_\_\_\_\_\_ US 6406693 B1 20020618 US 1999-351543 19990712 PATENT INFORMATION: APPLICATION INFO .: 19990712 (9)

NUMBER DATE ------

PRIORITY INFORMATION: US 1998-110608P 19981202 (60) US 1998-92672P 19980713 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GANTED
PRIMARY EMAMINER: Bansal, Geetha P.

LEGAL REPRESENTATIVE: Williams, Morgan and Amerson

NUMBER OF CLAIMS: . 9

EMEMPLARY CLAIM:

NUMBER OF DRAWINGS: Figure 5.; 3 Drawing Page 5.

LIME COUNT:

CAS IMPEXING IS AVAILABLE FOR THIS PATEMET.

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserin- and phosphatidylethanolamine, are stable and specific markers appressible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antipody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholip.d antibody-kased methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antiropy conjugates and combinations are thus provided, the use of maked, or unconjugated, anti-phosphatiqylserine antibodies is a particularly important aspect of

the invention, due to simplicity and effectiveness of the approach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 13 OF 189 USPATFULL

Methods and compositions for treating platelet-related TITLE:

disorders using MPL pathway inhibitory agents

Hanson, Stephen R., Stone Mountain, GA, United States INVENTOR (3):

PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S.

corporation)

NUMBER KIND DATE PATENT IMPORMATION: US 6376242 B1 20020423 APPLICATION INFO:: US 2000-666224 20000921 20000921 (9)

NUMBER DATE 

PRIORITY INFORMATION: US 1999-154929P 19990921 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Davis, Ruth A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 47

NUMBER OF CLAIMS: 1 EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s) LINE COUNT: 0699

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 19 OF 189 USPATEULL

ACCESSION NUMBER: 2000:91487 USPATFULL

.beta.-sheet mimetics and methods relating to the use TITLE:

thereof

Qabar, Maher N., Redmond, WA, United States INVENTOR(S):

> McMillan, Michael K., Bellevue, WA, United States Hahm, Michael S., Kirkland, WA, United States Tulinsky, John E., Seattle, WA, United States Ogb., Cyprian O., Bellevie, WA, United States Mathew, Jessymol, Bellevie, WA, United States

PATENT AUSIGNEE G.: Mol-cumetics Ltd., Bellevue, WA, United States 'U.S.

corporation/

PATENT INFORMATION:

US 6372744 B1 20020416 US 0100-501052 20000209 197 Division of Ser. No. US 1999-12834, filed on 12 Feb APPLICATION INFO.:

RELATED APPLN. IMFO.:

1993, now patented, Pat. No. US 6117896

Continuation-in-part of Ser. No. US 1997-797915, filed on all Neb 1997, how abandoned Continuation-in-part of

Ser. No. US 692420, now abandoned

NUMBER DATE

US 1997-47067P 19970519 160) PRIDRITY INFORMATION:

DOCUMENT TYPE: Utility

DOCUMENT ATEL.

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Higel, Floyd D.

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC

TOTAL OF CLAIMS: 73

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 4223

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta. sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein bunding interaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 20 OF 189 USEATFULL

ACCESSION NUMBER: 2000:19060 USPATFULL

Antibody conjugate compositions for selectively TITLE:

inhibiting VEGF

Thorpe, Philip E., Dallas, TX, United States INVENTOR(3):

Brekken, Rolf A., Seattle, WA, United States Board of Regents, The University of Texas System,

PATENT ASSIGNEE(S):

Austin, TX, United States (U.S. corporation)

KIND DATE NUMBER -------

PATENT INFORMATION: US 6342221 B1 20020129 US 2000-561108 20000428 20000428 (9) APPLICATION INFO.:

NUMBER DATE 

PRIORITY INFORMATION: US 1999-131432P 19990428 (60)

PRIORITY INFORMATION: Us isseribility
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Hughh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amersin
NUMBER OF CLAIMS: 63

EKEMPLARY CLAIM:

NUMBER OF DEAWINGS: 7 Drawing Figure's); 4 Drawing Page(s) LINE COUNT: 104.42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous

immuniconjugate and progrug compositions and methods using the new VESF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 AMBWER 21 OF 189 UNFATFULL

ACCESSION NUMBER: 1002:19058 USPATFULL

TITLE: Antibody compositions for selectively inhibiting VEGF

INVENTOR.3.: Thorpe, Philip E., Dallas, TX, United States

Brekken, Folf A., Seattle, WA, United States Board of Regents, The University of Texas System,

PATENT ASSIGNEE(S): Austin, TX, United States (U.S. corporation)

KIND DATE NUMBER 

PATENT INFORMATION: US 6342219 B1 20020129 APPLICATION INFO:: US 2000-561500 20000428 20000428 (9)

NUMBER DATE -----

PRIORITY INFORMATION: US 1999-131432P 19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 20

NUMBER OF DEAWINGS: 7 Draw LINE COUNT: 10403 7 Drawing Figure(s); 4 Drawing Page(s)

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhabit anglogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGE-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 22 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: .:002077267 PCTFULL ED 20021011 EW 200240

NUCLEIC ACID MOLECULES ENCODING A TRANSMEMBRAN SERINE TITLE (ENGLISH):

PASTEASE 9, THE ENCODED POLYPEPTIDES AND METHODS BASED

THEREON

MOLECULES D'ACIDE NUCLEIQUE CODANT UNE SERINE PROTEASE TITLE (FRENCH):

TRANSMEMBRANAIRE 9, POLYPEPTIDES CODES ET PROCEDES

FONDES SUR GES DERNIERS

MADISON, Edwin, L.; ONG, Edgar, O. INVENTOR(S):

CORVAS INTERNATIONAL, INC., for all designates States PATENT ASSIGNEE(S):

except US; MADISON, Edwin, L., for US only; ONG, Edgar,

O., for US only

SEIDMAN, Stephanie, L. AGENT:

LANGUAGE OF FILING: English LANGUAGE DE PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE 

WG 2102077267 A2 20021003 AE AG AL AM AT AG AZ BA BB BG BR BY BZ CA CH CN CO CR LESIGNATED STATES

CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD

MG MK MN MW MM MZ NO NZ OM PH PL PT RO RU SO SE SG SI SK SL TJ TM TN TR TT TZ TA US US UZ VN YU ZA ZM ZW SH GM KE LS MW MZ SO SI SI IZ UG IM ZW AM AZ BY KG KZ MI RE TU TM AT BE SHOW DE SKIES FI FR 35 35 IE IT LU MO NI PT SE TR BE BI OF CO I IM GA GN GO GW ML ME NE SN

#1..000-059411 A .0000327 US..001-60/179,2.8 100.0307 US..001-60/191,5.1 100.05.5 are type IT than APPLICATION INFO.: PRIGRITY INFO.:

Privided herein are type II transmembrane sering protesse 9 (MTSP9) ABEN polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domaine are also provided. Methods using the polypoptides to identify compounds that modulate the protease activity of an MTSP\* are provided.

La presente invention conterne des polypertides de serines proteases ABFR transmembranaires 9 (MTSP9), les tormes zymodenes et activées de ces polypeptides ainsi que les formes monocatenaires et bicatenaires que domaine protease. Des procedes d'utilisation de ces polypeptides pour identifier des composes qui modulent l'activité protease d'une MTSP9 sont egalement presentees.

ANSWER 23 OF 189 POTFULL COPYRIGHT 2001 Univention L104

ACCESSION NUMBER: 2000007/263 PCTFULL ED 20021011 EW 200240

NUCLEIC ACID MOLECULES EMCODING SERIME PROTEASE CVSP14, TITLE (ENGLISH):

THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON MOLECULES D'ACIDE NUCLEIQUE CODANT LA SERINE PROTEASE TITLE (FRENCH):

CVSP14, POLYPEPTIDES CODES ET PROCEDES

MADISON, Edwin, L.; YEH, Jiunn Chern INVENTOR(S):

CORVAS INTERNATIONAL, INC., for all designates States PATENT ASSIGNEE(S):

except US; MADISON, Edwin, L., for US only; YEH,

Jiunn-Chern, for US only

AGENT: SEIDMAN, Stephanie, L.

LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Fatent

PATENT INFORMATION:

KIND DATE NUMBER 

Wo 2002077263 A2 20021003

AE AG AL AM AT AU AZ BA BB BG BF BY BZ CA CH CN CO CR DESIGNATED STATES CU CZ DE DK DM DC EC EE ES FI GB GD GE GH GM HF HU ID

IL IN IS JE KE KG KE KE KZ DO DK DE DS DT DU DV MA MD MG MK MN MW MX ME NO ME OM PH PL PT RO RU SD SE SG SI

SK 3L TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG CM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

NL PT SE TR BE BUICE OG CI CM GA GN GQ GW ML MR NE SN TD TG

Wo 1002-US9039 A 20020320 APPLICATION INFO .: We .002-003000 US 0001-60/078,166 20010302 PRIORITY INFO.:

Provided herein are polypeptides designated CVSP14 polypeptides that ABEN exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptimes to identify compounds that modulate the protease activity thereof are provides. The polypeptides also serve

as tumor markers. L'invention porte sur des polypertides apreles rolypertides CVSF14 qui ABFR presente l'activité de la protease sous forme d'une chaine unique ou sous une forme activée a deux chainés. L'invention porte egalement sur des procedes utilisant ses polypertides pour identifier des composes qui modulent l'activité de la protéase. Les polymentides de cette invention

peuvent egalement etre utilises comme marquears tumoraux. ANSWER 24 OF 189 POTFULL COPYRIGHT 210: Univention

ACCESSION NUMBER: 2002077185 POTFULL ED 21021011 EW 200240

FERATINDOYTE GROWTH FACTUR-2 TITLE ENGLISH:

TITLE : FRÊNCH): FACTEUR DE GROISSANCE DES KERATINOCYTES-2 AUBEN, Steven, M.; JIMENHZ, Pablo; DUAN, D., Roxanne; INVENTOR:S:: RAMPY, Mark, A.; MENDRICH, Donna; ZHANG, Jun; NI, Jian; MOORE, Paul, A.; JOLEMAN, Timothy, A.; GRUBER, Joachim, R.; DILLON, Patrick, J.; GENTZ, Reiner, L. HUMAN JENOME SCIENCES, INC., for all designates States PATENT ASSIGNEE (St.: except US; RUBEN, Steven, M., for US only; SIMENEZ, Eaplo, for US only; DMAN, D., Roxanne, for US only; BAMPY, Mark, A., for US only; MENDELGE, Donna, for US only; CHANG, Jun, for US only; MI, Jian, for US only; MIGRE, Paul, A., for US only, SOLEMAN, Timothy, A., for US only; GRUBER, Joachum, R., for US only; DILLON, Patrick, J., for US only; GENTI, Reiner, L., for US only STEFFE, Brid, K. AGENT: LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE WO 2000077155 AP 20021003 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES

CU CZ DE DK DM DZ EC SE ES FI G8 GD GE GH GM HR HU ID

IL IN IS JP KE KG KP KR KD DO DK DR DS DT DU DV MA MD MG MK MN MW MK MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TO UA UG US UZ VN YU ZA ZM DW GH EM KE LS MW MZ SD SL SC TO UG EM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

NL PT SE TR BE BJ OF OG CI OM GA GN GQ GW ML MR NE SN

TE TG

Wo 2002-US101 A 20020104 APPLICATION INFO .: US 2001-60/259,853 20010108 PRIORITY INFO .: US 2001-60/286,368 20010436 US 2001-60/331,168 20011109

This invention relates to newly identified polynucleotides, polygeptides ABEN encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynuclectides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinopyte Growth Factor, sometimes hereinafter referred to as KGP-2 also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased

stability, higher yield or better solubility. ABFF: La presente invention concerne des polynucleotides, des polypeptides codes par ces polynucleotides nouvellement identifies, l'utilisation de des polynucleotides et polymeptides, ainsi que la production de des polynucleotides et polypeptides. Plus precisement, le polypeptide de la presente invention est un facteur de proissance des keratinocytes, parfeis signale di-dessous sous le nom generiqu- de \$#x2264; KGE-2 %#x2265; et egalement connu sous le nom generique de facteur de croissance des fibroblastes 12 (FGF-12). La presente invention concerne egalement l'utilisation therapeutique du KGF-2 your promouvoir ou appelerer la dicatrisation. La presente invention concerne egalement de nouvelles formes mutantes du KGF-2 presentant une activité amoliorée, une plus grande stabilite, un meilleur rendement ou une meilleure

DDSYRIGHT 2002 Univentio ANSWER 25 OF 189 POTFULL 1104 ACCESSION NUMBER: 201107:979 POTFULL ED 20:2171: EW 200239
TITLE (ENGLISH): EXPRESSION PROFILES AND METHODS OF USE
TITLE (FRENCH): PROFILE AND METHODES D'UTILISATION
INVENTORIS: WAN, Jackson; WANG, Yixin PATENT ASSIGNEE'S:: CRTHO-CLINICAL DIAGNOSTICA, INC.

sclubilite.

PELTS, Don LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English IOCUMENT TYPE: Patent PATENT INFOFMATION: NUMBER

KIND DATE

DESIGNATED STATES

WD 2132074979 AL 2000092€ AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR OY DE DE DE DE DE DE ES ES ES ES ES ED GE EN EM HR HU ID IL IN IS JP KE KG KP KW KZ LO LK ER LS LT LU LV MA MD MG MH MN MW MX M3 NO NO OM PH PL PT RO RU 30 SE 3G SI SK SL TO TM TN TR TT TO WA WG WZ WN YW ZA ZM ZW GH GM KE LS MW MŽ SD SI SZ TO UG DM OW AM AZ BY KG KZ MĐ ĐƯ TI TM AT BE OH OY DE DR ES FI PR GB GR IE IT LU MO NL PT SE TR BE BUIGE OF OF OI OM GAIGN GO GW ML MR NE SN TO  $T^{\ast}\mathbb{G}$ 

APPLICATION INFO .: PRIORITY INFO.:

WD 2002-US9456 A 20000320 US 2001-60/276,947 20010320

ABEN The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms. The present invention further relates to protein expression profiles, algorithms to generate protein expression profiles, microarrays comprising protein-capture agents that bind proteins comprising protein expression profiles, methods of using protein expression profiles and microarrays, and business methods directed to the use of protein expression profiles, microarrays, and algorithms.

ABFF:

La presente invention concerne des profils d'expression genetiques, des algorithmes permettant de proquire des profils d'expression genetiques, des jeux profonnées de microephantillons contenant des sequences d'acide nucleique representant des profils d'expression genetiques, des methodes d'utilisation des profils d'expression geniques et des jeux ordonnées de microechantillons, et des techniques commerciales destinées a l'utilisation des profils d'expression genetiques, des jeux ordonnées de microechantillons et des algorithmes. L'invention concerne en outre des profils d'expression de proteines, des algorithmes permettant de produire des des profils d'expression de proteines, des jeux ordonnées de microechantillons comprenant des agents de capture de proteines qui se lient a des proteines comprenant des profils d'expression, des methodes d'utilisation des profils d'expression de proteines et des jeux ordonnees de microechantillons, et des techniques commerciales destinees a l'utilisation des profils d'expression de proteines, des jeux ordonnées de microechantillons et des algorithmes.

ANSWER 26 OF 189 POTFULL COPYRIGHT 2002 Univention L104

ACCESSION NUMBER: 2002074929 PCTFULL ED 20021010 EW 200239 EVOLVING NEW MOLECULAR FUNCTION TITLE (ENGLISH):

TITLE (FRENCH): EVOLUTION D'UNE NOUVELLE FONCTION MOLECULAIRE LIU, David, E.; GARTNER, Sev. J.; KANAN, Mattew, W. INVENTOR(S):

PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE, for all designates States except US; LIU, Tavid, R., for US only; GARTNER, Zev, J., for US only; KANAN, Mattew, W.,

for US only

SHAIR, Karcline, K., M. AGENT:

LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION:

NUMBER KIND DATE **WO 2002074929** A2 200.0926

AB AG AL AM AT AU AZ BA BB BG BR BY BZ GA CH CN CO GR LESIGNATED STATES

CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM GM HR HU IL IL IN IS JE KE KG KE KE KZ LC LK LE LS LT LU LV MA MD MG MK MN MW MM MZ NO NZ OM PH PL PT RO RU 3D SE SG SI SK SL TJ TM TN TR TT IZ UA UG US UZ VN YU ZA ZM ZW GH UM FE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT SE CH CY DE LK ES FI FR 3B GR LE IT LU MC NL FT SE TR BF EJ CE CG CI CM GA GN GQ GW ML MR NE SN

APPLICATION INFO.: PRIORITY INFO.:

wo 2002-US8546 A 20020319
US 2001-60/277,081 20010319
US 2001-60/277,094 20010319
US 2001-60/306,691 20010720
US 2002-10/101,030 20020319
Iological molecules Tut

ABEN Nature evolves biological molecules such as proteins through iterated rounds of diversification, selection, and amplification. The present invention provides methods, compositions, and systems for syntheiszing, selecting, amplifying, and evolving non-natural molecules based on nucleic acid templates. The sequence of a nucleic acid template is used to direct the synthesis of non-natural molecules such as unnatural polymers and small molecules. Using this method combinatorial libraries of these molecules can be prepared and screened. Upon selection of a molecule, its encoding nucleic acid template may be amplified and/or evolved to yield the same molecule of the present invention allow for the amplification and evolution of non-natural molecules in a manner analogous to the amplification of natural biopolymer such as

polynucleatides and protein. ABFR La nature fait evoluer les molecules biologiques telles que les proteines en les soumettant a des cycles repetes de diversification, selection et amplification. La presente invention se rapporte a des procedes, des compositions et des systemes permettant de synthetiser, selectionner, amplifier et faire evoluer des molecules artificielles basees sur des modeles d'acides nucleiques. La sequence d'un modele d'acide nucleique est utilisée pour dirigér la synthèse de molécules artificielles, telles que des polymeres et de petites molecules artificielles. Cette methode permet la preparation et le criblage de bibliothèques combinatoires de ces molecules. Lors de la selection d'une molecule, il est possible d'amplifier et/ou de faire evoluer son modele d'acide nucleique codant de manière a produire la meme molecule ou des molecules associees aux fins d'un nouveau criblage. Les methodes et les compositions de la presente invention permettent l'amplification et l'evolution de molecules artificielles d'une manière analogue a l'amplification des biopolymeres naturels du type polynucleotides et

L104 ANSWER 27 OF 189 FCTFULL COFYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001072736 PCTFULL ED 20020927 EW 200238

TITLE (ENGLISH): MUGLEIC ACID MOLECULES ENCODING A TRANSMEMBRANE SERINE

PROTEASE 7, THE ENCODED POLYPEPTIDES AND METHODS BASED

THEF.ECN

TITLE (FRENCH): MODECULES D'ACIDES NUCLEIQUES CODANT POUR UNE SERINE

PROTEASE TRANSMEMBRANAIRE 7, POLYPEPTIDES CODES ET

PROCEDES ASSOCIES

INVENTOR(S): MADISON, Edwin, L.; ONG, Edgar, O.

PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., for all designates States

except US; MADISON, Edwin, L., for US only; ONG, Edgar,

O., for US only

AGENT: SEHIMAN, Stephanie, L.

LANGUAGE OF FILING: English LANGUAGE OF PUBL: English DOCUMENT TYPE: Patent

proteines.

PATENT INFORMATION:

NUMBER KIND DATE

WO 2102072796 A2 21020919

DESIGNATED STATES - AE AG AL AM AT AC AZ BA BE BG BR BY BZ CA CH CN CO OR

ON OZ DE DK DM DZ EG EE ES FI GB GD GE GH GM HR HU ID DIN IS JE KE KU KE KE KE LO LK LE AS AT LU LV MA MO M3 MK MN MW MX MD NO NZ AM EH PL ET BO BU 30 3E 39 31 SK SI TO TM IN TR TT TO VA UG VO WO YU YU ZA ZM ZW GH BM KE LS MW MZ SD SI SZ TZ UG ZM ZW AM AZ BY KG KZ MD ST TJ TM AT BE CH CY DE DK ES ET FR GB GR IE IT LU MC NI PT SE TA PF BU TE TO NI OM GA GN GQ GW MI MA ME SN

APPLICATION INFO.: PRIORITY INFO.:

W0 1 02-0379 3 A 0.0020314 

Provided herein are type II transmembrane serine protease 7 (MT3P7) polypeptides. Zymogem and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP7 are provided.

La presente invention concerne des polypeptides de serine protease ABFR transmembranaire 7 (MTSP7) de type II. L'invention concerne egalement des proenzymes et des formes activées de ces polypéptides ainsi que des formes simple chaine et double chaine du domaine protease. Sette invention concerne equilement des procedes consistant a utiliser les polypeptides pour identifier les composes qui modulent l'activité protease d'une MTSP7.

ANSWER 28 OF 189 POTFULL COPYRIGHT 2002 Univentia L104

2002072024 PCTFULL ED 20020927 EW 200238 ACCESSION NUMBER:

TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, TITLE (ENGLISH):

COMPOSITIONS, USES AND THE LIKE RELATING THERETO PROTEINES TRANSGENIQUES OBTENUES A PARTIE DE SYSTEMES TITLE (FRENCH):

MULTIGENIQUES, PROCEDES, COMPOSITIONS, UTILISATIONS ET

ANALOGUES APPARENTES

COOPER, Julian, D; O'SICKEY, Tanya, K; BUTLER, Stephen, INVENTOR(3):

PROGENETICS LLC, for all designates States except US; PATENT ASSIGNEE(S):

COOPER, Julian, D; O'SICKEY, Tanya, K; BUTLER, Stephen,

AGENT: CRAWFORD, Robert, J.

LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND ĽATE 

WG 2002072024 A2 30020919

AS AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES

CU CZ DE DK DM DZ EC HE ES FI GB GD GE GH GM HR HU ID IL IN IS JE KE KG KE KR KZ LC LK LR LS LT LU LV MA MD

M3 MK MN MW MK MD NO NZ PH PL PT RO RU SD SE SG SI SK

SI TU TM TH TT TI WA WE US UZ VN YW ZA ZW EH EM KE LS MW MG 3D Sh 3Z TO UG DM DW AM AD BY KG KZ MD BU TO TM

AT BE CHICY DE DK ES FI FRIGBIGRIE IT LU MC NL PT SE

TE BE BUICE OF CE CM CA GN GQ GW ML ME NE SN TO TO

W1 L062=U37540 A L00320311 APPLICATION INFO .: US 1001-60/274,983 PRIORITY INFO.:

TY INFO:: US 1001-63/274,983 100010312 A non-human transgen: mammalian animal, is described above, contains one or more exogenous double stranged DNA sequence(s) stably integrated into the denome of the unimal, which comprises trans-acting regulatory units controlling extression of DNA sequences enocding proteins to be segreted into the mile of transgenic mammals. The DNA sequence of the trans-regulatory generations transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed on a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins

which require specialized propeptides for proper post-translational pricessing is also described.

l'invention porte sur un animal mammalien transgenique comprenant une ou ABFR rlusieurs sequences exogenes à'ADN double brin integrées de manière stable dans le genome de l'animal et des motifs de repetition regulateurs transactivateurs regulant l'extression des sequences d'ADN codant de proteines à secreter dans le lait des mammiferes trânsgeniques. La sequence d'ADN du gene transregulateur code des proteines d'activation transcriptionnelles qui ne sont pas secretees, mais fabriquees de manière reguler dans le temps et de manière specifique du tissu mammaire. La sequence d'ADN contenant la proteine a secreter dans le lait est construite su: une sequence genique separee stus la regulation d'un promoteur minimal et d'un domaine de liaison de transactivation. Les mammiferes transgeniques sont de preference des porcs, des vaches, des moutons, des chevres et des lapins. L'invention porte equiement sur une composition apparentée et sur un procede de fabrication de proteines transgeniques qui ont bescin de propeptides specialises pour un traitement post-translationnel correct(.)

ANSWER 29 OF 189 POTFULL COPYRIGHT 2002 Univertid L104

ACCESSION NUMBER: 2002063017 PCTFULL ED 20020807 EW 200233

TITLE (ENGLISH):
INTEGRIN-BINDING CHIMERAS
TITLE (FRENCH):
CHIMERES POUVANT SE LIER A L'INTEGRINE
INVENTOR(S):
LU, Kinjie; KAKKAR, Vijay, Vir
PATENT ASSIGNEE(S):
TRIGEN LIMITED, for all designates States except US;
LU, Kinjie, for US only; KAKKAR, Vijay, Vir, for US

only

AGENT: HARRISON GODDARD FOOTE

English LANGUAGE OF FILING: LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

Wo 2002063017 A2 20020816

AE AG AL AM AT AU AS BA BB BG BR BY BC CA CH ON CO CR DESIGNATED STATES

CU CO DE DK DM DO EC HE ES FI GB GD GE GH GM HR HU ID IL IN IS JE KE KG KE KR KZ DC LK LE DS DT DU DV MA MD MG MK MI MW MM MI NO MI OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ VA UG US UZ VN YU ZA ZM ZW GH

GM KE LS MW MZ SE SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BE BJ OF OG DI CM GA GN GQ GW ML MR NE SN

TD TG

 
 WO
 2002-GB500
 A
 20020005

 US
 2001-607267,234
 20010005
 APPLICATION INFO.:

PRIORITY INFO.:

ABEN Froducts which contain two interlinked functional moleties of which one is an integrin-binding protein 'e.g. a snake venom protein) or a homologue thereof. The products comprise a first portion which is an integrin-binding protein, a homologue thereof having a kinding activity or a fragment of either which has integrin binding activity, and,

ligated to the first portion, a second portion which has a different

function.

L'invention concerne des produits qui sontiensent deux fragments ABFR fonctionnels entrelapes dont l'un est une proteine de liaison a l'integrine (p. ex. une proteine du venin du serpent) ou un homologue de ladite proteine. Jes produits comprennent une première partie qui est une proteine de liaison à l'integrine, un nomploque de ladite proteine ayant une activité de limison, ou un fragment de l'un su l'autre ayant une activité de liais m a l'integrine; et une seconde partie liée a la premiere partie et ayant une fonction differente.

1104 ANSWER 30 OF 189 POTFULL COPYRIGHT 2002 Univertic ACCESSION NUMBER: 2002/57273 POTFULL ED 20020501 EW 200230 TITLE ENGLISH: SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND

ACCEPTOR

TITLE FRENCH : INHIBITEURS DE LA SERINE PROTEÀSE COMPRENANT UN

ACCEPTEUR LE LIAISIN HYDROJEME

INVENTOR S:: DEADMAN, John, Joseph; SPENDER, John; GREENIDGE,

Paulette, Angela; 3000WIM, Christopher, Andrew; KAKKAR,

Vijay, Vir: SCULLY, Michael, Finbarr

TRIGEN LIMITED, for all designates States except US; PATENT ASSIGNEE(S):

DEADMAN, John, Joseph, for US only; SPENCER, John, for US Enly; GREENIEGE, Paulette, Andela, for US only;

GOODWIN, Christopher, Andrew, for US only; KAKKAR,

Vijay, Vir, for V3 only; SCULLY, Michael, Finbarr, for

US only

HARRISON GODDARD EDOTE AGENT:

LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE Wo 2002057273 A1 100000705

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES

> CU CO DE DE DE DM DO EC EE ES FI GB GD GE GH GM HE HU ID IL IN IS JE KE KG KE KR KU LO LK LE LS LT LU LV MA MD MG MK MN MW MK MC NO NZ OM PH PL PT RO RU 3D 3E SG SI SK SL TJ TM TN TR TT TO UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MS SD SL SS TO UG SM SW AM AZ BY KG KZ MD

> RU TU TM AT BEICH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BE BUICE OG CI CM GA GN GQ GW ML MR NE SN

TD TG

WO 0002-GB024 A 20020118 APPLICATION INFO .: GB 2001-0101537.9 20010120 PRIORITY INFO.: US 2001-60/267,172 20010206

Compounds, useful as protease inhibitors, of the formula (I): where: Ar ABEN is a ring or

ring system, for example a benzene ring, and may be substituted by one or more majeties

in addition to X and LJ; X is a functional group which is a hydrogen-bond acceptor,

e.g. a nitro or boronate group BYKsp>10/sp-YKsp-20/sp-; L is a linker,

preferably (CR<sp>5./sp>R<sp>6</sp>)-3-; J is a modety containing a basic

nitrogen atom but not containing an amino acid residue, preferably amidino, quanidino,

amino, carboxamido, hydroxylamino, or imidacolyl, or an N-substituted analogue

thereof.

ABFR L'invention concerne des composes utilises comme inhib:teurs de protease representes par la formule (I). Dans tette formule, Ar represente un noyau ou un systeme cyclique, par exemple, un noyau benzenique,

et peut etre substitue par au moins une fraction en plus de X et LJ; X represente un groupe fonctionnel accepteur de liaisen hydrogene, par exemple, un groupe nitro ou boronate EFGsp-FG/sp>YGsp>2</sp>; L represente

un liant, de preference (CRdsp>5</sp>Rdsp>6d'sp>)-U-; I represente une fraction contenant un atome d'arote basique mais ne contenant pas de résidu d'acide amine, et contenant de preference amidino, quaniding, amino, rashoxamido, hydroxylamino, ou imidazelyl, ou un

analogue

de ceux-ci substitue par un N.

ANDWER 31 OF 189 POTFULL COPYRIGHT 1002 Univentic

ACCESSION NUMBER: -2002042336 PUTFULL ED 20020610 EW 200222

FGF-AFFINITY CHRCMATOGRAPHY TITLE (ENGLISH):

TITLE FRENCH: CHPOMATOGRAPHIE D'AFFINITE AVEC FGF MCKEEHAN, Wallace, L.; LUC, Yougde THE TEXAS A & M UNIVERSITY SYSTEM INVENTOR F.: PATENT ASSIGNEE S : AGENT: REEJE, Raymond, S. LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English BOOUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE WD . 002042336 A2 21020530 AE AG AL AM AT AH AL BA BE EG BR BY BZ CA CH CN CO CR DESIGNATED STATES CU CZ DE DK DM DC EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS IF HE HG HR HR HR LC LH LE LS LT LU LV MA MD MG MK MN MW MX MD NO NO OM PH PL PT RO RU 3D SE 3G SI SK SL TU TM TR TT TO UA UG UZ VN YU DA ZM ZW GH GM KE LS MW MZ SD SL SC TO UG OM ZW AM AZ BY KG KZ MD RU TJ TM AT BE OH CY DE DE ES FI FR GB GR IE IT LU MO NL PT SE TR BE BU OF OG OI OM GA GN GQ GW ML MR NE SN TO TG 

 W0 0001-US43817
 A 00011121

 US 0000-60/252,205
 0001101

 US 0001-60/277,735
 00010301

 US 0001-60/305,613
 00010908

 US 0001-60/325,502
 00010928

 APPLICATION INFO .: PRIORITY INFO.: ABEN The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoaqulant heparan sulfate onto an affinity matrix and separating the non-bound material from the bound material. The affinity matrix is made of a fibroblast growth factor immobilized on a support. The invention also relates to a method and composition for neutralizing anticoagulant catalysed by heparin, a heparin mimic, or a heparin derivative, by contacting heparin, a heparin mimic, or a heparin derivative with a fibroblast growth factor. L'invention concerne un procede et un dispositif servant a isoler de ABFR l'heparine anticoaqulante ou du sulfate d'heparane par fixation de l'heparine anticoaquiante ou du sulfate d'heparane anticoaquiant sur une matrice d'affinite et separation du materiau non fixe et du materiau fixe. Cette matrice d'affinité est constituée par un facteur de croissance de fibroblastes immobilise sur un support. Elle concerne egalement un procede et une composition servant a neutraliser l'anticoaquiation catalysee par heparine, un analogue d'heparine ou un derive d'heparine, par mise en contact d'heparine, d'un analogue d'heparine ou d'un derive d'heparine avec un facteur de proissance de fibroblastes. ANSWER 32 OF 189 POTFULL COPYRIGHT 2002 Univentio ACCESSION NUMBER: 2000040654 POTFULL ED 2002061 / EW 200221 POLYNUCLEOTICE ENCODING A NOVEL HUMAN SERPIN SECRETED TITLE (ENGLISH): FROM LYMPHOLD CELLS LSI-01 POLYNUCLEOTICE COCANT FOUR UNE NOUVELLE SERVINE HUMAINE TITLE (FRENCH): (LSI-01) SECRETEE A PARTIR DES CELLULES LYMPHOIDES CHEN, Jian; FEDER, John, N.; NELSON, Thomas; SEILER, Steven; BASSOLIMO, Donna, A; CHENEY, Daniel, L.; INVENTOR(S):DUCLOS, Frank BRIGTOL-MYERS SQUIBB COMPANY, for all designates States PATENT ASSIGNEE(S): except US; CHEN, Jian, for US only; FEDER, John, N., for US only; NELSON, Thomas, for US only; SEILER, Steven, for US only; BASSILING, Donna, A, for US only; CHEMEY, Daniel, L., for US only; DUCLOS, Frank, for US BRISTOL-MYERO SQUIBB COMPANY AGENT:

LANGUAGE OF FILING: English
DANGUAGE OF PUBL: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE	
Wa 2002040654	A2	29023523	
AE AG AL AM AT A	U AZ BA	BB BG BR	BY BZ CA CH CN CO CF
CU CZ DE DK DM D.	Z ED EE	ES FI 35	S GD GE GH GM HR HU II
II. III IS JP KE K	3 KP KR	KZ LO LK	: LR LS LT LU LV MA MI
MG MK MG MW MX M	Z 110 11Z	PH FL PT	TRO RU BD SE BB SI SE
SL DA TM TR PT T.	J UA UG	US UZ WW	: YU ZA ZW GH GM KE LS
NW MZ ŠD SL SZ TI	z da zw	AM AZ BY	' KU KU MD RU TI TM AX
BE OH OY DE DK E.	a FI FR	GB GR IE	I IT LU MO HL PT SE TE
BF BJ OF OF CI C	M 3A 311	GQ GW MI	, MA, NE SN DD TG
WD .001-US43965	$\dot{A}$	11011114	
TS 1000-80/248,4	34	110011114	
us 1000-60/257,6	1.0	10001221	
us 2001-60/282,7	45	20010410	1
	MO 2002040654  AE AS AL AM AT A OU OZ DE DK DM D IL IN IS JE KE K MG MK MN MW MX M SL DA TM TB PT T MW MZ SD SL SZ T BE CH CY DE DK E BE BT OF OS OF CO WO 1001-0343965 US 1000-607248,4 US 1000-607257,6	MO 2002040654 A2 AE AS AL AM AT AU AZ BA OU OZ DE DK DM DZ ED EE IL IN IS JE KE KG KP KR MG MK MN MW MX MZ NO NZ SL IJ TM TR IT TI UA US MW MZ SD SL SZ TZ UG ZW BE OH CY DE DK ES EL ER BF BI OF OS OL CM GA ON WO 1001-US43965 VS 1000-607248,434 US 1000-607257,610	NUMBER         KIND         DATE           W0 2032043654         A2 20020523           AE AG AL AM AT AU AZ BA BB BG BF         BB BG BF           CU CZ DE DK DM DZ ED EE ES FI GB         BL BE BF BF GB           IL IN IS JF KE KG KF KR KZ LD LR         MG KK KZ LD LR           MG MK MM MW MX MZ ND NZ PH FL BT         SL DX TZ UG ZW AM AZ BY           MW MZ SD SL SZ TZ UG ZW AM AZ BY         BE CH CY DE DK ES FI FR GB GR IE           BF BI DF CG CI CM GA GN GQ GW MI         WO 1001-0843965         A 20011114           WS 1000-607248,434         L10011114           US 1000-607382,745         20010410

ABEN The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention furtherrelates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseas and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ABFR La presente invention concerne des nouveaux polynucleotides codant pour des polypeptides LSI 01, des fragments et des homologues desdits polypeptides. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps et des methodes de recombinaison et des methodes synthetiques destinees a la production de ces polypeptides. Ladite invention se rapporte en outre a des methodes dragnostiques et therapeutiques permettant d'appliquer ces nouveaux polypeptides LSI-01 au diagnostic, au truitement et/ou a la prevention de maladies et/ou de troubles divers associes auxdits polypeptides. Elle porte enfin sur des methodes de criblage destinees a identifier des agonistes et des antagonistes des polynucleotides et des polypeptides susmentionnes.

L104 ANSWER 33 OF 189 FCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 20020339997 PCTFULL ED 20020610 EW 200221

TITLE (ENGLISH): ACE-2 MODULATING COMPOUNDS AND METHODS OF USE THEREOF

TITLE (FRENCH): COMPOSES MODULANT ACE-2 ET PROCEDES D'UTILISATION

ASSOCIES

INVENTOR(S): ACTON Susan L : OCAIN Timothy D : GOULD Alexandr

INVENTOR(S):

ACTON, Susan, L.; OCAIN, Timothy, D.; GDULD, Alexandra, E.; DALES, Natalie, A.; GUAN, Bing; BROWN, James, A.; PATANE, Michael; KADAMBI, Vivek, J.; SOLOMON, Michael; STRICKER-KRONGRAD, Alain

PATENT ASSIGNEE(S):

MILLENNIUM PHARMACEUTICALS, INC., for all designates
States except US; ACTON, Susan, L., for US only; OCAIN,
Timothy, D., for US only; GCULD, Alexandra, E., for US
only; DALES, Natalie, A., for US only; GUAN, Bing, for
US inly; BROWN, Tames, A., for US only; PATANE,
Michael, for US only; HADAMBI, Vivek, J., for US only;
SCLOMON, Michael, for US only; STRICKER-KRONGRAD,

AGENT: Alain, for US only HANLEY, Elizaketh, A.

LANGUAGE OF FILING: English
LANGUAGE OF PUBL: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

DESIGNATED STATES

AE AG AL AM AT AT AZ BA BB BG BR BY BL TA CH CN CO TR
CU TZ DE DK DM DZ EG ER ES FI GE GE GE GM HR HU ID
IL IN IS JP KE KJ KP KR KZ LC LK LR LS LT LU LV MA MD

MG MK MN MW MX MZ NO NZ DM PH PL PT BU RU SD SE SG SI SK SL TJ TM TR TT TE WA MG WE WE WN YN ZA ZW GH GM KE IS MW MZ 30 SI SZ TZ MG ZW AM AD BY KU KZ MD RU IU TM AT BE OF DY DE DE ES PI FR GB GR IE ID LY MO NL PT SE TR BE BUIGE OF OF SECTION RATE BY BUIGE BY ML MR ME BY TO TO WO 2 91-0845713  $_{\odot}$  A  $_{\odot}$  3011031 APPLICATION INFO.: ts 2 00-09/704,216 . 0001101 PRICRITY INFO.: vs 2001-09 870,382 vs 0.01-60 371,741 10011529 ..0011019 ACE-2 modulating compounds for the treatment of kody disorders are ABEN: disclosed. Methods it using the compounds and pharmaceutical compositions containing the compounds are also claimed. L'invention concerne des composes modulant ACE-2, destines au traitement ABFE. de problemes de poids. L'invention concerne egalement des procedes d'utilisation de des composés et des compositions pharmaceutiques contenant lesdits composes. ANSWER 34 OF 189 FORFULL COPYRIGHT 2000 Univentic L104 ACCESSION NUMBER: 2001032446 PCTFULL ED 2 020515 EW 200217 PHARMAGEUTICAL COMBINATIONS TITLE (ENGLISH): COMBINAISONS PHARMACEUTIQUES TITLE (FRENCH): BREARLEY, Christopher, John; BUTLER, Paul; CHAHWALA, INVENTOR( $\mathbb{S}$ ): Suresh, Babubhai; CHOPP, Michael; KRAMS, Michael; LOOBY, Michael; MACINTYRE, Fron; MCELROY, Andrew, Brian; MCHARG, Aileen, Dorothy PFICER LIMITED, for GB only; PFIZER INC., for all PATENT ASSIGNEE(S): designates States except GB US; BREARLEY, Christopher, John, for US only; BUTLER, Paul, for US only; CHAHWALA, Suresh, Babubhai, for US only; CHOSP, Michael, for US only; KRAMS, Michael, for US only; LOOBY, Michael, for US only; MACINTYRE, Fion, for US only; MCELROY, Andrew, Brian, for US only; MCHARG, Aileen, Dorothy, for US only AGENT: WooD, David, J. LANGUAGE OF FILING: Engl:sh LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND DATE NUMBER \_\_\_\_\_ WO 0002032446 A2 00020425 AE AG AL AM AT AU AZ BA BB BG BR BY BC CA CH CN CO CR DESIGNATED STATES CU CO DE DE DE DE DO EC EE ES ET GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LO LK LE LS LT LU LV MA MD MG MK MN MW MK MC NO NO PH PL PT RO RU SD SE SG SI SK SE TJ TM TR TT T2 UA UG US U2 VN YU ZA ZW GH GM KE L3 MW ME SD SE SE TE UG EW AM AE BY KG KE ME EU TI TM AT BE ON MY DE DE ES ET FR GB GR IE IT LU MO NL PT SE TR BE BI OF OG OI OM GA GN GQ GW ML ME NE SN TD TG APPLICATION INFO .: WC 0001-IB1936 A 20011015 20001017 GB 2000-0025473.0 PRIORITY INFO.: This invention relates, inter alia, to methods of treating ABEN mathophysiological conditions involving neutrophils, comprising administering to a patient in need of such treatment a combination therapy comprising at least one Neutrophil Inhibitory Factor (NIF) and at least one other agent that protects neurons from toxic insult, inhibits the inflammatory reaction after brain damage or promotes perekral reperfusion i.e. neuroprotective or thromokytic/fribrinolytic agents), or a pharma wutically acceptable salt thereif. ABFR La presente invention concerne notamment des methodes de traitement d'etats pathophysicl: fiques impliquant des polynupleaires neutrophiles, lesquelles methodes Unsistent a administrer a un patient necessitant un

tel traitement une polytherapie comportant au moins un facteur

inhibiteur des polynucleaires neutrophiles 'NIE' et au moins un autre agent qui protege les neurones d'une attaque tomique, innibe la reaction

inflammatoire suite a une lesion perebrale, ou favorise une reperfusion perebrale prest-a-dire des agents neuroprotecteurs ou thrompolytiques / fibrinolytiques, ou un sel pharmaceutiquement appentable.

1154 AMRWER 35 OF 189 POTFULL COMMINGHT 2 00 Univention -2002029032 POTEVIL ED 23020627 EW 200219 ACCESSION NUMBER: WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL TITLE ENGLISH: PORTION OF A STARTING SENOME, COMBINING MUTATIONS, AND DEFIGNALLY REPEATING MANIPULATION DE CELLULE EXTIERE PAR MUTAGEMESE D'UNE TITLE FRENCH: FARTIE SUBSTAUTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT PAR REPETITION SHORT, Jay, M.; FU, Pengtheng; LATTERICH, Martin; WEI, INVENTOR(S): Tina; LEVIN, Michael DIVERSA CORPORATION, for all designates States except PATENT ASSIGNEE S): US; SHORT, Jay, M., for US only; FU, Pengcheng, for US only; LATTERICH, Martin, for US only; WEI, Jing, for US only; LEVIN, Michael, for US only BINHORN, Gregory, P. AGENT: LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND ETAC NUMBER \_\_\_\_\_ WO 20029032 AD 30020411 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES CU CO DE DK DM DO EC SE ES FI GB GD GE GH GM HR HU ID IL IN IS JE KE KG KE KE KZ LC LK LE LE LT LU LV MA MD MG MK MN MW MM MD NO NO PH PL PT FO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MO SD SL SO TO UG OW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BE BUICE OF OF ON GAIGN GO GW ML MR NE SN TO TO WO 2001-US31004 A 20011001 APPLICATION INFO.: 20000935 US 0000-09/677,584 PRIORITY INFO.: US 1001-60/274,702 20010323 US 2001-PCT/US01/19367 20010614 ABEN An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. In one embediment, this invention provides a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. This invention also provides a of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, this conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant sell. This invention also provides a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products. This invention provides methods for determining polypertide profiles, and protein expression variations. which methods are applicable to all sample types disclosed herein. The

invention provides methods of simultaneously identifying and quantifying individual proteins in complex protein mixtures. Additionally this invention provides methods for cellular and metabolic engineering of new and modified. premotypes by using on-line or real-time metabolic flux analysis. L'invention concerne des procedes de transformation cellulaire, ABFR d'evolution dirigée et de priblage utiles pour produire de nouveaux organismes transgeniques possedant des proprietes voulues. Dans une forme de realisation, l'invention concerne un procede de production d'organisme transgenique, tel qu'un microbe ou une plante, comportant une pluralite de caracteristiques activables de manière differenciee. L'invention concerne aussi un procede de remaniement de genes et de voies geniques par l'introduction de sequences regulatrices, tels des promoteurs, qui peuvent etre activees chez un hote voulu et sont ainsi capables de conferer une capacité d'activation à une nouvelle voie genique apres introduction de celle-ci dans un hote voulu; par exemple, une nouvelle voie genique artificielle, produite sur la de modeles de progeniteurs derives de misrobes, qui peut etre activee dans une cellule vegetale. Cette invention concerne aussi un procede de production de nouveaux organismes hotes possedant une expression accrue de caracteristiques voulues, de genes recombines et de produits geniques; de nouveaux procedes servant a determiner des profils de polypeptides et des variations d'empression de proteines, des procedes pouvant etre appliques a tous les types d'echantillons decrits; des procedes permettant d'identifier et de quantifier simultanement des proteines individuelles dans des melanges complexes de proteines. De plus, l'invention concerne des procedes de mise au point cellulaire et metabolique de nouveaux phenotypes modifies utilisant une analyse de flux metabolique ≤ en ligne ≥ ou \$#x2264; en temps real ≥. ANSWER 36 OF 189 POTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 2002326781 PCTFULL ED 20020701 EW 200214 TITLE (ENGLISH): IGE RECEPTOR ANTAGONISTS ANTAGONISTES DU RECEPTEUR D'IGE TITLE (FRENCH): LOWMAN, Henry B.; REYNOLDS, Mark E.; NAKAMURA, Gerald INVENTOR( $\mathcal{Z}$ ): R.; STAROVASNIK, Melissa A. GENENTECH, INC., for all designates States except US; PATENT ASSIGNEE(S): LOWMAN, Henry B., for US only; REYNOLDS, Mark E., for US only; NAKAMURA, Gerald R., for US only; STAROVASNIK, Melissa A., for US only SVOBODA, Craig G. AGENT: LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE Wo 2002026781 A2 20020404 AB AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES THOS DE DRIOM DO ES EE ES ET GE GO GE GH GM HR HU ID IL IN IS JE KE KS KE KR KZ DO DK DR DS DT DU DV MA MD M3 MF MN MW MM M0 M0 M2 PH PL PT RO RU SD SE SG SI SK

APPLICATION INFO.:

PRIORITY INFO.: US 2000-61/235,353 20000926 US 2001-60/275,540 20010303

ABEN The invention provides novel compounds which bind to the high affinity

reseptor for

immunoglobulin E lgE: designated Fc%epsilon; RI and methods for

identifying and

preparing such compounds. In particular aspects, the invention provides to

the treatment of disorders mediated by IgE utilizing the novel compounds of the

invention. The invention also provides compositions, such as pharmaceutical compositions,

comprising the navel compounds, as well as for their use in research, diagnostic,

therapeutic, and prophylactic methods.

ABFR L'invention concerne de nouveaux composes se liant a un recepteur de haute affinite pour l'immunoglobuline E (iqE), designe par

Forepsilon; RI, ainsi que des procedes d'identification et de

preparation de tels composes. Sous des aspects particuliers, l'invention concerne le traitement de troubles occasionnes par IgE, traitement utilisant

les nouveaux composés de l'invention. L'invention concerne en outre des compositions, telles que des compositions pharmaceutiques, renfermant

les nouveaux composes, ainsi que leur utilisation en recherche et dans des methodes de diagnostio, therapeutiques et prophylactiques.

L104 ANSWER 37 OF 189 EUROPATEULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1179541 EUROPATFULL EW 200207 FS OS

TITLE: Compositions and methods for cancer treatment by

selectively inhibiting VEGF.

Busammensetzungen und Verfahren zur Krebsbehandlung

durch die selektive Hemmung von VEGF.

Compositions et procedes de traitment du cancer par

l'inhibition selective du VEGF.

INVENTOR(S): The designation of the inventor has not yet been filed

PATENT ASSIGNEE(S): BOAFD OF FEGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Office

of General Council, 201 West 7th Street, Austin, Texas

73701, US

PATENT ASSIGNEE NO: 266341

AGENT: Gowshall, Jonathan Vallance, FOFFESTER & BOEHMERT

Pettenkoferstrasse 20-22, 30336 Muenchen, DE

AGENT NUMBER: 61531

OTHER SOURCE: BEPA2002015 EP 1179541 A1 0144

SOURCE: Wila-EPZ-2001-H07-Tla

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Verdeffentlichung in Englisch DESIGNATED STATES: F AT; R BE; F CH; R CY; R DE; F DK; R ES; F FI; R FR; R

GE; F GF; F IE; F IT; R LI; F LU; R MC; R NL; R PT; R

SE; R AL; R LT; F LV; R MK; F FO; R SI

PATENT INFO. PUB. TYPE: EPAL EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO KIND DATE

EP 1179541 A1 20020113

 'CFFENLEGUNGS' DATE:
 20020013

 APPLICATION INFO.:
 EP 2001-125801
 20000426

 PRIORITY APPLN. INFO.:
 US 1999-131432
 19390425

RELATED DOC. INFO.: EP 9301939 DIV

L104 ANSWER 38 OF 189 EUROPATFULL COPYRIGHT 2502 WILA

AddEssion Number: 994893 EUROPATFULL EW 200201 ES PS

TITLE: SELECTIVE FACTOR XA

INHIBITORS CONTAINING A FUSED AZEPINONE

STRUCTURE.

SELEKTIVE INHIBITOREN DES FAKTORS K, EINE

AZEPINONSTRUKTUR ENTHALTEND.

INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE

STRUCTURE D'AZERINONE CONDENSES.

INVENTOR(S): SCARBOROUGH, Ribert, M., 2544 Belmont Canyon Road,

Belmint, CA 94002, US

PATENT ASSIGNEE(S): COR THERAPEUTICS, INC., 256 East Grand Avenue, Suite 80,

South San Francisco, CA 94030, US

PATENT ASSIGNEE NO: 1193200

AGENT: Drireau, Marc et al., Tabinet Dres 6, avenue de Messine,

79008 Paris, FR

AGENT NUMBER: 44325

CTHER SOURCE: BEPB1000001 EP 0994893 B1 0062

SOURCE: Wila-EFS-2002-H01-T1

DOCUMENT TYPE: Patient

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR;

R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_\_ EP 994893 B1 20020102 20000426 'OFFENLEGUNGS' DATE: APPLICATION INFO .: EB 1998-939911 19990811 PRICRITY APPLN. INFO.: US 1997-92316 19970811 US 1997-907779 19970811 Wo 98-US16704 980811 INTAE2 RELATED DOG. INFO.: WG 9907730 990218 INTPNR

REFERENCE PAT. INFO.: WO 97-05160 A

PEF. NCN-PATENT-LIT.: J A FOBL ET AL.: "Iwal metalloprotease inhibitors. II.

Effect of substitution and stereochemistry on

benzazepinone based mercaptoacetyls" BIODRGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 15, 1994, pages 1735-1800, XP000196070 Amsterdam J A ROBL ET AL.: "Dual

metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors" JOURNAL OF MEDICINAL AND

PHAFMACEUTICAL CHEMISTRY., vol. 39, 1996, pages 494-502,

DUPLICATE 1

X9000749701 EASTON US

LID4 ANSWER 39 OF 189 USEATFULL

ACCESSION NUMBER:

2001:150554 USPATFULL

TITLE: PROTEAGE INHIBITOR PEPTIDES

INVENTOR(S): WHITE, R. TYLER, FREMONT, CA, United States

DAMM, DEBORAH, REDWOOD CITY, CA, United States
LESIKAR, DAVID D., PALO ALTO, CA, United States
MCFADDEN, KATHLEEN, MCUNTAIN VIEW, CA, United States

MARRICK, BRETT L., PALO ALTO, CA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	us 1001020003	A1	200109 <i>1</i> 6	
	US 6:76648	B2	20020423	
APPLICATION INFO.:	US 1949-234974	Al	19990121	9)
POCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			

LEGAL REPRESENTATIVE: FOLEY & LAPHDER, 3000 K STREET NW, SUITE 500,

WASHINGTON, DO, 200075109

NUMBER OF CLAIMS: EMEMPLARY CLAIM:

NUMBER OF OPAWINGS: \$3 Drawing Page's LINE COUNT: \$113

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

Analogues of the Munito Protease Inhibitor (KPI)

abmain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors Vila, IMa, Xa, MIa, and XIIa. Pharmaceutical compositions containing the MPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as plood loss related to cardiopulmonary bygass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 40 DE 189 USPATFULL

ACCESSION NUMBER: 2001:91499 USPATFULL

TITLE: HIGH THROUGHPUT METHOD FOR FUNCTIONALLY CLASSIFYING

PROTEINS IDENTIFIED USING A GENOMICS APPROACH

FANTOLIANO, MICHAEL W., AVONDALE, PA, United States INVENTOR(S):

SALEMME, F. RAYMOND, YARDLEY, PA, United States

CARVER, THEOLORE E., JR., THORNDALE, PA, United States

NUMBER KIND DATE US 2001003648 A1 20010614 US 1998-190128 A1 19981112 (9)

NUMBER ΡΑΊΕ 

PRIORITY INFORMATION: US 1997-651299 19971112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STEFNE KESSLER GOLDSTEIN AND FOX, SUITE 600, 1100 NEW

YORK AVENUE NW, WASHINGTON, DC, 200053934

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

PATENT INFORMATION: APPLICATION INFO.:

NUMBER OF DEAWINGS: 11 Drawing Page(s)
LINE COUNT: 5511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides a method for functionally classifying a protein that is capable of unfolding due to a thermal change. The method comprises screening one or more of a multiplicity of different molecules for their ability to shift the thermal unfolding curve of the protein. wherein a shift in the thermal unfolding curve indicates that the molecule binds to the protein or affects the stability in a measurable way; generating an activity spectrum for the protein wherein the activity spectrum reflects a set of molecules, from the multiplicity of molecules, that shift the thermal unfolding curve, of the protein and therefore are ligands that bind to the protein, comparing the activity spectrum for the protein to one or more functional reference spectrum lists; and classifying the protein according to the set of molecules in the multiplicity of different molecules that shift the thermal unfolding durve of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 41 OF 199 UNPATFULD

ACCESSION NUMBER: 2001:235319 USPATFULD

TITLE: Kallikrein-binding "Kunitz dimain" proteins and analogues thereof

Markland, William, Milford, MA, United States INVENTOR (S):

Ladner, Robert Charles, Ijamsville, MD, United States

Byam Corp., Cambridge, MA, United States U.S. PATENT ASSIGNEE S:

corperation:

NUMBER. KIND DATE \_\_\_\_\_\_

us 6/33402 B1 20011225 us 1999-421097 19991619 :9 PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1994-208264, filed on 10 Mar

1994, now patented, Pat. No. US 6057287

Continuation-in-part of Ser. No. US 1994-179964, filed

on 11 Jan 1994, now abandoned

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

Achutamurthy, Ponnathapu PRIMARY EXAMINER:

ASSISTANT EXAMINER: Pak, Yong

LEGAL REPRESENTATIVE: Yankwich, Leon R., Zwicker, Kenneth P.,

Maraviz-Magovcevic, Ivana

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 53 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 53 Drawing Figure(s); 15 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 42 OF 189 USPATFULL

ACCESSION NUMBER: 2001:196603 USEATFULL

Cancer treatment methods using therapeutic conjugates TITLE:

that bind to aminophospholipids

Thorpe, Philip E., Dallas, TX, United States INVENTOR(3):

Ran, Sophia, Dallas, TX, United States

Board of Regents, The University of Texas System, PATENT ASSIGNEE(S):

Austin, TX, United States (U.S. corporation)

NUMBER KIND DATE ....... .... -----US 6312694 B1 20011106 US 1999-351457 19990712 FATENT INFOFMATION: 19990712 (9) APPLICATION INFO.:

NUMBER DATE 

PRIORITY INFORMATION: US 1993-925899 19930713 (60) US 1993-110600P 19981202 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
FRIMARY EXAMINER: Bansal, Geetha P.

LEGAL REPRESENTATIVE: Williams, Mirgan & Amerson

NUMBER OF CLAIMS: 50 EXEMPLARY CLAIM: 1,2,1,4

NUMBER OF DEAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s) LIME COUNT: 5243

CAS INDEXING IS AVAILABLE FOR THIS EATENT.

Displaced is the surprising dispovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolaminie, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provide: aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antifody-therapeutic agent conjugates and constructs that bind to

aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INTEXING IS AVAILABLE FOR THIS PATENT.

LIG4 ANSWER 43 OF 189 USPATFULL

2001:131342 USPATFULL ACCESSION NUMBER:

Dinjugates of dithiscarbamate disulfides with TITLE:

rnarmacologically active agents and uses therefor INVENTOR(S):

Lai, Ching-San, Encinitas, CA, United States Vassilev, Vassil P., San Diego, CA, United States

Wang, Tingmin, San Marcos, CA, United States

Medinam, Inc., San Diego, CA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE \_\_\_\_\_\_\_ PATENT INFORMATION: US 6274627 B1 20010814 US 1999-416619 19991012 (9) APPLICATION INFO.:

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.

LEGAL REPRESENTATIVE: Reiter, Stephen E.Foley & Lardner NUMBER OF SLAIMS: 4

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 5 Drawing Page(s)

2173 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically

active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 44 OF 189 USPATFULL

INVENTOR(3):

ACCESSION NUMBER: 2001:86465 USPATFULL

.heta.-sheet mimetics and use thereof as inhibitors of TITLE:

> hiplogically active peptides or proteins Fahn, Michael, Kirkland, WA, United States

Ogbu, Cyprian O., Bellevue, WA, United States Eguchi, Masakatsu, Bellevue, WA, United States

Fim, Hwa-Ok, Redmond, WA, United States

Bratman, Jr., Patrick Douglas, Issaquan, WA, United

States

Molecumetics Ltd., Bellevue, WA, United States (U.S. PATENT ASSIGNEE(S):

cornoration.

NUMBER KIND DATE PATENT INFORMATION: US 6245764 B1 20010618 APPLICATION INFO.: US 1998-9665 19990120

PELATEL APPLN. INFO.: Continuation of Ser. No. US 1996-725073, filed on 2 Opt

1998, now abandoned Continuation-in-part of Ser. No. US 1996-624690, filed on 25 Mar 1996, now akandoned Continuation-in-part of Ser. No. US 1995-549006, filed

in 17 Dat 1995, now apandoned Continuation-in-part of Fer. No. US 1995-419518, filed on 24 Mar 1995, now

arandoned Ttility

FILE SEGMENT: GRANTED PRIMARY EXAMINER: Gukton, David

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

DOCUMENT TYPE:

NUMBER OF DRAWINGS: f Drawing Figure(s); 4 Drawing Page(s) LINE COUNT: 2875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There are disclosed .beta. sheet mimetics and methods relating to the same for imparting or stabilizing the .beta.-sheet structure of a peptide, protein or molecule. In one aspect, .beta.-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and Factor M inhibitors. In one embodiment, the .beta.-sheet mimetic is a thrombin inhibitor.

# CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LID4 ANSWER 45 OF 189 USPATFULL

2001:82499 USPATFULL ACCESSION NUMBER:

Immunoussays for catalytically active, serine proteases TITLE:

Mann, Kenneth G., Shelburne, VT, United States INVENTORUS,: Williams, Brady, St. Paul, MN, United States

Tracy, Russell P., Essex Junction, VT, United States University of Vermont and State Agriculatural College,

PATENT ASSIGNEE(S): Burlington, VT, United States (U.S. corporation)

> NUMBER KIND DATE ......

PATENT INFORMATION: US 6242173 B1 20010605 APPLICATION INFO.: US 1992-833646 19920207 (7)

RELATED APPEN. INFO.: Continuation of Ser. No. US 1998-252506, filed on 30

Sep 1988, now abandoned

Utility DOCUMENT TYPE: FILE SEGMENT: Granted
PRIMARY EXAMINER: Marschel, Ardin H.

LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A.

NUMBER OF CLAIMS: 36 EXEMPLARY CLAIM.

NUMBER OF DRAWINGS: 3 Dra
1226 EXEMPLARY CLAIM:

3 Drawing Figure(s); 2 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods for detecting and/or quantifying catalytically-active, serine proteases in a biological fluid are disclosed. The methods are useful for measuring the active enzymes of the coagulation/fibrinolytic system and evaluating the system or components of the system as indicative of thrombosis-related disorders. The methods involve the combined use of halomethyl ketone probes having broad specificity for catalytically-active serine proteases and immunological reagents specific for serine proteases of particular types. The halomethyl ketone profes are active site specific; they are only incorporated into catalytically-active serine proteases. An antibody is used to provide specificity for the particular type of serine protease. By the commined active-site-specificity of the halamethyl ketone probes and the type-specificity of the antibody, the catalytically-active fraction of a particular derine protease is determined.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1114 ANSWER 46 OF 189 USPATFULL

Accession Number: 2001:43957 Uspatfull

TITLE: Methids of determining endogenous thrombin potential ETP: and thrombin substrates for use in said methods

INVENTOR:S : Hemker, Hendrik Coemraad, Tongerstraat 41, NL-6211 LM

Maastricht, Netherlands

Rijkers, Dirk Thomas Sigurd, Eindhoven, Metherlands Tesser, Godefridus Ignatius, Niemegen, Netherlands

PATENT ASSIGNEE (S): Hemker, Hendrik Coenraad, Maastricht, Netherlands

non-U.S. individual)

NUMBER KIND DATE -----us 6207399 B1 20010327 Wb 9621740 19960718 PATENT INFORMATION: 19960718 APPLICATION INFO.: us 1997-360308 19970905 (8) W0-1996-NL18 19960110 19970905 PCT 371 date 19970905 PCT 102(e) date

NUMBER DATE

PRIORITY INFORMATION: EP 1995-43 19950110

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: Tung, Mary Beth

LEGAL REPRESENTATIVE: Fillsbury Winthrop LLP 36

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 30 Drawing Figure(s); 10 Drawing Page(s) LINE COUNT: 3996

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A method for determining the endogenous thrombin potential of a sample having a total anticoagulant activity of or equivalent to at least 0.07 U ISH/ml, includes using a thrombin substrate or a salt thereof that is soluble in the sample to determine the ETP of the sample. Suitable thrombin substrate include those of the formula P-Val-Xaa-S, in which P is an amino protective group, that is non-aromatic and polar, Val is a valine residue attached via a peptide bond to Maa, Maa is an amino acid residue comprising a terminal quanidino group or ureido group separated by at least 2 carbon atoms from the peptide backbond the amino acid residue is attached to 3 and 3 is a signal group such as a chromophore that can be enzymatically hydrolyzed. Other substrates include substrates comprising the structure Zaa-Pipecolyl-Yaa-S or Zaa-Pro-Yaa-S, wherein Zaa represents D-Phenylalanine, D-Tryptophan or D-Tyrosine, Pro represents proline, Yaa is an amino acid residue other than arginine and 3 is a signal marker can also be used. The substrates Boc-Gly-Val-Arg-pNA and H-Glu-Gly-Gly-Val-Arg-pNA are also applicable. Furthermore ETP determination methods can be improved by addition of hydroxylamine to the sample to dirgumvent defibrination of the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWEE 47 OF 189 FOTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: .: 001096561 POTFULL ED 20020936 TITLE /ENGLISH:: WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL

FORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND

OFTICNALLY REPEATING

TITLE \* FRENCH:: INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE I'UNE PARTIE SMESTANTIELLE D'UN GENUME DE DEPART, PAR

COMBINAISON DE MUTATIONS ET EVENTUELLEMENT REPETITION

INVENTOR:S:: SHORT, Jay, M. DIVERSA CÜRPORATION; SHORT, Jay, M. PATENT ASSIGNEE'S : DOCUMENT TYPE: Patent PATENT INFORMATION: KIND DATE NUMBER W0 2001096551 A2 20011220 AE AG AL AM AT AU AZ BA BB BG BE BY BL CA CH CN GG GR DESIGNATED STATES BU 12 DE DK DM DZ EC ER ED FI GB GD GE GH GM HR HU ID II. IN IS IF HE KE KE KE KE LO LE LE LE LE LU LU MA MD MG MK MN MW MX MZ NO NZ PL PT BO BU SO SE SG SI SK SL TO TM TR TT TO UA UG US DO VM YU ZA ZW GH GM KE LS MW MZ 30 SL 32 TZ U3 3W AM AC BY KG KZ MO RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BUICE OF CLICK GAIGN SWIME MR NE SNITO TO Wo ::001-US19367 A ::0019614 APPLICATION INFO.: US 1000-09/594,459 20000614 US 1000-09/677,594 20000930 PRIORITY INFO.: An invention comprising cellular transformation, directed evolution, and ABEN screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a midrobe or a of regulatory sequences, such as promoters, that are operable in an it is introduced into an intended host. For example a novel man-made

plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction intended host, thus conferring operability to a novel gene pathway when gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

L'invention porte sur des procedes de transformation cellulaire, ABFR d'evolution dirigee et de criblage en vue de creer de nouveaux organismes transgeniques aux proprietes souhaitees. En variante, cette invention porte sur un procede de generation d'un organisme transgenique tel qu'un microbe ou une plante presentant une pluralité de caracteristiques pouvant etre activées de manière differentielle. L'invention porte aussi sur un procede permettant de restructurer des genes et des mecanismes d'action genetiques par l'introduction de sequences regulatrices telles que dos promoteurs pouvant agir dans un hote determine, ce qui confere une operabilité a un nouveau mecanisme d'action genetique lorsqu'il est introduit dans un hote determine. Par exemple, un nouveau mecanisme d'action genetique artificiel, genere a partir de gabarits de progeniteurs derives de microbes, peut être utilise dans une cellule vegetale. L'invention porte en poutre sur de nouveaux organismes hotes dont les caracteristiques souhaitees, les genes de recombinaison et les produits geniques ont une expression accrue.

ANSWER 48 OF 139 ECTEVILL COPYRIGHT 2002 Univentic ACCESSION NUMBER: 2001094332 PCTFULL ED 20020826

PROFILING OF PROTEASE SPECIFICITY USING TITLE (ENGLISH):

COMBINATORIAL FLUOROGENIC SUBSTRATE LIBRARIES

PROFILAGE DES PARTICULARITES D'ENZYMES A L'AIDE DE TITLE (FRENCH):

BIBLIOTHEQUES COMBINATOIRES DE SUBSTRATS FLUCROGENES

HARRIS, Jennifer, L.; BACKES, Bradley, J.; ELLMAN,

Jonathan, A.; JRAIK, Charles, S.

REGENTS OF THE UNIVERSITY OF CALIFORNIA; HARRIS, PATENT ASSIGNEE'S):

Jennifer, L.; BACKES, Bradley, J.; ELLMAN, Jonathan,

A.; CRAIK, Charles, S.

DOCUMENT TYFE: Patent

PATENT INFORMATION:

INVENTOR(S):

NUMBER KIND WD 2001094332 A1 20011213 DESIGNATED STATES

AE AG AL AM AT AV AZ BA BB BG BR BY BZ CA CH CN CD CR
CU CZ DE DK DM DZ EC BE ES FI 3B GD GE 3H 3M HR HU ID
IL IN IS UP KE KG KP KR KC LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ ND NZ PL PT RD RU SD SE SG SI SK SL
II IM TR TT TZ VA VG NS VC VN YU ZA PW GH GM KE LS MW
MZ SD SL SZ TZ UG CW AM AC BY KG KC MD RU II IM AT BE
CH CY DE DK ES FI FR 3B GR IE IT LU MC NL PI SE TR BF
BI DF CG CI CM GA 3N W ML MR NE SN TO TG
APPLICATION INFO.:
WD 2001-U317265
PRIORITY INFO.:
US 1001-09/886,112
ABEN Fluorogeric montide to be the company of the com

Fluorogenic peptide substrates allow for the configuration of ABEN general substrate libraries to rapidly identify the primary and extended specificity of enzymes, such as proteases. The substrates contain a fluorogenic-leaving group, such as 7-amino-4-carbamoylmethylcommarin (ACC). Substrates incorporating the ACC leaving group show comparable kinetic profiles as those with the traditionally used 7-amino-4-methyl-coumarin (AMC) leaving group. The bifunctional nature of ACC allows for the efficient production of single substrates and substrate libraries using solid-phase synthesis techniques. The approximately 3-fold increased quantum yield of ACC over AMC permits reduction in enzyme and substrate concentrations, so that a greater number of substrates can be tolerated in a single assay, thus enabling an increase in the diversity space of the library. Employing this screening method, the substrate specificities of a diverse array of proteases were profiled, including serine proteases and cysteine proteases.

L'invention porte sur des substrats de peptides fluorogenes ABFR servant a preer des bibliothèques de substrats generaux permettant d'identifier rapidement les particularites primaires et étendues d'enzymes, telles que des proteases. Les substrats contiennent un groupe partant fluorogene tel qu'un groupe 7-amino-4-darbamoylmethyl-coumarine (ACC). Les substrats contenant le groupe partant ACC presentent des profils cinetiques comparables a deux du groupe partant 7-amino-4-methyl-coumarine (AMC) utilise ocuramment. La nature pifonctionnelle de l'ASC permet de produire efficacement differents substrats et biblictheques de substrats à l'aide de techniques de synthese en phase solide. Le rendement quantique sensiblement triple de l'ACC par rapport a l'AMC permet de reduire la concentration des enzymes et des substrats, d'ou un plus grand nombre de substrats par essai et la possibilite d'accroitre l'espace pour divers de la bibliothèque. Avec ce procede de criblage, on a pu profiler les particularites d'un reseau divers de proteases dont des proteases de serine et de cysteine.

L104 ANSWER 49 OF 189 POTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 2001087842 POTFULL ED 20020326

TITLE (ENGLISH): SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES

USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION

CASCADE

TITLE (FRENCH): SYRIDONES ARYLE ET HETERGARYLE BOLYCYCLIQUES

SUBSTITUEES UTILISEES POUR L'INHIBITION SELECTIVE DE LA

CASCADE DE COAGULATION

INVENTOR(S: SCUTH, Michael, S.; ZENG, Qingping; RUEPPEL, Melvin,

L.; HAMME, Ashton, T., II

PATENT ASSIGNEE(3): PHARMACIA CORPORATION; SOUTH, Michael, 3.; DENG,

Qingping; RUEPPEL, Melvin, L.; HAMME, Ashton, T., II

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WG 2001787842 A1 20011122

DESIGNATED STATES AE AG AL AM AT AU AZ 5A BB 8G 8R 8Y CA CH CN CR CU CZ
DE DY DM DC 8E 88 F1 G8 G8 3E GH GM HR HU 1D 11 IN 18
JP KF K3 KP KR KZ LC LK LF 88 LT LU LV MA MD M3 MK MC

MW MM NO NZ PL PT RO PU SĐ ŠE SG SI SK SL TJ TM TR TT

TZ WA WG WA WZ WN YW ZA ZW GH GM KE LS MW MZ SD SL SZ TZ MG ZW AM AZ BY KG KZ MD RU TU TM AT BE CH CY DE DK ES FI FR GH GR LE IT LY MO NL PT SE TR BF BJ OF CO CI

OM HAR ON OW MIL MR NE ON TO TO

APPLICATION INFO.: W0.0000-U8/1803 A 20001100 PRIORITY INFO.: U8 0000-09.574,040 200000518

ABEN The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds of the formula (I) weful as inhibitors of serine protesse of the cosquiation rascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombiti: conditions inclusing occomary artery and cerebrovascular diseases.

L'invention concerne des composes de pyridone aryle et hetercaryle ABFE: polycycliques substitues de formule (I) utiles comme inhibiteurs de la serine protease de la cascado de coagulation, ainsi que des composes, des compositions et des methodes destinés à la théraple anticoagulante pour le traitement et la prevention d'une pluralité d'états thrombotiques tels que les coronaropathies et les affections vasculaires cerebrales.

ANSWER 50 OF 189 POTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001081561 PCTFULL ED 20020826

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS TITLE (ENGLISH):

OF ACNE VULGARIS

COMPOSITIONS ET PROCEDES FOUR LA THERAFIE ET LE TITLE (FRENCH):

DIAGNOSTIC DE L'ACHE VULGAIRE

SKEIKY, Yasır, A., W.; PERSING, David, H.; MITCHAM, INVENTOR(S):

Jennifer, L.; WANG, Siging, Steven; BHATIA, Ajay; L'MARISONNEUVE, Jean-Francois; ZHANG, Yanni; JEN,

Shylan; CARTER, Darrick

CORINA CORPORATION; SKEIKY, Yasır, A., W.; PERSING, PATENT ASSIGNEE(S):

David, H.; MITCHAM, Jennifer, L.; WANG, Siging, Steven;

BHATIA, Afay; L'MAISONNEUVE, Jean-Francois; ZHANG,

Yannı; JEN, Shylan; CARTER, Darrick

DOCUMENT TYPE: Patent

PATENT INFORMATION:

KIND DATE NUMBER 

Wo 0001081581 AD 00011101

AE AG AL AM AT AU AG BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES

OU OZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KC DC LK LE LS LT DU DV MA MD MG MK MN MW MM MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TO UA UG US UC VN YU DA ZW GH GM KE LS MW MZ

SP SE SZ TZ UG DW AM AD BY KG KZ MĐ RU TJ TM AT BE CH CY DE DK ES FI FR GB GR 1E IT LU MC NL FT SE TR BF BJ

OF OG OI OM GA ON GW ML MR NE SN TD TG

- **W**O UJ031-U310865 A 00010400 APPLICATION INFO.: PRIORITY INFO.:

US 2000-60/199,047 200000401 US 2000-60/203,841 20000602 US 2000-60/216,747 20000707

Compositions and methods for the therapy and diagnosis of ache vulgaris ABEN and other related conditions are disclosed. Compositions may comprise

one or more <i>Propiumibacterium aches /i · proteins, immunogenia portions thereof, or polynucleotides that encode such portions.

Alternatively, a therapeutic composition may comprise an antibody that rings a ri>Propioniba terium aches« i> protein, antigen presenting cell that expresses a <i:Propionibacterium ames @i> protein, or a T cell that is specific for rells empressing such a protein. Such compositions

may be used, for example, for the prevention analor treatment of aone.

L'invention concerné les compositions et les pricédes pour la théraple ABFE et le diagnostic de l'ache vulgaire et d'autres états apparentes. Les compositions peuvent comprendre une ou plusieurs proteines de l'apropionibacterium (chesk/l/, des fractions immunogenes de celles-ci,

ou des polynucleotides qui codent de telles fractions. Selon une

variante, une composition therapeutique peut comprendre un anticorps qui fixe une proteine de <i>Propionipacterium acnes</i>, une cellule presentant un antigene qui exprime une proteine de siofropionipacterium acnes</i>, or une rellule T qui agit specifiquement sur les cellules exprimant une telle proteine. De telles compositions peuvent etre utilisées, par exemple, pour la prévention et qu'le traitement de l'ache.

LID4 ANSWER 51 OF 189 ESTEULL SUPPRESHT 2065 Univentib

ACCESSION NUMBER: 2001072725 POTFULL ED 2 020822
TITLE (ENGLISH): BICYCLI SULFONYL AMINO INHIBITORS OF

FACTOR Xa

TITLE (FRENCH): INVENTOR(S):

INHIBTEURS AMINOSULFONYLES BICYCLIQUES DU FACTEUR XA LI, Wenhao; MARLOWE, Charles, K.; SCARBORDUGH, Echert,

М.

PATENT ASSIGNEE(S):

COR THERAPEUTICS, INC.; LI, Wennac; MARLOWE, Charles,

K.; SCARBOROUGH, Robert, M.

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

HIND DATE NUMBER \_\_\_\_\_

DESIGNATED STATES

W0 2001072725 AT 20011004 AE AG AL AM AT AU AL BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KO LO LK LR LS LT LU LV MA MD MG MK MN MW MM MZ NO NZ PL PT RO RU 3D SE 3G SI SK SL TJ TM TE TT TO UA UG US US VN YU ZA DW GH GM KE LS MW MZ SD SE SZ TZ UG SW AM AZ BY KG KZ MĐ ĐU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF

OG OT CM GA GN GW ML MR NE SN TD TG | WO 2001-US9375 | A | 2001032€

APPLICATION INFO.:

US 2000 60/191,715 00000324

PRIORITY INFO.: ABEN

Novel compounds of formulae (I) or (Ia), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The compounds and compositions are useful <i>in vitros/i> orkibin vivok/ib for preventing or treating conditions in mammals characterized by undesired thrombosis.

ABFR L'invention concerne les composes de formule (I) ou (Ia), ainsi que leurs isomeres, sels, hydrates, solvates et derives pro-medicamenteux pharmaceutiquement acceptables, lesdits composes ayant une activité contre le facteur MA mammifere. L'invention concerne eqèlement des compositions contenant de tels composes. Des composes et compositions selon l'invention servent au traitement et a la prevention in vitro et in vivo de maladies mammiferes caracterisées par la presence de thromboses indesirables.

ANSWER 52 OF 189 POTFULL COPYRIGHT 2000 Univentic

ACCESSION NUMBER: 2001072195 PCTFULL ED 24020821

TITLE (ENGLISH):

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS

OF LUNG CANCER

TITLE (FRENCH):

COMPOSITIONS ET METHODES POUVANT TRAITER OU

DIAGNOSTIQUER LE CANCER DU FOUMON

INVENTOR  $(\mathcal{Z})$ :

REED, Steven, G.; LGDES, Michael, J.; MOHAMATH, Rapdoh; SECRIST, Heather; BENSON, Darin, R.; INDIRIAS, Carol, Yoseph; HENDERSON, Achert, A.; FLING, Steven, P.; ALGATE, Paul, A.; ELLIOT, Mark; MAUNION, Jane; KALOS, Michael, D.

PATENT ASSIGNEE(S):

CORIMA CORPORATION: READ, Steven, G.: LCDES, Michael, J.; MOHAMATH, Racach; SECFIST, Heather; BENSON, Darin, R.; INDIRIAS, Carol, Yoseph; HENDERSON, Robert, A.; FLING, Steven, P.; ALGATE, Paul, A.; ELLIGT, Mark;

MARNION, Jame; KALOU, Michael, D.

POCUMENT TYPE:

Patent

PATENT I	NFORMATION:	NUMBER	KIND	DATE		
APPLICAT	ED STATES  ION INFO.: INFO.:	WI .001072095 AE AG AL AM AT AU OU GE DE DE DE DE DE IN LE JP EE EG EP ME MU MW MM ME NO TM TE TT TO UA UG SI SU SO TO UG ZW OY DE DE ES FI FE OF CG OI CM GA GN WO 1001-US#991 US 2000-09/538,03	AZ BA BB EE ES FI KR KZ LC NU FL PT US UZ VN AM AZ BY GB GR IE GW ML ME A 20	BG BB BY GB GI GE LK LB IS RC BC SD YU GA ZW KG HZ MD IT LU MG NE SN TD 011329	SH SM HR LT LU LV SE SG SI SH SM KE BU TJ TM NL PT SE	HU ID IL MA MD MG SK SL TJ LS MW MZ AT BE CH
		Us 1000-09/588,93 Us 2000-09/640,87 Us 2000-60/234,51 Us 2000-09/704,51 Us 2000-09/738,97 methods for the ti	7	000605 000813 000922 001101 001214	is of cano	·PY.
ŗ.	articularly lun	g cancer, are disc more lung tumor po	losed. Il	lustrativ	e composit	ions
t P sj c a ABFR L d	hereof, polynuc resenting cell pecific for cel empositions are nd/or treatment 'invention conc iagnostiquer le xemplaires cont	leotides that encountries expressing such useful, for example of diseases, particular designment iennent un ou plus	de such p n polypept polypept le, in the icularly ons et de- le cance ieurs pol-	olypeptid tides, an ides. The e diagnos lung cano s methode r du poum ypeptides	es, antige d T cells disclosed is, prever er. s pouvant on. Des co de tumeur	that are that are tion traiter ou empositions
ני פ ני ני ני	brothe-pulmonaire, des parties immunogenes desdits polypeptides, des polypucleotides codant des polypeptides, une dellule antigenique exprimant des polypeptides, et des lymphodytes T specifiques de dellules exprimant des polypeptides. Les compositions de l'invention sont utiles, par exemple, pour diagnostiquer, prevenir et/ou traiter des maladies, notamment le cancer du poumon.					
ACCESSION TITLE (EX	N NUMBER:	PCTFULL COPYRIO 2001063090 PCTFUL BCMP-7 AS MARKER BCMP-7 EN TANT QU CANCER DU SEIN	L ED 200. FOR DIAGN	20822 OSIS OF B	REAST CANO	
INVENTOF:	(S):	BOYD, Robert, Sime Jonathan, Alexande				TERRETT,
FATENT A	PATENT ASSIGNEE(S): OMFORD GLYCOSCIENCES (UK: LTD.; BOYD, Robert, Simon; STAMPS, Alasdair, Craig; TERRETT, Jonathan, Alexander; TYSON, Kerry, Louise					Simon; Alexander;
DOCUMENT PATENT I	TYPE: NEOFMATION:	Patent NUMBER	KINI)			
DESIGNAT	ED STATES	WO DOOLG63290 AE AG AL AM AT AU DZ DE DK DM DD EE LS TP KE KG KE KR MN MW MK MC NO NZ TE TT TO UA UG US	A1 000 AC BA BB ES FI GB EC LC LE FL PT RO UC VM YU	010830 BG BR BY GD GE GH LR LS LT BU DD SE ZA DW GH	GM HR HU LU LV MA SG SI SK GM KE LS	ID IL IN MD MG MK SL TJ TM MW MZ SD
PRIORITY ABEN T	INFO.: he present inve ancer cell memb	SL SZ TZ UG ZW AM DE DK EL FI FE GB CP AI CM 3A SW GW WO 1001 G5734 GB L000 20045 6.5 ntion provides the ranes, known as BC ophylaxis of preas	GR IS IT ML ME NE A 20 20 use of a MP 7, in	EM MO ML SM TO TG 011/21 001225   protein the diagn	PT SE TR found in sosis, sore	BF BJ CF ereast ening,

comprising BCMP 7, including vaccines and antibodies that are immunospesific for BCMP 7.

ABFR La presente invention concerné l'utilisation d'une proteine presente dans des membranes cellulaires de cancer du sein, connue en tant que BOMP 7, dans le diagnostic, le criblage, le traitement et la prophylaxie du cancer du sein. L'invention concerne egalement des compositions contenant BCMP 7 et des vaccins et anticorps immunaspecifiques a BCMP 7.

L104 AMSWER 54 OF 189 POTFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 2001062086 ECTFULL ED 201208/2

PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND TIPLE (ENGLISH):

USES THEREFOR

FORMES PROTEGEES D'AGENTS PHARMACOLOGIQUEMENT ACTIFS ET TITLE (FRENCH):

UTILISATIONS CORRESPONDANTES

INVENTOR(3): LAI, Ching-San; WANG, Tingmin; VASSILEV, Vassil, P. PATENT ASSIGNEE(S): MEDINOX, 193.

DOCUMENT TYPE: PATENT INFORMATION: Patent

NUMBER KIND DATE W0 2001062095 A1 00010830

AE AG AL AM AT AU AD BA BB BG BR BY CA CH ON OR OU CD DESIGNATED STATES

DE DE DM DC EE ES FI GB SD GE GH GM HR HU ID IL IN IS JE KE KG KP KE K3 LC LK LE LS LT LU LV MA MD MG MK MN MW MM ME NO NE PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG DW AM AD BY KG KD MD RU TJ TM AT BE CH CY DE DK ES

FI FR GB GR IE IT LU MO NL PT SE TR BF BJ CF CG CI CM

GA GN GW ML MR NE SN TO TG

W0 0001-035977 A 20010223 U3 0000-09/515,043 20000025 APPLICATION INFO.: PPIORITY INFO.:

ABEN In accordance with the present invention, there are provided conjugates of dithiocarbamates ("DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein.

ABFR La presente invention se rapporte a des conjugues de dithiocarbamates ("DC") et a des agents pharmacologiquement actifs (par exemple, des AIN3). Lesdits conjugues fournissent une nouvelle classe d'agents pharmacologiquement actifs (par exemple, d'agents anti-inflammatoires) qui provoquent une apparition bien moindre d'effets secondaires en raison des effets protecteurs conferes par la modification des agents pharmacologiquement actifs decrits ci-dessus.

ANSWER 55 OF 189 PCTFULL COPYRIGHT 2002 Univention L104

ACCESSION NUMBER: 2001057010 FCTFULL ED 20020807

TITLE (ENGLISH): USE OF DEMDROASPIN AS A VEHICLE FOR NON-DEMDROASPIN

DOMAINS

UTILISATION DE DENDROASPINE EN TANT QU'EXCIPIENT POUR TITLE (FRENCH):

DOMAINES EMEMPTS DE DENDROASPINE

INVENTOR(S): LU, Kinjie; KAKKAR, Vijay, Vir

PATENT ASSIGNEE(S): TRIGEN LIMITED

DOCUMENT TYPE: Patent

PATENT INFOFMATION:

NUMBER KIND CATE 

W0 0001057.10 A2 00010809

AB AG AL AM AT AV AC BA BB BG BR BY BZ CA CH CN CR CU DESIGNATED STATES CZ DE DY DM CC EE ES FI GE GO GE GH GM HR HU ID IL IN

IS JP KE KO KE KR KZ LO LK LR IS LT LU LV MA MO MG MY MN MW MM MN NO NO PL PT RO RU ED SE SG SI SK SL TJ TM

TR TT TO UA UG UO VN YU DA ZW GH GM KE LS MW MZ SD SU

SZ TZ UG ZW AM AZ BY KG KZ MD KU TJ TM AT BE CH CY DE PK ES FI FR GB GR IE IT LU MO ML PT SE TR BF BJ GF GG

```
OI OM GA RN GW ML MR NE RN TO TG
```

 
 W0 0001-35439
 A 10010205

 gs 0008-0000825.2
 00000280
 APPLICATION INFO.: PRIORITY INFO::

ABEN The use of dendroaspin as a coaffold for one or more non wild-type dendriaspin domains, the dendroaspin staffold being modified in that the native ROD motif has keen deleted or has been replaced by it an amino acid sequence having no integrin-bunding activity or ii, an integrin-binding amin: acid sequence other than HGO which contains aspartic acid (D) or plutamic acid (E).

L'invention concerne l'utilisation de sénarbaspine en tant que structure ABFR pour au moins un domaine de dendroaspine qui n'est pas du type sauvage, la structure de dendroaspine etant modofice du fait que le motif endogene RGD a ete elimine ou remplace (i) par une sequence d'acides amines ne possedant pas d'activité de liaisin aux integrines ou (ii) par une sequence d'abides amines se liant aux integrines qui differe de EGD et renferme de l'acide aspartique (D) ou de l'acide glutamique (E).

ANSWER 56 OF 139 POTFULL COPYRIGHT 2002 Univertib L104

AGCESSION NUMBER: 3001057194 PUTFULL ED 20020827

NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE TITLE (ENGLISH):

PROTEASES, THE ENCODED PROTEINS AND METHODS BASED

THEREON

TITLE (FRENCH): - Molecules D'Acides Nucleiques codant pour des Proteases

A SERINE TRANSMEMBRANAIRES, PROTEINES CODEES ET

PROCEDES ASSOCIES

INVENTOR(3):

MADISON, Edwin, L.; ONG, Edgar, O.; YEH, Jiunn-chern

CORMAS INTERNATIONAL, INC.; MADISON, Edwin, L.; ONG,

Edgar, O.; YEH, Jiunn-chern

DOCUMENT TYPE:

PATENT INFORMATION:

PATENT ASSIGNEE(S):

KIND DATE NUMBER 

WO 2001057134 A2 20010809

Patent

AE AG AM AT AU AC BA BB BG BR BY BC CA CH CN CR CU CZ DESIGNATED STATES DE DK DM DZ EE ES ET GB GD GE GH GM HR HU ID IL IN IS

JE KE KG KE KE KE LE LK LE LS LT LU LV MA MD MG MK MN MW MM MZ NO NZ PL PT PO BU SD SE SG SI SK SL TJ TM TR

TT TZ UA UG US UC VN YU CA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AJ BY KG KZ MD RU TJ TM AT BE CH CY DE

DR ES PI FR GB GR IE IT DU MO NU PT SE TR BF BJ CF CG

CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: PRIORITY INFO.:

 Wo
 2001-US3471
 A
 20010202

 US
 2000-80/179,982
 20000203

 US
 2000-80/183,542
 20000218

 US
 2000-80/213,124
 20000622

20000736 US 2000-60/220,970 US 2000-60/234,640 20000922

ABEN Provided herein are polypeptides that include the protease domain of a type II transmembrane serine protouse (MTSP) as a single chain. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP are provided. Also provided are MTSPs designated MTSP3 and MTSP4 and a form of an MTSP designated MTSP6.

L'invention concerne des polypeptides comportant un domaine de protease ABFR du type de protease a serine transmembranaire de type II (MTSP) sous forme d'une chaine unique. Elle concerne aussi des procedes utilisant ces polypeptides afin d'identifier des composes qui modulent l'activité problemse d'une MTSP. Elle converne encore des MTSP de designation MTSP3 et MTSP4 ainsi qu'une forme de MTSP de designation MTSP6.

AMSWER 57 OF 199 FOTFULL AMPYRIGHT . WOLD Universition

ACCESSION NUMBER: 2101055291 PUTFULL ED 20020807
TITLE (ENGLISH): NUCLEIC ACIDO, PROTEINS, AND ANTIBODIES
TITLE FRENCH: ACIDES NUCLEIQUES, PRUTEINES ET ANTICOPPS
INVENTOR(S): RISEN, Draig, A.; BARASH, Steven, C.; RUBEN, Steven, M.

```
PATENT ASSIGNEE'S':
                        HUMAN GENOME SCIENCES, INC.; ROSEN, Craig, A.; BARASH,
                         Steven, C.; RUBEN, Steven, M.
POCUMENT TYPE:
                        Patent
PATENT INFORMATION:
                         NUMBER
                                             KIND
                                                      DATE
                                           ------
                         W0 0001055205 A1 20010800
PESIGNATED STATES
                        AS AG AL AM AT AU AD BA BB BG BR BY BZ CA CH CN CR CU
                         CZ DE DK DM DZ ER ES FI BB BD BE GH GM HR HU ID IL IN
                         13 TO KE K3 KD KR KZ LO 1K 1R 13 LT 1U 1V MA MD MG MK
                         M: MW MX ME NO NO PL PT RO RU NO SE SG SI SK SL TJ TM
                         THE TT TZ MA MG MG MZ VN YW ZA DW GH GM KE LS MW MZ SD
                         SL SZ TZ UG DW AM AZ BY MG MZ MD RU TJ TM AT BE CH CY
                         DE DK ES FI FR GB GR IE IT LW MC NL PT SE TR BF BJ CF
                         OG GI CM GA GN GW ML MR NE SN TD TG
                                            . 71
. 00010117
.00000131
.0000022
                        W0 0001-US1337 A 00010117
APPLICATION INFO.:
                        US 1000-60/179,065
PRIORITY INFO.:
                        US 2000-60/190,608
                        US 2000-60/184,664
                        US 2000-60/196,350
                                                 20000302
                         US 2000-60/189,874
                                                 20000314
                         US 1000-60/190,076
                                                 20000317
                         US 2000-60/198,123
                                                  20000041%
                         US 2000-60/205,515
                                                  200000519
                         US 2000-60/209,467
                                                  20000607
                         US 2000-60/214,836
                                                  20000623
                        US 2000-60/215,135
                                                 20000630
                                                  .:0000707
                         US 2000-60/216,647
                         US 2000-60/316,880
                                                  20000707
                        US 0000-60/017,487
                                                  20000711
                         US 2000-60/217,496
                                                 .00000711
                         US 2000-60/318,390
                                                  20000714
                        US 2000-60/220,963
                                                  200000736
                        US 2000-60/330,964
                                                 20000726
                         US 2000-60/229,757
                                                  20000314
                         US 2000-60/225,270
                                                  20000314
                         US 2000-80/005,447
                                                  20000314
                         US 0000-60/205,267
                                                  20000814
                        US 2000-60/225,758
                                                 20000814
                        US 2000-60/225,268
                                                 20000814
                        US 2000-60/224,518
                                                  20000814
                        US 2000-60/224,519
                                                 20000814
                        US 2000-60/115,759
                                                 20000814
                        US 7000-60/228,213
                                                  20000814
                        US 2000-60/325,386
                                                 20000814
                        US 2000-60/105,1114
                                                 20060814
                                                 200000818
                        US 2000-60/226,273
                                                 20000883
                        US 3000-60/336,863
                        US 3000-60/3.7,182
                                                 200000833
                                                 200000822
                        US 2000-60/226,681
                                                 200000823
                        US 1000-60/217,609
                                                 <u>ებიიიმო</u>ვი
                        US 0000-60/118,924
                                                 200000991
                        US 1000-60/...9,344
                                                 2000091.
                        US 0000-60/119,343
                        US 2000-60/3.9,387
                                                 ..0000091.
                        US 2000-80/219,345
                                                 .:00000901
                                                 .:000009+
                        ชร 2000-60 แปล,ช.3
                         US 10000-60-119,519
                                                 2000009 0
                        US ..000-60 ..±0,438
                                                 20000316
                        ts 1000-801 80,437
us 1000-801 81,433
                                                 20000456
                                                 20100773
                         us 1965-85 1 €2,585
                                                 20000908
                        tis 2000-601 31,414
tis 2000-60 131,244
                                                20000908
                                                20000908
                         US 2000-60/232,091
                                                 200000909
```

US	2040-60 231,242	20000908
	111111111111111111111111111111111111111	
13.5		200000958
	231,243 231,764	20400912
1.5		210109.4
		217777714
113	1300-40 132,3**	30003914
	.:210=4032 <b>,</b> 4	10000004 3
$\mathbb{M} \mathcal{Z}$	1960-6-60 192,3*1	.:000009.4 .:00009.4 .:00009.4
		. 1 " 0 0 4 . 4
115		20000914
	.:000೧−೯೮ .:33, ಕನ4	
US	. 300-40°′. 33, 1€°	000009.4
115	2000-40/232,34+ 2000-40/134,223	.00000914
	2000	
115		. 000009. 1
US	2000-00/334,374	100009.1
US	3000-80/334,947	200009.5
US	2000-60/234 <b>,</b> 94±	20000925
US	000-607035,484	30000920
ŲЗ	2000-00/235,834	30000927
US	2000-60/235 <b>,</b> 935	20000927
IJß	_000-60/036,362	20000914
U.S.		20000929
IJЗ	2000-60/336,370	20000923
US	2000-60/236,366	2000099
U.S		20000923
U.S	2000-60/237,039	20001002
IJЗ	2000-60/337,035	20001002
IJS	2000-60/237,040	20001002
US	2000-60/237,037	00001092
U.S	2000-60/236,302	20001002
US	2000-60/239,937	20001013
	2000-00/235,557	
US		20001013
US	2000-60/241,735	20001020
IJЗ	วกกก=ลัก/วงไว้ สถา	20001020
	2000-60/241,303 2000-60/240,960	
US	7000-00/240 <b>,</b> 300	20001020
U.S	2000-60/241,737	20001020
US	2000-60/241,808	30001030
U3	2000-60/241,771 2000-60/241,786	20001020
US	2000-60/241,786	200010.00
1.3	2000-60/241,826	20001020
	2000 00/241,010 2000 00/241,010	
US		20001101
US	2000-60/246,474 2000-60/246,532	20001108
U.S	2000=607246 532	20001108
	2000-60/246,476	
US	こしせいこうかい/こまり。4.7か	
U.5		20001108
	2000-60/246,526	
113	2000-60/246,526	20001108 20001108
IJ3	2000-60/246,526	20001108 20001108 20001108
UЗ	2000-60/246,526 2000-60/246,475 2000-60/246,525	20001108 20001109 20001108 20001108
	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523	20001108 20001108 20001108 20001108
US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523	20001108 20001108 20001108 20001108
US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527	20001108 20001108 20001108 20001108 20001108
US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477	20001108 20001108 20001108 20001108 20001108 20001108
US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611	20001108 20001108 20001108 20001108 20001108
US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611	20001108 20001108 20001108 20001108 20001108 20001108 20001108
U3 U3 U3 U3 U3 U3	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,610	20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,613	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
U3 U3 U3 U3 U3 U3	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,613	20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,523 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,613 2000-60/246,613	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,528 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,524	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,477 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,478 2000-60/246,478 2000-60/246,524 2000-60/246,524	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,475 2000-60/246,524 2000-60/246,524 2000-60/246,524	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US US US US US US US US US	2000-60/246,526 2000-60/246,475 2000-60/246,528 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,478 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108
US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,524 2000-60/246,523 2000-60/246,524 2000-60/246,524 2000-60/246,524 2000-60/246,523 2000-60/246,524	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117
US	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,524 2000-60/246,523 2000-60/246,524 2000-60/246,524 2000-60/246,524 2000-60/246,523 2000-60/246,524	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,513 2000-60/246,514 2000-60/246,514 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,513 2000-60/246,513 2000-60/246,514 2000-60/246,514 2000-60/246,513 2000-60/246,514 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,511 2001-60/243,117 2001-60/243,117	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 20001117 20001117 20001117
U3 U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,513 2000-60/246,513 2000-60/246,514 2000-60/246,514 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,511 2000-60/248,211	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117
U3 U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,513 2000-60/246,513 2000-60/246,514 2000-60/246,514 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,513 2000-60/246,511 2000-60/248,211	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117
US U	2000-60/246,526 2000-60/246,475 2000-60/246,525 2000-60/246,527 2000-60/246,527 2000-60/246,611 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,613 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523 2000-60/246,523	20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001108 20001107 2000117 2000117 2000117 2000117 2000117 2000117 2000117 2000117

```
US 2500-60 149,207 .:0001117
TS 2000-60 049,245
rs 2001-60 .49,300
TE 2001-40 149,265
             ..0101.17
MS 10000-601050,391
              16801301
..0001..05
US 2000-60/051,479
              20001.06
us 2000-60/051,969
             us 2000-60/051,856
              00001009
             20001203
US 2000-60/051,868
             .10001.108
```

The present invention relates to novel proteins. More specifically, ABEN isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

 La presente invention se rapporte a de nouvelles proteines. Plus ABFR specifiquement, elle se rapporte a des molecules d'acides nucleiques isolees codant pour de nouveaux polypeptides. Elle se rapporte a de nouveaux polypeptides et a des anticorps qui se lient a ces polypeptides. L'invention se rapporte a des vecteurs, a des cellules hotes et a des procedes de synthese et de recombinaison pour la production de polynucleotides et/ou de polypeptides humains et d'antiporps. L'invention se rapporte a des methodes diagnostiques et therapeutiques permettant de diagnostiquer, de traiter, de prevenir et/ou de pronostiquer des troubles associes a des nouveaux polypeptides. L'invention se rapporte en outre a des procedes de criblage permettant d'identifier des agonistes et des antagonistes des polynucleotides et des polypeptides décrits di-dessus. Elle se rapporte enfin a des procedes et/ou a des compositions permettant d'inhiber ou de favoriser la production et la fonction desdits polypertides.

ANSWER 58 OF 189 POTFULL COPYRIGHT 2002 Univertie L104

ACCESSION NUMBER: 2001081087 POTFULL ED 20020827

MULTIPLE INACTIVATED BLOOD FATTOR ANTICOAGULANT TITLE (ENGLISH):

COMPOSITION

COMPOSITION ANTICOAGULANTE A FACTEURS SANGUINS INAUTIVES MULTIPLES TITLE (FRENCH):

INVENTOR/S): JOHNSON, Richard, J.; LUNDBLAD, Roger

THYBRITOR(S): COMMSON, Rinhard, J., LUN PATENT ASSIGNEE'S): BAXTER INTERNATIONAL INC.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE WO 1001051047 A1 20010719

DESIGNATED STATES AU HAUDA JP AT BEIGH CY DE DK ES FI FR GB GR IE IT LU MC

NL PT SE TR

 

 W0 2000-U834734
 A ..0001220

 Us 2000-60 17 ,821
 ..000113

 Us 2000-09 74 ,239
 ..0001.1+

 APPLICATION INFO.: PRICRITY INFO.:

ABEN An anticragulant composition is provided which comprises at least two inactivated blood factors in a pharmaceut.cally acceptable carrier, such inactivated blood factors being present in a therapeutically effective desage. Methods for utilizing Euch anticoagulant compositions comprising providing to a patient a bougulation innikiting amount thereof are also provided, as are methods for the preparation of such compositions.

La presente invention concerne une composition antipolagulante comprenant ABFF: au moins deux facteurs sanquins inactives dans un vecteur acceptable du point de vue pharmaceutique, les facteurs sanguins inactives de ce type etant presents en un dosage efficace du point de vue pharmaceutique. Tette invention concerne equilement des procedes d'utilisation des compositions anticoaquiantes do l'invention, comprenant l'administration a un patient d'une quantité desdites compositions permettant d'inhiber la coaquiation, ainsi que des procedes de preparation de des compositions.

ANSWER 59 OF 189 POTFULL COPYRIGHT 2000 Univention ACCESSION NUMBER: 2001049675 PCTFULL ED 20020927

TITLE (ENGLISH):

DIHYDROBENJOPYRANS, DIHYDROBENZOTHIOPYRANS, AND

TETRAHYDROQUINGLINES FOR THE TREATMENT OF

COK-2-MEDIATED DISORDERS

TITLE (FRENCH):

DIHYDROBENDOPYRANNES, DIHYDROBENZOTHIOPYRANNES ET

TETRAHYDROQUINDLINES DESTINES AU TRAITEMENT DES TEQUBLES INDUITS PAR COX-2

INVENTOR(3):

FOGIEF, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY,

John, J.

PATENT ASSIGNEE(S):

PHARMACIA CORPORATION; ROGIER, Donald, J., Jr.; CARTER,

Jeffrey, S.; TALLEY, John, J.

DOCUMENT TYPE:

PATENT INFORMATION:

DESIGNATED STATES

Patent

NUMBER. EIND DATE 

W0 2001049675 A1 00010712

AL AM AT AU AC BA BB BG BR BY CA CH ON CU OC DE DK EE ES FI GB GD GE GH GM HE HU ID IL IS JP KE KG KP KR KZ LO LK LR LO LY LU LY MO MG MK MW MW MX NO NO PL PT RO FU SD SE SG SI SK SL TJ TM TR TT UA UG US UN VN YU EW GH GM KE LS MW M2 SD SL SZ TC UG ZW AM AZ BY KG KZ MD FU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NU PT SE TR BE BUIGE OG DI OM GA GN GW ML MR NE SN TD

TG

APPLICATION INFO.: PRIORITY INFO.:

 
 WO 0000-US34525
 A 00001219

 US 0000-60/174,281
 20000103
 ABEN A class of dihydrobenkopyrans, dihydrobencithiopyrans,

tetrahydroguinolines, tetrahydronaphthalenes, and analogs thereof, is described for use in treating syclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I) wherein X, Al, A2, A3, A4, R, R'', R1 and R2 are as described in the specification.

ABFR L'invention concerne une categorie de dihydropendopyrannes, dinydrobenzothiopyrannes, tetrahydroquinolines, tetrahydronaphthalenes, et leurs analogues, destinés à être utilisés dans le traitement des troubles induits par la cyclockygenase-2. Des composes presentant un interet particulier sont representes par la formule (I), ou X, Al, A2, A3, A4, E, R'', E1 et R2 sint tels que definis dans le descriptif.

ANSWER 60 OF 189 FOLFULL COPYRIGHT 2000 Univentit

ACCESSION NUMBER: 200.099498 POTFULL ED 20020-0

MUNITZ-TYPE PROTEASE IMHIBITIR POLYMUGLECTIVES, TITLE 'ENGLISH::

POLYPEPTIDES, AND ANTIBODIES

PULYMUDLECTIDES INHIBITEURS DE PROTEASE DU TYPE DE TITLE FREMCH:

KUNITZ, POLYPEPTIDES ET ANTICORPS INVENTOR'S:: RTBEN, Steven, M.; NI, Jian PATENT ASSIGNEE'S:: HOWAN GENOME SCIENCES, INC.; RUBEN, Steven, M.; NI, Jian DOCUMENT TYPE: Patent PATENT INFORMATION: KIND DATE NUMBER WB 1001 3-486 A2 10001571 AE AG AL AM AT AU AC BA 65 BG 68 BY 62 CA CH CN CE CU DESIGNATED STATES TO DE DE DM DZ EE ES FI SE SD SE SH SM HE HU ID IL IN MN: MW MX MN NO NO PL PT FO RU 3D SE SG SI SK SL TJ TM THE TT TO UA UG US WO VN YU ZA OW GH GM KE LS MW MZ SD SE SZ TO UG OW AM AD BY MG MO MD RU TU TM AT BE OH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF OG OI OM GA ON OW MI MR NE EN TO TG W0 0000-US31917 A 20001101 APPLICATION INFO .: US 1999 671107,751 19991172 PRIORITY INFO.: ABEN The present invention relates to nivel human KTPI polypeptides and isplated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KTPI polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human KTPI polypeptides. APFE. L104 ANSWER 61 OF 189 PCTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 2001032611 PCTFULL ED 20020920 M GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, TITLE (ENGLISH): AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM TITLE (FRENCH): N GUANIDINOALKYLAMIDES, LEUR PREPARATION, LEUR UTILISATION, ET PREPARATIONS PHARMACEUTIQUES RENFERMANT CEUX=CI KLINGLER, Otmar; ZOLLER, Gerhard; DEFOSSA, Elisabeth; INVENTOR(3):

AL-OBERT, Fahad; WALSER, Armin; OSTREM, James

PATENT ASSIGNEE(S): AVENTIS PHARMA DEUTSCHLAND GMBH Patent

DOCUMENT TYPE:

PATENT INFOFMATION:

MUMBER TATE OMIN . .\_.\_\_\_\_

Wo 2001032611 A1 20010510

AE AG AL AM AT AU AC BA BB BG BE BY BZ CA CH ON CE CU DESIGNATED STATES

CO DE DK DM DO EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KO KE KE KE LO LK LE LS LT LU LV MA MD MG MK MN MW MM MO NO NO PL PT PO RU 3D SE SG SI SK SL TJ TM THE TT TO UA UG UD MI YU DA BW GH GM KE LS MW MZ SD SL SE TE UG EW AM AE BY KG KE MD AU TO TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

CM GA GN GW ML ME NE SN TO TG

APPLICATION INFO.: WO 0000 EP10395 A 000010.11 PRIORITY INFO.: EN 1999 99121623.5 19991030

The present invention relates to sempounds of formula (I), in which A, ABEN L, Y and k have the meanings indicated in the claims. The compounds of the formula (I) are valuable rharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylamis of pardiovascular disorders like

thromboembolic diseases or restenuses. They are reversible inhibitors of the blood altating enzymes factor

Xa and/or factor VIIa and bun in meneral be applied in conditions in which an undesired activity of factor Xa

and/or factor VIIa is present or for the cure or prevention of which an

inhibition of factor Xa and/or factor VIIa

is intended. The inventiin furthermire relates to processes for the

preparation of compounds of the formula 'I , their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

ABFR

1114 ANSWER 62 OF 189 POTFULL QUEYRIGHT 2002 Universio ACCESSION NUMBER: 0.0011020141 POTFULL ED 20020820

TITLE ENGLISH: INHIBITORS DE FACTOR XA

HAVING AN ARGININE OR ARGININE

ALDEHYDE MIMIC

TITLE (FREE: CH): INHIBITEURS DU FACTEUR XA POSSEDANT UNE

ARGININE DU UN ANALOGUE DE L'

ARGININE

INVENTOR S : DEMPLE, Joseph, Edward; BRUNDK, Terence, Kevin; LEVY,

Odile, Esther: TAMUFA, Susan, Y.

PATENT ASSIGNEE(S): HORMAS INTERNATIONAL, INC.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

KIND DATE NUMBER 

Wo 0001027141 Al 20010419

CA JP AT BE CHICY DE DK ES FI FR GB GR IE IT LU MC NL DESIGNATED STATES

PT SE

APPLICATION INFO.: WO 2000-U827615 A 20001006 PRIORITY INFO.: US 1999-09/414,903 19991008

ABEN Peptidyl aldehydes having an arginine or arginine

mimic at P3 which are selective inhibitors of certain serine

proteases, including factor Xa, are described. These

compounds are useful in prevention and treatment of conditions

characterized by abnormal thrombosis in mammals.

ABFF.

L104 ANSWER 63 OF 189 ECTFULE COPYRIGHT 2002 Univentio

ACCESSION NUMBER: U001025413 POTFULL ED 20020920 TITLE (ENGLISH): USE OF A CONTEXT-DEPENDENT FUNCTIONAL ENTITY TO ENHANCE

THE EFFICACY OF AN AGENT

EFFICACITE ACCEUE D'UN AGENT GRACE A L'UTILISATION TITLE (FRENCH):

D'UNE ENTITE FONCTIONNELLE DEPENDANT DU CONTEXTE

INVENTOR(S): HOUSTON, L., L.

PATENT ASSIGNEE(S): NUVAS, LEC; HOUSTON, L., L.

DOCUMENT TYPE:

DOCUMENT TYPE: Patent

PATENT INFOFMATION:

KIND DATE NUMBER 

W0 2001025413 Al 20010412

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU DESIGNATED STATES

CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JE KE KG KE KE ED LO LK LE LS LT LU LV MA MD MG MK MN MW MM MD NO NO PL PT RO EU SD SE SG SI SK SL TJ TM TRITT TO UA UG US UD VN YU ZA ZW GH GM KE LS MW MZ SD SI SE TO UG EW AM AO BY KG KE MD RU TU TM AT BE CH CY DE DK ED FI FR GB GA IE IT LU MC NL PT SE BF BJ CF CG

CI CM GA GN GW ML MF NE SN TD TG

AFPLICATION INFO.: WO 0000-US27794 A 20001004 PRIORITY INFO.: US 1999 09/411,067 19991014

ABEN The present invention relates to a method of enhancing the efficacy of one or more agents in a subject by administering the agent or agents and a context-dependent functional entity to the subject, wherein a

context-dependent functional entity includes a substructure with thrombogenic potential operably linked to a selective recognition dimain, and interacts with a function-forming context expressed by a cell or tissue in the subject. The invention also relates to a method of treating a pathologic condition in a subject by administering to the subject a therapeutic agent and a context-dependent functional entity.

The invention further relates to a pharmaceutical composition, which

contains an agent and a context-dependent functional entity in a pharmaceutically acceptable form. The invention further provides a peptide having the amino adia sequence Fro-Arg Lys-Leu-Tyr-Asp Rabo ID No: 1..

ABFE

1104 AMSWER 64 OF 189 FORFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 2001021259 POTFULL ED 20020810 TIPLE 'ENGLISH': METHODS AND DIMPOSITIONS FOR TREATING PLATELET-RELATED

DIFORDERS

PROCEDES ET COMPOSITIONS DE TRAITEMENT DES PATHOLOGIES APPARENTEES AUX PLAQUETTES TITLE (FRENCH):

INVENTOR S:: HANSON, Stephen, R. PATENT ASSIGNEE(S): EMORY UNIVERSITY DOCUMENT TYPE: Patent

PATENT INFORMATION:

KIND DATE NUMBER. \_\_\_\_\_\_

W0 1001021259 A2 100010309

AU CA OF AT BEIGH BY DE DE ES FI FRIGBIGRIE IT LU MO DESIGNATED STATES

ML PT SE

APPLICATION INFO.: W0 2000-U828781 A 00000901 PRICRITY INFO: U8 1999-60/154,929 19990821

ABEN The invention relates to the prophylactic and therapeutic treatment of

subjects for the purpose of inhibiting vaso occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical

preparations comprising such agents are provided.

ABFE

L104 ANSWER 65 OF 189 PCTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: D001021163 PCTFULL ED 20000800
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS
TITLE (FRENCH): PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES LIES AUX PLAQUETTES AU MOYEN D'AGENTS INHIBITEURS DE

TRAJET DE MEL

INVENTOR(S): HANSON, Stephen, R.
PATENT ASSIGNEE(S): EMORY UNIVERSITY
DOCUMENT TYPE: Patent INVENTOR (S):

FATENT INFOFMATION:

KIND DATE NUMBER \_\_\_\_\_\_\_\_ Wo 0001021163 A2 20010309

DESIGNATED STATES AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

ABEN. The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmadeutical preparations

comprising such agents are provided.

ABFR

Li04 ANSWER 66 OF 189 POTFULL COPYRIGHT 2000 Univentio

ACCESSION NUMBER: .:C01013046 PCTFULL ED 200.0823

TWAFIAN TUMBE SERVENCES AND METHODS OF USE THEREFOR

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

DEQUENCES DE TUMEURS IVARIENNES ET PROCEDES

D'UTILISATION CORRESPONDANTS

INVENTOR'S:

PATENT ASSIGNEE(S):

DOCUMENT TYPE:

NUMBER:

NUMB

KIND DATE NUMBER

WC 0001018046 A2 00010315 AB AB AL AM AT AN AZ BA BB BG BR BY BZ CA CH CN CR CV LESIGNATED STATES CZ DE DW DM DZ EE ES FI 38 GD 38 GH GM HR HU ID IL IN IS UB KE KG KB KK KS TO TK TH TO TA TA WE WE WE MN MW MX M2 NO NO EL PT RO RU SD SE SO SI SK SL TO TM TH TT TZ WA WE US UZ WW YU ZA ZW EH GM KE IS MW MW ED SI 32 TZ UG UW AM AZ BY HG HZ MD BU TJ TM AT BE CH CY DE OK ES FI FR GB OR IE IT LU MO ML PT SE BE BJ OF OG OM GA ON FW MU MR NE FN TO IG W0 0000-U3.14:27 A 00000905 APPLICATION INFO.: 1222-04,344,374 US 0000-090541,778 US 0000-090111 19990910 US 1999-09/3-4,374 PRIORITY INFO.: 10000551 
 US 2000-09/640,173
 20000815

 US 2000-09/656,668
 20000907

Compositions and methods for the therapy and diagnosis of cancer, such ABEN as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Eplypeptides and polynucleptides as provided herein may further be used for the detection and monitoring of ovarian cancer.

#### ABFE:

L104 ANSWER 67 OF 189 PCTFULL COPYRIGHT 2000 Univentio

ACCESSION NUMBER: 2001012836 PCTFULL ED 20020828

CRYSTAL OF A TRUNCATED PROTEIN CONSTRUCT CONTAINING A TITLE (ENGLISH):

COAGULATION FACTOR VIII 02 DOMAIN IN THE PRESENCE OR ABSENCE OF A BOUND LIGAND AND METHODS OF USE THEREOF

CRISTAL DE PRODUIT DE RECOMBINAISON PROTEIQUE TRONQUE TITLE (FRENCH):

RENFERMANT UN DOMAINE ON DU FASTEUR DE COAGULATION

MITH, AVEC OU SANS LIGAND LIE, ET PROCEDES

D'UTILISATION

STODDARD, barry, L.; PRATT, Kathleen; FUJIKAWA, Kazuo; INVENTOR(S):

CAVIE, Earl, W.

FFED HUTCHINSON CANCER RESEARCH CENTER; UNIVERSITY OF PATENT ASSIGNEE(S):

WASHINGTON; STODDARD, Barry, L.; PRATT, Kathleen;

FUJIKAWA, Kapub; DAVIE, Earl, W.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER. KIND DATE \_\_\_\_. WP 0001012836 A1 00010222

AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU DESIGNATED STATES

MO NE ET SE

APPLICATION INFO:: WO 0000-US02026 A 00000811 PRIORITY INFO:: US 1999-60/148,907 19990813

A detailed three-dimensional structure for the C-terminal C2 domain of ABEN blood coagulation factor VIII is disclosed. The novel truncated factor VIII constructs which were designed so as to smit a significant portion of the flexible full length protein are also part of the present invention. In addition, the prystals of the protein, both in the presence and absence of bound ligands are also included. Furthermore, methods of identifying antagonists of the human factor VIII protein which can be used to inhibit spagulation or to stabilize and activate factor VIII mutants are also disclosed. Furthermore, methods of identifying variations of the 32 domain sequence and structure that can he incorporated into intact factor VIII for the purpose of administration to hemorphiliae patients who are immunoreactive against wild type factor VIII are displosed.

## ABFR

ANSWER 68 OF 189 POTFULL CHEYRIGHT 2018 Univention ACCESSION NUMBER: 2001010592 PCTFULL ED 20020829

TITLE ENGLISH,: FVIIA ANTAGONISTS TITLE (FRENCH::
INVENTOR 9: AMTAGONISTE DU FALIA DERWIT, Mark, 8. INVENTOR S: DENVIS, Mark, S
PATENT ASSIGNEE S: SEMENTECH, INC. DOGUMENT LYPH: Patent PATENT INFORMATION: NUMBER KIND PATE W0 1001010392 A2 00010215 AE AF AL AM AT AT AZ BA BB BG BR BY BZ CA CH CN CR CV DESIGNATED STATES DE DE DE DE DE DE ES FI GB GD GE GH GM HR HU ID IL IN IS TO HE KG HO HE HZ LO LE LE LG LT LU LV MA MD MG MK MON MAN MON MONO PL PT RO RU SD SE SG SI SK SL TF TM TRITTIZ UA UG UD VN YU DA ZW GH GM KE LS MW MZ 30 SL SZ TZ UG SW AM AS BY KG KS MD RU TJ TM AT BE CH SY DE DR ES FI FR GB GR IE IT LU MO NL PT SE BF BJ OF GG CI CM GA GN GW ML MF. NE SN TO TG APPLICATION INFO.: WD 2000-USD1296 A 20000804 US 1999-60/147,617 19990806 US 1999-60/150,315 19990823 PRIORITY INFO.: This invention provides havel campounds which prevent or klock a FVIIa AFEN mediated or associated process or event such as the datalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIII (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods. ABFE. ANSWER 69 OF 189 PCTFULL COPYRIGHT 2002 Univentib L104 ACCESSION NUMBER: 2001003735 PCTFULL ED 20020828 CANCER TREATMENT USING ANGIOPOLETINS TARGETED TO TITLE (ENGLISH): AMINOPHOSPHOLIPIDS TRAITEMENT ANTICANCEREUX DANS LEQUEL SONT UTILISEES DES TITLE (FRENCH): ANGIDPOIETINES CIBLANT DES AMINOPHOSPHOLIPIDES INVENTOR(S): THORPE, Philip, E.
PATENT ASSIGNEE(S): MAINE MEDICAL CENTER RESEARCH INSTITUTE; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THORPE, Philip, E. DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBEE KIND DATE WO 0001003735 Al 00010118 - AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU DESIGNATED STATES MC NL PT SE APPLICATION INFO.: Wo 2007-US18779 A 20000711 PRIORITY INFO.: US 1999-60/143,762 19990715 ABEN Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention particularly provides therapeutic constructs and conjugates that bind to aminophospholipids and contain angiopoietins, and various methods of specifically delivering angiopoietins to the stably-expressed aminophospholipids of tumor blood vessels, thereby exerting anti-tumor effects. AEFR

L104 ANSWER 70 OF 189 POTFULL COPYRIGHT 2002 Univentic

ACCESSION NUMBER: 2001001749 FOTFULL ED 20020828

TITLE (ENGLISH): FVIIA ANTAGONISTS

TITLE (FRENCH): ANTAGONISTES DE FVIIA
INVENTOR(S): DENNIS, Mark, S.; EIGENBROT, Charles; LAZARUS, Robert,

PATENT ASSIGNEE 'SA: GENERTECH, INC. DOCUMENT TYPE: Patent

PATENT INFORMATION:

K.1312 NUMBER DATE \_\_\_\_\_ W0 0001001749 A2 00010111

AF AG AL AM AT AU AZ FA BB BG BR BY BZ CA CH CN GR CU DESIGNATED STATES

CO DE DE DE DE DE ES FI GB GI GE GH GM HR HU ID IL IN 1: TP KE KG KP KR KI LO LK LR LS IT LU LV MA MD MG MK MC: MW MC MI NO NI FL FT RC RU SD SE 3G SI 3K SL TJ TM

THITT TO MAING WE VN YU DAIZW GHIGM KE LS MW MZ SDISL BO TO UG OW AM AC BY MG FO MO BU TU TH AT BE CH CY DE

DE ES FI PR GB GP IE IT LU MO NE FT SE BF BJ CF CG CI

CM GA GN GW ML MF NE AN TO TG

APPLICATION INFO.: WC 2000 US18284 A 20000630 PRIORITY INFO.: US 1999 60/142,211 19990702

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FK to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention kind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a

peptide compound of the present invention. The invention also provides pharmaceutical acompositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

ABEE.

L104 ANSWER 71 OF 189 PCTFULL COPYRIGHT 2002 Univentic ACCESSION NUMBER: 2001001150 PTTFULL ED 20020828

DIAGNOSTIC TEST FOR THROMBOTIC OR THROMBOEMBOLIC TITLE (ENGLISH):

DISEASE

EMAMEN DIAGNOSTIQUE POUR LA THEOMBOSE OU LA TITLE (FRENCH):

THFOMBOEMBOLIE

MORRIS, Timothy, A. INVENTOR(S):

PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; MORRIS,

Timothy, A.

DOCUMENT TYPE: Eatent

PATENT INFORMATION:

KIND LATE NUMBER \_\_\_\_\_\_ WD 2001001150 A2 20010104

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DESIGNATED STATES

DE DK DZ EE ES FI GB GD GE GH GM HE HU ID IL IN IS JP KE KG KP KR KZ LO LK LR LS LT LU LV MD MG MK MN MW MX MO NO NO PL ET BO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG OW AM AC BY MG ME MD AU TU TH AT BE OH CY DE DK ES FI

FR GB OR IE IT LU MC ML PT SE BF BJ OF OG CI CM GA GN

GW ML ME NE SN TD TG

APPLICATION INFO:: WO 2000-US17977 A 20000630 PRIORITY INFO:: US 1999-60/141,734 19990630

Thrombotic or thromboembolic disease is detected or monitored by ABEN

determining the presence or amount B in a physiological sample.

ABEE.

ANSWER 72 OF 189 POTFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 2001000867 POTFULL ED 20020868

ANTI-THROMBIN PEPTIDE FROM ANDPHELES TITLE (ENGLISH):

ALBIMARTUS SALIVARY GLAND

TITLE (FRENCH): NOUVEAU PEPTIDE ANTI-THROMBINE

VALENZUELA, Pasus, G.; RIBRIRO, Jose; FRANCISCHETTI, INVENTOR S):

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as PATENT ASSIGNEE(S):

represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN MERVICES; VALENZUELA, Jesus, G.; RIBEIRG, Jose;

FRANCIQUHETTI, 170

DOCUMENT TYPE:

Patent

FAIRN - MFORMALION:	NUMBER	KIND	DATE	
	wp 2001000867			
LESIGNATED STATES				BY BZ GA CH CN CR CU
	CO DE DE DM DM DZ EE	EC FI	GB GI GE	GH GM HR HU ID IL IN
	IN JP KE KG KP KE	KZ LC	LK LE LS	LIT 10 LV MA MP MG MK
	MOL MW MOL MZ NO NZ	PL PT	RI RU SD	SE 3G SI 3K SL TJ TM
				GH GM KE LS MW MZ 3D
				RU TU TM AT BE CH CY
	DE DK ES FI FR GE	GH. IE	IT LU MC	NL PT SE BF BJ OF CG
	CI OM GA GN GW ML	MF NE	SN TD TG	
APPLICATION INFC.:	WC-2000 U.418078	А	2.0-16-623	
PRIORITY INFC.:	U.s 1393-6:/141,42			

ABEN The DNA and amino acid sequences are disclosed for a novel anti-thrombin peptide, anophelin, one embodiment of which was isolated form the salivary glands of the mosquito (i>Anopheles albimanus</i>
Also disclosed are anti-thrombotic therapeutic applications of anophelin.

ABER

L104 ANSWER 73 OF 189 EUROPATEVILL COPYRIGHT 1002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET MELIVRE

ACCESSION NUMBER: 800986 EUPOPATFULL EW 200138 FS PS STAR
TITLE: METHODS OF DETERMINING ENDOGENOUS THROMBIN POTENTIAL
(ETP) AND THROMBIN SUBSTRATES FOR USE IN SAID METHODS.
VERPAHPEN DUM NACHWEIS DES ENDOGENEN THROMBIN-POTENTIALS
UND THROMBIN SUBSTRATE ZUR VERWENDUNG IN DIESEN
VERFAHPEN.
PROCEDES POUR LA DETERMINATION DU POTENTIEL THROMBINE

PROCEDES FOUR LA DETERMINATION DU POTENTIEL THROMBINE ENDOGENE (ETF), ET SUBSTRATS POUR THROMBINE UTILISES DANS CES PROCEDES.

HEMKER, Hendrik, Coenraad, Tongersestraat 41, NL-6211 LM Maastricht, NL;

RIJKERS, Dirk, Thomas, Siguri, Arieslaan 13, NL-5632 AS

Eindhoven, NL;

TESSER, Godefriedus, Ignatius, Kronenburgersingel 64,

NL-6511 AT Nijmegen, NL

PATENT ASSIGNEE(S): Hemker, Hendrik Coenraad, Tongersestraat 41, NL-6211 LM

Maastricht, NL

PATENT ASSIGNEE NO: 1277340

AGENT: de Bruijn, Leendert C. et al., Nederlandsch

Optrobibareau F.O. Box 29700, 2502 LS Den Haag, NL

AGENT NUMBER: 19641

OTHER SOURCE: BEPB2001043 EP 0302986 B1 9031

SOURCE: Wila-EFS-2001-H38-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldur.q in Englisch; Verbeffentlichung in Englisch

DESIGNATED STATES: R CH; R DE; R ES; R FR; R GB; R IT; R LI; R NL FATENT INFO.PUB.TYPE: EPBL EUROPAEISCHE PATENTSCHRIFT (Internationale

Armeldung)

PATENT INFORMATION:

INVENTOR(S):

PATENT INFURMATION:	PATENT NO	KIND DATE
	EF 803986	B1 20 H0919
'DFFENLEGUNGS' DATE:		19471029
APPLICATION INFO.:	EF 1996-902007	19#60110
PRICRITY APPLN. INFO.:	EF 1991-200043	19950110
	WD 96-ML18	9-00110 INTAKZ
	WD 962.740	9-0718 INTPNR
REFERENCE PAT. INFO.:	Es 290419 A	EP 420332 A
	WD 96-01209 A	US 4214049 A
	US 4247494 A	

REF. NON-PATENT-LIT.: THROMBOSIS AND HAEMOSTASIS, vol. 70, no. 4, 1993,

STUTTBART DE, pages 617-624, MP300567560 H.C. HEMKER ET AL.: "Continuous registration of thromkin generation in plasma, its use for the determination of the thrombin potential" cited in the application THFCMB0818 RESEARCH, vol. 74, no. 1-6, 15 September 1998, WASHINGTIN US, pages 491-499, MP103000516 D.T. RICKERS ET AL.: "Design and Synthesis of thrombin substrates with modified kinetic parameters" THROMB0818 AND HAEM08TA818, vol. 74, no. 1, July 1995, STUTTGART LE, pages 134-138,

MP990136941 H.C. HEMKER ET Al.: "Thrombin generation in plasma: its assessment via the endogenous thrombin potential" Biochemistry, vol.34, p.3750, (1998)

7.Mea.Chem., vol.38, p.1148, (1998) J.Med.Them., vol.37, p.38x3, (1994) J.Med.Chem., vol.33, p.4527, (1996) Structure, vol.4, p.1353~1362, (1996) J.Med.Chem.,

vol.33, p.4531, (1996)

L104 ANSWER 74 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVEE

ACCESSION NUMBER: 692025 EUROPATFULL EW 200142 FS P3 STA R TITLE: YEAST CHILS ENGINEERED TO PRODUCE PHEROMONE SYSTEM

PROTEIN SURROGATES, AND USES THEREFOR.

HEFE ZELLEN SO KONSTRUIERT, DASS SIE PROTEINSURROGATE DES PHEROMENSYSTEMS PRODUZIEREN UND ANWENDUNGEN DAFUER. CELLULES DE LEVURE TRAITEES POUR PRODUIRE DES SUBSTITUTS DE PROTEINES DU SYSTEME DE PHEROMONES, ET LEURS EMPLOIS.

FOWLKES, Dana, Merriman 90 Green Street, Apartment 2,

New York, NY 10012, US;

BROACH, Jim 360 East 88th Street, Apartment 2A, New

York, NY 10128, US;

MANFREDI, John 666 Greenwich Street, Apartment 556, New

York, NY 10014, US;

KLEIM, Christine 666 Greenwich Street, Apartment 556,

New York, NY 10014, US;

MUEPHY, Andrew, J., 17 Windsor Place, Montclair, NJ

97043, US;

PAUL, Jeremy, 197 Route 9W, Falisades, NY 10964, US; TRUEHEART, Joshua, 212 South Broadway, South Nyack, NY

10960, US

PATENT ASSIGNEE(S): Cadus Fharmaceutical Corporation, 7th fl:or, 180 Varick

Street, New York, NY 10138, US

PATENT ASSIGNEE NO: 1860560

AGENT: Frice, Vincent Andrew et al., FRY HEATH & SPENCE The Old

College 53 High Street, Horley Surrey RH6 7BN, GB

AGENT NUMBER: 79513

OTHER SOURCE: BEPB3001051 EP 0692025 B1 9068

SOURCE: Wila EPS-2001-H42-T1

DOCUMENT TYPE: Fatent

LANGUAGE: Anmeldung in Englisch; Verdeffentlichung in Englisch DESIGNATED STATES: A AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MI; R NL; R PT; R SE

PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHEIFT (Internationale

Anmeldung)

PATENT INFORMATION:

INVENTOR(S):

	PATENT NO	KIND DATE
	EP 692025	£1 20011017
'DFFENLEGUNGS' DATE:		14963117
APPLICATION INFO.:	EP 1994-912292	19940323
PRIORITY APPLN. INFO.:	US 1993-41431	19930331
	UP 1994-190328	19940131
RELATED DOG. INFO.:	WG 94-US3143	940323 INTAKZ

941113 INTPNR W0 9423025

REFERENCE PAT. INFO.: WC 92-05244 A REF. NON-PATENT-LIF.: SCIENCE vol. 250, Cotober 1990, LANCASTER, PA US pages

121 - 123 KLIM KING ET AL. 'Control of yeast mating signal transduction by a mammalian beta2-adrenergio

reseptor ana 9s alpha subunit' CELL vol. 66, 29

September 1-91, CAMBRIDSE, NA US pages 1197 - 1206 D. J. LEW ET AL. 'Isolation of three novel numan cyclins by rescue of G. syclin (Cln) function in yeast' CELL vol. 60, 10 May 1991, CAMBRIDGE, NA US pages 691 - 699 YUE XIONG ET AL. 'Human D-type cyclin' PROCEEDINGS OF THE MATICMAL ACADEMY OF SCHEMORS OF USA vol. 89, Dotober 1992, WASHINGTON US pages 3410 - 9414 M. WITHEWAY ET AL. 'Dominant negative selection of heterologous genes:

Isolation of Candida albicans genes that interfere with Saccharomyces perevisiae mating factor-induced cell cycle arrest' JOURNAL OF CELLULAR BIOCHEMISTRY vol. 18B, February 1994 page 224 J. MANFREDI ET AL. 'Autocrine stimulation of yeast through human G-coupled receptors' A. KOFF ET AL.,: 'HUMAN CYCLIN E, A NEW CYCLIN THAT INTERACTS WITH TWO MEMBERS OF THE CDC2 GENE FAMILY' CELL

vol. 66, 1991, pages 1217 1218 D.A. HUGHES ET AL.,: 'COMPLEMENTATION OF EVEL IN FISSION YEAST BY MAMMALIAN MAP KINASE REQUIRES COEXPRESSION OF RAF KINASE' NATURE

vol. 364, 1993, pages 394 - 352

L104 ANSWER 75 OF 189 USEATFULL

2000:164081 USPATFULL ACCESSION NUMBER:

Tissue factor methods and compositions for coaquiation TITLE:

and tumor treatment

Thorpe, Philip E., Dallas, TK, United States INVENTOR(S):

King, Steven W., Foothill Ranch, CA, United States

Gao, Boning, Dallas, TX, United States

PATENT ASSIGNEE(S): Board Of Regents, The University of Texas System,

Austin, TM, United States (U.S. corporation)

NUMBER KIND DATE \_\_\_\_\_ 20001305

US 6156321 US 1998-9800 PATENT INFORMATION: APPLICATION INFO.: 19980120 (9)

NUMBER PATE 

PRIORITY INFORMATION: US 1997-42427F 19970327 (60) US 1997-36205F 19970127 (60) US 1997-35930F 19970122 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geotha P.

LEGAL REPRESENTATIVE: Williams, Morgan and Amerson

NUMBER OF CLAIMS: 47 EXEMPLARY CLAIM: 1,3

NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 7500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention embedies the surprising discovery that Tissue Factor (TF) compositions and variants thereif specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coaquiation and fir use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutlo drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa 'FVIIa' or FVIIa

activators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 76 OF 189 USPATFULL

ACCESSION NUMBER: #330:137820 USPATFULL

TITLE: Tempined tissue factor and factor VIIa methods and

compositions for coaquiation and tumor treatment INVENTOR: S1: Thorpe, Philip E., Dallas, TX, United States

King, Steven W., Foothill Ranch, CA, United States

Gac, Boning, Dallas, TX, United States

PATENT ASSIGNEE S:: Board of Regents, The University of Texas System,

Austin, TM, United States (U.S. corporation)

NUMBER KIND DATE 
 US 613273 /
 20001017

 US 1995-9656
 19980120
 PATENT INFORMATION: APPLICATION INFO .: 19980120 (9)

NUMBER DATE \_\_\_\_\_ PRIORITY INFORMATION: US 1997-42427P 1997-327 (60) US 1997-36205P 19970127 (60) US 1997-35920P 19970122 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.

LEGAL REPRESENTATIVE: Williams, Morgan & Amerson

NUMBER OF CLAIMS: 31 EXEMPLARY CLAIM: 1,3

NUMBER OF DRAWINGS: US Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 7436

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coaquiation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

### CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 77 OF 189 USPATFULL

2000:137819 USPATEULL ACCESSION NUMBER:

TITLE: combined tissue factor and chemotherapeutic methods and

compositions for coagulation and tumor treatment

INVENTOF(S.: Thorpe, Philip E., Dallas, TX, United States

King, Steven W., Frothill Fanch, CA, United States

Gac, Boning, Dallas, TX, United States

Brand of Regents, The University of Texas System, PATENT ASSIGNEE(S):

Austin, TM, United States (U.S. corporation)

NUMBER KIND DATE MS 6132729 2 0001017 PATENT INFURMATION: ## 1998-9917 APPLICATION INFO.: 14980127 9.

NUMBER DATE 

PRIORITY INFORMATION: US 1997-42427P 19970327 160:

US 1997-36205P 19970127 (60 19970122 765 US 1997-35920P

Tellier DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Bansal, Geetha P.

LEGAL REPRESEMMATIVE: Williams, Morgan & Amerson

NUMBER OF CLAIMS: 46 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 25 Drawing Figure(s): 15 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising ccagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

### CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LID4 ANSWER 78 OF 189 USEATFULL

ACCESSION NUMBER: 2000:131912 USPATFULL Serine protease inhibitors TITLE:

Green, Donovan St. Clair, London, United Kingdom INVENTOR(S): Elgendy, Said Mohammed Anwr Ahmed, London, United

Kingdom

Patel, Geeta, London, United Kingdom

Soully, Michael Finbar, Essex, United Kingdom Goodwin, Christopher Andrew, Avon, United Kingdom

Kakkar, Visay Vir, Hants, United Kingdom Deadman, John Joseph, Surrey, United Kingdom

Trigen Limited, London, United Kingdom (non-U.S. PATENT ASSIGNEE(S):

corporation)

	NUMBER	KIND DATE	
PATENT INFORMATION:	US 6127340	20001003	
EMIDNI INCOMMATION:	WO 3605407	19960822	
APPLICATION INFO.:	US 1998-994120	19980330	(3)
	WO 1996-GB352	19960215 19930330	POT 371 date
		19930330	PCT 102(e) date

	NUMBER	DATE	
-			

PRIORITY INFORMATION: GB 1940-2995 19950216 DOCUMENT TYPE:

Utility

Granted FILE SEGMENT:

PRIMARY EXAMINER: Davemport, Avis M.

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: - 6 EKEMPLARY CLAIM: LINE COUNT: 2442

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention is directed to peptide inhibitors of serine protesses, especially thrombin, in which the PlaP2 natural amide linkage is replaced by another bond. Exemplary thrompin inhibitors have the formula: X-(aa.sup.3)-(aa.sup.2)-.psi.-(aa.sup.1)~Z wherein X is H or a substituent on the N-terminal amind group, aa.sup.3 is a hydrophobic amino acid, aa.sup.23 is Pro, aa.sup.1 is Arg or an Arg

analogue, Z is -- COOH or a heterpatem acid group and .psi. is a non-amide linkage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 79 OF 189 USPATFULL

ACCESSION NUMBER: 0000:121539 USPATFULL

TITLE: Methods for regulating transcription factors INVENTOR S : Qapar, Maner N., Redmind, WA, United States

McMillan, Michael K., Bellevue, WA, United States Hahn, Michael S., Kirkland, WA, United States Tulinsky, John E., Seattle, WA, United States Ogpu, Cyprian O., Bellevue, WA, United States Mathew, Jessymol, Bellevue, WA, United States

Molecumetics Ltd., Bellevue, WA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE DATE

PATENT INFOFMATION: US 8117896 20000912 US 1998-22934 19980212 (9) APPLICATION INFO :

RELATED APELN. INFO.: Continuation-in-part of Ser. No. US 1997-797915, filed

on 10 Feb 1997, now abandoned And a

continuation-in-part of Ser. No. US 692420

NUMBER DATE

FRIORITY IMFORMATION: US 1997-47067P 19970519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLS

NUMBER OF CLAIMS: 34 EXEMPLARY CLAIM:

WINGS: / Drawing Figure(s); 6 Drawing Page(s) NUMBER OF DEAWINGS:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 80 OF 189 USPATFULL

ACCESSION NUMBER: 2000:102075 USPATFULL

TITLE: Yeast cells engineered to produce pheromone system

protein surrogates, and uses therefor

Fowlkes, Dana Merriman, New York, NY, United States INVENTOR(S):

Broach, Jim, New York, NY, United States Manfredi, John, New York, NY, United States Elein, Christine, New York, NY, United States Murphy, Andrew J., Montolair, MJ, United States

Paul, Jeremy, Palisades, NY, United States

Trueheart, Joshua, Soith Nyack, NY, United States

Cadus Pharmaceutical Corporation, Tarrytown, NY, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE PATENT INFORMATION: US 6100042 200008438

US 1994-322137 19941013 (8) APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-309313, filed

on 20 Sep 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1994-190328, filed

on 31 Jan 1994, now akangened which is a

continuation-in-mart of Ser. No. US 1993-41431, filed

on 31 Mar 1993, now abandened

Ttility DOCUMENT TYPE: FILE SEGMENT: Granted PRIMARY EXAMINER: Ulm, John

LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, Lauro, Esq., Peter C., Kara,

Catherine I.

NUMBER OF CLAIMS: 4.5 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: II Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 6899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a factor, pheromone receptors, atc.) and a potential

peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.

### CAS INDEKING IS AVAILABLE FOR THIS PATENT.

LID4 ANSWER 81 OF 189 USPATFULL

2000:87702 USPATEULL ACCESSION NUMBER: TITLE: Prothrombin derivatives

INVENTOR(S): Fischer, Bernhard, Vienna, Austria Schlokat, Uwe, Orth/Donau, Austria

Mitterer, Artur, Orth/Donau, Austria Falkner, Falko-Gunter, Orth/Donau, Austria

Eibl, Johann, Vienna, Austria

Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. PATENT ASSIGNEE(S):

| derporation)

	NUMBER	KIND DATE	
PATENT INFOFMATION:	US 6036871	20000711	
	WO 9641868	199612.77	
APPLICATION INFO.:	US 1998-952967	19980136	(3)
	WO 1996-AT105	19960612	
		19980136	PCT 371 date
		19980176	PCT 102(e) date

19980136 PCT 102(e) date

NUMBER DATE

PRIORITY INFORMATION: AT 1995-1005 19950613

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Prouty, Rebecca E. ASSISTANT EXAMINER: Saidha, Tekchand LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 2.2 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 14 Drawing Figure's:; 14 Drawing Page(s)

LINE COUNT: 1363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to new prothrombin mutantu or derivatives thereof which comprise one or more changes in their protein sequence as compared to natural protein, are either inactive or have an activity of approximately 10- at the most, preferably approximately  $0.25^{\circ}$  at the most, of the natural protein and which have a kinding capabity relative

to natural ligands natural or synthetic anticoagulants substantially corresponding to that of the natural protein. Furthermore, the use of mutated prothrombin mutants or derivatives, respectively, as pharmaceutical rreparations is described.

CAS INDEKING IS AVAILABLE FOR THIS PATENT.

LIG4 ANSWER 82 OF 189 USPATFULL

3000:87745 USPATFULL ACCESSION NUMBER:

TITLE: Thromain inhibitors based on the amino acid sequence of

nirugin

DiMais, John, Montreal, Canada INVENTOR(S):

Honishi, Yasuo, Hirkland, Canada Ni, Feng, Fierrefonds, Canada

Steinmetzer, Torsten, Jena, Germany, Federal Republic

⇒ f

PATENT ASSIGNEE(S): The National Research Council of Canada, Ottawa, Canada

non-U.S. corporation)

NUMBER KIND DATE 

PATENT INFORMATION: US 6060451 20000509 APPLICATION INFO.: US 1995-406142 19950320 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-302245, filed

on 9 Sep 1994, now abandoned which is a continuation of

Ser. No. US 960425

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Delacroix-Muirheid, C. LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 53 EXEMPLARY CLAIM: 1

NUMBER OF DEAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)

3086 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and abidue character of amino abids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-abetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 parbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of Desconfiguration. The compounds are useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 83 OF 189 USPATFULL

2000:54070 USPATFULL ACCESSION NUMBER:

Hallikrein-binding "Kunitz domain" proteins and TITLE:

analogues thereof

Markland, William, Milford, MA, United States INVENTOR S):

Ladner, Echert Charles, Ijamsville, MD, United States

PATENT ASSIGNEE(S): Dyam Corp., Cambridge, MA, United States (U.S.

corporation.

NUMBER KIND DATE PATENT INFORMATION: US 6057287 20000802 APPLICATION INFO.: US 1994-209264 19940310

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-179964, filed

on li Jan 1994, now abandoned

DOCUMENT TYPE: Meility Grantei FILE SEGMENT:

PFIMARY EXAMINER: 'elsa, Bennett

LEGAL REPRESENTATIVE: Yankwich, Leon R., Zwicker, Kenneth P.

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: .4 Drawing Figure's:; 15 Drawing Page s

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to Munito domain proteins that kind to, and preferably inhibit, one or more kallikreins, and to therapeutic,

diagnostic, and purification use of these proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 84 OF 139 POTFULL COPYRIGHT 2000 Univentio L104

ACCESSION NUMBER: 200006494% POTFULL ED 20020515

COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY TITLE (ENGLISH):

SELECTIVELY INHIBITING VEGE

COMPOSITIONS ET PROCEDES DE TRAITEMENT DU CANCER PAR TITLE (FRENCH):

INHIBITION SELECTIVE DE VEGE

THORRE, Philip, E.; BREKKEN, Rolf, A.

PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM LANGUAGE OF BUBL: English

DOCUMENT TYPE: Patent

FATENT INFORMATION:

KIND DATE NUMBER 

W0 2000064946 A2 20001102 DESIGNATED STATES

AE AG AL AM AT AU AZ BA BB BG BR EY CA CH CN CR CU CZ DE DK DM DC EE ES FI GB GD GE GH GM HR HU ID IL IN IS IP KE KG KP KR KZ LG LK LR LS LT LU LV MA MD MG MK MN MW MM NO NO PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UN VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG 2W AM AZ BY KG KZ MD RU TU TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

GW ML MR NE EN TO TG

Wo 2000-US11367 A 20000428 APPLICATION INFO.: US 1999-60/131,432 19990428 PRIORITY INFO.:

Disclosed are antibodies that specifically inhibit VEGF binding to only ABEN

one (VEGFR2) of the two

VEGF receptors. The antibodies effectively inhibit angiogenesis and

induce tumor regression, and yet

have improved safety due to their specificity. The present

invention thus provides new

antibody-based compositions, methods and combined protocols for treating

cancer and other angiogenic

diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new

VEGF-specific antibodies are also provided.

L'invention concerne des anticorps qui inhibent specifiquement le VEGF ABFR se liant a un seul

(VEGFR2) des deux recepteurs VEGF. Les anticorps inhibent efficacement l'angiogenese et induisent

aussi efficacement une regression de tumeur, tout en presentant une securité accrue du fait de leur

specificite. L'invention concerne par consequent de nouvelles

compositions a base d'anticorps, ainsi

que des procedes et des protocoles combines pour traiter le cancer et d'autres maladies

angiquentques. Elle concerne egalement des compositions

d'immunosonjugues et de promedicaments ainsi

que des procedes interessants faisant appel aux nouveaux anticorps pour le VEGF.

```
1104 AMSWER 85 OF 189 POTFULL COPYRIGHT 2002 Univention
ACCESSI N NUMBER: 2000063243 POTFULL ED 20020515
TITLE ENGLISH :
                       TERIVATIVES OF THE B OR Z DOMAIN FROM STAPHYLOGOCCAL
                       PROTEIN A USPAy INTERACTING WITH AT LEAST CHE DOMAIN OF
                       HUMAN FACTOR VIII
                       PERIMES ON POMAINE BOU 2 D'UNE PROTEINE
TITLE "FRENCH::
                       STAPHYLOGOCCIQUE A (SPA) AYANT UNE INTERACTION AVEC AU
                       MOINS UN DEMAINE DU FACTEUR VIIT HUMAIN
                       DUTNOKVIST, Tharlotta; MORD, Karin; NYGREM, Per-Ake;
INVENTOR F ::
                       UHLEM, Mathias
                      PHARMACHA & UFJOHN AB; LINNGOVIST, Charlotta; NORD,
PATENT ASSIGNEE S):
                      - Harin; NYGREN, Per-Ake; UHLEN, Mathias
LANGUAGE OF PUBL.:
                      English
DOCUMENT TYPE:
                      Patent
PATENT INFORMATION:
                       NUMBER
                                         KIND
                                                  I/ATE
                        Wo 2500163243 AI 20001026
                      AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DESIGNATED STATES
                       DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
                       KG KE KE KI LI IK LE LS LT LU LV MA MD MG MK MN MW MX
                       NO NE PL PT RO RU SD SE SG SI SK SL TJ TM TK TT TZ UA
                       UG US UZ VN YU ZA ZW GH GM KE LS MW 3D 3L SZ TZ UG ZW
                       AM AS BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                       GB GR IE IT LU MO NL PT SE BF BJ OF OG OI OM GA GN GW
                      ML MR NE SN TD TG
APPLICATION INFO.: W0 2000-SE732 A 200000417 PRIORITY INFO.: SE 1999-3901379-9 19990419
      The present invention relates to modified polypeptides which are
ABEN
       derivatives of the B domain or
       2 domain from staphylococcal protein A (SPA), wherein between 1 and 20
      amino acid residues of the
      said B or Z domain have been substituted by other amino acid residues,
      said substitution being made
       without substantial less of the basic structure and stability of the
      said B or 2 domain, and said
      substitution resulting in interaction capacity of the said polypeptide
      with at least one domain of
      human Factor VIII protein.
ABFR. La presente invention porte sur des polypeptides modifies qui sont des
       derives du domaine B ou
       I de la proteine staphylococcique A (SPA), et dans lesquels entre 1 et
       30 restes d'acides amines de
       ce domaine B ou Z ont été substitues par d'autres restes d'acides
       amines, cette substitution se
       faisant pratiquement sans perte de la structure basique et de la
       stabilite du domaine B ou 2, et
       conferant au polypeptide une capacite d'interaction avec au moins un
      domaine de la proteine du
       Factor VIII humain.
     ANSWER 36 OF 189 POTEULL COPYFIGHT 2002 Univention
ACCESSION NUMBER: 20000061789 PCTFULL ED 20020515
TITLE (ENGLISH):
                      METHODS AND PEAGENTS FOR DETERMINING ENZYME SUBSTRATE
                      SPECIFICITY, AND USES RELATED THERETO
                      PROCEDES ET PEACTIFS SERVANT A LETERMINER LA
TITLE (FRENCH):
                      SEECIFICITE DE SUBSTRATS ENZYMATIQUES ET UTILISATIONS
                       CORRESPONDANTES
INVENTOR'S::
                      BACHOVIHIN, William
PATENT ASSIGNEE'S::
LANGUAGE OF PUBL::
                      TRUSTEES OF TUFTS COLLEGE; BACHOVCHIN, William
                      English
DECUMENT TYPE:
                      Patent
PATENT INFORMATION:
                      NUMBER FIND DATE
```

```
WG 2000061789
                                            A1 20001019
                       AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
LESIGNATED STATES
                       DK IM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
                       KO KP KR KZ LO LF LR LS LT LU LV MA MD MG MK MN MW MX
                       NO NZ PL PT RO RU SD SE SG SI SK EL TJ TM TR TT TZ UA
                       UG US UZ MN YU ZA ZW GH GM KE LS MW SP SL SZ TZ UG ZW
                       AM AZ BY KG KZ MD RU TO TM AT BE CH CY DE CK ES FI FR
                       GB GR IE IT LU MO NA PT SE BE BU DE GG GI CM GA GN GW
                       ML MR NE SH TO TG
                       WD 1193-US9497
                                            A 20010410
APPLICATION INFO.:
PRIORITY INFO.:
                       US 1999-60/123,471
                                               19990409
ABEN
     The invention provides a method for determining a preferred amino acid
       sequence motif for an
       active site an associated substrate specificity subsites of an
       enzyme. In the method of the
       invention, an enzyme is contacted with an oriented degenerate
       peptide library, sertain peptides
       within the library which are substrates for the enzyme are bound by the
       enzyme, and bound
         peptide/enzyme complexes are separated from unbound
       peptides. The bound peptides are released from
       the enzyme and are sequenced. A preferred amino acid sequence motif for
       the active site and
       associated specificity subsites is determined based upon the
       relative abundance of different amino
       acids residues at each degenerate position. The invention also provides
       peptides, peptide analogs,
       and other small molecules which have a variety of uses and can be
       derived from the present
       invention.
       L'invention concerne un procede permettant de determiner un motif
ABFR
       prefere de sequence d'acides
       amines pour un site actif d'une enzyme et ses sous-sites de specificite
       associes. Selon le procede
       de l'invention, on met en contact une enzyme avec une banque de
       peptides degeneres orientes,
       certains peptides de la panque etant des substrats pour
       l'enzyme qui s'y lie, puis on separe les
       complexes peptide/enzyme lies et non lies. Les
       peptides lies sont liberes de l'enzyme puis
       sequences. On determine un motif prefere de sequence d'acides amines
       pour le site actif et ses
       sous-sites de specificite associes en fonction de l'abondance relative
       des differents residus
       d'acides amines a chaque position degeneree. L'invention concerne
       egalement des peptides, des
        analogues peptidiques et d'autres petites molecules convenant
       pour de nombreuses utilisations et
      pouvant etre derives de l'invention.
      ANSWER 87 OF 189 POTEULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000061782 POTFULL ED 20020515
TITLE (ENGLISH):
                      EDUTINE DERIVATIVES
TITLE (FRENCH):
                      DERIVES D'ECOTINE
INVENTOR(S):
                       DRAIK, Charles, S.; FLETTERICK, Robert, J.; LUNDBLAD,
                       Roger, L.; SCHWARZ, Hans, P.
                       THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; CRAIK,
PATENT ASSIGNEE(S):
                        Charles, S.; FLETTERICK, Robert, J.; LUNDBLAD, Roger,
                       L.; SCHWARZ, Hans, P.
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                       Eatent
PATENT INFORMATION:
                       NUMBER
                                         KIND DATE
                        WG 2000081782 A1 20001019
```

```
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CE CU CZ DE
DESIGNATED STATES
                       DK IM EE ES FI 38 30 3E 3H 3M HR HU ID IL IN IS JP KE
                       KB KP KR KZ LO LK LR LS LT LU LV MA MD MG MK MG MW MW
                       NO NZ PL PT RO RU SP SE SG SI SK SL TJ TM TR TT TZ UA
                       MG US UZ MN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
                       AM AZ BY KO KO MO RU TO TM AT BE CH DY DE DK ES BU FR
                       35 OR IE IT IN MO NL PT SE SE BJ OF OG CI CM GA GN GW
                       MI MA NE SM TO TO
                       W0 2(0)-US3773
                                            A 80000412
APPLICATION INFO.:
                       73 1999-09/289,930
PRIORITY INFO.:
                                               19991412
      This invention provides a class binding proteins that specifically kind
ABEN
       to and modulate (e.g.
      ennance) the activity of polypeptides having a chymctrypsin fold (e.g.
       serine proteases). The
      kinding proteins are based on the structure of ecotin. It was discovered
      that modification of the
      amino or carboxyl terminus and/or randomization of one or more of loops
      50s, 60s, 80s or 100s will
      provide an ecotin variant library from which can be selected binding
      molecules (e.g. protease
      modulators) specific to virtually any serine protease. Depending on the
      epotin variant and the
      target serine protease, the modulator can act as a serine protease
      inhibitor or as a serine protease
      activator. Specific agonists (enhancers) of Factor IXa are disclosed.
     L'invention concerne une classe de proteines de liaison qui se lient
AEFR
      specifiquement aux
      polypeptides comprehant un enroulement de chymotrypsine (p. ex. protease
       a serine) et modulent (p.
      ex. renforcent) l'activité de ceux-ci. Ces proteines de liaison reposent
      sur une structure ecotine.
      On a decouvert que la modification du terminus amino ou carboxyle et/ou
      la randomisation d'une ou
      plusieurs boucles selectionnees dans les boucles 50, 60, 80 ou 100
      permet d'obtenir une banque de
      mutants d'ecotiné a partir de laquelle des molecules de liaison (p. ex.
      modulateurs de protease)
      specifiques de pratiquement n'importe quelle protease a serine peuvent
      etre selectionnees. Selon le
      mutant d'ecotine et la protease à serine cible, le modulateur peut avoir
      une action d'inhibiteur de
      protease a serine ou d'activateur de protease a serine. L'invention
       concerne equlement des agonistes
       (renforcateurs-fabilitateurs) du facteur IX.
     ANSWER 38 OF 189 PCTFULL COPYRIGHT 2002 Univention
1.104
ACCESSION NUMBER:
                      -2000055196 PCTFULL ED 20020515
                       PROTAMINE FRAGMENT COMPOSITIONS AND METHODS OF USE
TITLE (ENGLISH):
TITLE (FRENCH):
                      COMPOSITIONS CONTENANT DES FRAGMENTS DE PROTAMINE ET
                      PROCEDES D'UTILISATION
                      YANG, Victor, C.; BYFN, Youngro
INVENTOR(S):
                      THE REGENTS OF THE UNIVERSITY OF MICHIGAN; YANG,
PATENT ASSIGNEE(3):
                       Victor, C.; BYRN, Youngro
LANGUAGE OF FUBL.:
                       English
DCCUMENT TYPE:
                       Patent
PATENT INFOFMATION:
                       NUMBER.
                                         KIND
                                                   DATE
                        Al 20000921
                       WG-2000055196
                       AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DESIGNATED STATES
                       DK DM 12 BB E3 B1 GB GD GE GH GM HR HU 1D 1L IN IS JP
                       KE KO MP KR KZ LO LK LR LS LO LU LV MA MD MG MK MO MW
                       MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
                       MA UG US UZ WM YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG
                       ZW AM AZ BY KG K7 MD RU TU TM AT BE CH CY DE DK ES FI
```

FR GR GR IE IT LU MO NU PT SE BF BJ OF OG OI OM GA GN

GW ML MF NE SN TD TG

A 20000315 APPLICATION INFO.: WO 2 00-US6876 US 1999-60/124,873 19990317 PRIGRITY INFO.:

ABEN Provided are bloadtive, low toxicity protamine fragments, compositions,

combinations, kits and

methods of using these components in a variety of embodiments, including neutralizing heparin and

reducing post-operative bleeding. Improved protamine fragment-insulin solutions and methods for

treating diabetes are also provided.

L'invention concerne des fragments de protamine bicactifs de faible ABFE toxicite, des compositions,

des combinaisons, des trousses et des protedes d'utilisation de des composants dans diverses formes

de realisation, y compris pour neutraliser l'héparine et reduire un saidnement postoperatoire.

L'invention concerne egalement des solutions amelionees contenant des fragments de

protamine-insuline et des methodes de traitement du diabete.

ANSWER 89 OF 189 PCTFULL COPYRIGHT 2000 Univentio

20000053210 POTFULL ED 20020515 ACCESSION NUMBER:

METHODS OF TREATMENT AND PREVENTION OF RESTENDSIS TITLE (ENGLISH):

METHODES DE TRAITEMENT ET DE PREVENTION DE LA RESTENOSE TITLE (FRENCH): ROSEM, Craig, A.; MI, Jian; WANG, Mingsheng; SHI, Y., INVENTOR(3):

Eric

HUMAN GENOME SCIENCES, INC.; LONG ISLAND JEWISH MEDICAL PATENT ASSIGNEE(S):

CENTER; ROSEN, Craig, A.; NI, Jian; WANG, Mingsheng;

SHI, Y., Eric

LANGUAGE OF FUBL.:

English DOCUMENT TYPE: Patent

PATENT INFOFMATION:

NUMBER KIND DATE

\_.... -----Wo 2000053310 A1 20000914

DESIGNATED STATES

AE AL AM AT AU AL BA BE BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE CH GM HR HU ID IL IN IS JP KE KG KP KR KU LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NO PL PT RO RU SO SE SG SI SK SL TJ TM TR TT TO UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AS BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BE BJ CF CG CI CM GA GN GW

ML ME NE SH TO TG

APPLICATION INFO .:

WO 2000-US6279 A 20000313 19990311

US 1999-09/266,424 PRIORITY INFO.:

The present invention describes methods of treating or preventing ABEN restenosis, vascular injury,

and vascular disease in a subject by administering TIMP-4. The inventors have surprisingly found

that TIME-4 has an important role in the accumulation of the

extracellular matrix in a vessel wall and as such facilitates the healing process of an injured vessel. Also privided by the present

invention is a method of innihiting migration of smooth muscle cells, such as vascular smooth muscle

cells, by introducing to the cell an amount of TIMP-4 effective to inhibit the migration, as well as

inhibiting extracellular matrix degradation of a vessel, such as an artery, wein or capillary, by

introducing TIMP-4 to the vessel.

ABFR La presente invention concerne des methodes de traitement ou de prevention de la restentse, d'une lesion vasculaire, et d'une maladie vasculairé chez un sujet, en

lui administrant la TIMP-4.

Les inventeurs ant découvert avec surprise que la TIMP-4 jouait un role important dans

l'assumulation de la matrice extracellulatre dans la parci d'une veine, fazilitant ainsi le

processus de regeneration d'une veine lesee. En outre, cette invention concerne une methode

a'inhibition de la migration des cellules du muscle lisse, comme par exemple les dellules du muscle

lisse vasculaire, en introduisant dans la cellule une quantite efficace me FIME-4 pour inhiber la

migration, bette methode inhibant egalement la degradation de la matrice extracellulaire d'une

veine, telle qu'une artere ou un capillaire, en introduisant la TIMP-4 dans la veine.

AMSWER 90 OF 139 POTFULL COPYRIGHT 2002 Univention L104

ACCESSION NUMBER:

2000052034 ECTFULL ED 20020515

TITLE (ENGLISH):

INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND

COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS

TITLE (FRENCH):

INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET

COMPOSITIONS DE TRAITEMENT D'INFECTIONS VIRALES

INVENTOR(3):

SHAPIRO, Leland

PATENT ASSIGNEE(S): THE TRUS LANGUAGE OF PUBL.: English

THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	I:ATE
Wo 2000052034	A2 200	00908

DESIGNATED STATES

AE AL AM AT AU AZ BA BB BG BF BY CA CH CN CF CZ DE DK DM EE ES FI GB GD GE GH GM HE HU ID IL IN IS JP KE KG KE KE LO LK LE LS LT LU LV MA MD MG MK MN MW MK NO NE PL PT FO FU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG K3 MD FU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MO NL ET SE BE BU JE OG DI OM GA GN GW ML ME NE SN TO TG

APPLICATION INFO .: PRIORITY INFO .:

WO 2000-US5558 A 20000303 US 1999-60/123,167 19990305 US 1999-60/137,795 19390603

ABEN A novel method of treating and preventing viral infection is provided. In particular a method

of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which

consists of administering to a subject suffering or about to suffer from viral infection a

therapeutically effective amount of a compound having a serine protease inhibitory or serpin

activity. Among compounds are %alpha; l-antitrypsin (AAT),

peptide derivatives from the

carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such

compounds. The preferred viral infections include retroviral infection such as numan

immunodeficiency virus (HIV) infection.

L'invention concerne une nouvelle methode de traitement et de prevention ABFR d'une infection

virale. L'invention concerne, en particulier, une methode destinée à combattre une infection virale

favorisee par une activite de serine proteolytique 'SP', consistant a amministrer a un sujet

scuffrant ou susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace

d'un compose presentant une activité d'inhibition de serine protease ou serpin. Parmi les composes

se trouvent l'antitrynsine Galpha; l AAT., des dérives peptidiques de l'extremité carboxyterminale de l'AAT, et des composes synthetiques artificiels imitant l'action de des composes. Parmi les injections virales prejerees se trouvent les infections retrovirales telles que l'infection du virus de l'immunadeficience humaine "VIH:. ANGWER 91 OF 189 FORFULL GDFYRIGHT 2002 Univentia ACCESSION NUMBER: 210 (181628 POTFULL ED 20020818 TITLE (ENGLISH): INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF HERPES VIRUSES INHIBITEURS D'ACTIVITE DE SERIME PROTEASE, METHODES ET TITLE (FRENCH): COMPOSITIONS DE TRAITEMENT DE VIRUS DE L'HERPES SHAPIRO, Leland INVENTOR(3): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION PATENT ASSIGNEE(S): LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND NUMBER I:ATE WO 2000051625 Al 20000908 AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DESIGNATED STATES DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC IK LE LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MO NE PT SE BE BJ OF OG CI CM GA GN GW ME MR NE SN TD TG Wo 2000-US5557 A 20000303 APPLICATION INFO.: US 1999-60/123,167 19990305 PRIORITY INFO.: us 1999-60/153,942 19990915 Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteclytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a substance having serine protease inhibitory activity or serpin activity. Among the substances found to be useful are %alpha; l-antitrypsin (AAT), peptide derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family. L'invention concerne de nouvelles acompositions et methodes de traitement et de prevention d'une infection virale. L'invention concerne une methode visant a bloquer une infection virale favorisee par une activite proteclytique de serine (SP), consistant a administrer a un sujet souffrant ou susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace d'une substance presentant une activité d'inhibition de serine protease ou serpin. Parmi les substances utiles se trouvent l'antitrypsine α l (AAT), des derives peptidiques de l'extremite carboxyterminale de l'AAT et des medicaments synthetiques imitant

L'invention est particulièrement appropriée dans le dépistage d'une

ABEN

ABFF.

l'action de ces substances.

infection virale a mediation de

membres de la famille des Herpesviridae.

```
LID4 ANSWER 92 OF 189 POTFULL COPYRIGHT 2002 Univertio
ACCESSION NUMBER:
                      ...0000333844 PUTFULL ED 20020515
                       ARYL AND HETEROCYCLYL SUBSTITUTED FYRIMIDINE
TITLE ENGLISH::
                      DERIVATIVES AS ANTI-COAGULANTS
                       DERIVES DE SYRIMIDINE A SUBSTITUTION ARYLE ET
TITLE 'FRENCH':
                      HETEROGYCLYLE EN TANT QU'ANTIODAGULANTS
DAVEY, David, D.; PHILLIES, Gury, B.
INVENTOR 3::
                     BERLER LATURATIONIES, INC.; DAVEY, David, D.; PHILLIPS,
PATENT ASSIGNEE S:
                      Bury, 5.
LANGUAGE OF PUBL.:
                      Englist.
DOCUMENT TYPE:
                      Patent
PATENT INFORMATION:
                       NUMBER
                                        KIND
                                                 DATE
                        WO 2000033844 A1 20000618
                       AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DESIGNATED STATES
                       DK DM EE ES EI GB GD GE GH GM HR HU ID IL IN IS JP KE
                       KO KE KR KO LO LK LE LS LT LU LV MA MD MG MK MN MW MX
                       MO NO PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                       UG US UZ VN YU ZA 3W CH GM KE LS MW SD SL SZ TZ UG ZW
                       AM AC BY KG KC MD KU TJ TM AT BE CH CY DE DK ES FI FR
                       GB GR IE IT LU MO NL PT SE BE BU OF CG CI OM GA GN GW
                       ML MR NE SN TD TG
APPLICATION INFO.:
                                           A 13931203
                     WO 1399-US08537
APPLICATION INFO:: WO 1999-US08537 A 19991004
PRIORITY INFO:: US 1998-09/205,493 19991004
ABEN This invention is directed to aryl and heterocyclyl substituted
      pyrimidine derivatives selected
      from formulae (I), (II) and (III), wherein Z1, Z2, E1, R2, R3, R4, R5
      and Ré are defined herein.
      These compounds are useful as anti-coagulants.
      L'invention concerne des derives de pyrimidine a substitution aryle et
ABFR
      heterocyclyle choisis
      parmi les formules (I), (II) et (III), dans lesquelles Z1, Z2, R1, R2,
      R3, R4, R5 et R6 sont definis
      dans le descriptif. des composes sont utiles en tant qu'anticoagulants.
     ANSWER 93 OF 189 POTFULL COPYRIGHT 2002 Univention
ACCESSION NUMBER: 20000024718 PCTFULL ED 20020515
                      SERINE PROTEASE INHIBITOR
TITLE (ENGLISH):
TITLE (FRENCH):
                      INHIBITEUR DE LA SERINE PROTEASE
                     TIMMERS, Cornelis, Marius; REWINKEL, Johannes,
INVENTOR(3):
                      Bernardus, Maria
                     AKZO NOBEL N.V.; TIMMERS, Cornelis, Marius; REWINKEL,
PATENT ASSIGNEE(S):
                      Johannes, Bernardus, Maria
LANGUAGE OF FUBL.:
                      English
DOCUMENT TYPE:
                      Patent
PATENT INFOFMATION:
                                KIND DATE
                       NUMBER
                       WO 2000024718 AL 20000504
                       AL AU BA BB BG BR CA ON OU CZ BE GE HU ID IL IN IS UP
DESIGNATED STATES
                       KP KP LC LK LP LT LV MG MK MN MX NO NZ EL RO RU SG SI
                       SK SL TR TT UA US UZ VN YU ZA GH GM KE LS MW SD SL SZ
                       TO UG ZW AM AZ BY KG KZ MD EU TO TM AT BE CH CY DE DK
                       ES ET ER GB GE IE IT LU MO NL ET SE BE BJ DE CG CL CM
                       BA GN GW ML MR NE SN TD TG
                      W1 1999-EP1926 A 19991419
AFPLICATION INFO.:
                      EP 1995-98: 03559.4 19961422
PRIORITY INFO.:
ABEN
     The invention relates to a serine protease inhibitor having formula (I),
      in which I is H, El,
      R1-C+C(O)-, R1-C()(+, R1-SO2-, R3000-(CHR2)p-, 'R2a, R2b(N-CO-(CHR2)p-
      or Het-CO-'CHR2:p-; D is an
      amino-acid of the formula -NH-CHR1-C(0)-, -NR4-CH[(CH2)gC(0)(GR1]-C(0)-,
      -NR4-CH[ CH2 qC/O N R2a,
```

```
ROE ]-0'0,-, -MR4-OH( OH2-qC O/Het]-0'0 -, D-1-Tiq, D-3-Tiq, D-Ato, Aid,
D-1-Pig or D 3-Pig; E is
-NR2-CH2 or the fragment .a., optionally substituted with (1-60.alkyl,
1-60salkiny or cenzylomy; Bl
is selected from (1-120salkyl, (2-120salkenyl, 2-120salkynyl,
(.-63) alkowy, exc, CH, GF3 or halogen, and from (6-140/aryl,
   1-1:00 aralkyl, (3:100 aralkenyl and
((4),00) (risaryl)alkyl, whereby the aryl groups may optionally be
substituted with (1-80 alkyl,
(3-100)cycloalkyl, (1-60)alkoxy, OH, OF3 or halogen; R2, R2a and R2b are
each independently selected
from H, (1-80) alkyl, (3-80) alkenyl, (3-80) alkynyl, (3-80) cycloalkyl and
(3-60) sycloalkyl(1-40) alkylene, which can each be optionally substituted
with (3-60) cycloalkyl,
(1-60) alkowy, CF3 or halogen, and from (6-140) aryl and (7-150) aralkyl
whereby the aryl groups may
optionally be substituted with (1-60)alkyl, (3-60)dydloalkyl,
(1-60) alkoxy, GF3 or halogen; R3 is
defined for R2 or Het-(1-60)alkyl; R4 is H or (1-30)alkyl; X and Y are
CH or N with the proviso that
they are not both N; Het is a 4-, 5- or 6-membered heterocycle
containing one or more heteroatoms
selected from 0, N and S; m is 1 or 2; p is 1, 2 or 3; q is 1, 2 or 3; t
is 2, 3 or 4; or a prodrug;
or a pharmaceutically acceptable addition salt and/or solvate thereof
and its use in therapy and
manufacture of a medicament for treating or preventing thrombin-mediated
and thrombin-associated
diseases.
L'invention concerne un inhibiteur de la serine protease ayant la
formule (I), dans laquelle J
est H, R1, R1-0-0(0)-, R1-0(0)-, R1-302-, R3000-(0HR2)p-, (R2a,
R3b/N-30-(CHR2)p- tu
Het-CO-(CHRL)p-; D est un acide amine de formule NH-CHRl-C(O)-,
-NR4-CH[(CHD)qC(O)OR1]-C(O)=,
\label{eq:nr4-ch} \texttt{NR4-ch}[\,(\texttt{CH2})\,\texttt{qC}\,(\texttt{O})\,\texttt{N}\,(\texttt{R}2a,\texttt{R}2b)\,]\,+\texttt{C}\,(\texttt{O})\,+\text{,}\\ \ \texttt{NR4-ch}[\,(\texttt{CH2})\,\texttt{qC}\,(\texttt{O})\,\texttt{Het}\,]\,+\texttt{C}\,(\texttt{O})\,+\text{,}\\ \ \texttt{CH2}\,(\texttt{O})\,+\text{,}\\ \ \texttt{CH2}\,
D 1-Tig, D-3-Tig, D-Atc, Aic,
D-1-Pig ou D 3-Pig; E est MP.2-CH2- ou le fragment, facultativement
remplace par (1-60)alkyle,
(1-60) allowy ou benzyloxy; El choisi dans (1-120) alkyle,
(2-120) alcenyle, (2-120) alkynyle,
(3-100)cycloalkyle et (3-100)cycloalkyle(1-60)alkylene, groupes qui
peuvent facultativement etre
remplaces par (3-12C)cycloalkyle, (1-6C)alcoxy, oxo, OH, OF3 ou
halogene, et dans (6-140)anyle,
(7-15C)aralkyle, (8-16C)aralbenyle et (14-20C)(bisaryle)alkyle, les
groupes aryle pouvant
facultativement etre remplaces par (1-60)alkyle, (3-120)cycloalkyle,
(1-6') alcoxy, OH, CF3 ou
halogene: RD, RDa et RDb sont, chacun, choisis de manière independante
dans H, (I-RC)alkyle,
(3-30) alcenyle, (3-30) alkynyle, (3-30) by cloyalkyle et
(/-{:) systoalkyle 1-40/alkylene, qui peuvent,
charun, etre facultativement remplaces par (3-60) dycloalkyle,
(1-83) alcoxy, SF3 ou halogene, et dans
08-140% aryle et (7-160% aralkyle, les groupes aryle pouvant etre
facultativement remplaces par
 .-60.alkyle, (3-40.sycloalkyle, (1-60.alcoxy, CF3 cu halogéne; R3 est
tel que defini pour R2 ou
	ext{H} 	o 	au (1-30)alkyle; R4 est H ou (1-30)alkyle; X et Y sont CH ou N, a
cindition qu'ils he soient pas
thus deum N; Het est 4-, 5- or 6-heteropyble ramifie contenant au moins
```

ABFR

0, N et S; m est egal a 1 ou 2; p a 1, 2 ou 3; q a 1, 2 ou 3,; t a 2, 3 cu 4; un promedicament; une adjonation de sel et/lu de solvate pharmadeutiquement addeptable(s) de relai-ci, ainsi que son utilisation en theraple et pour la fabrication d'un medicament pour traiter ou prevenir des maladies induites par la thrombine ou associées a delle-di. ANSWER 94 OF 189 PURFULL GOPYRIGHT 2002 Univentia 1194 ACCESSION NUMBER: 2000 22160 POTFULL ED 20020515 METHODS FOR ASSESSING COMPLEMENT ACTIVATION TITLE (ENGLISH): METHODE D'EVALUATION DE L'ADTIVATION DU COMPLEMENT HUGLI, Tony, E.; STOUGHTON, Roland, B. TITLE (FRENCH): INVENTOR(S): CELL ACTIVATION, INC.; THE SCRIPPS RESEARCH INSTITUTE PATENT ASSIGNEE(S): LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE \_\_\_\_\_ Wo 2000022160 A1 20000420 AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CF CU CZ DE DESIGNATED STATES DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR K2 LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NO PL PT RO RU SO SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR LE LT LU MO NL ET SE BE BU CE CG CL CM GA GN GW ML ME NE SN TO TG WO 1999-US24150 A 19991015 APPLICATION INFO .: US 1998-09/173,579 19981015 PRIORITY INFO.: 19990205 Methods for measuring i(in vivo) activation of the lectin pathway by ABEN measuring mannan-binding serine protease activity (MASE) are provided. The methods are accomplished by measuring CBa and C4a levels in i(in vitro) activated EDTA plasma. In particular, the increase in C3a and/or C4a as a function of time is an indicator of the amount of activated MASP in EDTA plasma. Methods are also provided for measuring the alternate and classical pathways of complement activation, exclusive of the lectin pathway, and thereby disorders associated therewith. To perform such measurements, Futhan or other serine protease inhibitor is added to blood or plasma, containing a divalent metal ion chelator, and C3a and C4a are measured. L'invention se rapporte a des methodes permettant d'evaluer l'activation ABFR i(in vivo) de la voie de la lectine par mesure de l'activité de la serine protease se fixant a la mannane (MASP). Ces methodes consistent a mesurer les taux de 33a et de 64a dans du plasma a'EDTA active i(in vitro). En particulier, l'accroissement de C3a et/ou C4a en fonction du temps est un indicateur de la quantité de MASP activee dans le plasma d'EDTA. L'invention se rapporte egalement a des methodes permettant de mesurer les votes classiques et autres de l'activation du complement, a l'exclusion de la voie de la lectine, et permettant par consequent d'evaluer les troubles ass cies. Pour permettre ces mesures, on ajoute un inhibiteur de serine protease de type Futhan ou analogue a du sang ou du plasma contenant un agent de chelation des ions metalliques bivalents et l'on mesure les taux de 33a

un heteroatome choisi dans

```
1104 AMSWER 95 OF 189 POTFULL COPPYRIGHT 2002 Univention
ACCESSION NUMBER: 2000014382 POTFULL ED 20020515
TITLE (ENGLISH):
                     ARRAYS OF PROTEINS AND METHODS OF USE THEREOF
TITLE FRENCH :
                      GROMPEMENTS DE PROTEINES ET PROCEDES D'UTILISATION DE
                       DEUX-CI
INVENTOR St:
                      - WAGMER, Peter; AULT-RICHE, Dana; NCCK, Steffen; ITIN,
                       Christian
PATENT ASSIGNEE(S):
                       IYOMYN, INC.
LANGUAGE OF FUBL.:
                      English
DOCUMENT TYPE:
                      Patent
PATENT INFORMATION:
                       NUMBER
                                        KIND
                                                 DATE
                       Wo 0000004332 Al 20000127
                       AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
DESIGNATED STATES
                       EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                       KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
                       PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU
                       CA CW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
                       RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
                      NL PT SE BE BU OF OG OI OM GA GN GW ML MR NE SN TD TG
APPLICATION INFO .:
                      WO 1999-US15971 A 19990714
PRIDRITY INFO.:
                      US 1998-09/115,455
                                           19980714
     Protein arrays for the parallel, i(in vitro) screening of biomolecular
ABEN
      activity are provided.
      Methods of using the protein arrays are also disclosed. On the arrays, a
      plurality of different
      proteins, such as different members of a single protein family, are
      immobilized on one or more
      organic thin films on the substrate surface. The protein arrays are
      particularly useful in drug
      development, proteomics, and clinical diagnostics.
ABFR
     L'invention concerne des groupements de proteines permettant de mettre
      en seuvre un criblage
      i(in vitro) en parallele d'activité biomoleculaire. Des procedes
      d'utilisation des groupements de
      proteines sont egalement decrits. Dans les groupements, plusieurs
      proteines differentes telles que
      des membres differents d'une seule famille de proteines, sont
      immobilisees sur un ou plusieurs films
      minces organiques a la surface du substrat. Les groupements de proteines
      sont particulierement
      utiles dans le developpement de medicaments, la proteomique et le
      diagnostic clinique.
     ANSWER 96 OF 189 FOTFULL COPYRIGHT 2000 Univention
ACCESSION NUMBER: 2000002587 PCTFULL ED 20020515
                      CANCER TREATMENT METHODS USING THERAPEUTIC CONJUGATES
TITLE (ENGLISH):
                      THAT BIND TO AMINOPHOSPHOLIPIDS
                      PROCEDES DE TRAITEMENT DU CANCER METTANT EN APPLICATION
TITLE (FRENCH):
                       DES CONJUGUES THERAPEUTIQUES SE FIXANT A DES
                      AMINOPHOSPHOLIPIDES
INVENTOR(S):
                      THOMPE, Philip, E.; RAN, Sophia
                     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
PATENT ASSIGNEE(S):
LANGUAGE OF PUBL.:
                      English
DOCUMENT TYPE:
                      Fatent
PATENT INFORMATION:
                       NUMBER
                                        KIND
                                                 EATE
                        Wa 200002587 Al 20000120
                      AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
DESIGNATED STATES
                       HE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                       HR KZ LC LK LR LS LT LU LV MĐ MG MK MN MW MX NO NZ PL
```

```
PT RO RU SO SE SG SI SK SL TJ TM TR TT VA UG UZ VN YU
                         ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
                         RU TO IM AS BE SHOW DE DK ER FI FR GB GR IE IT LU MS
                         NL PT SE BF BJ OF 03 CI CM GA GN SW ML MR NE SN TD TG
                                              A 19990712
APPLICATION INFO.:
                         WO 1999-US15669
PRIGRITY INFO.:
                        us 1998-65 032,884
                                                 19930713
                        WS 1993-81 110,800
                                                 19991202
ABEN
       Disclosed is the surprising discovery that amonophospholopids, such as
       phosphatidylserine and
       phosphatidylethan:lamine, are specific, accessible and stable markers of
       the luminal surface of
       tumor blood vessels. The present invention thus provides
       aminophospholipid targeted diagnostic and
       therapeutic constructs for use in tumor intervention.
       Antibody-therapeutic agent conjugates and
       constructs that bind to aminophospholipids are particularly provided, as
       are methods of specifically
       delivering therapeutic agents, including toxins and coagulants, to the
       stably-expressed
       aminophospholipids of tumor blood vessels, thereby inducing thrombosis,
       neorbsis and tumor
       regression.
ABFE
       On a decouvert que des aminophospholipides, tels que phosphatidylserine
       phosphatidylethanolamine, sont des marqueurs specifiques, accessibles et
       stables de la surface
       intracavitaire de vaisseaux sanguins tumoraux. L'invention concerne, de
       ce fait, des produits de
       recombinaison diagnostiques et therapeutiques ciblant les
       aminophospholipides et concus pour
       intervenir sur la tumeur. Elle concerne en particulier des conjugues
       d'agents therapeutiques et
       d'anticorps et des produits de recombinaison se fixant aux
       aminophospholipides, ainsi que des
       procedes servant à administrer de facon specifique des agents
       therapeutiques, y compris des toxines
       et des coagulants, aux aminophospholipides d'expression stable de
       vaisseaux sanguins tumoraux, re-
       qui provoque une thrombose, une necrose et une regression de la tumeur.
       ANSWER 97 OF 189 POTFULL COPYRIGHT 2002 Univentio
L104
                       2000002584 POTFULL ED 20020515
ACCESSION NUMBER:
TITLE (ENGLISH):
                        CANCER TREATMENT METHODS USING ANTIBODIES TO
                        AMINOPHOSPHOLIPIDS
TITLE (FRENCH):
                        PROCEDES DE TRAITEMENT DU CANCER REPOSANT SUR
                        L'UTILISATION D'ANTICORPS VIS-A-VIS DES
                        AMINOPHOSPHOLIPIDES
INVENTOR (3):
                        THORPE, Philip, E.; RAN, Sophia
                       BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
PATENT ASSIGNEE(S):
LANGUAGE OF FUBL.:
                        English
DOCUMENT TYPE:
                         Patent
PATENT INFORMATION:
                        NUMBER
                                            KIND
                                                      DATE
                        Wo 1000002584 A2 10000120
                        AE AD AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
DESIGNATED STATES
                         HE HS FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                        FR HZ LC LF LR LS LT LU LV MD MG MK MN MW MK NO NZ PL
                         ET RO RU SO SE SG SI SK SL TJ TM TR TT NA NG NU WN YU
                         JA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KS KZ MD
                        RU TU TM AT BE 3H GY DE DK ES FI FR GB GF IE IT LU MO
                        ML PT SE BF BJ OF OG DI CM GA GN GW ML MR NE SN TD TG

    Wd 1999-Ud.5600
    A 19990712

    US 1998-60.092,672
    19980713

    US 1998-60.092,672
    19980713

    US 1998-60.092,672
    19980713

APPLICATION INFO.:
PRIORITY INFO.:
```

US 1998-60/110,608

19981202

ABEN Disclised are the surprising discoveries that aminophospholipids, such as phosphatidylserine

and phosphatidylethanclamine, are stable and specific markers accessible on the luminal surface of

tumor blood vessels, and that the administration of an

anti-aminophospholipid antibody alone is

sufficient to induce thrombosis, tumor necrosis and tumor regression

i(in vive). This invention

therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the

specific destruction of tumor block vessels and in the treatment of solid tumors. Although various

antipody conjugates and combinations are thus provided, the use of maked, or unconjugated,

anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to

simplicity and effectiveness of the approach.

ABFR L'invention concerne la decouverte surprenante selon laquelle les aminophospholipides, du type

phosphatidylserine et prosphatidylethanolamine, sont des marqueurs stables et accessibles a la

surface intracavitaire des vaisseaux sanguins de tumeur, et selon laquelle la simple administration

d'anticorps vis-a-vis des aminophospholipides suffit a induire la thrombose, la necrose tumorale et

la regression tumorale i(in vivo). En consequence, l'invention concerne des procedes reposant sur

l'utilisation d'anticorps vis-a-vis des aminophospholipides, et des compositions destinées à être

utilisees pour la destruction specifique des vaisseaux sanguins de tumeur et le traitement des

tumeurs solides. Bien que l'invention concerne ainsi plusieurs conjugues et combinaisons

d'anticorps, l'utilisation d'anticorps nus ou non conjugues vis-a-vis du type phosphatidylserine est

un aspect particulièrement important de l'invention, grace a la simplicite et a l'efficacite de

l'approche considereea

L104 ANSWER 98 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 930371 EUROPATFULL EW 200051 FS 9S TITLE: 1MIDAZO(1,5A) PYRIDINE DERIVED SERINE PROTEASE

INHIBITORS

AUS IMIDAZO-(1,5A)-PYRIDIN STAMMENDE INHIBITOREN VON

SERINPROTEASEN.

INHIBITEURS DE SERINE PROTEASE DERIVES DE

IMIDAZO(1,5A) EYRIDINE.

INVENTOR(S): OTTENHEYM, Henricus Carl Joseph, Gagelveld 5, 6596 CC

Milsreek, NL;

ADANG, Anton Egbert Peter, Le Sage ten Broeklaan 77,

5615 CR Einahoven, NL;

PETERS, Jacobus Albertus Maria, Meerval 23, 5345 DB Oss,

37.

PATENT ASSIGNEE(S): Akzo Nobel N.V., Velperweg 76, 6824 BM Arnnem, NL

PATENT ASSIGNEE NO: 200754

AGENT: Hogenbirk, Marijke et al., P.O. Box 20, 5340 EH Oss, NL

AGENT NUMBER: 86991

OTHER SOURCE: BEPB2000060 EP 0830371 B1 0019

SOURCE: Wila-EPS-2001-H51-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FP; P GB; R GR; R

IE; R IT; R LI; R NL; R PT; R SE

EPBL EURPPAEISCHE PATENTSCHRIFT Internationale PATENT INFO. PUB. TYPE:

Anmeldung:

PATENT INFORMATION:

PATENT NI KIND PATE B1 ..3501233 EP 3:0371

'OFFENLEGUNGS' DATE:

. 99635..9 APPLICATION INFO.: EP 1498-916636 1995000 PRICRITY APPLM. INFO.: EP 1998-201448 RELATED DOG. INFO.: WO 94-EP1198 960523 INTAKZ

WO 9.3847 F

REFERENCE PAT. INFO.: EP 335483 A

REF. NON-FATENT-LIT.: LIEBIGS ANNALEN DEF CHEMIE, no. 9, September 1983, WEINHEIM DE, pages 1623-1637, MPD02014819 C KLEIN ET

961201 INTENA

AL.: "Umwandlung von omega-Guanidino- und

omega-Ureido-alpha-aminosaeuren in alpha-Ketosaeuren und deren heterocyclische Folgeprodukte " cited in the application TETRAHEDRON, vol. 48, no. 24, 12 June 1992, DMFORD GB, pages 5191-5198, MP002014820 R GONZALEZ-MUNIZ

19987315

ET AL.: "Synthesis of 2-substituted 8-amine-3-

expirablicidine-2-carboxylic acid derivatives as peptide

conformation mimetics"

L104 ANSWER 99 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

539031 EUROPATEULL EW 200031 FS PS ACCESSION NUMBER:

IMPROVED INHIBITORS OF THROMBIN. TITLE:

VERBESSERTE THROMBININHIBITOREN. INHIBITEURS AMELIORES DE THROMBINE.

MARAGANORE, John, M., 17 Highland Street, Concord, MA INVENTOR(S):

01742, US;

JABLONSKI, Jo-Ann, M., 9 Summer Street, Middleborough,

MA 00346, US;

BIURDON, Paul, R., 17 1/2 Vinal Avenue, Sommerville, MA

03143, US

FATENT ASSIGNEE(S): BIOGEN, INC., 14 Cambridge Center, Cambridge

Massachusetts 02142, US

PATENT ASSIGNEE NO: 1049451

VOSSIUS & PARTNER, Ebstfach 86 07 67, 81634 Muenchen, DE AGENT:

AGENT NUMBER: 100311

BEPB3000029 EP 0529031 B1 0026 OTHER SOURCE:

Wila-EPS-2000-H21-T1 SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: F AT; F BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R DESIGNATED STATES:

IT; R LI; R LU; R MO; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROFAEISCHE FATENTSCHRIFT (Internationale

Anmeldung

PATENT INFORMATION:

KIND DATE PATENT NO EP 539031 B1 20000524 'OFFENLEGUNGS' DATE: 19930303 EB 1992-9:8748 19920303 APPLICATION INFO .: PRIORITY APPLN. INFO.: US 1491-682929 19910258 RELATED DOG. INFO.: WORLBUIEUSBB6 92020: INTAKZ WD 9213952 92082 / INTPNE - WU BLIBEL - EP 19889 - A REFERENCE PAT. INFO.: 5.P 113280

WD 91-02750 A

Bischemistry, vol. 29, 1990, 'Easton, PA, US), J.M. REF. NON-PATENT-LIT.:

MARAGANCRE et al.: "Design and characterization of Hirulogs: A novel class of Bivalent peptide inhibitors of thrombin" pages 7095-7101, see abstract, page 7099, left-nand column, lines 21-23 Scand. J. Haematol., vol. 31, 1953, Coopennagen, DK , G.F. HANDELANG et al.: "Simplified assay for antithrombin III activity using onromogenio peptide substrate", pages 427-436, see abstract; page 435, left-hand selumn, paragraphs 2-3

1104 ANSWER 100 OF 189 PASCAL CUPYRIGHT 2012 INTSTRUMES. ALL RIGHTS

RESERVED.

2006-0087234 PASCAL ACCESSION NUMBER:

COPYRIGHT NOTICE: Copyright .COPYRGT. 2000 ININT-CNRS. All rights

reserved.

TITLE (IN ENGLISH): Design, synthesis and structure-activity relationship

of a series of arginine aldehyde

factor Xa inhibitors. Part

1 : Structures based on the (D)-Arg-Gly-Arg tripeptide

sequence

MARLOWE C. K.; SINHA U.; GUNN A. C.; SCARBOROUGH R. M. AUTHOR:

COR Therapeutics, Inc., 256 East Grand Avenue, South San Francisco, CA 94930, United States CORPORATE SOURCE:

Biporganic & medicinal chemistry letters, (2000), SDURCE:

10(1), 13-16, 24 refs.

ISSN: 0960-894X

DOCUMENT TYPE:

Journal BIBLIOGRAPHIC LEVEL: Analytic COUNTRY: United K

enited F English IMTer United Kingdom

LANGUAGE:

AVAILABILITY: INIST-22446, 354000081025360040

AN 2000-0087254 PASCAL

CF Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.

AB A series of arginine aldehyde inhibitors was designed as transition state (TS) analogues based on the known factor Xa specific substrate Cbz-D-Arg-Gly-Arg-pNA.

BnSO.sub.2-(D)Arg-Gly-Arg-H (20) was found to be the most potent and

selective inhibitor of factor Xa and prothrombinase activity in this series.

L104 ANSWER 101 OF 189 USPATFULL

ACCESSION NUMBER: 1999:163833 USPATFULL

Human tissue factor related DNA segments polypeptides TITLE:

and antibodies

INVENTOR(S): Edgington, Thomas S., La Jolla, CA, United States

Morrissey, James H., Oklahoma City, OK, United States

The Scripps Research Institute, La Jolla, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE 

US 0001978 19991214 US 1997-844806 19970422 (8) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1992-990079, filed on 29 Apr

1992, now patented, Pat. No. US 5622931 which is a division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1937, new patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047,

filed on 31 Mar 1987, now abandoned

DICUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Stanted Budens, Robert D.

LEGAL REPRESENTATIVE: Fitting, Thomas, Holmes, Emily

40 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 21 Drawing Figure's:; 15 Drawing Page's:

LINE COUNT: 3241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IMA segments that include DMA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor firm of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Firther disclosed are human tissue factor heavy chain kinding site relypeptide analogs as well as methods for their use.

CAS INJEMING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 102 OF 189 USPATFULL

ACCESSION NUMBER: 1999:151182 USPATFULL

TITLE: Agents affecting thrombosis and hemostasis Wilf, David L., Palo Alto, CA, United States INVENTOR(S): Sinha, Uma, San Francisco, CA, United States

PATENT ASSIGNEE(S): COR Therapeutics Inc., South San Francisco, CA, United

States (U.S. corporation)

NUMBER KIND DATE 

PATENT INFCEMATION: US 5990079 19991123 APPLICATION INFG.: US 1998-16400 19980130 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-469301, filed on 6 Jun

1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-263003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on

16 Dec 1991, now abandoned which is a

continuation-in-part of Ser. No. US 1990-578646, filed

on 4 Sep 1990, now patented, Pat. No. US 5273144

DOCUMENT TYPE: Utility FILE SEGMENT: Granted PRIMARY EXAMINER: Degen, Namely

LEGAL REFRESENTATIVE: Morgan, Lewis & Bockius LLE

NUMBER OF CLAIMS: 16 EKEMPLARY CLAIM:

NUMBER OF DEAWINGS: 24 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 1981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be adylated

forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 103 OF 189 USPATFULL

1999:128513 USPATFULL ACCESSION NUMBER:

Agents affecting thrombosis and hemostasis TITLE: Wolf, David L., Palo Alto, CA, United States INVENTOR(S):

Sinha, Yma, San Francisco, CA, United States DOR Therapeutics, Inc., South San Francisco, CA, United PATENT ASSIGNEE(S):

States (U.F. corporation)

NUMBER KIND DATE \_\_\_\_\_\_

PATENT INFORMATION: US 5969197 19991019 APPLICATION INFO.: US 1998-16403 19980130 '9)

FELATED APPLN. INFO.: Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a

division of Ser. No. US 1994-268003, filed on 29 Jun 1994, new patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, new patented, Eat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on

16 Des 1941, now abandoned which is a

continuation-in-part of Ser. No. US 1990-578646, filed

on 4 Sep 1990, new patented, Pat. No. US 5278144

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy

LEGAL REPRESENTATIVE: Morgan, Lewis & Bookius LLP

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 24 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT: 1908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 104 OF 189 USPATFULL

ACCESSION NUMBER: 1999:121300 USPATFULL TITLE: Factor VII-derived peptides

INVENTOR(S): Sakariassen, Kjell Steinar, Oslo, Norway

Stephens, Poss Wentworth, Copenhagen, Denmark

Orning, Lars, Oslo, Norway

PATENT ASSIGNEE(S): Nydomed Imaging A/S, Oslo, Norway (non-U.S.

corporation)

	NUMBER	KIND DATE	
PATENT INFORMATION:	US 5962418	19991005	
	WO 9500541	19950105	
APPLICATION INFO .:	บร 1996-5ศ4063	19960523	(8)
	WO 1994-GB1315	19940617	
		19960523	PCT 371 date
		19960529	PCT 102(e) date

	NUMBER	DATE
PFIORITY INFOFMATION:	GB 1993-13601	19930613
DOCUMENT TUBE.	GB 1994-9335	19940510
DOCUMENT TYPE: FILE SEGMENT:	Utility Granted	
PFIMARY EXAMINER:	Tsang, Cesilia J.	
ASSISTANT EXAMINER:	Gupta, Anish	0.15

LEGAL REPRESENTATIVE: Testa, Hurwitz & Thikeault LLP

NUMBER OF CLAIMS: 15 EXEMPLARY CLAIM: 1

NUMBER OF ORAWINGS: 23 Brawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 1015

CAS INDEMING IS AVAILABLE FOR THI. PATENT.

The present invention relates to compounds comprising the amino acid sequences of the firmulae [IA]: -CVNENGGCEQYCSD-, (IB): -FCLPAFEGRNCE-and/or (IC): -ECHEGYSLLADG/SCT- as well as peptide fragments thereof, esters, amides, salts and cyclic derivatives thereof, functional analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments, for use in the prevention or inhibition of

binding of tissue factor to FVII.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 105 OF 189 USPATFULL

ACCESSION NUMBER: 1999:..1169 USPATFULL

TITLE: Protesse inhibitor peptides

White, R. Tyler, Fremont, CA, United States INVENTOR(S): Damm, Debarah, Redwood City, CA, United States Lesikar, David D., Palo Alto, CA, United States

McFadden, Kathleen, Mountain View, CA, United States Garrick, Brett L., Palo Alto, CA, United States

Scips, Inc., Mountain View, CA, United States (U.S. PATENT ASSIGNEE (S):

corporation)

NUMBER KIND DATE \_\_\_\_\_\_\_

PATENT INFORMATION: US 5960266 19991005 APPLICATION INFO.: US 1997-829876 19970402 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-436555, filed on 8 May

1,995

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Slobedyansky, Elizabeth

LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 32 EXEMPLARY CLAIM: l

NUMBER OF DRAWINGS: 53 Drawing Figure(s); 53 Drawing Page(s) LINE COUNT: 4412

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Analogues of the Kunitz Protease Inhibitor (KFI)

domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 106 OF 189 USPATFULL

ACCESSION NUMBER: 1999:110297 USPATFULL

Basic .alpha.-aminoalkylphosphonate derivatives TITLE: Powers, James C., Atlanta, GA, United States INVENTOR(S):

Jackson, Delwin S., Bear, DE, United States Ni, Liming, Little Canada, MN, United States

Georgia Tech Research Corp., Atlanta, GA, United States PATENT ASSIGNEE(S):

(U.S. corporation)

NUMBER KIND DATE ...... ------PATENT INFORMATION: US \$952307 19990914 APPLICATION INFO.: US 1997-907840 19970814 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-184286, filed

on 21 Jan 1994, now patented, Pat. No. US 5686419

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PFIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David

LEGAL REPRESENTATIVE: Deveau, Colton & Marquis

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: . 1787 LINE COUNT:

CAS INTEXING IS AVAILABLE FOR THIS PATENT.

Reptidyl derivatives of diesters of Lalpha. -aminoalkylphosphonic acids with basic substituents, their use in inhibiting serine proteases with

trypsin-like specificity and their roles as anti-inflammatory agents, anticoagulants, and anti-tumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LIG4 ANSWER 107 OF 189 USPATFULL

ACCESSION NUMBER: 1999:88791 USPATFULL

TITLE: Modified plasmin precursors with resistance to

inhibitors of plasmin

Dawson, Keith Martyn, Cowley, United Kingdom INVENTOR(S):

Gilbert, Richard James, Cowley, United Kingdom

PATENT ASSIGNEE(S): British Bistech Pharmaseuticals, Ltd., Oxford, United

Kingdom (non-U.S. corporation)

KIND DATE NUMBER 

PATENT INFORMATION: US 5931213 19990803 APPLICATION INFO.: US 1997-889078 19970707 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-379621, filed on 3 Feb

1995

NUMBER DATE \_\_\_\_\_\_

PRIORITY INFORMATION: GB 1992-16558 19920804

DOCUMENT TYPE: Utility FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.

LEGAL REPRESENTATIVE: Hale and Dorn LLP

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 19 Drawing Figure(s); 16 Drawing Page(s) LINE COUNT: 1059

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Plasmin precursors are modified so that they exhibit resistance to inhibitors of plasmin. These modified plasmin precursors have fibrinolytic, thrombolytic or antithrombotic properties, which are useful in the treatment of blood clotting diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 108 OF 189 USPATFULL

ACCESSION NUMBER: 1999:72602 USFATFULL

 Confugates of dithiodarbamates with pharmacologically TITLE:

active agents and uses therefore

INVENTOR(3): Lai, Ching-San, Encinitas, CA, United States

PATENT ASSIGNEE(S): Medinex, Inc., San Diego, CA, United States (U.S.

corporation)

NUMBER KIND DATE US 591691) 19990629 US 1997-869158 19970604 (8) PATENT INFOFMATION: APPLICATION INFO.:

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington

LEGAL REPRESENTATIVE: Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich NUMBER OF CLAIMS: 27

NUMBER OF CLAIMS: EXEMPLARY CLAIM: LINE COUNT: 1842

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarkamates, or "DC") and pharmacologically active agents (e.g., MSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents, which cause a much lower incidence of sine-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially namaging effects of mitric exame overproduction induced thereby as a result of the co-production of nitric exide scavenger (e.g., dithiocarkamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 109 OF 189 USPATFULL

ACCESSION NUMBER: 1999:72590 USPATFULL

TITLE: Imida:o[1,5A]pyridine derived sorine protease

inhibitors

INVENTOR(S): Feters, Jacobus Albertus Maria, Oss, Netherlands

Ottenheym, Henricus Carl Joseph, Milsbeek, Netherlands

Adang, Anton Egbert Peter, Eindhoven, Netherlands

PATENT ASSIGNEE(S): Akzo Mobel, M.V., Arnhem, Netherlands (non-U.S.

corporation)

	NUMBER	KIND DATE	
PATENT INFORMATION:	US 5916888 WO 9638470	19990629 19961005	
APPLICATION INFO.:	US 1997-973255 WO 1996-EP2298	19971.:02 19960529	(8)
			PCT 371 date PCT 102(e) date

NUMBER DATE

PRIORITY INFORMATION: EP 1995-201448 19950602 DOCUMENT TYPE: Utility

FILE SEGMENT: Stanted
PRIMARY EXAMINER: Raymond, Richard L.

PRIMARY EXAMINER: Raymond, Richard L LEGAL REPRESENTATIVE: Girmley, Mary E.

NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1019

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

The invention relates to an imidazole[1,5a]pyridine derived serine protease inhibitor comprising a unit having general formula (1) ##STRl## wherein F.sub.1 is hydrogen, lower alkyl or an adyl group; R.sub.2 is hydrogen or lower alkyl; R.sub.3 and R.sub.4 are independently hydrogen, lower alkyl or together form .dbd.CH--NR.sub.5 MR.sub.6, R.sub.5 and F.sub.6 being lower alkyl. The compounds are serine protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blo4 Answer 110 OF 189 USFATFULL

ACCESSION NUMBER: 1999: 3980 USPATFULL TITLE: Inhibitors of factor Xa

INVENTOR-S): Brunck, Terence Kevin, San Diego, CA, United States

Webb, Thomas Roy, Entinitias, MA, United States

Ripka, William Charles, San Diego, CA, United States

PATENT ASSIGNEE:S:: Corvas International, Inc., San Diego, CA, United

## States 'U.S. corporation'

NUMBER KIND DATE \_\_\_\_ -\_- ----<del>\_\_</del>-- ----- ----- 
 US 59:3077
 19990316

 US 1943-168964
 19931215
 PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. IMFO.: Continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now acandoned Ttility DOCUMENT TYPE: Grant⊹d FILE SEGMENT: PRIMARY EXAMINER: Tsang, Cecilia J. ASSISTANT EXAMINER: Lukton, David LEGAL REPRESENTATIVE: Lyon ( Lyon LLE 1.3 NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 1521 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial potency and specificity as inhibitors of mammalian factor Xa are further disclosed. The compounds are thought useful as inhibitors of factor xa in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed. CAS INDEXING IS AVAILABLE FOR THIS PATENT. L104 ANSWER 111 OF 189 USEATFULL ACCESSION NUMBER: 1999:07415 USPATFULL TITLE: Yeast cells engineered to produce pheromone system protein surrogates and uses therefor Fowlkes, Dana M., Chapel Hill, NC, United States INVENTOR(3): Broach, Jim, Princeton, NJ, United States Manfredi, John, Ossining, NY, United States Klein, Christine, Ossining, NY, United States Murphy, Andrew J., Montclair, NJ, United States Paul, Jeremy, South Nyack, NY, United States Trueheart, Joshua, South Nyack, NY, United States Cadus Eharmaceutical Corporation, Tarrytown, NY, United PATENT ASSIGNEE(S): States (U.S. corporation) NUMBER KIND DATE \_\_\_\_\_ US 5876951 19990302 US 1995-461598 19930605 (3) PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned DOGUMENT TYPE: Utility FILE SEGMENT: Granted Ketter, James PRIMARY EXAMINER: ASSISTANT EXAMINER: Yusel, Irem LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara,

Catherine J.

NUMBER OF DRAWINGS: 14 Drawing Figure's:, 13 Drawing Page's:

51

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

LINE COUNT: 6645

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Yeast cells are engineered to express both a surrogate of a pheromone system protein letg., enzymes involved in maturation of .alpha.-factor, transporters of a-lactor, pheromone receptors, etc.) and a rotential

peptide modulator of the surrogate, in such a manner that the innimition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the spreening/selection system.

CAS INDEKING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 112 OF 189 USPATFULL

ACCESSION NUMBER: 1339:19118 USPATFULL

Arginine Reto-amide enzyme inhibitors TITLE:

Webb, Thomas Roy, Enginitas, CA, United States INVENTOR(S): Miller, Todd Anthony, Encinitas, CA, United States Vlasuk, George Phillip, Carlshad, CA, United States Abelman, Matthew Mark, Solana Beach, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE \_\_\_\_\_

US 5869454 19990009 US 1995-462899 19950605 (8) PATENT INFORMATION: APPLICATION INFO .:

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-139300, filed on 18 Oct 1993, new patented, Pat. No. US 5597804 which is a continuation-in-part of Ser. No. US 1992-962301, filed

on 16 Oct 1992, now patented, Pat. No. US 5371072

Utility DOCUMENT TYPE: Granted FILE SEGMENT: FILE SEGMENT: Granted PRIMARY EXAMINER: Weber, Jon P. LEGAL REPRESENTATIVE: Lyon & Lyon LLP NUMBER OF JLAIMS: 42

EXEMPLARY CLAIM:

NUMBER OF ORAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s) LINE COUNT: 3090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention is directed to novel arginine alpha-keto-amide derivatives, their pharmaceutically acceptable salts and compositions thereof which are useful as antithrombotic agents in mammals and also the use of these compounds as antithrombotic agents. Also, described are methods of using these inhibitors as inhibitors of coagulation proteases and as therapeutic agents for disease states characterized by abnormal thrombus formation and/or disorders of the blood coagulation process. Further described herein are compounds useful as intermediates in the preparation of these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 113 OF 189 POTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 1999084037 PCTFULL ED 20020515

MOMEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC TITLE (ENGLISH):

PROCESSES

NOUVEAUX AGENTS THERAFEUTIQUES MODULANT LES PROCESSUS TITLE (FRENCH):

ENCYMATIQUES

GRIFFIN, John, H.; JUDICE, J., Kevin INVENTOR(3):

PATENT ASSIGNEE(S): ADVANCED MEDICINE, INC.; GRIFFIN, John, H.; JUDICE, J.,

Kevin

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

KIND DATE NUMBER

```
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
DESIGNATEL STATES
                       EE ES FI 3B GO GE GH 3M HR HU ID IL DW IS JP KE KG KP
                       KR KZ IC IK IR IS IT IV IV MI MG MK MN MW MW NO NZ PI
                       PT RO RU SO SE SG SI SK SL TO TM TR TT VA UG US US UZ
                       VN YU ZA ZW GH GM KE LO MW SO SL SZ DG ZW AM AZ BY KG
                       KZ MO RU TJ TM AT BE CH CY DE OK ES EI ER 35 GR IE IT
                       LU MO NE PT SE BE BU OF DO CI CM GA EN GW ME MA ME SN
                                          A 1999(303
APPLICATION INFO.:
                       WD 1999-U3.2620
PRIORITY INFO.:
                       WS 1998-60 DRS,448
                                              19931608
                       US 1998-60/093,072
                                              19980716
ABEN Novel multi-binding compounds are disclosed that modulate encymatic
      processes. The compounds of
      the invention comprise from 2-10 ligands covalently connected, each of
      said ligands being capable of
      binding to an enzyme, enzyme substrate or enzyme cofactor thereby
      modulating the biblogical
      processes/functions thereof.
ABFF.
      L'invention porte sur de nouveaux composes multi-liants modulant les
      processus enzymatiques.
      Leadits composes comportent de 2-10 liganda unia par covalence dont
       chacun peut se fixer a une
      enzyme, a un substrat d'enzyme ou a un cofacteur d'enzyme et modifier
      par la leurs processus et
      fonctions biologiques.
1.104
     ANSWER 114 OF 189 PCTFULL GOPYRIGHT 2002 Univention
ACCESSION NUMBER: 1999063090 PCTFULL ED 20020515
TITLE (ENGLISH):
                      PROTEASE INHIBITOR PEPTIDES
TITLE (FRENCH):
                     PEPTIDES INHIBITEURS DE PROTEASE
INVENTOR(S):
                      WHITE, R., Tyler; DAMM, Deborah; LESIKAR, David, D.;
                       McFADDEN, Kathleen; GARRICK, Brett, L.; LUCAS, Anne,
                       Bergstrom; POLLITT, N., Stephen; LAM, Andrew, O.
                       SCIOS, INC.; WHITE, R., Tyler; DAMM, Deborah; LESIKAR,
PATENT ASSIGNEE(S):
                       David, D.; McFADDEN, Kathleen; GARRICK, Brett, L.;
                       LUCAS, Anno, Bergstrom; POLLITT, N., Stephen; LAM,
                       Andrew, O.
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                 KIND DATE
                       ____
                       Wo 9963030 A2 19991209
                       AE AL AM AT AU AZ BA BB BG BF BY CA CH CN CU CZ DE DK
DESIGNATED STATES
                       EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                       KF KZ LC LK LR LS LT LU LV MD MG MK MN MW MK NO NZ PL
                       PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
                       YU ZA ZW GH GM KE LS MW SO SI SZ UG ZW AM AZ BY KG KZ
                       MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
                       MC NL PT SE EF BJ CF CG CI CM GA GN GW ML MR NE SN TD
                       TG
APPLICATION INFO.:
                      WO 1999-US13276
                                          A 19990603
                      us 1998-00/387,885
PRICRITY INFO .:
ABEN
      Analogues of the Kunitz Protease Inhibitor (KPI)
      domain of amyloid predursor protein kind to an
      inhibit activity of serine proteases, including kallikrein, plasmin and
      cragulation factors such as
      factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical
       compositions containing the FPI analogs, along
      with methods for using such compositions, are useful for ameliorating
      and treating clinical
      conditions associated with increased serine protease activity, such as
      blood loss related to
      cardicpulmonary byrass surgery. Nucleic acid sequences encoding these
```

WO 9964037

Al 19991216

```
analogs and systems for
      expression of the peptides of the invention are provided.
       l'invention concerne des analogues du domaine inhibiteur de
ABFR
      pritease de Kunitz (KEI: de la
       proteine precurseur amyloide qui se lient aux proteases serines et
       inhibent l'activité de ces
      proteases, y compris la kallikreine, la plasmine et les facteurs de
       spagulation du type VIIa, IXa,
      Ma MIa et MIIa. L'invention concerne en cutre des compositions
      charmaceutiques renfermant des
        analogues de l'innikiteur KPI, ainsi que des procedes relatifs
       a l'utilisation desdites
      compositions, utiles pour ameliorer et traiter les etuts cliniques lies
       a une augmentation de
      l'activité de la protease serine, comme par exemple dans le cas des
      pertes sanguines inherentes a
      une intervention chirurgicale avec direulation extra-corporelle.
      L'invention concerne enfin des
      sequences d'acides nucleiques codant les analogues consideres,
      et des systemes permettant d'exprimer
      les peptides decrits dans l'invention.
      ANSWER 115 OF 189 POTFULL COPYRIGHT 2002 Univention
L104
ACCESSION NUMBER: 1999041276 PCTFULL ED 20020515
                       β -SHEET MIMETICS AND METHODS RELATING TO THE USE
TITLE (ENGLISH):
                       THEREOF
                       IMITATEURS DE BETA FEUILLETS ET PROCEDES LIES A LEUR
TITLE (FRENCH):
                       UTILISATION
                       QABER, Maher, N.; McMILLIAN, Michael, K.; KAHN,
INVENTOR(S):
                       Michael, S.; TULINSKY, John, E.; MATHEW, Jessymol
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; QABER, Maher, N.; McMILLIAN,
                      Michael, K.; KAHN, Michael, S.; TULINSKY, John, E.;
                       MATHEW, Jessymol
LANGUAGE OF FUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFOFMATION:
                       NUMBER
                                         KIND DATE
                       WO 9941276 A1 19990819
                       AL AM AT AU BA BB BG BE BY CA CH CN CU CZ DE DK EE ES
DESIGNATED STATES
                       FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK
                       LR LS LT LU LV MD MG MK MN MW MX NO NZ FL FT RO RU SD
                       SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM
                       KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD EU TJ TM AT BE
                       CH DE DK ES FI FR GB GR IE IT LU MC NL FT SE BF BJ CF
                       CG CI CM GA GN ML MR NE SN TD TG
                      WO 1998-US2891 A 19980212
APPLICATION INFO .:
      Sbeta; - sheet mimetics and methods relating to the same are disclosed.
ABEN
      The β -sheet mimetics
      have utility as protease and kinase inhibitors, as well as inhibitors of
      transcription factors and
      protein-protein binding interactions. Methods of the invention include
       administration of a
      Sbeta; - sheet mimetic, or use of the same for the manufacture of a
      medicament for treatment of a
      variety of conditions associated with the targeted protease, kinase,
      transcription factor and/or
      protein-protein binding interaction.
ABFR
      L'invention concerne des imitateurs de &keta;-feuillets et de procedes
       associes. Les imitateurs
       de Abeta;-feuillets sint utiles en tant qu'inhibiteur. de protease et de
      kinase, ainsi que comme
      innibiteurs de facteurs de transcription et d'interaction de liaison
      proteine-proteine. Les procedes
       consistent a administrer un imitateur de β-feuillets ou a utiliser
```

celui-si pour fabriquer un medicament pour le traitement d'une grande variete de pathologies associees a la protease, a la kinase, au facteur de transcription et/ou a l'interaction de liaison proteine-proteine dibles.

ANSWER 116 OF 189 POTFULL COPYRIGHT 2002 Univention 1104

ACCESSION NUMBER: 19990. 6920 POTFULL ED 20020515

SUBSTITUTED 3-AMINO-2-HYDROMYPHENYLAGETAMION TITLE SENGLISH::

DERIVATIVES AS EMZYME INHIBITORS (II)

DERIVES DE 3-AMINO-2-HYDROKYPHENYLAGETAMIDE SUBSTITUE TITLE (FREMCH):

UTILIZES EN TANT QU'INHIBITEURS (II) D'ENZYME

SEMPLE, Joseph, Edward; LIM-WILBY, Marguerita, S.; BRUNCK, Terence, K. INVENTOR( $\varepsilon$ ):

PATENT ASSIGNEE S): CORVAS INTERNATIONAL, INC.; SEMPLE, Joseph, Edward;

LIM-WILBY, Marquerita, S.; BRUNCK, Terence, K.

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE Wc 9916920 Al 19990633

AL AM AT AU AS BA BB BG BE BY SA SHOWN OU SO DE DK EE DESIGNATED STATES

ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LO LK LR LS LT LU LV MD MG MK MN MW MX NO NE PL PT RO RU SD SE SG SI SK SL TJ TM TR TT JA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM

AT BE CHICY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

BE BUICE OG CI OM GA GN GW ML MR NE SN TD TG

WO 1998-US25167 A 19981103 APPLICATION INFO .: US 1997-08/980,114 19971126 US 1997-08/979,440 19971126 PRIORITY INFO.:

The present invention provides peptide aldehydes having an ABEN

3-amino-2-nydroxyphenyl acetamide

group as part of the peptide backbone and an arginine

group or analog at El. These compounds are

potent and specific or inhibitors of thrombin. Their pharmaceutically acceptable salts,

pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents

for disease states in mammals characterized by Abnormal thrombosis are also described. Also

described are 3-amino-2-hydroxyphenyl-acetamide derivatives having in history activity towards

proteases of the trypsin/chymotrypsin class.

ABFR. La presente invention concerne des aldehydes peptidiques comprenant un groupe

3-amino-2-hydroxyphenyle acetamide faisant partie du squelette peptidique et un groupe arginine ou

analogue sur Pl. des composes sont des inhibiteurs puissants et specifiques de la thrombine.

L'invention concerne equlement leurs sels pharmaceutiquement acceptables, leurs compositions

pharmaceutiquement acceptables, et leurs procedes d'utilisation en tant qu'agents therapeutiques

destines a des etats pathologiques chez des mammiferes carabterises par une thrombose anormale.

L'invention concerne, «n outre, des derives de --amino-2-hydroxyphenylacetamide presentant une

activite connue vis-a-vis de proteases de la dategorie trypsine chymotripsine.

L104 ANSWER 1.7 OF 189 POTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 1939024050 POTFULL ED 20020010

HIGH THROUGHPUT METHOD FOR FUNCTIONALLY CLASSIFYING TITLE ENGLISH:

```
PROCEDE A HAUT RENDEMENT PERMETTANT DE CLASSER
TITLE FRENCH):
                        FINITIONNELLEMENT DES PROTEINES IDENTIFIEES PAR UNE
                       METHODE DES GENOMES
INVENTOR'S::
                       PANTOLIANO, Michael, W.; SALEMME, Francis, R.;
                       PETRELLA, Eugenio, C.; CARMER, Theodore, E., Jr.;
                       RHIND, Alexander, W.
                       PROFIMENSIONAL PHARMAGEUTICALS, INC.
PATENT ASSIGNEE S -:
LANGUAGE OF PUBL.:
                       English
DOGUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                          KIND
                                                  DATE
                       Wo 9924050 Al 19990520
DESIGNATED STATES
                       AL AM AT AU AZ BA B5 BG BR BY CA CH CN CU CZ DE DK EE
                       ES EL GE GD GE GH GM HR HU LD LL LS JE KE KG KP KR KZ
                       LO LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
                       RU SD SE SG SI SK SL TJ TM TF TT UA UG UZ VN YU ZW GH
                       GM KE LS MW 3D 32 UG ZW AM AZ BY KG KZ MD RU TJ TM AT
                       BE OH OY DE DK ES FI FR GB GF IE IT LU MO NL PT SE BF
                       BJ OF OG OI OM GA GN GW ML MR NE SN TD TG
                       WO 1998-US24035 A 19981112
APPLICATION INFO.:
                      us 1997-60/065,129 19971112
PRIORITY INFO.:
     The present invention provides a method for functionally classifying a
ABEN
      protein that is capable
      of unfolding due to a thermal change. The method comprises screening one
      or more of a multiplicity
      of different molecules for their ability to shift the thermal unfolding
      curve of the protein,
      wherein a shift in the thermal unfolding curve indicates that the
      molecule binds to the protein or
      affects the stability in a measurable way; generating an activity
      spectrum for the protein wherein
      the activity spectrum reflects a set of molecules, from the multiplicity
      of molecules, that shift
      the thermal unfolding curve, of the protein and therefore are ligands
      that bind to the protein,
      comparing the activity spectrum for the protein to one or more
      functional reference spectrum lists;
      and classifying the protein according to the set of molecules in the
      multiplicity of different
      molecules that shift the thermal unfolding curve of the protein.
ABFF.
      Cette invention a trait a un procede a haut rendement permettant de
      classer fonctionnellement
      une proteine capable de se deplier sous l'effet d'un changement d'ordre
      thermique. Ce procede, qui
      consiste a cribler l'une, sinon plusieurs, des multiplicites de
      molecules differentes aux fins de la
      determination de leur aptitude a decaler la courbe thermique de depliage
      de la proteine, un decalage
      de cette courbe indiquant que la molecule se fixe a la proteine ou
      influe sur sa stabilité de facon
      mesurable, consiste egalement a generer un spectre d'activite de la
      proteine, spectre qui correspond
      a un ensemble de molecules de la proteine, ces molecules etant issues de
      la multiplicate
      susmentionnee decalant la courbe thermique de depliage et étant, de ce
      fait, des ligands qui se
       fixent a la proteine. On compare ensuite, dans le cadre de ce procede,
       le spectre d'activite relatif
      a la proteine a une liste de spectres de reference fonctionnels, sinon a
      plusieurs, et l'on classe
       la proteine d'après l'ensemble de molecules de la multiplicate de
      molecules differentes qui detalent
       la courbe thermique de depliage de la proteine.
```

PROTEINS IDENTIFIED USING A GENOMICS APPROACH

1104 AMSWER 118 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

EUROPATFULL EW 199919 FS OS 915154 ACCESSION NUMBER:

Yeast dells engineered to produce pheromone system TITLE:

protein surrogates, and uses therefor.

Hefe Zellen so kanstruiert, dass sie Proteinsurrogate des Pheromonsystems producieren und Anwendungen dafuer. Cellules de levure traitées pour produire des substituts de proteines du système de pheromones, et leurs emplois.

Fowlkes, Dana Merriman, 30 Green Street, Apartment 2, INVENTOR(S):

New York, NY 10012, US;

Broach, Jim, 360 East 38th Street, Apartment 2A, New

York, NY 10128, US;

Manfredt, John, 666 Greenwich Street, Apartment 556, New

York, NY 10014, US;

Klein, Christine, 666 Greenwich Street, Apartment 556,

New York, NY 10014, US;

Murphy, Andrew J., 17 Windsor Place, Montclair, NJ

07043, US;

Paul, Jeremy, 197 Route 9W, Palisades, NY 10964, US; Trueheart, Joshua, 212 South Broadway, South Nyack, NY

10980, US

Cadus Pharmaceuticals, Inc., 7th floor, 180 Varick PATENT ASSIGNEE(S):

Street, New York, NY 10014, US

1860561 PATENT ASSIGNEE NO:

Frice, Vincent Andrew et al, FRY HEATH & SPENCE The Old AGENT:

College 53 High Street, Horley Surrey RH6 7BN, GB

79513 AGENT NUMBER:

ESP1999034 EP 0915154 AL 990512 OTHER SOURCE:

SOURCE: Wila EP2-1999-H19-Tla

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE: DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MO; R NL; R PT; R SE

PATENT INFO. PUB. TYPE: EPAI EUROPAEISCHE PATENTANMELDUNG

PATELT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_ EP 915154 A1 19990513 'DFFENLEGUNGS' DATE: 19990512 EB 1998-203997 19940323 APPLICATION INFO .: PRIORITY APPLN. INFO.: US 1993-41431 19930331 US 1994-190328 19940131

RELATED DOG. INFO.: EP 698005 DIV

L104 ANSWER 119 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

EUROPATFULL EW 199904 ES PS ACCESSION NUMBER: 765339

3-AMINO D-OMO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING TITLE:

AN ARGININE MIMIC AS ENZYME INHIBITORS.

3-AMINO-11-0WO-PIPERIDINESSIGSA-UREDERIVATE, DIE EINE ARGININNACHAHMENDE VERBINDUNG, MIT ENZYMINHIBITORISCHEN

WIRKUNG ENTHALTEN.

DERIMES D'ACIDE 3-AMINO-2-0MO-PIPERIDINEACETIQUE

CONTEMANT UN ANALOGUE DE L'ARGININE

TILLICES EN TANT QU'INHIBITEURS D'ENZYME.

SEMPLE, Joseph E., 9711 Caminity Pudregal, San Diego, CA INVENTOR(S):

9218., MD; LEVY, Cd.le E., 9278 Avenida Navidad 3, San Diego, CA

92122, UJ;

NUTT, Ruth F., 4 Colibir Tierra, Santa Fe, New Mexico

87501, US;

RIPKA, William C., 10819 Red Rock Drive, San Diego, CA

92131, TS

CORVAS INTERNATIONAL, INC., 30:0 Science Park Road, San PATENT ASSIGNEE(S):

Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1101190

MEXIMMELL & STOLBERG, Fatentianwhelte Beselerstrasse 4, AGENT:

23617 Hamburg, DE

AGENT NUMBER:

EFB1499006 EP 0765339 B1 990107 OTHER SCURCE:

Wila-EPS-1999-H04-T1 S DURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeff-ntlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAELSCHE PATENTSCHRIFT (Internationale

Anmeldung:

PATENT INFORMATION:

KIND DATE PATENT NO EP 765339 B1 19940127 19970403 'OFFENLEGUNGS' DATE: 19950619 BP 1995-924623 APPLICATION INFO .: 19940617 PRIORITY APPLN. INFO.: US 1994-261498 US 1994-356831 19941213 

FR 2490632 A

REF. NON-PATENT-LIT.: PHARMACIE, vol.39, no.5, May 1984, BERLIN DD pages 315 -317 G WAGNER ET AL. 'Synthese von N-alpha-(Tosyl-beta-

alanyl) - und N-alpha (Tosyl-epsilon-aminocapronyl)

amidinophenylalanylamiden als stark wirksame

thrombininhibitoren' PHAFMAZIE, vol.42, no.4, April 1987, BERLIN DD page 208 H VIEWEG ET AL. 'Synthese von N-alpha-(ary Isulphonylglycyl)-3-amidinophenylalaninest ern als aktive und relativ specifische Inhibitoren von

Faktor Ma'

ANSWER 120 OF 189 EUROPATFULL COPYRIGHT 1000 WILA L104

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 765338 EUROPATFULL EW 199916 FS PS

ARGININE MIMIC DERIVATIVES AS ENZYME TITLE:

INHIBITORS.

ARGININ AHNLICHE DERIVATE ALS ENZYM-INHIBITOREN.

DEFIVES D'ANALOGUES DE L'ARGININE UTILISES COMME INHIBITEURS D'ENLYME.

LEVY, Odile, Esther, 8278 Avenida Navidad 3, San Diego, INVENTOR(S):

CA 90102, US;

TAMURA, Susan, Y., 8997 Gainsborough Avenue, San Diego,

CA 92109, US;

MUTT, Ruth, F., 4 Colibir Tierra, Santa Fe, New Mexico

87501, US;

RIFKA, William, C., 10419 Red Wock Drive, San Diego, CA

A2131, US CDEVAS INTERMATIONAL, INC., 3030 Science Park Road, San PATENT ASSIGNEE(S):

Diego JA 92121-1102, UJ

1501.90 PATENT ASSIGNEE NO:

UEXECULA STOLBERG, Patentanwaelte Beselerstrasse 4, AGENT:

22607 Hamburg, DE

AGENT NUMBER: 100011

EPB1999024 EP 0765338 bl 990421 OTHER SCURCE:

Wila-EPS-1999-H16-T1 SCURCE:

DICUMENT TYPE: Patent

LANGVAGE: Anmeldung in Englisch; Verbeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R CE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

Anmeldura)

EATENT INFORMATION:

PATEINT NO KIND DATE \_\_\_\_\_\_\_\_\_\_ EP 765 238 B1 139 40421

'OFFENLEGUNGS' DATE:

19970402 19950613 EP 1995-924618 APPLICATION INFO .: 19940617 PRIORITY APPLN. INFO.: US 1994-261478

US 1995-487611 19950607
FELATED DOC. INFO.: WD 95-US7799 950619 INTAKD WD 9539312 951329 INTENR FEFERENCE PAT. INFO.: EE 526877 A FR 349063

FR 0490632 A

REF. NON-PATENT-LIT.: PHARMACIE, vol.39, no.5, May 1984, BERLIN DD pages 315 -

317 G WAGNER ET AL. 'Synthese von N-alpha-(Tosyl-betaalanyl) - und N-alpha- (Tosyl-epsilon-aminocapronyl)

amidinophenylalanylamiden als stark wirksame

thrombininhibitoren' PHARMADIE vol. 42, no. 4, April 1987, BERLIN DD, page 268 H VIEWEG ET AL. 'Synthese von

N alpha-(arylsulphonylglycyl)-3-

amidinophenylalaninestern als aktive und relativ

spezifische Inhibitoren von Faktor Ka'

ANSWER 121 OF 189 EUROPATFULL COPYFIGHT 2002 WILA L104

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 684830 EUROPATFULL EW 199924 FS PS

INHIBITORS OF THROMBOSIS. TITLE: INHIBITOREN GEGEN THROMBOSE. INHIBITEURS DE LA THFOMBOSE.

VLASUK, George Phillip, 3014 Garboso Street, Carlsbad, INVENTOR(S):

CA 92009, US;

WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA

90024, US;

PEARSON, Daniel Andrew, 149 Beals Road, Bedford, NH

03110, US;

ABELMAN, Matthew Mark, 873 Stevens Avenue, 3312, Solana

Beach, CA 92075, US

PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San

Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501290

Irvine, Jonquil Claire et al, J.A. KEMP & CO. 14 South AGENT:

- Square Gray's Inn, London WCIR 5LX, GB

AGENT NUMBER: 74180

EPB1999035 EP 0684830 B1 990616 OTHER SOURCE:

Wila-EPS-1999-H24-T1 SCURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: RAT; RBE; RCH; RDE; RDM; RES; RFR; RGB; RGR; R DESIGNATED STATES:

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE 

EF 634430 B1 19990616 19951206 'OFFENDEGUNGS' DATE:

EH: 199:-909:29 19940314 APPLICATION INFO.: PRIORITY APPLN. INFO.: Up 1994-17125 19930212 US 1994-195995 19940011 RELATED 100. INFO.: W0 94-US1611 940014 INTAKZ W0 9410810 940-18 INTERE

PEFERENCE PAT. INFO.: WD 93-1477/4 A WD 93-15756 A

US 4:99065 A

1/104 ANSWER 122 OF 189 EUROPATFULL COPYRIGHT 000/2 WILA

GRANTED PATENT - ERTEILTES PATENT BREVET DENIVAE

ACCESSION NUMBER: 675849 EUROPATFULL EW 149011 FS PS

TITLE: NOVEL INHIBITORS OF FACTOR

XA.

NEUE INHIBITOREN VON FAKTOR XA. NOUVEAUX INHIBITEURS DU FACTEUR XA.

INVENTOR(S): BRUNCK, Terence Kevin, 4949 Quincy, San Diego, CA 92109,

US;

WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA

92034, US;

RIFKA, William Charles, 19819 Red Rock Drive, San Diego,

GA 91024, US

PATENT ASSIGNEE(S): CURVAS INTERNATIONAL, INC., 3030 Science Park Road, San

Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501290

AGENT: Viering, Jentschura & Partner, Postfach 22 14 43, 80504

Muenchen, DE

AGENT NUMBER: 100045

OTHER SOURCE: EPB1999015 EP 0675899 B1 990317

SOURCE: Wila EPS-1999-H11-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Verbeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

KIND DATE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT NO

PATENT INFORMATION:

EF 675899
B1 19990317
'OFFENLEGUNGS' DATE: 1994-904466 19931015
PRIORITY APPLN. INFO.: US 1992-991004 19931015
RELATED DOC. INFO.: WO 93-US12255 931015 INTAKE
WO 9413693 940623 INTPNR
REFERENCE PAT. INFO.: EP 093881 A EP 095645

REFERENCE PAT. INFO.: EP 093881 A EP 095645 A WO 93-12076 A

US 4883863 A US 5153176 A

REF. NON-PATENT-LIT.: JOURNAL OF MEDICINAL CHEMISTRY, vol.33, no.1, January

1999, WASHINGTON US pages 36 - 93 R M MCCONNELL ET AL. 'New leupeptin analogues; synthesis and inhibition data' JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol.114, no.8, 3 April 1992, GASTON, PA US pages 3156 - 3157 A M

MURPHY ET AL. 'Automated synthesis of peptide C-terminal aldehydes' JOUPNAL OF MEDICINAL CHEMISTRY, vol.36, no.3, 16 April 1993, WASHINGTON US pages 1034 - 1089 R M

MCCONNELL ET Al. 'Inhibition studies on some serine and thing proteinases by new leupeptin analogues' Helvetica Chimica Acta, Volume 51, No. 5, issued 1969, VON St.

GUTTMARN et al., "Synthese des Thyreocalcitonins", pages

1155-1158

1104 ANSWER 123 OF 189 EURIPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

EUROPATFULL EW 199912 FS PS ACCESSION NUMBER: 664786 ARGININE KETO-AMIDE ENZYME INHIBITORS. TITLE: INHIBITOREN DES ARGININ-KET AMID-ENZYMS. CETO-AMIDE D'ARGININE COMME INHIBITEURS ENZYMATIQUES. INVENTOR S.: WEBB, Thomas, Roy, 2250 Colony Ferrage, Enginitas, CA 920.4, 98; MILLER, Todd, Anthony, 1710 South El Camino Real, E-209, Endinitäs, CA 92024, UE; MIANUK, George, Phillip, 2014 Garbasa Street, Carlsbad, CA 92009, US; ABELMAN, Matthew, Mark, 873 Stevens Avenue, 8312, Solana Beach, CA 92075, US CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San PATENT ASSIGNEE(S): Diego CA 92121-1102, US PATENT ASSIGNEE NO: 1501390 AGENT: Viering, Jentschura & Partner, Postfach 22 14 43, 80504 Muenchen, DE AGENT NUMBER: 160045 OTHER SOURCE: EPB1999017 EP 0664786 B1 990324 SOURCE: Wila-EPS-1999-H12-T1 DOCUMENT TYPE: Patent LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R DE; R DH; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung) PATENT INFORMATION: PATENT NO KIND DATE EP 664786 B1 19990324 'OFFENLEGUNGS' DATE: 19950803 APPLICATION INFO.: EP 1993-924369 19931013 PRIORITY APPLN. INFO.: US 1992/962301 19921016 SELATED DOC. INFO.: WO 93-US10015 931018 INTAKE WO 9408941 940428 INTENR REFERENCE PAT. INFO.: EP 195213 A WO 32-11850 A WO 32-12140 A US 3966701 A US 4161522 A US 4478745 A US 4171299 A US 5221752 A REF. NON-PATENT-LIT.: J. AM. CHEM. SOC., vol.112, 1990 pages 7053 - 7054 N. FUSETANI, S. MATSUNAGA 'Cyclotheonamides, Potent Thrombin Inhibitors from a Marine Sponge' L104 ANSWER 124 OF 189 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. ACCESSION NUMBER: 2000:433589 BIOSIS PREV200000433589 DOCUMENT NUMBER: TITLE: Incorporation of nancoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor. De Filippis, Vincenzo; Eusso, Ilaria; Vindigni, Alessandro; AUTHOF(S): Di Cera, Enrico; Salmaso, Stefano; Fontana, Angelo (1) (1) Department of Pharmaceutical Sciences, CRIBI CORPORATE SOURCE: Biotechnology Center, Viale G. Colombo 3, 35121, Padua Italy Protein Science, (Oct., 1999) Vol. 8, No. 10, pp. SOURCE: 2215-2817. print. ISSN: 0961-8368.

DOCUMENT TYPE: Article LANGUAGE: English SUMMARY LANGUAGE: English AB Harudin is an anticasus

AB Hirudin is an anticcapulant polypeptide isolated from a medicinal leech that inhibits thrombin with extraordinary potency (Fd = 0.2-1.0 pM) and selectivity. Hirudin is composed of a compact N-terminal region (residues 1-47, cross-linked by three disulfide kridges, that binds to the

active site of thrombin, and a flexible C-terminal tail 'residues 49-64; that interacts with the excepte I of the enzyme. To minimize the sequence of hirudin able to bind thrombin and also to improve its therapeutic profile, several M-terminal fragments have been prepared as potential anti-coagulants. However, the practical use of these fragments has been impaired by their relatively poor affinity for the enzyme, as given by the increased value of the dissociation constant [Kd] of the corresponding thrombin complexes (Ed = 30-400 nM). The aim of the present study is to obtain a derivative of the M-terminal domain 1 47 of hirudin displaying ennanced inhibitory potency for thromkin compared to the natural product. In this view, we have synthesized an analogue of fragment 1-47 of nirudin HM2 in which Vall has been replaced by tert-butylglycine, Ser2 ry Arg, and Tyr3 by beta-naphthylalanine, to give the BugArgNal analogue. The results of chemical and conformational characterization indicate that the synthetic peptide is able to fold efficiently with the correct disulfide topology (Cys6-Cys14, Cys16-Cys29, Cys22-Cys37), while retaining the conformational properties of the natural fragment. Thrombin inhibition data indicate that the effects of amino acid replacements are perfectly additive if compared to the singly substituted analogues (De Filippis V, Quarzago D, Vindigni A, Di Cera E, Fontana A, 1998, Biochemistry 37:13507-13515), yielding a molecule that inhibits the fast or slow form of thrombin by 2,670- and 6,813-fold more effectively than the natural fragment, and that binds exclusively at the active site of the encyme with an affinity (Kd, fast = 15.4 pM, Kd, slow = 220 pM) comparable to that of full-length hirudin (Kd, fast = 0.2 pM, Kd, slow = 5.5 pM). Moreover, BugArgNal displays absolute selectivity for thrombin over the other physiologically important serine proteases trypsin, plasmin, factor Xa , and tissue plasminogen activator, up to the highest concentration of inhibitor tested (10 muM).

L104 ANSWER 125 OF 189 USPATFULL

ACCESSION NUMBER: 1998:157127 USPATFULL TITLE: Factor Xa inhibitors

INVENTOR(S): Al-Obeidi, Fahad, Tudson, AZ, United States Lebl, Michal, Tucson, AZ, United States

Ostrem, James A., Tucson, AZ, United States Safar, Pavel, Tucson, AZ, United States Stierandova, Alena, Tucson, AZ, United States

Strop, Peter, Tucson, A2, United States Walser, Armin, Tucson, AZ, United States

Selectide Corporation, Tucson, A2, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE \_\_\_\_ PATENT INFORMATION: US 5849510 19991215 APPLICATION INFO.: US 1997-947794 19971008 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-428404, filed on 25

Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-233054, filed on 26 Apr 1994, now

abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Leary, Louise N. LEGAL REPRESENTATIVE: Campbell & Flores LLP

NUMBER OF CLAIMS: 43 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 4 Drawing Figure's:; 4 Drawing Page(s) LINE COUNT: 5368

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention provides compounds which specifically inhibit

factor Xa activity. The compounds consist of the

structure X.sub.1 -YIR-X.sub.2, wherein M.sub.1 is H, acyl, alkyl, acylalkyl, arylalkyl or one or more amino acids, and M.sub.2 is a

modified 3-terminal group, one or more park-bxy-protecting groups or one or more amino acids or other substituent, and Y, I and R are tyrosine, isoleucine and arginine, respectively, or reptidomimetic or organic structures that possess the same functional activity as Y, I and F, respectively. In addition, the present invention provides a compound having the structure Al-Al-(Al-, sub.m --B, where m is 0 or 1. A compound of the invention can be linear or cyclic and can be about 2 and 43 residues in length. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a K.sub.i of .ltoreg.100 .m..M, preferably .ltpreq.1 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of factor Xa and of inhibiting blood clotting in vitro and in an individual and methods of detecting factor Xa levels or activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 126 OF 189 USPATFULL

INVENTOR(S::

PATENT INFORMATION:

1998:144233 USPATFULL ACCESSION NUMBER:

Vascular antiboagulant proteins DNA which codes them, TITLE:

processer for preparing them and their use Hauptmann, Rudolf, Ebreichsdorf, Austria

Maurer-Fogy, Ingrid, Vienna, Austria Bodo, Gerhard, Vienna, Austria Swetly, Peter, Vienna, Austria

Stratowa, Christian, Vienna, Austria Falkner, Edgar, Kritzendorf, Austria Adolf, Gunther, Vienna, Austria

Reutelingsperger, Christiaan Maria Peter, Maastricht,

Netherlands

Boehringer Ingelheim International GmbH, Ingelheim am PATENT ASSIGNEE(S):

Rhein, Germany, Federal Republic of (non-U.S.

corporation)

NUMBER KIND DATE \_\_\_\_\_ US 5837842 19981117 US 1995-376050 19950123 (8)

APPLICATION INFO.: RELATED APPLN. INFO.: Division of Ser. No. US 1994-230875, filed on 20 Apr

1994, now abandoned which is a continuation of Ser. No. US 1992-868337, filed on 7 Apr 1992, now abandoned which is a division of Ser. No. US 1989-294602, filed

on 30 Jan 1989, now abandoned

	NUMBER	DATE	
PETORITY INFORMATION:	DE 1987-3710364	19870308	
THE ORDER	DE 1387-3710303		
	DE 1987-3710430	19870338	
	DE 1937-3737367	19871104	
	WO 1998-EP266	19830326	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prouty, Rebecca E	•	
ASSISTANT EXAMINER:	Longton, Enrique	D.	
LEGAL REPRESENTATIVE:	Sterne, Kessler,	Goldstein & Fi	x P.L.I
NUMBER OF CLAIMS:	4		
EKEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:		is;; 65 Drawin	.g Page
LINE COUNT:	3 3 3 0		
CAS INDEXING IS AVAILA			
AB This invention	relates to biologic	ally active pr	oteins,

molecules coding for them, processes for preparing them and their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 127 OF 189 USPATFULL

1991:144079 USPATFULL ACCESSION NUMBER:

TITLE: Agents affecting thrombosis and hemostasis INVENTOR SI: Wolf, David L., Palo Alto, CA, United States Sinna, Uma, San Francisco, CA, United States

- COR Therapeutics, Inc., South San Francisco, CA, United PATENT ASSIGNEE(S):

States (U.S. porporation)

NUMBER KIND DATE \_\_\_\_\_\_ US 5337679 19931117 US 1995-469301 19950606 (8) PATENT INFORMATION:

APPLICATION INFO.: RELATED APPLN. INFO.: Division of Ser. No. US 1994-268003, filed on 29 Jun

1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed

on 4 Sep 1390, now patented, Pat. No. US 5278144

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Fleisher, Mindy ASSISTANT EXAMINER: Degen, Nancy J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP

NUMBER OF CLAIMS: 46 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT: 2092

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be adylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 128 OF 189 USPATFULL

ACCESSION NUMBER: 1998:131542 USPATFULL

Methods for detecting genetic mutations resulting in TITLE:

protease inhibitor insufficiencies

Rubin, Harvey, Philadelphia, PA, United States INVENTOR(3):

Cooperman, Barry, Penn Valley, PA, United States Schechter, Norman, Philadelphia, PA, United States Plotnick, Michael, Havertown, PA, United States Wang, Zhi Mei, Philadelphia, PA, United States

The Trustees of the University of Pennsylvania, PATENT ASSIGNEE(S):

Philadelphia, PA, United States (U.S. corporation)

NUMBER	KIND	DATE

US 5327662 US 5827662 19981027 US 1998-721268 19981018 (8) PATENT INFORMATION: APPLICATION INFO .:

Continuation-in-part of Ser. No. US 1994-276936, filed RELATED APPLN. INFO.: on 19 Jul 1994, now patented, Pat. No. US 5812194 which

is a continuation-in-part of Ser. No. US 1994-229286, filed on 1% Apr 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1994-221171, filed on 31 Mar 1994, now patented, Pat. No. US 5723316 And Ser. No. US 1994-221078, filed on 31 Mar 1994, now patented, Pat. No. US 5674708 , each Ser. No. US which

is a continuation-in-part of Ser. No. US 1993-5908, filed on 15 Jan 1993, now patented, Pat. No. US 5367364 76 Jer. No. US 1991-735335, filed on 24 Jul 1991, now patented, Pat. No. US 5252725 which is 4 division of Ser. No. US 1989-370704, filed on 23 Jun 1989, now

ratented, Pat. No. US 5679336

DOJUMENT TYPE: <u>Teiliey</u> FILE SEGMENT: Granted PRIMARY EXAMINER: PRIMARY EXAMINER: Wax, Robert A. ASSISTANT EXAMINER: Mobile, William W.

LEGAL REPRESENTATIVE: Law Offices of Jane Massey Ligata

NUMBER OF TLAIMS: EXEMPLARY CLAIM: LINE COUNT: 1026

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 129 OF 189 USPATFULL

1998:112054 USPATFULL ACCESSION NUMBER:

Bovine pancreatic trypsin inhibitor derived inhibitors TITLE:

of factor VIIa-tissue factor complex

INVENTOR(S): Lasters, Ignace, Antwerp, Belgium

De Maeyer, Marc, Groot-Bijgaarden, Belgium

Ripka, William Charles, San Diego, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE -----

PATENT INFORMATION: US 5807980 19980915 APPLICATION INFO.: US 1993-86328 19930701 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-952801, filed

on 25 Sep 1992, now abandoned which is a

continuation-in-part of Ser. No. US 1992-913232, filed

on 13 Jul 1992, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A. ASSISTANT EXAMINER: Lau, Kawai LEGAL PEPPESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS: -4 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 3750

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Compounds derived from BPTI which inhibit factor VIIa-TF complex with an inhibition constant of less than 500 nM, their pharmaceutical compositions, and methods of use. Also disclosed are isolated nucleic acid segments endeding for the compounds, vectors comprising the nucleic acid segment and promoter, transformed host cells, and a method for preparing the compounds using transformed host cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 130 OF 189 USEATFULL

1993:91815 UNPATFULL ACCESSION NUMBER:

TITLE: Yeast cells engineered to produce pheromone system

protein surrogates, and uses therefor Fowlkes, Dana M., Chapel Hill, NC, United States INVENTOR (S':

Broach, Jim, Princeton, NJ, United States Manfredi, John, Ossining, NY, United States Klein, Onristine, Ossining, NY, United States Murphy, Andrew J., Montplair, NJ, United States Paul, Jeremy, South Myack, NY, United States

Trueheart, Joshua, South Nyack, NY, United States

PATENT ASSIGNEE S : Cadus Pharmaseutical Corporation, Tarrytown, NY, United States (U.S. corporation)

> NUMBER KIND DATE

US 5759184 19980804 US 1995-464531 19950605 (8) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser.

No. US 1994-309313, filed on 20 Sep 1994, now abandoned

which is a continuation-in-part of Ser. No. US

1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431,

filed on 31 Mar 1993, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Grar.ted

PRIMARY EXAMINER: Retter, James ASSISTANT EXAMINER: Yucel, Irem

LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara,

Catherine J.

48 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 14 Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 6731

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve

the signal-to-noise ratio of the screening/selection system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LID4 ANSWER 131 OF 189 USPATFULL

ACCESSION NUMBER: 1998:72722 USPATFULL

TITLE: Process for production of inhibited forms of activated

blood factors

King, Robert, Fremont, CA, United States INVENTOR(S):

PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United

States (U.S. corporation)

NUMBER KIND DATE 

PATENT INFORMATION: US 5770699 19980623 APPLICATION INFO.: US 1996-774592 19961230 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-330978, filed on 28

Opt 1994, new patented, Pat. No. US 5589571

DOCUMENT TYPE: Utility FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy

LEGAL PEPRESENTATIVE: Morgan, Lewis & Epokius LLP

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 4 Drawing Figure(s.; 4 Drawing Page(s)

LINE COUNT: 1471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing a highly purified preparation of an inhibited

form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the plood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 132 OF 189 USPATFULL

ACCESSION NUMBER: 1996:48367 USPATFULL

TIPLE: Bovine pancreatic trypsin inhibitor derived

inhibitors of factor XA

INVENTOR(S): Lasters, Idnace, Antwerpen, Belgium

De Maeyer, Marc, Groot-Bijgaarden, Belgium

Finka, William Charles, San Diego, CA, United States

PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United

States (U.S. corporation)

NUMBER KIND DATE 

PATENT INFORMATION: US 5747449 19930505 APPLICATION INFO.: US 1993-86630 19930701 (8) APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-913232, filed

on 13 Jul 1992

Utility DOCUMENT TYPE:

FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Lau, Kawai

LEGAL REPRESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF DEAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s) LINE COUNT: 2111

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

A compound derived from BPTI which inhibits Factor Xa A =

with an inhibition constant less than 50 nM.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 133 OF 189 USPATFULL

ACCESSION NUMBER: 1998:39504 USPATFULL TITLE: Inhibitors of factor Xa

INVENTOR(S): Brunck, Terence Kevin, San Diego, CA, United States

Webb, Thomas Roy, Encinitas, CA, United States

Fipka, William Charles, San Diego, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE

------PATENT INFORMATION: US 5739112 19980414 APPLICATION INFO:: US 1995-465115 19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-168964, filed on 15 Dec 1993 which is a continuation-in-part of Ser. No. US

1992-991204, filed on 15 Dec 1992, now abandoned

Utility DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Granted

ASSISTANT EXAMINER: Lukton, David LEGAL REPRESENTATIVE: Lyon & Lyon LLP

10 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 1498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Novel commounds, their salts and compositions related thereto having AВ

astivity against mammalian factor Xa are disclosed.

The novel compounds include peptide aldehyde analogues

having substantial potency and specificity as

inhibitors of mammalian factor Xa are

further disclosed. The compounds are thought useful as

inhibitors of factor Xa in vitro or as a

therapeutic agent for the prevention and treatment of conditions: characterized by abnormal thromposis in mammals. Intermediates useful

for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 134 OF 189 USFATFULL

1999:39493 USPATFULL ACCESSION NUMBER:

TITLE: Tissue factor mutants useful for the treatment of

myocardial infarction and coagulopathic disorders

Roy, Soumitra, San Francisco, CA, United States INVENTOR(3:: Vehar, Gordon A., San Carlos, CA, United States

Generited, Inc., South San Francisco, CA, United States PATENT ASSIGNEE(S):

/U.S. parperation)

NUMBER KIND DATE 

 
 US 5739101
 19980414

 US 1995-440814
 19950515 (8)
 PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1994-246978, filed on 20 May

1994, now patented, Pat. No. US 5589363 which is a division of Ser. No. US 1991-714819, filed on 13 Jun

1991, now patented, Pat. No. US 5346991

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C. LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s) DINE COUNT: 2482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A tissue factor protein mutant capable of neutralizing the ability of endagenous tissue factor to induce coaquiation is provided. A representative tissue factor mutant designated Kló5A, Kló6A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an unticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 135 OF 189 USPATFULL

ACCESSION NUMBER: 1998:12120 USPATFULL TITLE: Trypsin Inhibitors

INVENTOR (3): Brunck, Terence H., San Diego, CA, United States Pepe, Michael G., San Diego, CA, United States

Fearson, Daniel A., Solana Beach, CA, United States

Webb, Thomas R., Encinitas, CA, United States

PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United

States (U.S. corporation)

NUMBER KIND DATE US 571498) 19980303 US 1999 405974 19950631 (8) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-11666, fixed on 29 Jan 1993, now patented, Pat. No. US 5534498, issued on 4

Jul 1995 which is a continuation-in-part of Ser. No. WS

```
1992-828388, filed on 30 Jan 1992, new ahandoned
DOCUMENT TYPE:
                        Utility
FILE SEGMENT:
                       Granted
PRIMARY EXAMINER:
                       Joheiner, Toni R.
ASSISTANT EXAMINER:
                      Huff, Sheela J.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS:
EKEMPLARY CLAIM:
NUMBER OF DRAWINGS: 3 Drawing Figure's); 3 Drawing Page's LINE COUNT: 1331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      Novel compounds having activity against trypsin are disclosed.
       Sredifically, novel peptide aldehyde analogues that
       have substantial rotency and specificity as inhibitors of
       mammalian pancreatic trypsin are presented. The compounds are useful in
       the prevention and treatment of the tissue damage or destruction
       associated with pandreatitis.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 136 OF 189 PCTFULL
                                  COPYRIGHT 2002 Univention
ACCESSION NUMBER: 1999055453 POTFULL ED 20020514
                       CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY
TITLE (ENGLISH):
                       ACTIVE AGENTS AND USES THEREFOR
TITLE (FRENCH):
                       CONJUGUES DE DITHIOCARBAMATES COMPRENANT DES AGENTS
                       PHARMACOLOGIQUEMENT ACTIFS ET UTILISATIONS DESDITS
                       CONJUGUES
                       LAI, Ching-San
INVENTOR(S):
PATENT ASSIGNEE(S): MEDINOX, ÎNC.; LAI, Ching-San LANGUAGE OF PUBL.: English
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                       Patent
: NOITAMRORMI THETAR
                                         KIND DATE
                       NUMBER
                        _____
                       WD 9855453 A1 19981210
                       AL AM AT AU AZ BA B5 BG BR BY CA CH CN CU CZ DE DK EE
DESIGNATED STATES
                       ES EL GB GE GH GM GW HU ID IL IS JE KE KG KE KE KZ LC
                       LK LR LS LT LU LV MD MG MK MN MW MK NG NE PL PT RO RU
                       SD SE SG SI SK SL TJ TM TR TT UA UG US UU VN YU ZW GH
                        GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
                       BE CHICY DE DK ES FI FR GB GR IE IT LU MU NL PT SE BF
                       BU OF OG OF OM GA GN ML MR NE SN TD TG
                      Wo 1998-US10295 A 19980519
APPLICATION INFO .:
                       us 1997-8/869,158
                                             19970604
PRIORITY INFO.:
      In appordance with the present invention, there are provided conjugates
ABEN
       of nitric oxide
       scavengers (e.g., dithiocarbamates, or DC) and pharmacologically active
       agents (e.g., NSAIDs).
       Invention conjugates provide a new class of pharmacologically active
       agents (e.g., anti-inflammatory
       agents) which cause a much lower incidence of side-effects due to the
       protective effects imparted by
       modifying the pharmacologically active agents as described herein. In
       addition, invention conjugates
       are more effective than unmodified pharmacologically active agents
       because cells and tissues
       contacted by the pharmacologically active agent(s) are protected from
       the potentially damaging
       effects of nitric oxide overgroduction induced thereby as a result of
       the as-production of mitric
       oxide scavenger (e.g., dithiotarbamate), in addition to free
      pharmacologically active agent, when
       invention conjugate is cleaved.
       L'invention concerne des conjugues d'accepteurs de monoxyde d'azote
ABFR
```

"dithiocarbamates ou DJ,

exemple. Les conjugues de l'invention donnent une nouvelle dategorie d'agents pharmacologiquement actifs vadents ant: inflammathires, par exemple) qui ont une inbidence d'effets secondaires beauccup moinare en raison de l'effet de protection produit par la modification de des agents pharmadologiquement actifs. En outre, les conjugues de l'invention vont plus efficaces que les agents pharmacologiquement actifs puisse que des cellules ou des tissus places au contact desdits agents sont proteges contre les effets potentiellement deteriorants de la surproduction de monomyde d'azote ainsi induite par la coproduction d'accepteurs de monoxyde d'azote (des dithiocarbamates, par exemple), a laquelle s'ajoute celle d'un agent libre pharmacologiquement adtif lorsque le conjudue est clive. ANSWER 137 OF 139 ECTEULL COPYRIGHT 2002 Univentib ACCESSION NUMBER: 1993031394 PCTFULL ED 20020514 TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION TITLE (ENGLISH): AND TUMOR TREATMENT METHODES ET COMPOSITIONS DE THROMBOPLASTINE TISSULAIRE TITLE (FRENCH): POUR LE TRAITEMENT DE LA COAGULATION ET DES TUMEURS THOSPE, Philip, E.; KING, Steven, W.; GAO, Boning INVENTOR(3): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; PATENT ASSIGNEE(S): THOPPE, Philip, E.; KING, Steven, W.; GAO, Boning LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFOFMATION: KIND DATE NUMBER \_\_\_\_\_ Wo 9831394 A2 19980723 AL AM AT AU AC BA BB BG BR BY CA CH CN CU CZ DE DK EE DESIGNATED STATES ES ET GB GE GH GM GW HU IT IL IS JP KE KG KP KR KZ LC LK LE LS LT LU LV MD MG MK MN MW MK NO NZ PL ET EO EU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BE BU OF OG OI OM GA GN ML MR NE SN TD TG WO 1998-US1010 A 19980120 APPLICATION INFO .: US 1997-60/035,920 19970132 PRIORITY INFO.: US 1997-60/036,205 199701.17 US 1997-60/042,427 19970337 The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic gruss, targeted immunitaxins, targeted coaguligends, and/or in combination with Factor VIIa/FVIIa) or FBVIIa activators. La presente invention a trait a la despuverte interessante de la localisation specifique de compositions de thromooplastine tissulaire (TF) et de variantes de cette derniere dans les vaisseaux

ABEN

ABFR

par exemple, et des agents pharmacologiquement actifs 'AINS, par

thromioplastine tissulaire deficiente en coaquiants destinee a etre utilisee pour effectuer une coaquiation specifique et pour traiter des tumeurs. Les compositions et methodes de TF de la presente invention peuvent etre utilisees seules, comme conjugues de TF presentant une demi-vie amelioree; ou en compinaison avec q'autres agents, tels que des medicaments chimistherapeutiques, des immunitaxines diblees, des coaquligands cibles; et/ou en combinaison avec un Facteur VIIa(FVIIa) ou des activateurs de FVIIa. ANSWER 139 OF 189 POTFULL COPYRIGHT 2002 Univentic L104 ACCESSION NUMBER: 1998009937 POTFULL ED 20020514 TITLE (ENGLISH): LACTAM INHIBITORS OF THROMBIN INHIBITEURS LASTAME DE LA THROMBINE TITLE (FRENCH): ST-DENIS, Yves; SIDDIQUI, M., Arshad; CODY, Wayne, INVENTOR (3): Livingston; EDMUNDS, Jeremy, John; PLUMMER, Janet, Samartino PATENT ASSIGNEE(S): BIOCHEM PHARMA, INC.; ST-DENIS, Yves; SIDDIQUI, M., Arshad; CODY, Wayne, Livingston; EDMUNDS, Jeremy, John; PLUMMER, Janet, Samartino English LANGUAGE OF FUBL.: DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE Wo 9809987 Al 19980312 AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CU DE DK EE DESIGNATED STATES ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MK NO NZ PL PT FO FU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ GF GG CI CM GA GN ML MR NE SN TD TG APPLICATION INFO .: Wo 1997-US15312 A 19970905 US 1996-60/025,599 19960906 GB 1996-9613687.9 19960906 us 1996-60/025,599 PRIORITY INFO.: This invention relates to heterocyclic inhibitors of the enzyme ABEN thrombin, their preparation, and pharmaceutical compositions thereof having general formula (I), wherein W, X, Y Rl to R3 are as defined herein. Also, the invention relates to the use of such compounds and compositions as anticoagulants and as agents for the treatment and prophylaxis of thrombotic disorders such as venous thrombosis, pulmonary embolism and arterial thrombosis resulting in adute ischemic events such as myocardial infarction or cerebral infarction. L'invention concerne des inhibiteurs heterocycliques de l'enzyme ABFR thrombine, la preparation de ceux-ci ainsi que des compositions pharmaceutiques contenant des inhibiteurs possedant la formule generale (I), dans laquelle W, X, Y, El a E3 presedent les notations données dans la description. De meme, l'invention se rapporte a l'utilisation de tels composes et compositions, en tant qu'anticpagulants et agents destines au traitement et a la prophylaxie de troubles thrombotiques, tels que la thrombose veineuse, l'embolie pulmonaire et la thrombose arterielle, lesquels surviennent lors d'accidents ischemiques aidus comme l'infarctus du

sanguins, a l'interieur d'une tumeur vascularisée, a la suite d'une

L'invention concerne donc des methodes et compositions comprehant une

administration systemique.

myodarde ou l'infarctus cerebral.

ANSWER 139 OF 189 PCTFULL COPYRIGHT 2002 Univentic 1998015333 PUTFULL ED 20020514 ACCESSION NUMBER: USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE TITLE ENGLISH: INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS TITLE (FRENCH): UTILITATION DE MIMETIQUES DE FEUILLETS BETA COMME IMHIBITEURS DE PROTERSE EN DE KINASE OU GOMME INHIBITEURS DE FACTEURS DE TRANDCRIPTION KAHN, Michael; QABAR, Maner, Nicola; McMILLAN, Michael, INVENTOR(3): Kim; DGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; UREMN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd MILENUMETICS LTD.; KAHN, Michael; QABAR, Maher, Nicola; PATENT ASSIGNEE(S): McMILLAN, Michael, Kim; OGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; URBAN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: DATE NUMBEE: KIND WO 9805333 AT 19980212 AL AM AT AU BA BB BG BR BY CA CH IN CU CZ DE DK EE ES DESIGNATED STATES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT FO EU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TU TM AT BE CH DE DK ES FI FR GB GR IE IT LU MO NL PT SE BF BJ CF CG CI CM GA GN ML MP NE SN TD TG WO 1997-US13622 A 19970305 APPLICATION INFO .: 19960305 PRIORITY INFO.: US 1996-8/692,420 US 1996-8/725,073 19961002 US 1997-3/797.915 19970210 US 1997-60/047,067 19970519 ABEN 'beta'-sheet mimetics and methods relating to the same are disclosed. The 'beta'-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors. Methods of the invention include administration of a 'beta'-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase and/or transcription factor. L'invention concerne des mimetiques de feuillets beta et des procedes ABFF. les concernant. Les mimetiques de feuillets beta sont utiles comme inhibiteurs de protease et de kinase ainsi que comme inhibiteurs de facteurs de transcription. Des procedes de l'invention comprennent l'administration d'un mimetique de feuillets beta su l'utilisation dudit mimetique pour fabriquer un medicament destine au traitement d'une variete d'etats pathologiques associes a la protease, a la kinase et/ou au facteur de transpription dibles. ANSWER 140 OF 189 POTFULL COPYRIGHT 2002 Univertib 1194ACCESSION NUMBER: 1999100442 POTFULL ED 20021514 TITLE (ENGLISH:: SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE LA SERINE PROTEASE
INVENTOR(S): DEALMAN, John, Joseph; ELGENDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finkarr;

GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir
PATENT ASSIGNEE S: THROMBOŠIS RESEARCH INSTITUTE; DEADMAN, John, Joseph;

ELIGHNDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr; GOLDWIN, Christopher, Andrew;

KAKKAR, Vijay, Vir

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WD 9800442 A1 19960106

DESIGNATED STATES AL AM AT AU AL BA BB BG BR BY CA CH CN CU CZ PE DK EE

E3 F1 GB GE GH HU IL IS JF KE KG KP KR KZ LC LK LR LS LT LU LV MO M3 MK MN MW MX NO NZ PL FT RO EU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SO SZ UG ZW AM AC BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL FT SE BF BJ CF CG CI CM GA

ON ML MR NE SN TD TG

APPLICATION INFO.: WD 1997-GB1574 A 1997-0611 PRIORITY INFO.: GB 1996-9613719.5 1996-0629

ABEN Bifunctional serine protesse inhibitors and methods of preparing

boron-containing peptides are

provided. The serine protease inhiitors comprise a catalytic

site-directed moiety, which binds to

and inhibits the active site of a serine protease, and an exosite

associating moiety, which are

joined by a connector moiety. The catalytic site directed moiety and the

exosite associating moiety

are capable of binding simultaneously to a molecule of the serine

protease.

ABFR L'invention concerne des inhibiteurs bifonctionnels de la serine

protease et des procedes de

preparation de peptides contenant du bore. Ces inhibiteurs

comprennent une fraction datalytique

dirigee qui se lie au site actif d'une serine protease et l'inhibe, et

une fraction se liant a un

exisite, des deux fractions etunt reunies par une fraction de couplage.

La fraction dirigee

catalytique et la fraction se liant a un exosite sont capables de se

lier simultanement a une

molecule de la serine protease.

L104 ANSWER 141 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG + DEMANDE DE BREVET

ACCESSION NUMBER: \$18744 EUFOPATFULL EW 199803 FS OS

TITLE: Process for selecting candidate drug compounds.

Verfahren zur Auswahl von Kandidat-Drogenverbindungen. Procede de selection des compositions medicamenteuses

potentielles.

INVENTOR(S): Young, Stephen Clinton, 8 Granbourne Road, Heaton Moor,

Stockbort, Cheshire SK4 4DL, GB;

Murray, Christopher, I Wheatfield Close, Titherington,

Marclesfield, Cheshire 3Kl0 2TT, GB

PATENT ASSIGNEE(S): Froteus Molecular Design Limited, Beechfield House, Lyme

Green Business Park, Macclesfield, Cheshire SK11 0JL, GB

PATENT ASSIGNEE NO: 906234

AGENT: Cookhain, Julian, Dr., Frank B. Dehn & Co., European

Patent Attorneys, 179 Queen Vistoria Street, London EC4V

4EL, 3B

AGENT NUMBER: 52641

OTHER SOURCE: ES91949004 EP 0818744 A2 980114

SOURCE: Wila-EPZ-1998-H03-T2a

FOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R DESIGNATED STATES:

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO. PUB. TYPE: SEA2 EUROPABISCHE FATENTANMELDUNG

FATENT INFO-MATION:

FATENT NO KIND DATE

EP 818744 AD 19990114 199-0114 'OFFENLEGUNGS' DATE:

EP 1-97-304412 APPLICATION INFO.: 19970624 PRIORITY APPLN. INFO.: GB 1-96-14302 19960709 GB 1-96-16562 19900807

L104 ANSWER 142 OF 189 EUROPATFULL COFYRIGHT 2002 WILA

GRANTED PATENT - ESTELLTES PATENT - BREVET DELIVEE

EUROPATEULL EW 199841 FS PS 703923 ACCESSION NUMBER:

FACTOR VII-DEFIVED PEPTIDES. TITLE:

FARTOR VII-PEPTIDE.

PEPTIDES DERIVES DU FACTEUR VII.

STEPHENS, Ross Wentworth, Silurveien 19, N-0380 Oslo, INVENTOR(S):

OFFILING, Lars, Thomas Heftyes gate 47B, N-0267 Oslo, NO;

SAKARIASSEN, Kjell Steinar, Kygd Alle 33B, N-0262 Oslo,

NYCOMED IMAGING AS, Nycoveier 1-2, 0401 Oslo 4, NO PATENT ASSIGNEE(S):

PATENT ASSIGNEE NO: 1564564

Matthews, Derek Peter et al, Frank B. Dehn & Co., AGENT:

European Patent Attorneys, 179 Queen Victoria Street,

London EC4V 4EL, GB

AGENT NUMBER: 60131

OTHER SOURCE: EPB1998055 EP 0703923 B1 981007

SOURCE: Wila-EPS-1998-H41-T1

DOCUMENT TYPE: Batent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE: R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EFB1 EUROPAELSCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_... EP 703923 B1 19981007 'OFFENLEGUNGS' DATE: 19960403 EP 1994 918437 APPLICATION INFO .: -13940617PRIORITY APPLN. INFO.: GB 1993-12601 19930618
GB 1994-9335 19940510
RELATED DOC. INFO.: WO 94-GB1815 940617 INTAKZ
WO 9500541 950105 INTPNR
REFERENCE PAT. INFO.: EP 446747 A WO 90-033

WO 90-03390 A

W0 93-09804 A

L104 ANSWER 143 OF 189 MEDLINE DUPLICATE 2

ACCESSION NUMBER: 19981:3983 MEDLINE
DOCUMENT NUMBER: 98128933 PubMed ID: 9454596

Discovery of a novel, potent, and specific family of TITLE:

> factor Xa inhibitors Via combinatorial chemistry.

Ostrem 'A; al-Oreidi F; Safar P; Safarova A; Stringer S K; AUTHOR:

Patek M; Cross M T; Spoonamore J; LoCascio J C; Kasireddy P; Thorpe 1: S; Seretov N; Lebl M; Wildgoose P; Strop P

DIRPORATE SOURCE: Selectide torporation, Tudson, Arizona 85737, USA...

dim.cstremahmrag.com

-BIOCHEMISTRY, (1998 Jan 27) 37 (4) 1053-9. SOURCE:

Journal code: 0370623. ISSN: 0006-2960.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199803

ENTRY DATE: Entered STM: 19980319

Last Updated on STN: 31001303 Entered Mealine: 19980306

A series of low molecular weight peptide inhibitors of factor Xa, unrelated to any previously described, was

identified by spreening a combinatorial peptide library composed of L-amino acids. The minimal inhibitory sequence is a tripeptide, L-tyrosinyl-L-ispleucyl-L-arginyl, which competitively inhibits the hydrolysis of small chromogenic substrates by factor Xa but binds in an prientation which prevents a productive nucleophilic

attack by serine 195 of the catalytic triad on the carbonyl carbon of the carbomyterminal arginine. The initial leads identified in an

obtamer combinatorial peptide library ranged in potency from 4

to 15 microM. These peptides were modified into peptide mimetics with a greater than 1000-fold increase in potency while retaining unusual selectivity for factor Xa over the

related serine proteases thrombin, factor VIIa/tissue factor, plasmin, activated protein C, kallikrein, and trypsin. One of the most potent

analogues, SEL 2711, with a Ki of 0.003 microM for factor xa and 40 microM for thrombin, is active in in vitro and ex vivo coagulation assays, suggesting the potential application of these inhibitors in anticoagulant therapy.

L104 ANSWER 144 OF 189 USPATFULL

97:109871 USPATFULL ACCESSION NUMBER:

Methods for coating invasive devices with inhibitors of TITLE:

thrombin

INVENTOR(S): Maraganore, John M., Concord, MA, United States

Fenton, II, John W., Malden Bridge, NY, United States

Eline, Toni, Cambridge, MA, United States

Biogen, Inc., Cambridge, MA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE ...... PATENT INFORMATION:

US 5691311 19971125 US 1995-439297 19950511 (8) APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1992-834259, filed on 10 Feb 1992, now patented, Pat. No. US 5433940, issued on 18 Jul 1995 which is a continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1990, now patented, Pat.

No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed

on 13 Aug 1989, now abandened

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.

LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.

1 = NUMBER OF CLAIMS: EKEMPLARY CLAIM:

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 2600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel biblogically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association modety 'ABEAM'; a linker portion of at least 18 .ANG. in length; and a thrombin datalytic site-directed moiety (CSDM). This invention also relates to communitions, combinations and methods which employ these molecules for

therapeutic, prophylastic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 AMSWER 145 OF 199 USPATFULL

ACCESSION NUMBER: 97:104449 USPATFULL

TITLE: Basic .alpha.-amincalkylphosphonate derivatives Powers, James C., Atlanta, GA, United States INVENTOR S:

Boduszek, Bogdan, Wroolaw, Ecland

Oleksyszyn, Jozef, Arlington, MA, United States

Georgia Tech Research Corp., Atlanta, GA, United States PATENT ASSIGNEE(3):

(U.S. corporation)

NUMBER KIND DATE .....

US 5686419 19971111 US 1994-184286 19940121 (8) PATENT INFORMATION: APPLICATION INFO.:

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David

LEGAL PEPPESENTATIVE: Devesu, Colton & Marquis

NUMBER OF CLAIMS: NUMBER OF CLAIM: LINE COUNT: 1660

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Pertidyl derivatives of diesters of .alpha.-aminoalkylphosphonic acids with basic substitutents, their use in inhibiting serine proteases with trypsin-like specificity and their roles as anti-inflammatory agents, anticoagulants, and anti-tumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 146 OF 189 USPATFULL

ACCESSION NUMBER: 97:53898 USPATFULL

TITLE: Inhibitor resistant serine proteases

Dawson, Keith Martyn, Cowley, United Kingdom INVENTOF(S): Gilbert, Richard James, Cowley, United Kingdom

PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, Oxford, United

Kingdom (non-U.S. corporation)

	NUMBEE	KIND DATE	
PATENT INFORMATION:	US 5645833 WO 9403614	19970708 19940217	
APPLICATION INFO.:	US 1995-379621 WO 1993-GB1632	19950203 19930803	(8)
		-,	PCT 371 date PCT 102(e) date

		NUMBER	DATE
PRIORITY	INFORMATION:	GB 1992-16558	19920804

PRIORITY INFORMATION: GB 1992-DOCUMENT TYPE: Utility FILE SEGMENT: Granted PRIMARY EXAMINER: Jacobson

Jacobson, Dian C. LEGAL REPRESENTATIVE: Hale And Doir

NUMBER OF CLAIMS: 22

NUMBER OF DRAWINGS: 19 Drawing Figure's); 18 Drawing Page's: LINE COUNT: 1370

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Serine proteases of the chymotrypsin superfamily are modified so that they exhibit resistance to serine protease inhibitors. If such modified serine proteases have fibrinolytic, thrombolytic, antithrombotic or

prothrombatic properties, they are useful in the treatment of blood clotting diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 147 OF 189 USPATFULL

97:51973 USPATFULL ACCESSION NUMBER:

TITLE: Peptide mediated enhancement of thrombolysis

methods and compositions

INVENTOR(S : Lawrence, Daniel A., Ann Arbor, MI, United States

Binskurg, David, Ann Arbor, MI, United States

Shore, Joseph D., Grosse Point Farms, MI, United States

Fay, William P., Ann Arbor, MI, United States Olson, Steven T., Chicago, IL, United States

Francis-Chmura, Ann Marie, Warren, MI, United States Eitzman, Daniel T., Ypsilanti, MI, United States

Paielli, Dell, Wyandotte, MI, United States

The Regents of the University of Michigan, Ann Arbor, PATENT ASSIGNEE(S):

MI, United States (U.S. corporation)

Henry Ford Health System, Detroit, MI, United States

(U.S. corporation)

NUMBER KIND DATE -----

PATENT INFORMATION: US 5639726 
 US 5639726
 19970617

 US 1994-315461
 19940930 (8)
 19970617 APPLICATION INFO.:

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Davenport, Avis M.

LEGAL REPRESENTATIVE: Arnold, White & Durkee

NUMBER OF CLAIMS: 59 EXEMPLARY CLAIM: 1

NUMBER OF LEAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT: 4817

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates generally to peptides which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using peptides which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWEF 148 OF 189 USPATFULL

useful in clot lysis.

ACCESSION NUMBER: 97:49542 USPATFULL

TITLE:

Activatable fibrinolytic and anti-thrombotic proteins INVENTOR(S): Dawson, Keith, Marlow, United Kingdom

Edwards, Fichard M., Thame, United Kingdom Forman, Joan M., Oxford, United Kingdom

PATENT ASSIGNEE(S): British Brotech Pharmaceuticals, England (non-U.S.

corporation)

	NUMBER	KIND DATE	
PATENT INFORMATION:	US 5637490	19970610	
	WO 3109118	19910:27	
APPLICATION INFO .:	US 1992-854603	19920604	(7)
	WO 1990-GE1912	19901207	
		19920604	PCT 371 date
		19920604	POT 102(e) date

	NUMBER	DATE	
MATTON	ar 1000 00000	10061007	

PRIORITY INFORMATION: GB 1989-27722 19891207

DOCUMENT TYPE: Utility

FILE SEGMENT: Grante: FRIMARY EXAMINER: Jacobson, Dian J. LEGAÉ REPRESENTATIVE: Banner & Witcoff, Ltd.

NUMBER OF CLAIMS: 14 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 15 Drawing Figure s., 15 Drawing Page's LINE COUNT: 1908

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

- Proteinaceous compounds are activatable by enzymes of the clotting

cuspade to have fibrinolytic or oldt formation inhibition activity. For example, a plasminogen analogue is activatable

to plasmin by thrombin or Factor Xa. Fibrinolytic or

clet formation inhibition activity is therefore directed to the site of clot formation.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 149 OF 189 USEATFULL

ACCESSION NUMBER: 97:337.16 USPATFULL

TITLE: Human tissue factor related DNA segments, polypeptides

and antibodies

INVENTOR(3): Edgington, Thomas S., La Jolla, CA, United States

Morrissey, James H., Oklahoma City, OK, United States

The Scripps Research Institute, La Jolla, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE

.....

PATENT INFORMATION: US 5622931 19970422 APPLICATION INFO.: US 1992-880079 19920429 (7)

RELATED AFFLN. INFO.: Division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047,

filed on 31 Mar 1987, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Carlson, K. Cochrane

LEGAL REPRESENTATIVE: Fitting, Thomas

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)

3119

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

IMA segments that include IMA seguences defining a structural gene boding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site

polypertide analogs as well as methods for their use.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L154 AMSWER 150 OF 189 USPATFULL

ACCESSION NUMBER: 97:31793 USPATFULL Apretinin analogs TITLE:

INVENTOR(S): Bj.: slashed.rn, Soren E., Lyngby, Dermark

Morris, Kjela, Hellerup, Denmark Diness, Viggo, Charlottenlund, Denmark

N.: slashed.rskov-Lauritsen, Leif, K.o slashed.ge,

Denmark

Christensen, Niels D., K.o slashed.venhavn, Denmark

Bregengaard, Claus, Hellerup, Denmark

Norris, Fanny, Hellerup, Denmark

Petersen, Lars C., H.o slashed.rsholm, Denmark

Nevo Mordisk A/S, Bagsvaera, Denmark non-U.S.

curporations

NUMBER KIND DATE 

PATENT INFORMATION: APPLICATION INFO.:

UN 5021074 19970415 UN 1991-443977 19950518 (8)

RELATED APPLN. INFO.:

PATENT ASSIGNEE'S :

Division of Ser. No. VS 1993-84718, filed on 23 Jun 1488 which is a continuation-in-part of Ser. No. US 199:-249:11, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on

21 Jun 1930, now abandoned , said Ser. No. US

1495-443977, filed on 18 May 1995 which is a continuation-in-part of Ser. No. US 1990-598737, filed or. 13 Nov 1990, now patented, Pat. No. US 5373090 And a continuation-in-part of Ser. No. US 1992-827687, filed

on 23 Jan 1992, now abandoned

DATE NUMBER ......... 
 DK 1987-4501
 19870328

 DK 1988-2254
 19880426

 DK 1990-2361
 19901001

 DK 1991-1118
 19910612
 FRIORITY INFORMATION:

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A. ASSISTANT EXAMINER: Hobbs, Lisa J.

LEGAL REPRESENTATIVE: Jelson, Esq., Steve T., Agris, Esq., Cheryl H.

NUMBER OF CLAIMS: 3 EXEMPLARY CLAIM: 1

18 Drawing Figure(s); 17 Drawing Page(s)
can; NUMBER OF DRAWINGS:

2401 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aproting analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 151 OF 189 USPATFULL

ACCESSION NUMBER: 97:29570 USPATFULL TITLE: Aprotinin analogs

INVENTOR (S.: Bi. slashed.rn, Soren E., Lyngby, Denmark

Morris, Kjeld, Hellerup, Denmark

Enness, Viggo, Charlottenlund, Denmark

N.o slashed.rskov-Lauritsen, Leif, K.o slashed.ge,

Christensen, Niels D., K.o slashed.venhavn, Denmark

Bregengaard, Claus, Hellerup, Denmark Morris, Fanny, Hellerup, Denmark

Petersen, Lars C., H.o slashed.rsholm, Denmark

PATENT ASSIGNEE(3): Novc Nordisk, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBEF.	KIND	DATE	
	· · · · · · · · · · · · · · · · · · ·			
PATENT INFURMATION:	W\$ 5619915		19975468	
APPITCATION INFO .	113 1445-1117476		444444	, a .

APPLICATION INFO.: US 1995-443976 1995/518 /8; RELATED APPLN. INFO.: Division of Ser. No. US 1993-94718, filed on 23 Jun

1993 which is a continuation-in-part of Ser. No. US 1993-24925, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on 31 Jun 1490, now akanasned , said Ser. No. US -34718 which is a continuation-in-part of Ser. No. US 1991-598737, filed on 19 Nov 1991, now patented, Pat. Ma. US 5373090 And a continuation in part of Ser. No. W2 1992-827687, filed on 29 Jan 1992, now abandoned

NUMBER PATE ....... DR 1987-4501 19870828 PRIORITY INFORMATION: DM 1988-2154 19880426 DM 1990-2381 19901001 DM 1991-1118 19910821

Utility DOCUMENT TYPE:

Granted
Wax, Robert A.
ASSISTANT EXAMINER: Hobbert
LEGAL PEPPERAMEN LEGAL REPRESENTATIVE: Celson, Esq., Steve T., Agris, Esq., Cheryl H.

NUMBER OF CLAIMS: EKEMPLARY CLAIM:

13 Drawing Figure(s); 17 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 2547

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

### CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 152 OF 189 USPATFULL

97:22638 USPATFULL ACCESSION NUMBER:

Methods of producing effective recombinant serine TITLE:

protease inhibitors and uses of these inhibitors INVENTOR(S): Rubin, Harvey, Philadelphia, PA, United States Cooperman, Barry, Fenn Valley, PA, United States Schechter, Norman, Philadelphia, PA, United States Plotnick, Michael, Havertown, PA, United States

Wang, Zhi M., Philadelphia, PA, United States Trustees of the University of Pennsylvania, PATENT ASSIGNEE(S):

Philadelphia, PA, United States (U.S. corporation)

NUMBER KIND DATE .\_\_\_\_\_

PATENT INFORMATION: APPLICATION INFO .: FELATED APPLN. INFO.: US 5613194 19970318 US 1994-276936 19940719 (8)

Continuation-in-part of Ser. No. US 1994-229286, filed

on 13 Apr 1994, now abandoned which is a

sentinuation-in-part of Ser. No. US 1994-221078, filed on 31 Mar 1994 And Ser. No. US 1994-221171, filed on 31 Mar 1994 , said Ser. No. US -221078 And Ser. No. US

221171 , each Ser. No. US - which is a

continuation-in-part of Ser. No. US 1993-5898, filed on 18 Jan 1993, now abandoned And Ser. Mo. US 1993-5909, filed on 15 Jan 1993, now patented, Pat. No. US 5367064 , each Ser. No. US - which is a division of Ser. No. NS 1991-73:335, filed on 24 Jul 1991, now patented, Pat. Mo. US 5252725 which is a division of Ser. Mo. US .989-370704, filed on 23 Jun 1989, now patented, Pat.

Na. TS 5079336

DOCUMENT TYPE: Stillty

FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Law Offices of Jane Massey Licata

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: LIME COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A method of producing a recombinant serine protease inhibitor capable of

effectively modulating serine protease activity is provided.

Communitions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L134 ANSWER 153 OF 189 USPATFULL

ACCESSION NUMBER: 37:12570 USPATFULL

Process for production of inhibited forms of activated TITLE:

klood factors

INVENTOFUS:: King, Robert, Fremont, CA, United States

PATENT ASSIGNEE(S): DOR Therapeutics, Inc., South San Francisco, CA, United

States (U.S. corporation)

NUMBER KIND DATE -------

PATENT INFORMATION: US 5602233 19970211 APPLICATION INFO.: US 1995-484558 19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-330978, filed on 28

Oct 1994

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP

NUMBER OF CLAIMS: 13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and ther purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 154 OF 189 USPATFULL

97:7908 USPATFULL ACCESSION NUMBER:

M-sulfonylarginine keto-amide compounds TITLE:

INVENTOR/S : Webb, Thomas R., Encinitas, CA, United States

Miller, Todd A., Encinitas, CA, United States Vlasuk, George P., Carlsbad, CA, United States

Abelman, Matthew M., Solana Beach, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER, KIND DATE PATENT INFORMATION: US 5597804 19970129
AFPLICATION INFO.: US 1993-139300 19931019

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-962301, filed

on 16 Set 1992, new patented, Pat. No. US 5371072

DECUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Wityshyn, Michael G. ASSISTANT EXAMINER: Weber, Jon P. LEGAL REPRESENTATIVE: Lyon & Lyon NUMBER OF CLAIMS: 73

NUMBER OF CLAIMS: EKEMPLARY CLAIM:

NUMBER OF DEAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s) LINE COUNT: 3290

CAS INTEXING IS AVAILABLE FOR THIS PATENT.

The present invention is directed to N-sulfonyl arginine alpha-ket:-amide derivatives, their pharmaceutically acceptable salts and compositions thereof which are useful as antithrombotic agents in mammals and also the use of these compounds as antithrombotic agents. Also, disclosed are methods of using these inhibitors in their various embodiments as therapeutic agents for disease states characterized by disorders of the blood coaquiation process. Further disclosed are compounds useful as intermediates in the preparation of these compounds.

#### CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 155 OF 189 USPATFULL

ACCESSION NUMBER: #7:1332 USPATFULL

Process for preparing aprotinin and aprotinin analogs TITLE:

in yeast cells

Bj.o slashed.rn, Soren E., Lyngby, Denmark INVENTOF(S):

Norris, Kjeld, Hellerup, Denmark Diness, Viggo, Charlottenlund, Denmark

N.o slashed.rskov-Lauritsen, Leif, K.o slashed.ge,

Denmark

Christensen, Niels D., K.o slashed.venhavn, Denmark

Bregengaard, Claus, Hellerup, Denmark Morris, Fanny, Hellerup, Denmark

Petersen, Lars C., H.o slashed.rsholm, Denmark Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.

corporation)

NUMBER KIND DATE \_\_\_\_\_\_ US 5591603 US 1993-84718 19970107 19930623 (8)

PATENT INFOFMATION: APPLICATION INFO .:

PATENT ASSIGNEE(S):

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-24925, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on 31 Jun 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-598737, filed on 19 Nov 1990, now patented, Pat. No. US 5373090 And a continuation-in-part of Ser. No. US 1992-827687, filed on 29 Jan 1992, now abandoned

	NUMBER	DATE	
PRIORITY IMPORMATION:	DK 1987-4501 DK 1988-0254 DK 1990-2361 DK 1991-1118	19870838 19880436 19901001 19910612	
DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER:	Utility Granted Draper, Garnette D Teng, Sally P.	).	
LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EMEMPLARY CLAIM:	-	ve T., Agris, Esq., Cheryl H	•

NUMBER OF DEAWINGS: 18 Drawing Figure(s); 17 Drawing Page(s) LINE COUNT: 2391

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for producing aprotinin and

analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions compositions compositions analogs.

CAS INDEMING IS AVAILABLE FOR THIS PATEWI.

ANSWER 156 OF 189 EMPOPATFULL COPYRIGHT 10 . WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVAE

EUROPATFULL EW 1947%0 FS PS ACCESSION NUMBER: 501965

ACTIMATABLE FIBEINGLYTIC AND ANTI-THROMBOTIC PROTEINS. TITLE:

AKTIVIERBARE FIBRINGLYTISCHE UND ANTITHROMBOTISCHE

PROTEINE.

PROTEINES FIBRINOLYTIQUES ET ANTITHROMBOTIQUES

ACTIVABLES.

DAWSON, Keith Martyn, 80 Barnards Hill, Marlow, Bucks INVENTOR(3):

SL7 LNE, GB;

EIWAFDS, Fichard Mark, 7 Ludlow Drive, Thame, Oxon OX9

3X3, GB;

FORMAN, Joan Mabel, 6 Margaret Foad, Oxford OX3 8NG, GB

BEITISH BIOTECH PHARMACEUTICALS LIMITED, Watlington PATENT ASSIGNEE(S):

Foad, Cowley Oxford, OM4 SLY, GB

PATENT ASSIGNEE NO: 9705.2

Walls, Alan James et al, British Biotech Pharmaceuticals AGENT:

Ltd., Watlington Road, Oxford GM4 5LY, GB

AGENT NUMBER: 37314

OTHER SOURCE: EPB1997047 EP 0502968 BL 970703

Wila-EPS-1997-H30-T1 SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroef:entlichung in Englisch LANGUAGE: DESIGNATED STATES:

F AT; R BE; R CH; R DE; R DK; F ES; R FR; R GB; R GR; R

KIND DATE

IT; R LI; R LU; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT NO

PATENT INFORMATION:

	ΕP	502968	B! 19970733
'DFFENLEGUNGS' DATE:			19920916
AFPLICATION INFO.:	$\mathbf{F}\mathbf{P}$	1991-900851	19901207
PRIORITY APPLN. INFO.:	GB	1989-27722	19891397
RELATED DOC. INFO.:	$W(\mathbb{C})$	90-GB1912	901207 INTAKE
	$W \ominus$	9109118	910627 INTPNR
EFFFERNCE DAT INFO .	FP	911399 A	표현 간기기의국의

EP 211293 A EP 292009 A EP 304013 A EP 303149 A EP 338841 A FEFERENCE PAT. INFO.: EP 297881 A EP 319944 A EP 330700 A WS 89 - 11036 A W1 89-96239 A W0 40 10081 A

WO 31 33.97 A WD 90-13640 A

REF. NON-PATENT-LIT: Biochemistry, vol. 29, 1990, American Chemical Society, E.J. Davidson et al.: "plasminagen activator activities of equimolar complexes of streptokinase with variant recombinant plasminigens", pages 3535-3530 Chemical Akstracts, vol. 103, 1985, Cylumbus, Ohio, US); J.Y. Chang: "Thrombin specificity, Requirement for apolar

aming abids adjacent to the thrombin cleavage site of prlypeptiede substrate", see page 412 Archives of

Piponemistry and Biophysics, vol. 271, no. 1, June 1989, Academic Press, Inc.; 7. Whitefilet-Smith et al.:

"Expression of human plasminoten cDNA in a haculovirus vector-infected insect cell system", pages 390-399 Proc. Natl. Acad. Sci. USA, vol. 79, October 1982; T. Miyata et al.: "Plasminogen Tornigi: inactive plasmin resulting from replacement of alanine- 610 by threonine in the active site", pages 6132-6136

L164 ANSWER 157 OF 189 USPATFULL

ACCESSION NUMBER: 98:120979 USPATFULL

TITLE: Process for production of inhibited forms of activated

klood factors

INVENTOR'S: Fing, Robert, Fremont, CA, United States

PATENT ASSIGNEE (S): TOR Therapeutics, Inc., South San Francisco, CA, United

States (U.S. corporation)

NUMBER KIND DATE \_\_\_\_\_\_

PATENT INFORMATION: US 5589572 19961231 APPLICATION INFO:: US 1995-474042 19960607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-330978, filed on 28 Oct 1994

Utility DOCUMENT TYPE: Granted FILE SEGMENT:

PRIMARY EXAMINER: Fleisher, Mindy ASSISTANT EXAMINER: Degen, Nancy J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP NUMBER OF CLAIMS: 13

1 EXEMPLARY CLAIM:

4 Drawing Figure(s); 4 Drawing Page(s)

NUMBER OF DRAWINGS: 4 Dr.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 158 DF 189 USPATFULL

ACCESSION NUMBER: 96:120978 USPATFULL

Process for production of inhibited forms of activated TITLE:

blood factors

King, Robert, Fremont, CA, United States INVENTOR(S):

PATENT ASSIGNEE(3): COR Therapeutics, Inc., South San Francisco, CA, United

States (U.S. corporation)

NUMBER KIND DATE ..... US 5589571 19961231 US 1994-330978 19941028 PATENT INFORMATION: APPLICATION INFO.: 19941028 (8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP

NUMBER OF CLAIMS: 16 EXEMPLARY CLAIM: 1

NUMBER OF DEAWINGS: 4 Drawing Figure's); 4 Drawing Page(s) LINE COUNT: 1395

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

A process for producing a highly purified preparation of an inhibited form of an activated klood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the

resulting inhibited activated blood factor.

CAS INJEMING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 159 OF 189 USPATFULL

96:120775 USFATFULL ACCESSION NUMBER:

INA encoding tissue factor mutants useful for the TITLE:

treatment of myodardial infarction and coagulopathic

disorders

Ray, Samitra, San Francisco, CA, United States INVENTORIS: Wehar, Bordon A., Ban Carlos, CA, United States

Benentech, Inc., South San Francisco, CA, United States PATENT ASSIGNEE(S):

(U.S. comporation)

NUMBER KIND DATE \_\_\_\_\_

PATENT INFORMATION: US 5589363 19961231 APPLICATION INFO.: US 1994-046978 19940520 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1991-714819, filed on 13 Jun

1991, now patented, Pat. No. US 5346991

Stility DOCUMENT TYPE: FRIMARY EXAMINER: Jacobar LEGAL DEPARTS

Jacobson, Dian C.

LEGAL REPRESENTATIVE: Kubinec, Jeffrey S., Winter, Daryl B. NUMBER OF CLAIMS: 16

l EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: 17 Drawing Figure(s); 8 Drawing Page(s)

2528 LINE COUNT:

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

BMA enclosing a tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.blll.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 160 OF 189 USPATFULL

ACCESSION NUMBER: 96:113900 USFATFULL

Agents affecting thrombosis and hemostasis TITLE: Wolf, David L., Palo Alto, CA, United States INVENTOR(S):

Sinha, Uma, San Francisco, CA, United States

COF. Therapeutics, Inc., South San Francisco, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE ... US 5583107 19961210 US 1994-268003 19940629 (8) PATENT INFOFMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994 which is a continuation of Ser. No. US

1991-308329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

Utility DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Elliott, George C. ASSISTANT EXAMINER: Degen, Nancy J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP

NUMBER OF CLAIMS: EXEMPLARY CLAIM: . ú

NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s) LINE COUNT: 1955

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Analogs of blood factors which are transiently inactive are useful in AВ treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilis conditions. These modified forms of the blood factor may be anylated forms which are slowly deacylated in vivo.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 1-1 OF 189, USPATFULL

ACCESSION NUMBER: 96:101466 USPATFULL

TITLE: INVENTOR S :

Directed evolution of novel kinding proteins Ladner, Robert C., Ijamsville, MD, United States Guterman, Sonia K., Belmont, MA, United States

Roberts, Bruce L., Milford, MA, United States Markland, William, Milford, MA, United States Ley, Arthur C., Newton, MA, United States

Kent, Pachel B., Boxborough, MA, United States

Protein Engineering Corporation, Cambridge, MA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: APPLICATION INFO.:

 US 5571698
 19961105

 US 1993-57667
 19930618 (8)

DISCLAIMER DATE:

20100629

RELATED APPLN. INFO.:

Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a

continuation-in-part of Ser. No. US 1990-487063, filed

on 2 Mar 1990, now abandoned which is a

continuation-in-part of Ser. No. US 1988-240160, filed

on 2 Sep 1988, now abandoned

DOCUMENT TYPE: FILE SEGMENT:

Utility Granted PRIMARY EXAMINER: Ulm, John

LEGAL REPRESENTATIVE: Cooper, Iver P.

NUMBER OF CLAIMS:

33

EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s) LINE COUNT: 15323

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isplated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel kinding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pandreatic trypsin inhibitor, the genetic package is MI3 phage, and the protein includes the cuter surface transport signal of the M13 gene III protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANOWER 102 OF 189 USPATFULL
ACCESSION NUMBER: 96:00684 USPATFULL
TITLE: Trypsin inhibitors
INVENTOR'S: Brunck, Terence K., San Diego, CA, United States

Pere, Michael G., San Diego, DA, United States Pearson, Daniel A., Solana Beach, CA, United States

Webb, Thomas R., Encinitás, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ADSIGNEE'S,:

States 'U.S. corporations

NUMBER KIND DATE 

ts 9534496 19960709 ts 1993-11666 19930129 (8) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPIN. INFO.: Continuation-in-part of Sec. No. US 1992-929388, filed

on 30 'an 1992, now abandoned

DUCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Marshall, 3. G. LEGAL REPRESENTATIVE: Lyon & Lyon NUMBER OF CLAIMS: 41

EKEMPLARY CLAIM: 1

NUMBER OF DEAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 1563

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Novel compounds having activity against trypsin are disclosed.

Specifically, novel peptide aldehyde analogues that have substantial potency and specificity as inhibitors of

mammalian pancreatic trypsin are presented. The compounds are useful in

the prevention and treatment of the tissue damage or destruction associated with pandreatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 163 OF 189 USPATFULL

ACCESSION NUMBER: 96:38638 USPATFULL

TITLE: Methods for coating invasive devices with inhibitors of

thrombin

Maraganore, John M., Concord, MA, United States INVENTOR(3):

Bourdon, Paul R., Sommerville, MA, United States

Jablonski, Jo-Ann M., Middleborough, MA, United States

PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S.

corporation)

NUMBER KIND DATE \_\_\_\_\_\_

PATENT INFORMATION: US 5514409 19960507 APPLICATION INFO.: US 1995-431678 19950502 (8) APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1992-924549, filed on 31 Jul 1992, now patented, Pat. No. US 5425936, issued on 20

Jun 1935 which is a division of Ser. No. US

1991-652929, filed on 8 Feb 1991, now patented, Pat. No. US 5240913, issued on 31 Aug 1993 which is a

continuation-in-part of Ser. No. US 1990-549338, filed on 6 Jul 1990, now patented, Pat. No. US 5196404,

issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now

abandoned Utility

DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Dusignar, Michael

LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S. NUMBER DF CLAIMS: 11

EMEMPLARY JUANA.

NUMBER OF DRAWINGS: 3 D: 1148 EXEMPLARY CLAIM:

- 3 Drawing Figure's); 5 Drawing Page's:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to coating invasive devies with novel

biologically active molecules which kind to and inhibit thrombin. These molecules comprise a datalytic site directed molety CSDM: of the firmula: ##STRl## wherein X is hydrogen or is characterized by a hacknone chair consisting of from 1 to 111 atoms; R.sub.1 is selected from the group pensisting of unsubstituted, mono-substituted, airsurstituted and tri-substituted saturated ring structures; R.sub.2 is a pond or is characterized by a backrone chain consisting of from 1 to 5 atoms; R.sup.3 is a pend or is characterized by a packbone chain consisting of from 1 to 3 atoms; R.sup.4 is any Amino acid; R.sup.5 is any Leamine acid which comprises a quantizinium- or amine-containing side main group; R.sup.6 is a non-amide wond; and Y is characterized by a packbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R.sub.1 ' is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R.sub.4 ' is any amino acid comprising a side chain group characterized by the cupacity to accept a hydrogen bond at a pH of between about 5.5 and 9.5; and X, R.sub.2, R.sub.3, R.sub.5, R.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18 .ANS. and 42 .ANS. in length which connects the Y to the ABEAM.

## CAS INDEMING IS AVAILABLE FOR THIS PATENT.

LID4 ANSWER 164 OF 189 PCTFULL COPYRIGHT 0002 Univention

ACCESSION NUMBER: 1996038470 PCTFULL ED 20020514

TITLE (ENGLISH): IMIDACO[1,5a]PYRIDINE DERIVED SERINE PROTEASE

INHIBITORS

TITLE (FRENCH): INHIBITEURS DE SERINE PROTEASE DERIVES DE

IMIDAZO[1,5A]PYRIDINE

INVENTOR(S): OTTENHEYM, Henricus, Carl, Joseph; ADANG, Anton,

Eghert, Peter: PETERS, Jacobus, Albertus, Maria

PATENT ASSIGNEE(S): AKZO NOBEL N.V.; CTTENHEYM, Henricus, Carl, Joseph;

ADANG, Anton, Egbert, Peter; PETERS, Jacobus, Albertus,

Maria

LANGUAGE OF FUBL.: German
DOCUMENT TYPE: Fater.

PATENT HISOFMATION:

NUMBER KIND DATE
WO 9633470 Al 19961205

DESIGNATED STATES AU BE CA CN CZ HU JE KE MK NO NZ PL RU SG TE US AT BE

CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1996-EP2298 A 19960529
PRIORITY INFO.: AT 1995-95201448.4 19950602

ABEN The invention relates to an imidazo[1,5a]pyridine derived serine protease inhibitor comprising

a unit having general formula (I) wherein Fl is hydrogen, lower alkyl or

an acyl group;  ${\rm R2}$  is hydrogen or lower alkyl;  ${\rm R3}$  and  ${\rm R4}$  are independently hydrogen, lower

alkyl or together form  $_{\rm SCH-NESE6},$  RS and R6 being lower alkyl. The compounds are serine

protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

ABFR Cotte invention concerne un inhibiteur de serine protease derive de imidamo[1,5a]pyridine,

leguel inhibiteur comprend une unite correspondant a la formule generale (:) cu  $\Re 1$  represente

nydrogene, alkyle inferieur ou un groupe aryle; F2 represente hydrogene ou alkyle inferieur; R) et

Ri representent independamment hydrogene, alkylë inferieur cu forment ensemble = CH-NR5R6, R5 et  $\rm Rel$ 

representant un alkyle inferieur. Jes composes sont des inhibiteurs de serine protease et peuvent

etre utilises dans le traitement et la prevention de thromboses et de maladies associées à la thrombine.

L104 ANSWER 165 OF 189 POTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 1996030035 PUTFULL ED 20020514

TITLE (ENGLISH): 'beta'-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF

BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS

TITLE /FREMCH:: IMMITATEURS DE FEUILLETS 'beta' ET LEUR EMPLOI COMME

INHIBITEURS DE PEPTIDES OU DE PROTEINES

BIGLOGIQUEMENT ACTIFS

INVENTOR(S): KAHN, Michael

PATENT ASSIGNEE(S): MOLECUMETICS LTD.; KAHN, Michael

LANGUAGE OF FUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WD 9630035 Al 19961003

DESIGNATED STATES AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI

98 GE HU IS JP KE KG KP KR KZ LK LE LS LT LU LV MD MG MK MN MW MK NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT SE CH DE DK ES FI FR GB GR IE IT LU MC NL

PT SE BE BU OF OG OI OM GA GN ML MR NE SN TD TG

APPLICATION INFO.: Wo 1996-US4044 A 199603.5 PRIORITY INFO.: US 1995-8/410,518 199503.4 US 1995-8/549,006 19951027

ABEN There are disclosed 'beta'-sheet mimetics and methods relating to the same for imparting or

stabilizing the 'beta'-sheet structure of a peptide, protein

or molecule. In one aspect, the

'beta'-sheet mimetics are covalently attached at the end or within the length of the **peptide** or

protein. The 'beta'-sheet mimetics have utility as inhibitors of one or more of proteases, kinases,

JAAM, peptides binding to SH2 domains and MHC-I and/or MHC-II

presentation of **peptides** to T cell receptors in warm-blooded animals.

ABFR La presente invention concerne des mimetiques de feuillets 'beta' et des procedes s'y

rapportant permettant de communiquer ou stabiliser la structure en feuillets 'beta' d'un **peptide**,

d'une proteine ou d'une molecule. Dans l'une des variantes, les mimetiques de feuillets 'beta' sont

fixes par covalence a l'extremite du peptide ou de la

proteine, ou entre ses extremites. Ces

imitateurs de feuillets 'beta' conviennent comme inhibiteurs d'une ou plusieurs proteases, kinases,

CAAX, de peptides se liant a des domaines SHS et de la

presentation MHC-I et/ou MHC-II de peptides a

des recepteurs de cellules T chez les animaux a sang chaud.

L104 ANSWER 166 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1996025427 PCTFULL ED 20020514

TITLE (ENGLISH): SERINE PROTEASE INHIBITORS

TITLE (FRENCH): INHIBITEURS DE SERINES PROTEASES

INVENTOR(S): GREEN, Donovan, St. Clair; ELGENDY, Said, Mchammed,

Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOCDWIN, Christopher, Andrew; KAKKAR, Vijay, Vir;

DEADMAN, John, Joseph

PATENT ASSIGNEE'S.: ELLERMAN PHARMACEUTICALS LIMITED; GREEN, Donovan, St.

Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Seeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher,

Andrew: KAKKAR, Vijay, Vir; DEADMAN, John, Joseph

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION:

NUMBER KIND DATE ------

WD 9625427 A1 19960822

AT CA JP NZ US AT BE OH DE DK ES FR GB GR IE IT LU MC PESIGNATED STATES

NL PT SE

APPLICATION INFO.: W0 1996-38352 A 19960215 PRIORITY INFO.: 35 1996-9502985.6 19950216

Peptide inhibitors of serine proteases, especially thrombin,

in which the Pl-P2 natural amide

linkage is replaced by another pond. Exemplary thrombin inhibitors are of the formula:

 $X = \{aa3\} = \{aa.1\} = \{psi^+ : (aa1) = 1\}$  wherein X is H or a substituent on the N-terminal amino group, aa3 is a

hydrophobic amino acid such as Phe, aad is Pro, aal is Arg or an Arg analogue such as

methoxypropylglycyl, 2 is -COOH or a heteroatom acid group, such as boronate, or a derivative of

either, and 'PSI' is a non-amide linkage, typically containing up to 5 in-chain atoms, such as

-002-, -CH20-, NHCO- or -CH2-CH2-.

On decrit des inhibiteurs peptidiques de serines proteases, notamment la ABFR thrombine, dans

lesquels la liaison amide naturelle P1-F2 est remplacee par une autre liaison. A titre d'exemple, on

decrit des inhibiteurs de thrombine possedant la formule

X-(aa3)-(aa1)-'PSI'-(aa1)-1 dans laquelle X

represente H ou un substituant sur le groupe amino N-terminal, aa3 represente un acide amine

hydrophobe tel que Phe, aa2 represente Pro, aa1 represente Arg ou un analogue de Arg tel que

methoxypropylglycyle, Z represente -COOH ou un groupe acide d'heteroatomes, tel qu'un boronate, ou

un derive de l'un ou de l'autre, et 'PSI' represente une liaison non amide, contenant typiquement

jusqu'a 5 atomes en chaine, tels que -CO2-, -CH2O-, NHCO- ou -CH2-CH2-.

ANSWER 167 OF 189 POTFULL COPYRIGHT 2002 Univentic L104

ACCESSION NUMBER: 1996013274 PCTFULL ED 20020514

TITLE (ENGLISH): PROCESS FOR PRODUCTION OF INHIBITED FORMS OF ACTIVATED

BLOOD FACTORS

TITLE (FRENCH): PROCEDE DE PRODUCTION DE FORMES INHIBEES DE FACTEURS

SANGUINS ACTIVES

INVENTOR(S): KING, Robert, S.
PATENT ASSIGNEE(S): COP THERAPEUTICS, INC.

LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent

PATENT INFOFMATION:

NUMBER KIND DATE ------WO 9813274 Al 19960509

DESIGNATED STATES CA JE MK AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT

.3 E

APPLICATION INFO.: WG 1995-UG13940 A 19951027 PRIORITY INFO.: US 1994-97330,978 19941028

ABEN A process, as shown in the figure, for producing a highly purified

preparation of an inhibited

form of an activated blood factor entails providing a partially purified preparation containing the

klood factor of interest, treating the partially purified preparation to convert the blood factor to

an inhibited activated form in a single step, and then purifying the resulting inhibited activated

blood factor. L'invention concerne un procede, comme illustre dans la figure, qui ABFR mermet d'imtenir une preparation des plus pures d'une forme inhibée d'un facteur de poarulation sanguine, consistant a produire une preparation partiellement purifiee contenant le facteur en question, a traiter sette preparation partiellement purifiee pour transformer en une seule etape le facteur de coaquiation en une forme innibee et, ensuite, a purifier le facteur active inhibe qui en :esulte. ANSWER 168 OF 189 POTFULL COPYRIGHT 2002 Univentib ACCESSION NUMBER: 1996004373 POTFULL ED 20020514 RECOMBINANT PRODUCTION OF BIOLOGICALLY ACTIVE TITLE (ENGLISH): PEPTIDES AND PROTEINS PRODUCTION PAR RECOMBINAISON DE PEPTIDES ET TITLE (FRENCH): PROTEINES BIOLOGIQUEMENT ACTIES WILLIAMS, Joh, I.; PIERCE, James, C.; ANDERSON, G., INVENTOR(3): Mark; KARI, Prasad PATENT ASSIGNEE(S): MAGAININ PHARMACEUTICALS, INC. LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE \_\_\_\_. WO 9604373 A2 19960215 DESIGNATED STATES AU CA JP KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE A 19950726 Wo 1995-US10219 APPLICATION INFO.: US 1994-8/282,030 PRIORITY INFO.: 19940729 The present invention relates to the recombinant production of APEN amphiphilic peptides with biologically and therapeutically significant activities. In one embodiment, this invention relates to recombinantly producing an amphiphilic peptide by providing a protease-deficient microbial host transformed with an expression vector containing DNA that encodes the amphiphilis peptide under the control of a regulatory sequence operable in the microbial host and expressing the amphiphilic peptide in the tranformed microbial host. In another embodiment, this invention relates to providing an E. coli protease-deficient K-12 cell transformed with a vector that expresses a cleavable fusion protein comprising at least part of a carbohydrate binding protein and the amphiphilic peptide in the cell, expressing the fusion protein in the cell, and cleaving the fusion protein to obtain the amphiphilic peptide substantially free of carbohydrate binding protein residues. The biologically active amphiphilic peptide so produced can be further treated chemically or enzymatically to obtain a chemically distinct amphiphilic peptide with improved biological and therapeutic properties. L'invention concerne la production par recombinaison de peptides AEFE amphiphiles qui presentent des artivites biologiques et therapeutiques significatives. Une variante de cette invention concerne la production par recombinaison d'un peptide amphiphile, qui consiste a produire un hote microbien presentant une deficience en protesse, transforme a l'aide d'un vecteur d'expression contenant un ADN codant de peptide amphiphile sur commande d'une sequence

regulatrice gu'on peut activer dans

l'hote miorobien, et a exprimer de peptide amphiphile dans l'hote microbien transforme. Une autre variante de l'invention consiste a prendre une cellule K-12 d'E. coli, présentant une deficience en protease, transformee a l'aide d'un vecteur qui exprime une proteine de fusion qu'on peut douper et qui comprend au moins une partie d'une proteine se liant a un glubide et le peptide ampniphile present dans la rellule, a exprimer rette proteine de fusion dans la cellule et a la couper pour donner un peptide amphiphile pratiquement depourvu de residu de la proteine se liant a un glucide. Le peptide amphiphile hiplogiquement actif ainsi obtenu peut alors etre traite par voie chimique ou enzymatique, de qui permet d'obtenir un peptide amphiphile chimiquement different date de proprietes hiologiques et therapeutiques ameliorees.

ANSWER 169 OF 189 PCTFULL COPYRIGHT 2002 Univentio 1.104

ACCESSION NUMBER: 1396000541 POTFULL ED 20020514

TITLE (ENGLISH): AN EXTERNAL URINARY CATHETER AND A HOSE CONNECTOR FOR

CONNECTION THEREWITH

CATHETER EMTERNE POUR LES URINES ET RACCORD DE CONDUITE DESTINE À CE CATHETER TITLE (FRENCH):

INVENTOR(S): JENSEN, Thomas, Dam
PATENT ASSIGNEE(S): COLOPLAST A/S; JENSEN, Thomas, Dam
LANGUAGE OF FUBL: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE \_\_\_\_\_ WO 9600541 Al 19960111

AM AT AU BB BG BR EY CA CH CN CZ DE DK DK EE ES FI FI DESIGNATED STATES

GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MK NO N3 PL PT PO EU SD SE SG SI SK TJ TM TT UA US UE VN KE MW SD SZ UG AT BE CH DE DK ES FE GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD

 $\mathrm{TG}$ 

APPLICATION INFO.: WO 1995-DE234 A 19950612 PRIORITY INFO.: DK 1994-774/94 19940629

An external catheter comprises a sheath essentially formed as a shaft ABEN and a constricted

drainage tube part (1) integrated therewith for connection with a hose connector (5) which is

connected to a draining hose. In order to facilitate the mounting of the drainage tube part (1) on

the hose connector (5), an end portion of the drainage tube part at the orifice thereof is divided

into at least two sections (2-3).

Un catheter externe pour les arines comprend une gaine venue d'une piece ABFF. avec une partie

resserree (1) formant un tube de drainage, de systeme etant raddorde par un raccord (5) a une

conduite de drainage. Four faciliter le montage de la partie resserree (1) formant un tube de

drainage sur le raccord (5), une portion terminale du tube de drainage au niveau de son crifice est

divisee en deux sections (2-3) au mains.

L104 AMSWER 170 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET BELIVKE

AUCESSION NUMBER: 489070 EUROPATFULL EW 199617 F3 P3

NOVEL INHIBITORS OF THROMBIN. TITLE:

NEUE THROMBININHIBITOREN.

NIUVEAUX INHIBITEURS DE THROMBINE.

INVENTOR SI: MARAGANDRE, John, M., 84 Patrick Road, Tewksbury, MA

01876, T.:

FENTCH, John, W., II, P.O. Box 37 Route 66, Maiden

Bridge, NY 12115, US;

KLINE, Tini, 47 Hayes Street, Cambridge, MA 02139, US BIGSEN, INC., 14 Cambridge Center, Cambridge

PATENT ASSIGNEE S :

Massachusetts 02142, US;

HEALTH RESEARCH INCORPORATED, 66 Hackett Boulevard, 3rd

Floor, Albany NY 12219, US

1049451; 522424 PATENT ASSIGNEE NO:

VOSSIUS & PARTNER, Postfack 66 17 67, D-81634 Muenchen, AGENT:

 $\Gamma \Xi$ 

AGENT NUMBER: 100311

OTHER SOURCE: EPB1996028 EP 0439070 B1 960424

SOURCE: Wila-EPS-1996 H17-T1

DOCUMENT TYPE: Patent

Anneldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: F AT; R RE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R DESIGNATED STATES:

LI; R LU; R NL; R SE

FATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Ar.meldung) בי אותי ביאיתי אני.

PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 439070	B1 199604.:4
'OFFENLEGUNGS' DATE:		19920610
APPLICATION INFO.:	EP 1990-912754	19900917
PRIORITY APPLN. INFO.:	US 1989-395482	19890318
	US 1990-549388	19900706
RELATED DOG. INFO.:	WO 90-U34642	900917 INTAKZ
	WO 9102750	910307 INTPNR
REFERENCE PAT. INFO.:	EP 276014 A	EP 291981 A
	EP 291932 A	EP 333356 A
	EP 341607 A	EP 357242 A
	Wo 79~00638 A	

REF. NON-PATENT-LIT.: Chemical Abstracts, volume 107, no. 11, 14 September

1987, (Columbus, Ohio, US), Kratenansky, John L. et al.: "Anticoagulant peptides. Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin", see page 733, abstract 97113d, & J. Med. Chem. 1987, 30( 9), 1688-169 Chemical Abstracts, volume 108, no. 19, 9 May 1988, (Columbus, Chio, US), Owen, Thomas J. et al.: "N-Terminal requirements of small peptide anti-coagulants based on hirudin", see page 701, abstract 167961z, & J. Med. Chem. 1948, 31(5), 1009-101 The Journal of Biological Chemistry, Vol. 264, No. 15, May 1989 John M. Maraganore et al.: "Anticoagulant Activity of Synthetic Hirudin Peptides" Thrombosis and Haemostasis, Vol. 63, No. 2, 1990 John L. Erstenansky et al.: "Development of MDL 28,051, a Small Stable Antithrombin AgentBased on a Functional Demain of the Leach Protein, Hirudin" Blood, Vol. 75, No. 3, January 1990 Joseph A. Jakubowski et al.: "Inhibition of Coaquiation and Thrombin-Induced Platelet Activities by a Synthetic Dodecapeptide Modeled on the Carboxy-Terminus of Hirudin"

L104 AMSWER 171 OF 189 USPATEULL

95:7595. USPATFULL ACCESSION NUMBER:

Method of treatment of neurodegeneration with calpain TITLE:

inhibitors

Bartus, Raymond T., Laguna Hills, CA, United States INVENTOR'S;:

Eveleth, David D., Irvine, CA, United States

Power, James C., Atlanta, GA, United States

PATENT ASSIGNEE'S': Cortex Pharmaceuticals, Irvine, CA, United States 'U.S.

correctation

Georgia Tech Research Corporation GTRC., Atlanta, GA,

United States (U.S. corporation)

NUMBER KIND DATE 

US :444142 19950822 US :1994-217881 19940307 (8) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-816120, filed on 27

> Tes 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-682925, filed on 9 Apr 1991, now abandoned which is a continuation of Ser. No. US

1990-635952, filed on 28 Dec 1990

Utility DOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Beisner, William H. ASSISTANT EXAMINER: Gittmer, Ralph

LEGAL REPRESENTATIVE: Knobbe Martens Olson & Bear NUMBER OF CLAIMS: 35

NUMBER OF CLAIMS: EXEMPLARY CLAIM.

NUMBER OF DRAWINGS: 9 Dr.
4963 EXEMPLARY CLAIM: 1

3 Drawing Figure(s); 3 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides a method of treating a neurodegenerative pathology in a human patient. This method includes selecting a patient for monitoring for the presence of a neurodegenerative pathology associated with enhanced Calpain activity and monitoring the patient for indicia of the onset or existence of such a pathology. In response to the detection of any such indicium of the presence or onset of the pathology, a therapeutically efficacious amount of a Peptide Ketoamide compound, or a pharmaceutically acceptable salt or derivative thereof, together with a pharmaceutically acceptable carrier is administered. The invention also provides additional methods of treatment and pharmaceutical compositions using Peptide Ketbamides, Peptide Ketbadids and Peptide

Ketbesters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 172 OF 189 USPATFULL

ACCESSION NUMBER: 95:69093 USPATFULL

Method of inhibiting blood coagulation in TITLE:

extracorporeal circulation by inhibiting human tissue

factor

Edgington, Thomas S., La Jella, CA, United States INVENTOR(3):

Colman, Robert W., Moylan, PA, United States

Kappelmayer, Janos, Debrecen, Hungary

Edmunds, Jr., L. Henry, Bryn Mawr, PA, United States Bernabei, Alvise, Philadelphia, PA, United States

The Scripps Research Institute, La Jolla, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

Trustees of the University of Pennsylvania,

Phialdelphia, FA, United States (U.S. corporation) Temple University - Of the Commonwealth Systems of Higher Education, Phialdelphia, PA, United States (U.S.

corporation)

NUMBER KIND DATE ...... VS 5437984 19350801 VS 1992-377281 19321116 (7)

PATENT INFORMATION: APPLICATION INFO.:

Continuation-in-part of Ser. No. US 1988-165939, filed RELATED APPLN. INFD.: on 9 Mar 1988, now patented, Pat. No. US 5223427 which

is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730

which is a continuation-in-part of Ser. No. US 1987-33047, filed in 31 Mar 1987, now abandoned

LOCUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Stances Mucker, Christine M. ASSISTANT EXAMINER: Dunningnam, T.

LEGAL REPRESENTATIVE: Spensley Horn Jubas & Lubito

NUMBER OF GLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 31 Drawing Figure(s); 23 Drawing Page(s) LINE COUNT: 3505

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as rardicpulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods.

# CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 173 OF 189 USPATFULL

ACCESSION NUMBER: 95:64843 USPATFULL

Fibrinalytic and anti-thrombotic cleavable dimers TITLE:

Dawson, Keith, Marlow, United Kingdom INVENTOR(3):

Hunter, Michael G., Aylesbury, United Kingdom Czaplewski, Lloyd G., Didcot, United Kingdom British Bio-Technology Limited, Oxford, England

PATENT ASSIGNEE(S): (non-U.S. corporation)

NUMBER KIND DATE US 5434073 19950718 WO 9109125 19910627 PATENT INFORMATION: US 1992-354596 19900603 (7) APPLICATION INFO.: WO 1990-GB1911 19901207 19920603 PCT 371 date

19920603 PCT 102(e) date

NUMBER DATE \_\_\_\_\_\_\_

PRIORITY INFORMATION: GB 1989-27722 19891207 DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen G.

LEGAL REPRESENTATIVE: Allegretti & Witcoff, Ltd.

NUMBER OF CLAIMS: 1 EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s) LINE COUNT: 2191

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Relatively inactive fusion proteins are activatable by enzymes of the slotting cascade to have fibrinolytic and/or slot formation inhibition activity. For example, a fusion protein comprising two hirudin or streptckinase molecules, linked by a cleavable linkage sequence, may be cleaved to yield anti-thromiptic hirudin or firringlytic streptokinase by thrombin or Factor Xa.

Fibrinelytic or clot formation inhibition activity is therefore directed to the site of clot formation. Cleavable

spreptokinase/hirudin heterodimers are claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 174 OF 189 USPACFULL

ACCESSION NUMBER: #5:64711 USPATFULL TITLE: Inhikitors of thrombin

INVENTOR S:: Maraganire, John M., Concord, MA, United States

Fentin, II, John W., Malden Bridge, NY, United States

Eline, Toni, Cambridge, MA, United States

PATENT ASSIGNEE(S): Bioden, Inc., Cambridge, MA, United States (U.S.

ocrporation)

NUMBER KIND PATE

PATENT INFORMATION: US 5433940 19950718
WO 9102750 19910307

APPLICATION INFO.: US 1992-834259 19920210 (7)

wo 1990-US4642 19900517

19920210 PCT 371 date 19920210 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-549388, filed

on 6 Jul 1990, new patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now

abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Prickril, Benet

LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.

NUMBER OF CLAIMS: 17 EXEMPLARY CLAIM: 1

NUMBER OF DEAWINGS: 22 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 2609

CAS INDEKING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding expsite association molety (ABEAM); a linker portion of at least 18.ANG. in length; and a thrombin catalytic site-directed molety (CSDM). This invention also relates to

compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 175 OF 189 USPATFULL

ACCESSION NUMBER: 95:54207 USPATFULL
TITLE: Inhibitors of thrombin

INVENTOR(S): Maragandre, John M., Tewksbury, MA, United States

Jablonski, Jo-Ann M., Middleborough, MA, United States

Bourdon, Faul R., Somerville, MA, United States

PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S.

dorporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5426936 1995 0420
APPLICATION INFO:: US 1992-924549 19920"31 (7)

RFLATED APPLN. INFO:: Division of Ser. No. US 1991-652929, filed on 8 Feb 1991, now patented, Pat. No. US 5241913, issued on 31

Aug 1998 which is a continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1890, now patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-398482, filed

on 18 Aug 1989, now abandoned

DOCUMENT TYPE: Stility FILE SEGMENT: Granted PRIMARY EXAMINER: Warden, Jill ASSISTANT EXAMINER: Salata, Carol A.

LEGAL REPRENENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF ORAWINGS: - A Drawing Figure se; 3 Drawing Page sk

LIME GOUNT: 1...32

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel riplogically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed molety (DSDM) of the formula: ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.l is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted saturated ring structures; R.sub.d is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; E.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a quanidiniumor amino-containing side chair group; R.sub. 6 is a non-amide bond; and Y is tharacterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STFL!## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.4 is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 3.5; and X, R.sub.2, R.sub.3, R.sub.5, F.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18.ANG, and 42.ANG, in length which connects the Y to the ABEAM. This invention also relates to compositions, combinations and methods which employ these molecules for

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 176 OF 189 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 95:598554 SCISEARCH

THE GENUINE ARTICLE: RT259

TITLE: PEPTIDE-DERIVED TRANSITION-STATE ANALOG

therapeutic, prophylactic and diagnostic purposes.

INHIBITORS OF THROMBIN - SYNTHESIS, ACTIVITY AND

SELECTIVITY

AUTHOF: JETTEN M (Reprint); PETERS C A M; VISSEF A; GROOTENHUIS P

D J; VANNISPEN J W; OTTENHEIJM H C J

CORPORATE SOURCE: NV OFGANON, 5340 BH OSS, NETHERLANDS

COUNTRY OF AUTHOR: NETHERLANDS

SOURCE: BIODEGANIC & MEDICINAL CHEMISTRY, (AUG 1995) Vol. 3, No.

> 8, pp. 1999-1114. ISSN: 0968-0896. Article; Journal

DOCUMENT TYPE:

LANGUAGE: ENGLISH

REFERENCE COUNT:

\*ABSTRACT IS AVAILABLE IN THE ALL AND TALL FORMATS\*

In a study to combine the transition state analogue concept with the principle of catalytic site spanning, a series of peptide -derived transition state analogue (TSA) inhibitors of thrombin has been synthesized and tested. In the sequence H-D-Phe-Pr:-Arg-Gly-CH (3) the Arg-Gly amide band has been replaced by three classes of transition state analogues, being the ketcmethylene, the hydroxyethylene and the hydroxymethylene amide bond replacements. Compound 12a, in which the amide bond has been replaced by the ketomethylene group, was found to be the most potent thromkin inhibitor of the series studied. Subsequently, penta- and hexapeptide sequences with good affinity for thrombin were developed, i.e.

H-D-Phe-Pro-Arg-Glv-Phe-OH 16 and H-D-Phe-Pro-Arg-Glv-Phe-Lys-OH 126..

In these sequences the Arg-3ly amide bond was then replaced by the ketomethylene group. The resulting compounds 43a and 47a, respectively, were evaluated in vitro as inhibitors of thromkin and factor Xa. Dompound 47a was found to be the most potent thromain inhibitor of the series studied (K-i a 28 nM). The combination of the transition state analogue concept and the principle of peptide elongation (tetrapeptide- ->hexapertide) yields thrombin inhibitors of high potency and selectivity. The effects of these two alterations reinforce each other indicating a synergistic effect. This might be rationalized by entropy factors.

L104 ANSWER 177 OF 189 USPATFULL

ACCESSION NUMBER: 34:109010 USPATFULL

Aprotinin analogues and a process for the TITLE:

production thereof

Norris, Kjeld, Hellerup, Demmark INVENTOR(S):

Petersen, Lars C., Horsholm, Denmark

PATENT ASSIGNEE(S): Movo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.

dorporation)

	NUMBER	KIND DATE	
PATENT INFORMATION:	US 5373090	19941213	
	Wo 8910374	19391102	
APPLICATION INFO .:	US 1990-598737	19901119	(7)
	WO 1939-DK96	19890425	
		19901119	PCT 371 date
		19901119	PCT 102(e) date

NUMBER DATE ...........

PRIORITY INFORMATION: DK 1983-225488 19880426

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Teng, Sally P.

LEGAL REPRESENTATIVE: Zelson, Steve T., Agris, Cheryl H.

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s) LINE COUNT: 758

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel aprotinin analogues having a selected inhibition profile against serine proteases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 178 OF 189 USEATFULL

ACCESSION NUMBER: 34:106771 USPATFULL

Asp-Pro-Arg .alpha.-keto-amide enzyme inhibitors TITLE: Webb, Thomas R., Encinitas, CA, United States INVENTOR:S:

Miller, Toad A., Enginitas, CA, United States Mlasuk, George P., Carlsbad, CA, United States

Corvas International, Inc., San Diego, CA, United PATENT ASSIGNEE(S):

States (%.S. corporation)

NUMBER KIND DATE ...... US 5371071 19941206 US 1992-962301 19921016 (7) PATENT INFORMATION:

APPLICATION INFO.: FILE SEGMENT: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Weber, Jon P.

LEGAL REPRESENTATIVE: Lyon & Lyon

NUMBER OF CLAIMS:

EKEMPLARY CLAIM:

NUMBER OF DRAWINGS: 1 Frawing Figure s.; 1 Drawing Page s

LINE COUNT:

CAS INCEMING IS AVAILABLE FOR THIS PATENT.

Asp-Ero-Arg alpha-kett-amide derivatives, and their pharmaceutically a sceptable salts and compositions, for use as antithrombotic agents in mammals are disclosed. The method of use of these inhibitor compounds for treatment or prevention of conditions of abnormal thrombus formation in mammals is also displosed. Further displosed are alpha-hydroxy amide summounds used as intermediates in the preparation of the keto-amide commounds.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 179 OF 189 USPATFULL

94:90075 USPATFULL ACCESSION NUMBER:

Tissue factor mutants useful for the treatment of TITLE:

myocardial infarction and coagulopathic disorders Roy, Soumitra, San Francisco, CA, United States

INVENTOR/S.: Venar, Gordon A., San Carlos, CA, United States

Genentech, Inc., South San Francisco, CA, United States PATENT ASSIGNEE(S):

(U.S. corporation)

NUMBER KIND DATE 

PATENT INFORMATION: US 5346991 19940913 APPLICATION INFO.: US 1991-714819 19910613 (7) APPLICATION INFO.:

DOCUMENT TYPE: Utility Granted FILE SEGMENT:

PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Jacobson, Dian C. LEGAL REPRESENTATIVE: Winter, Daryl B.

NUMBER OF CLAIMS: 1.3 EKEMPLARY CLAIM:

NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s) LINE COUNT: 2407

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coaquiation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

ANSWER 180 OF 189 EUROPATFULL COPYRIGHT 2002 WILA 5104

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

EUROPATFULL EW 198944 FS OS STA 8 339942 ACCESSION NUMBER:

Arrotinin analogues and process for the TITLE:

production thereof.

Aprotinin-Analoge und Verfahren zu ihrer Herstellung.

Analogues d'aprotinin et procede pour leur

production.

Norris, Kjeld, Anlmanns Alle 34, DK-2900 Hellerup, DK; INVENTOR S):

Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm,

DE

NOVO-MORDISK A/S, Novo Alle, DK-2990 Bagsvaerd, DK PATENT ASSIGNEE'S:

PATENT ADSIGNEE NO: 1099510

Brown, John David et al, FORRESTER & BOEHMERT AGENT: Widenmayerstrasse 4/I, D-8006 Muenchen 22, DE AGENT NUMBER: 28811

ESP1989046 EP 0339942 A2 891102 OTHER SOURCE:

SOURCE: Wila-EPZ-1984-H44-T1

DOCUMENT TYPE:

Pate:.t

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE: DESIGNATED STATES: RAT; RBE; RCH; RDE; RES; RFR; RGB; RGR; RIT; R

LI; R MU; R ML; R SE

PATENT INFO. PUB. TYPE: SPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFOFMATION:

PATENT NO KIND DATE EP 33994L A2 19991102

'DEFENLEGUNGS' DATE: APPLICATION INFO.:

EP 1939-3041.2 19890425 PRICEITY APPLN. INFO.: DK 1988-1254 19880426

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER:

339940 EUROPATFULL EW 193412 FS PS STA B

TITLE:

Aprotinin analogues and process for the

production thereof.

Aprotinin-Analoge und Verfahren zu ihrer Herstellung.

19891102

Analogues d'aprotinin et procede pour leur

production.

INVENTOR(S):

Norris, Kjeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK; Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm,

DE

FATENT ASSIGNEE(S): NOVO NOFDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK

231781

PATENT ASSIGNEE NO:

AGENT:

Thalsoe-Madsen, Kine Birgit et al, c/o Novo Nordisk A/S

Novo Alle, DK-2880 Bagsvaerd, DK

AGENT NUMBEF:

614.01OTHER SOURCE:

EPB1994021 EP 0339942 B1 940323

SOURCE:

Wila-EPS-1994-H12-T1

POCUMENT TYPE:

Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE: DESIGNATED STATES:

P AT; P BE; P CH; R DE; P ES; R FR; P GB; P GR; P IT; R

KIND DATE

LI; R LU; R ML; R SE

PATENT INFORMATION:

PATENT INFO. PUB. TYPE: EPB1 EUPOPAEISCHE PATENTSCHRIFT

	$\mathbb{E}\mathbb{P}$	339943	В1	19940323	
'OFFENLEGUNGS' DATE:				19891102	
APPLICATION INFO .:	ΞF,	1989-304122		19890425	
PFIORITY APPLN. INFO.:	$\Gamma^{i}K$	1988-0254		19880426	
PEFERENCE PAT. INFO.:	EF	130730 A		EP 238993	Α
	ÉΡ	244627 A		EP 307590	Α

PATENT NO

FEF. NON-PATENT-LIT.: SCIENCE, vol. 235, 13th March 1987, pages 1370-1373;

C.B. MAFKS et al.: "Mutants of bovine pandreatic trypsin inhibitor lacking cysteines 14 and 38 can fold properly" BIOCHEMISTRY, vol. 16, no. 8, 19th April 1977, pages 1531-1541, The American Chemical Society; N.H.Tan et al.: "Synthesis and characterization of a pancreatic Trypsin inhibitor homologue and a model inhibitor"

L104 ANSWER 181 OF 189 USPATFULL

ACCESSION NUMBER:

93:70051 USPATFULL Inhibitors of thrombin

TITLE: INVENTOR(S):

Maraganere, John M., Tewksbury, MA, United States Jaklonski, Jo-Ann M., Middleborough, MA, United States

Ecureon, Paul R., Somerville, MA, United States

PATENT ASSIGNEE(S): Bicgen, Inc., Cambridge, MA, United States (U.S.

correctation)

NUMBER KIND DATE \_\_\_\_\_\_

 
 UA 5240913
 19930831

 UJ 1991-652929
 19910208
 PATENT INFOFMATION: APPLICATION INFO.:

RELATED ASSIM. INFO:: Dintinuation-in-part of Ser. No. US 1990-549388, filed

on 6 Jul 1990 which is a continuation-in-part of Ser. Mr. US 1989-395482, filed on 18 Aug 1989, now abandoned

DOCUMENT TYPE: Trility FILE SEGMENT: Granted

PRIMARY EXAMINER: PRIMARY EXAMINER: Lee, Lester L. ASSISTANT EXAMINER: Perkins, Susan M. lee, lester L.

LEGAL REPRESENTATIVE: Fierri, Margaret A., Marks, Andrew S., Miraglia,

Loretta A.

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 1254

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed molety (CSDM) of the formula ##STRI## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unsubstituted, monosubstituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; E.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a quanidiniumor amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STRD## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.4 is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 9.5; and X, R.sub.2, R.sub.3, R.sub.5, R.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exesite associating domain (ABEAM) and a linker portion of between 18 .ANG. and 42 .ANG. in length which connects the Y to the ABEAM. This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylastic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 182 OF 189 USEATFULL

INVENTOR(3):

93:52505 USPATFULL ACCESSION NUMBER:

TITLE: Hybridomas producing monoclonal antibodies reactive

with human tissue-factor glycoprotein heavy chain Edgington, Thomas S., La Jolla, CA, United States

Morrissey, James H., San Diego, CA, United States The Scripps Research Institute, La Jolla, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

NUMBER KIND DATE ------

 
 U.: 5223427
 19930629

 U.: 1988-165939
 19880309
 PATENT INFORMATION: APPLICATION INFO.:

Sentin.ation-in-part of Ser. No. US 1987-33047, filed RELATED APPLN. INFO.: om 31 Mar 1987 And Ser. No. US 1987-67103, filed on 25

Jun 1987

Ttility DO-CUMENT TYPE: FILE SEGMENT: Granted

PRIMARY EXAMINER: Nucker, Christine ASSISTANT EXAMINER: Cunningham, T. LEGAL REPRESENTATIVE: Bingham, Douglas A. NUMBER OF CLAIMS: 6 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 22 Drawing Figure's:; 19 Drawing Page's: LINE COUNT: 5075 NUMBER OF DRAWINGS:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Murine hypridomas producing monoclonal antibodies capable of immunoreacting with nuTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in rody fluid, detecting thrombic events in vivo, isolating coagulation tastor, and neutralizing VII/VIIa coaquiation factor binding in vivo.

CAS INDEKING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 183 OF 189 USPATFULL

ACCESSION NUMBER: 93:50487 USPATFULL

Directed evolution of novel binding proteins TITLE: INVENTOR(S : Ladner, Robert C., Iramsville, MD, United States Guterman, Sonia H., Belmont, MA, United States Roberts, Bruce L., Milford, MA, United States Markland, William, Milfird, MA, United States Ley, Arthur J., Newton, MA, United States

Ment, Rachel B., Boxborough, MA, United States

PATENT ASSIGNEE(S): Protein Engineering Corp., Cambridge, MA, United States

(U.S. corporation)

NUMBER KIND DATE .... 4, ..... ----- -----PATENT INFORMATION: APPLICATION INFO:: US 5023409 19930629 US 1491-664989 19910301 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-487063, filed

on 2 Mar 1990, now abandoned And a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now

abandoned Utility Granted

PRIMARY EXAMINER: Hill, Jr., Robert J. ASSISTANT EXAMINER: Ulm, John D. LEGAL PEPRESENTATIVE: Cooper, Iver P.

NUMBER OF CLAIMS: 66 EXEMPLARY GLAIM:

DOCUMENT TYPE:

FILE SEGMENT:

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s) LINE COUNT: 15410

LINE COUNT: 15410

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

In order to obtain a novel binding protein against a chosen target, DNA molecules, each enording a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package; are introduced into a genetic puckage. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the kinding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential kinding domains, und the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine rancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the cuter surface transport signal of the M13 gene III protein.

CAS INTEXING IS AVAILABLE FOR THIS PATENT.

11:4 ANDWER 184 OF 189 USPATFULL

ACCESSION NUMBER: 93:22694 USPATFULL

TITLE: Inhibitors of thrombin

Maraganore, John M., Concord, MA, United States INVENTOR Set

Fentin, II, John W., Malden Bridge, NY, United States

Kline, Toni, New York, NY, United States

PATENT ASSIGNEE : S :: Brogen, Inc., Cambridge, MA, United States (U.S.

corporation;

Health Research, Inc., Albany, NY, United States U.S.

con: pration,

NUMBER KIND DATE -------

PATENT INFORMATION: US 196404 19930323 US 1990-549386 19900706 (7) APPLICATION INFO.:

RELATED AFPLN. INFO.: Continuation-in-part of Ser. No. US 1989-395482, filed

on 12 Aug 1989, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Lee, Lester L. ASSISTANT EXAMINER: Perkins, Susan M.

LEGAL REPRESENTATIVE: Haley, Jr., James F., Marks, Andrew S., Pierri,

Margaret A.

NUMBER OF CLAIMS: 3.7 EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: 23 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 2:4:

CAS INDEKING IS AVAILABLE FOR THIS PATENT.

This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding expsite association moiety (ABEAM); a linker

portion of at least 18 .ANG. in length; and a thrombin catalytic

site-directed moiety (CSDM). This invention also relates to

compositions, combinations and methods which employ these molecules for

therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 185 OF 189 ADJUALERTS COPYRIGHT 2002 (ADIS)

ACCESSION NUMBER: 1993:57163 ADISALERTS

DOCUMENT NUMBER: 800204139

Reocclusion after thrombolytic therapy: strategies for TITLE:

inhibiting thrombin-induced platelet aggregation

ADIS TITLE: Antithrombotics: pharmacedynamics.; Inhibition

of thrombin-induced platelet aggregation after

thrombolysis; Review (127 references)

Furi R N; Colman R W AUTHOR:

CORPORATE SOURCE: Temple University School of Medicine, Philadelphia,

Pennsylvania, USA

SOURCE: Blood Coaquiation and Fibrinolysis (Jun 1, 1993), Vol. 4,

pp. 465-478

POCUMENT TYPE: General Feview

Ischaemic Heart Disease (Summary): Alert no. 7, 1993; REFERENCE:

Antithrombotics (Summary): Alert no. 7, 1993

FILE SEGMENT: Summary LANGUAGE: English WORD COUNT: 5.34

LID4 ANSWER 186 OF 189 USPATFULL

93:46949 USPATFULL ACCESSION NUMBER:

TITLE: Serine protease inhibitors

INVENTOR S:: Glover, George I., Creve Coeur, MO, United States

Schasteen, Charles S., University City, MD, United

States

PATENT ASSIGNEE(S): MonJanto Company, St. Louis, MO, United States (U.S.

cor; cration)

NUMBER KIND LATE

PATENT INFORMATION: US 5157019 19921020 APPLICATION INFO.: US 1991-729002 19910701

FELATED APPIN. INFO.: Continuation of Ser. No. US 1988-200821, filed on 1 Jun 1988, now abandoned which is a continuation of Ser. No.

T95-, now abandened which is a dentification of Ser. No. US 1987-6725, filed on 6 Feb 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-340810,

filed on 15 Mar 1986, now abandoned

POGUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Chan, Y. Christina LEGAL REPRESENTATIVE: Bennett, Dennis A.

NUMBER OF CLAIMS: 25 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 1960

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Novel **peptides** which exhibit inhibitory activity toward serine proteases and methods for preparing and using same are disclosed. In one aspect, the present invention provides **peptides** comprising a generic inhibitory core having a functional site recognition sequence fused to the N-terminus. The functional site recognition sequence is adapted to provide enhanced **selectivity** and/or potency for a target protease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 187 OF 189 USPATFULL

PATENT ASSIGNEE(S):

ACCESSION NUMBER: 91:86794 USPATFULL

TITLE: Affinity matrices of modified polysaccharide supports

INVENTOR(S): Hou, Kenneth C., Glastonbury, CT, United States

Liao, Tung-Ping D., Missouri City, TX, United States

Roban, Robert, Columbia, CT, United States Cune Inc., Meridan, CT, United States (U.S.

correctation)

NUMBER KIND DATE

PATENT INFORMATION: US 5059654 19911022 APPLICATION INFO:: US 1989-311498 19890216 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1938-154815, filed

on 11 Feb 1988, now abandoned which is a

continuation-in-part of Ser. No. US 1987-130186, filed

on 3 Dec 1987, now abandoned which is a

continuation-in-part of Ser. No. US 1987-13512, filed

on 37 Jan 1937, now abandoned which is a

continuation-in-part of Ser. No. US 1984-656922, filed on 2 Oct 1984, now patented, Pat. No. US 4639513 which is a continuation-in-part of Ser. No. US 1984-576448, filed on 2 Feb 1984, now patented, Pat. No. US 4663163

which is a continuation-in-part of Ser. No. US 1383-466114, filed on 14 Fek 1983, now abandoned

DCCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Nutrer, Nathan M.

NUMBER OF CLAIMS: 28 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 34 Trawing Figure(s); 14 Drawing Page(s)

LINE COUNT: 3380

CAS INDEXING IS AVAILABLE FIR THIS PATENT.

AB The invention is sirested to a modified polysaccharide material which comprises: (1) polysaccharide covalently bended to a synthetic polymer; (2) the synthetic polymer being made from (a) a polymerizable compound which is capable of being covalently coupled directly or indirectly to

said polysaccharide, and (b) one or more polymerizable compounds containing (i) a chemical group capable of causing the covalent coupling of the compound 'b' to an affinity ligand or a biologically active melegule or (ii a hyarophebic compound.

The invention is also directed to devices for the chromatographic separation of at least two components of a mixture comprising the modified polysaccharine material of the invention, wherein the device is configured for radial or tangential flow.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1104 ANSWER 138 OF 189 USPATFULL

ACCESSION NUMBER: 91:46695 USPATFULL
TITLE: Factor VII/VIIA active site inhibitors

Edgington, T. Scott, La Jolla, CA, United States INVENTOR(S):

Pepe, Michael G., San Diego, CA, United States
PATENT ASSIGNEE(S): Sorvas, Inc., San Diego, CA, United States (U.S.

corporation)

NUMBER KIND DATE 

PATENT INFURMATION: US 5023236 19910611 APPLICATION INFO.: US 1989-320559 19890313 (7) APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1988-178495, filed

on 7 Apr 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINES: Lee, Lester L.

LEGAL REPRESENTATIVE: Greenlee and Associates

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1 LINE COUNT: 1349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes a class of compounds that inhibit the specific proteolytic activity of the bimolecular complex I[TF:VII/VIIa] that initiates the blood coaquiation systems. Both reversible and irreversible inhibitors are disclosed.

The invention encompasses the use of inhibitors of the active site of the factor VII and VIIa component of [TF:VII/VIIa] as diagnostic reagents, as analytical reagents, and as therapeutic drugs.

The invention includes the compounds based on the following general formula for both reversible and irreversible selective inhibition of [TF:VII/VIIa]. ##STE1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 189 OF 189 USEATFULL

ACCESSION NUMBER: 82:6372 USPATFULL

Substrates for the quantitative assay of enzymes and TITLE:

such assay

INVENTOR(S.: Yaron, Arieh, Rehovot, Isqael

Carmel, Amos, Rehovot, Israel

PATENT ASSIGNEE(S): Yeda Research and Development Co., Ltd., Rehovot,

Israel (non-U.S. corporation)

NUMBER KIND DATE ........ FATENT INFORMATION: US 4314936 19820219 APPLICATION INFO.: US 1980-211794 19801231 (6)

RELATED APPLN. IMPO.: Continuation-in-part of Ser. No. US 1979-48260, filed

on 13 Jun 1979, new abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1978-54940	19780616
	IL 1980-60888	19933921
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert	R.
LEGAL REPRESENTATIVE:	- Browdy and Neimar	2
	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	889	
CAS INDEXING IS AVAILAB	BLE FOR THIS PATENT.	

According to the present invention there are provided novel substrates for the determination of enzymes, and especially of the **peptide** AΒ hydrolases such as angiotensin-converting enzyme, trypsin and similar enzymes, and aminopeptidase-P, and to a process for the determination of these enzymes, which comprises contacting a biological fluid containing said enzyme with said substrate, which is cleaved, resulting in a pronounced fluorescence which is measured, thus giving a quantitative measure of the enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> S factor 'w, Ma. s. inhibitor or inhibition; .p. peptide s. analogue?
L105 10 FILE USPATFULL
           54 FILE POTFULL
1196
           17 FILE ETROPATFULL
11 17
1.
            # FILE CAPLUS
          10 FILE MEDLINE
1109
           10 FILE EMPASE
lii:
           6 FILE STISEARCH
            7 FILE BISSI:
           0 FILE DRUGU
Ll.3
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
           5 FILE BISTECHNO
            -0 FILE USPATS
L115
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
            3 FILE PASCAL
L115
L117
           0 FILE TOMCENTER
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
            4 FILE ESSIONASE
L1:3
L1.3
            3 FILE IFIFAT
L1.10
            5 FILE WEIDS
            1 FILE LIFESCI
Llll
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L122
            1 FILE BABS
L123
            0 FILE JICST-EPLUS
L1.14
            0 FILE CANCERLIT
L135
           1 FILE BIOBUSINESS
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'XA) (S)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'PERTIDE (S) ANALOGUE?'
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L1.16
            0 FILE CASPEACT
L127
            0 FILE AGRICOLA
L108
           0 FILE CABA
L129
           0 FILE CEN
L130
           0 FILE INVESTEXT
L131
           1 FILE PROMT
L1:\mathbb{Z}
           1 FILE ADISALERTS
L133
           0 FILE PHIN
L134
            0 FILE SYNTHLINE
1.1.35
           0 FILE AQUASCI
PROMIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L136 0 FILE BIOTECHDS
L137
            0 FILE VETU
TOTAL FOR ALL FILES
         139 (FACTOR (W) MA) (S) (INHIBITOR OR INHIBITION) (P) (PEPTIDE (S)
              ANALOGUE?)
=> dup rem 1138
DUPLICATE IS NOT AVAILABLE IN 'INVESTEXT, SYNTHLINE'.
ANDWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROJESSING COMPLETED FOR 1138
11:59
           100 DUP REM LIBS (39 DUPLICATES REMOVED,
== d 1139 1-110 ibib abs
L139 ANSWER 1 OF 100 PCTFULL COPYRIGHT 2002 UniventiabupLicate 1
                  2:02058734 PCTFULL ED 20020809 EW 200231
ACCESSION NUMBER:
```

TITLE ENGLISH:: COMBINATIONS OF STEROL ABSORPTION INHIBITOR'S: WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR COMBITIONS TITLE 'FRENCH: COMBINALSONS O'INHIBITEUR S O'ABSORPTION DES STEROLS ET DE MODIFICATEUR SE SANGUINASE POUR LE TRAITEMENT DES TROUBLES MASSULAIRES INVENTOR(S): MOSDGLOW, Teddy: RESS, Rudyard, Joseph; STROMY, John; MELTRI, Enrict, P. GINERING CORPORATION PATENT ASSIGNEE(S): CARRIONI, Ann. Marie AGENT: English LANGUAGE OF FILING: LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND NUMBER DATE Wo 0000058734 A2 00000801 AE AG AL AM AT AU AD BA BB BG BR BY BZ CA CH CN CO CR DESIGNATED STATES CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KE LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NE PH PL PT RD RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA OM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MO NL PT SE TR BE BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG WO 2002-US2013 A 30020125 APPLICATION INFO .: US 2001-60/064,396 20010126 US 0001-60/264,600 20010126 US 0001-60/264,275 00010126 US 0001-60/304,103 20010921 PRIORITY INFO.: The present invention provides compositions, therapeutic combinations ABEN and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols. L'invention concerne des compositions, des combinaisons therapeutiques ABFR et des procedes reposant sur l'utilisation: (a) d'au moins un inhibiteur d'absorption des sterols; et (b) d'au moins un modificateur sanguin. Ces compositions, combinaisons therapeutiques et procedes peuvent etre utiles pour le traitement des troubles vasculaires et pour la reduction du degre de concentration plasmique des sterols L139 ANSWER 2 OF 100 USPATFULL ACCESSION NUMBER: 2002:273409 USPATFULL TITLE: Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s; and treatments for vascular indications Davis, Harry R., Berkeley Heights, NJ, UNITED STATES INVENTOR(S): Roseglou, Teddy, Jamison, FA, UNITED STATES Picard, Gilles J., Brussels, BELGIUM PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation) NUMBER KIND DATE ...... US 2002151536 Al 20021017 US 2002-57323 Al 20020125 (10) PATENT INFORMATION: APPLICATION INFO.: NUMBER DATE -------PRIORITY INFORMATION: MS 2001-264336P 00010126 (6%) MS 2001-323939P 20010921 (6.) DOCUMENT TYPE: Mutility DOCUMENT TYPE: FILE SEGMENT: APPLICÁTION LEGAL REPRESENTATIVE: .....HERING-FLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1490), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,

NUMBER OF CLAIMS: 101

07033-1530

EXEMPLARY CLAIM: 1
LINE COUNT: 5304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted peta.-lastam sterol absorption inhibitor which can be useful for treating vas-ular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 3 OF 100 USPATFULL

ACCESSION NUMBER: 2000:272801 USPATFULL

TITLE: Sompositions and methods for the therapy and diagnosis

of colon cancer

INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES

Mu, Jiangshun, Bellevue, WA, UNITED STATES Chenault, Ruth A., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104

(U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2002150922 A1 20021017
APPLICATION INFO.: US 2001-998598 A1 20011116 (9)

PRIORITY INFORMATION: US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252322P 200001120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 9233

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L139 ANSWER 4 OF 100 USPATFULL

ACCESSION NUMBER: 2000::243051 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis

of ovarian cancer

INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES

Jines, Robert, Seattle, WA, UNITED STATES

Harlocke:, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Correction, Seattle, WA, UNITED STATES, 98104

(U.S. perporation)

NUMBER KIND DATE

PATENT INFORMATION: US 20021/3237 A1 20020919
APPLICATION INFO:: US 2001-867701 A1 20010529 (9

NUMBER DATE

PRIORITY INFORMATION: US 0000-207484P 20000546 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVE, SUITE 5300, SEATTLE, WA, 93104-7092

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25713

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian rancer, are disclosed. Illustrative compositions comprise one or more dvarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

### CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 5 OF 100 POTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 2002077155 PCTFULL ED 20021011 EW 200240

TITLE (ENGLISH): KERATINOCYTE GROWTH FACTOR-2

TITLE (FRENCH): FACTEUR DE CROISSANCE DES KERATINOCYTES-2

INVENTOR(S): RUBEN, Steven, M.; JIMENEZ, Pablo; DUAN, D., Roxanne; FAMFY, Mark, A.; MENDRICK, Donna; ZHANG, Jun; NI, Jian;

MOORE, Paul, A.; COLEMAN, Timothy, A.; GRUBER, Joachim,

R.; DILLON, Patrick, J.; GENTZ, Reiner, L.

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., for all designates States

except US; RUBEN, Steven, M., for US only; JIMENEZ, Pablo, for US only; DUAN, D., Roxanne, for US only; PAMFY, Mark, A., for US only; MENDRICK, Donna, for US only; CHANG, Jun, for US only; NI, Jian, for US only; MOORE, Paul, A., for US only; COLEMAN, Timothy, A., for US only; GRUBER, Joachim, R., for US only; DILLON,

Patrick, J., for US only; GENTZ, Reiner, L., for US

only

AGENT: STEFFE, Eric, K.

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

wo 0000077155 A2 00001003

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BC CA CH CN CO CR CU CC DE DK DM DZ EC EE ES FI GB GD GE GH GM HE HU ID

IL IN IS JP KE KG HP KR HZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH

GM KE LS MW MZ SD SL S2 TZ UG ZM ZW AM A2 BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG JI CM GA GN GQ GW ML MR NE SN

TD TG

APPLICATION INFO.: W0 0002-05101 A 00000104 PRIORITY 1MFO.: US 001-80/259,853 00010108

ABEN This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present

invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as KGF-2 also formerly known as Fibroblast Growth Factor 12 FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KSF-2 that show enhanced activity, increased stability, higher yield or ketter solubility.

La présenté invention concerne des polymucleotiqes, des polypeptides ABFR cines par des polynucleitides nouvellement lidentifies, l'utilisation de des polynucleotides et polygeptides, ainsi que la production de des polynucleitides et polypeptides. Plus pretisement, le polypeptide de la presente invention est un facteur de orbissance des keratinocytes, parfois signale di-dessous sous le nom generique de &#M2.64; KGF-2 %#x2265; et equilement connu sous le nom generique de facteur de proissance des fibroblastes 12 FGF-12). La presente invention concerne egalement l'utilisation therapeutique du KGF-2 pour promouvoir ou accelerer la dicatrisation. La presente invention concerne egalement de nouvelles formes mutantes du KGF-2 presentant une activite amelioree, une plus grande stabilite, un meilleur rendement ou une meilleure solubilité.

ANSWER 6 OF 100 POTFULL COPYRIGHT 3:00 Univentity

ACCESSION NUMBER: 2002063017 PCTFULL ED 20020827 EW 200233

TITLE (ENGLISH):

INTEGRINABINDING CHIMERAS

TITLE (FRENCH): INVENTOR(3):

CHIMERES POUVANT SE LIER A L'INTEGRINE

LU, Mingie; KAKKAR, Vigay, Vir

PATENT ASSIGNEE(S):

TRIGEN LIMITED, for all designates States except US;

LU, Minjie, for US only; KAKKAR, Vijay, Vir, for US

only

AGENT:

HARRISON GODDARD FOOTE

LANGUAGE OF FILING: LANGUAGE OF PUBL.:

English English

DOCUMENT TYPE: PATENT INFOFMATION: Patent NUMBER KIND DATE

DESIGNATED STATES

WO 2002063017 AD 00020915

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JE KE KG KE KE KE LO LK LE LS LT LU LV MA MD MG MK MIL MW MK ME NO NE OM PH PL PT RO KU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SC TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FP GB GR IE IT LU MC NL PT SE THEBE BUICF OG OI OM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

A 20020205 WO 2002-GB500

PRIORITY INFO.:

US 0001~60/267,234 20010205

ABEN Products which contain two interlinked functional moleties of which one is an integrin-binding protein (e.g. a snake venom protein) or a homologue thereof. The products comprise a first portion which is an integrin-binding protein, a homologue thereof having a bunding activity or a fragment of either which has integrin-binding activity, and, ligated to the first portion, a second portion which has a different function.

ABFE. L'invention concerne des produits qui contiennent deux fragments fonctionnels entrelaces dont l'un est une proteine de liaison a l'integrine (p. ex. une proteine du venin du serpent) ou un homologue de ladite proteine. Ces produits comprennent une première partie qui est une proteine de liaison a l'integrine, un homologue de ladite proteine ayant une activité de liaison, ou un fragment de l'un ou l'autre ayant une activite de liaicon a l'integrine; et une deconde partie liee a la premiere partie et ayant une fonction différente.

1139 ANSWER 7 OF 100 PCTFULL COPYRIGHT 2002 Univention Accession Number: 2002059733 PCTFULL ED 20020809 EW 200231

TITLE ENGLISH: DUMBINATIONS OF BILE ACID SEQUESTRANT(S: AND STEROL Absorption inhibitor's And Treatments for Vascular indications JUMBINAISONS DE CHELATEUR SU DES ACIDES BILIAIRES ET TITLE FRENCH: D'INHIBITEUR(C) D'ABSORPTION DES STEROLS, ET TRAITEMENTS POUR TROUBLES VASCULAIRES INVENTOR'S : NAMIS, Harry, R.; MOSCOLDU, Teddy PATENT ASSIGNEE(S): SCHERING CORPORATION AGENT: CARNINI, Ann, Marie LANGUAGE OF FILING: Eldlish. LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER. KIND DATE \_\_\_\_\_\_ W0 0000055733 A2 00020801 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CD CR DESIGNATED STATES CO DE DK DM DO EC EE ES FI GB GD GE HR HU ID IL IN IS UP KG KR KZ LC LK LE LT LU LV MA MD MG MK MN MX MC NO NO PH PL PT RO BU SE SG SI SK SL TJ TM TN TR TT TO UA UZ VN YU ZA CM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG HZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GR GR IE IT LU MO NL PT SE TR BE BU OF OG CI CM GA GN GQ GW ML MR NE SN TP TG A 20020125 APPLICATION INFO .: WO 2002-US2010 US 2001-60/303,842 20030931 PRIORITY INFO.: ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bule acid sequestrant; and (b) at least one substituted apetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. L'invention concerne des compositions, des combinaisons therapeutiques ABFR et des procedes reposant sur l'utilisation: (a) d'au moins un chelateur des acides biliaires; et (b) d'au moins un inhibiteur d'absorption des sterols d'azetidinone ou de beta-lactamine a substitution. Ces compositions, combinaisons therapeutiques et procedes peuvent etre utiles pour le traitement des troubles vasculaires, du diabete ou de l'obesite et pour la reduction du degre de concentration plasmique des sterols. ANSWER 8 OF 100 PCTFULL COPYRIGHT 2002 Univentio L139 ACCESSION NUMBER: 2002058732 FCTFULL ED 20020809 EW 200231 COMBINATIONS OF PEFOXISOME PROLIFERATOR-ACTIVATED TITLE (ENGLISH): RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOF(3) AND TREATMENTS FOR VASCULAR INDICATIONS COMBINAISONS D'ACTIVATEUR(S) DU RECEPTEUR ACTIVE PAR LE TITLE (FRENCH): PROLIFERATEUR DE PEROXYSOME ET D'INHIBITEUR(S) D'ABSORPTION DES STEROIS, ET TRAITEMENTS POUR TROUBLES VASCULATES INVENTOR(S): KOSOGLOU, Teddy; DAVIS, Harry, R.; PICARD, Gilles, Jean Bernard SCHERING CORPORATION PATENT ASSIGNEE(S): AGENT: CANNONI, Ann. Marie LANGUAGE OF FILING: English LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFOFMATION: MUMBER. KIND WG-2001054731 A2 20020801 AE AG AL AM AT AU AZ BA BB BG BR BY BE CA CH CN CO CR DESIGNATED STATES AND DE DY IM DO EC EE ES FI GB GD GE HR HU ID IL IN IS JP FG FR FZ LD LF LR LT LU LV MA MD MG MK MN MX MX NO NI PH PL PT NO BU SE SO SI SK SL TJ TM TN TB TT TI UA

```
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                        3B GR IE IT LU MO ML PT ME TR BF BJ OF MG OL MM GA GR
                        30 GW ML MR NÉ SN TO TG
APPLICATION INFO.:
                        WD 2002-WS0009 A 00020125
                        TW 2001-607164,396 00010108
TW 2001-60323,899 00010921
PRIORITY INFO.:
       The present invention provides compositions, therapeutic combinations
       and methods including: 'a 4t least one peroxisame proliferator-
       activated recepto: astivator; and (b) at least wine substituted
       azetidinine or substituted k-lastam sterol absorption innimitor which
       can be useful for treating vascular conditions, diabetes, obesity and
       lowering plasma levels of sterols.
       L'invention concerne des compositions, des combinaisons therapeutiques
ABFR
       et des procedes reposant su: l'utilisation: (a) d'au moins un activateur
       du recepteur active par le proliferateur de peroxysome; et (b) d'au
       moins un inhibiteur d'absorption des sterols d'azetidinone ou de
       beta-lactamine a substitution. Ces compositions, combinaisons
       therapeutiques et protodes peuvent etre utiles pour le traitement des
       troubles vasculaires, du diabete ou de l'obesité et pour la reduction du
       degre de concentration plasmique des sterols.
      ANSWER 9 OF 100 POTFULL COPYRIGHT 2002 Univention
ACCESSION NUMBER: 2002058731 PCTFULL ED 20020809 EW 200231
TITLE (ENGLISH):
                       COMBINATIONS OF STEEOL ABSORPTION INHIBITOR(S) WITH
                       CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR
                        CONDITIONS
                        COMBINAISONS B'INHIBITEUR(S) DE L'ABSORPTION DE STEROLS
TITLE (FRENCH):
                        ET D'AGENTS CARDIO-VASCULAIRES FOUR LE TRAITEMENT
                        L'AFFECTIONS VASCULAIRES
INVENTOR(S):
                        KOSOGLOU, Teddy; RESS, Rudyard, Joseph; STRONY, John;
                        VELTRI, Enrico, P.; HAUER, William
PATENT ASSIGNEE(S):
                        SCHEPING CORPORATION
AGENT:
                       CANNONI, Ann, Marie
LANGUAGE OF FILING:
                      English
                       English
LANGUAGE OF FUBL.:
DOCUMENT TYPE:
                        Patent
PATENT INFORMATION:
                        NUMBER
                                          KIND
                        WO 2002058731 A2 20020801
                        AE AG AL AM AT AU AZ BA BB BG BF BY BZ CA CH CN CO CP
DESIGNATED STATES
                        CX DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS
                        JP KG KE KZ LC LK LE LT LU LV MA MD MG MK MN MK MZ NO
                        NM PH PL PT BO RU SE SG SI SK SL TJ TM TN TR TT TZ UA
                        UZ VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
                        AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                        GB GF IE IT NU MO NE PT SE TR BF BJ OF OG OI CM GA GN
                        GO GW ML MR NE SN TO TG
APPLICATION INFO.:
                       Wo 2002-US1196 A 20020125
                                           20010126
PRIORITY INFO.:
                        us 2001-60/264,396
                                                20010108
                        us 2001-60/264,600

    US 2001-60/004,275
    20010106

    US 2001-80/3.3,342
    20010921

      The present invention provides compositions, therapeutic combinations
       and methods including: 'a. at least one sterol absorption inhibitor and
       (b) at least one pardiomascular agent different from the sterol
       absorption inhibitor, which can be useful for treating vascular
       conditions, chesity, diabetes and lowering plasma levels of sterols.
       L'invention concerne des methodes, des compositions, et des combinaisons
       therapeutiques contenant: 'a au moins un inhibiteur de l'absorption de
       sterols et (k) au moins un au-nt cardio-vasculaire different de
       l'inhibiteur de l'abstritit de stercls, utilisables pour traiter les
       affections vasculaires, l'obesite, et le diahete, et pour reduire le
       niveaux plasmatique des sterils.
```

ABEN

ABEN

ABFR

PZ VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

LIB9 ANSWER 10 OF 100 POTFULL COPYRIGHT 2000 Univention ACCESSION NUMBER: . 2000058696 PUTFULL ED 20020809 EW 200281 TITLE 'ENGLISH': THE USE OF SUBSTITUTED ALETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA UTILISATION DE COMPOSES D'AZETIDINONE SUBSTITUEE POUR TITLE (FRENCH): LE TRAITEMENT DE LA SITONTERGLEMIE INVENTOR(S): DAVIS, Harry, R. PATENT ASSIGNEE(S): SCHERING CORSORATION DANNUNI, Ann, Marie AGENT: LANGUAGE OF FILING: Erglish LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: FIND DATE NUMBER. WD 2002059696 A2 U0020801 AE AG AL AM AT AU AN BA BB BG BR BY BZ CA CH ON CO CR DESIGNATED STATES CO DE DK DM DO EO EE ES FI GB GD GE HR HU ID IL IN IS JE KG KR KO LO LK LE LT LU LV MA MD MG MK MN MK MO NO NO PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TO UA UE VN YU DA DM GH GM KE LS MW ME SD SL SE TE UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG WO 2002-US1195 A 20020125 APPLICATION INFO .: US 2001-60/204,645 20010126 PRIORITY INFO.: The present invention is directed to the use of sterol absorption ABEN inhibiting compounds, pharmacoutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided. L'invention concerne des composes inhibiteurs de l'absorption de ABFR sterols, des compositions pharmateutiques, des combinaisons therapeutiques, ainsi que leur utilisation en association a d'autres agents hypolipidemiants pour traiter ou prevenir la sitosterolemie et/ou reduire la concentration de sterol(s) autres que le cholesterol dans le plasma ou les tissus d'un mammifere. Par ailleurs, l'invention concerne des methodes de truitement ou de prevention des maladres vasculaires et des accidents vasculaires. ANSWER 11 OF 100 POTFULL COPYRIGHT 2000 Univentio L139 ACCESSION NUMBER: 20000058685 PCTFULL ED 20020809 EW 200231 COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF TITLE (ENGLISH): AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS COMBINALSONS D'ACIDE NICOTINIQUE ET DE DERIVES DE CE TITLE (FRENCH): DEFNIER, INHIBITEUR(S) D'ABSORPTION DE STEROLS ET TRAITEMENTS DE CONDITIONS VASCULAIRES INVENTOR(S): DAVIS, Harry, R.; KOSOGLOU, Teddy SCHERING CORPORATION PATENT ASSIGNEE(S): CANNONI, Ann. Marie AGENT: LANGUAGE OF FILING: English

LANGUAGE OF PUBL.:

English Patent

PATENT INFOFMATION:

DCCUMENT TYPE:

NUMBER HIND \_\_\_\_\_\_\_ WD D00205868 A2 10000801

DESIGNATED STATES

AE AG AL AM AT AT AZ BA 5B BG ER BY BZ CA CH CN CO CR ON LE DK DM DO ET EE ES FI GB GD GE HR HU ID IL IN IS JP FG KR KU LO LY LR LT LU LV MA MD MG MY MW MX MX NO NZ PH PL PT RO RU SE SG JI JK SL TJ TM TN TR TT TZ VA

```
WZ VN YW ZA ZM GH GM KE LS MW MZ SD SL SZ TZ WG ZM ZW
                  AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                  GR GR IE IT LU MO ML PT SE TR BF BT OF OG CL CM GA GN
                  BY GW MI MR ME SM TO TG
                  WD . 01-US1014
                                       A 1.00201.15
                                      ..0010126
                  us 1:01-61 284,275
                  T3 : 01-65 323,842
                                          100109.:1
 The present invention provides compositions, therapeutic combinations
 and methods including: At at least one of nicotinic acid or derivatives
 there:f; and (b) at least one substituted azetidinone or substituted
 k-lactam sterol absorption inhibitor which dan we useful for treating
 vascular conditions, diabetes, obesity and lowering plasma levels of
L'invention concerne des procedes, compositions et combinaisons
 therapeutiques renfermant a. au moins un element parmi l'acide
 nicotinique et des dérives de ce dérnier et b) au moins un inhibiteur
 d'absorption de sterols azetidinone substitue ou β-lactame
 substitue pouvant etre utile pour traiter des conditions vasculaires, le
 diabete, l'obesité et pour abaisser la concentration plasmique de
ANSWER 12 OF 100 POTFULL COPYRIGHT 2000 Univentio
                 2002057273 PCTFULL ED 20020801 EW 200230
                  SERIME PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND
                  ACCEPTOR
                  INHIBITEURS DE LA SERINE PROTEASE COMPRENANT UN
                  ACCEPTEUR DE LIAISON HYDROGENE
                  DEADMAN, John, Joseph; SPENCER, John; GREENIDGE,
                  Paulette, Angela; GOODWIN, Christopher, Andrew; KAKKAR,
                  Vijay, Vir; SCULLY, Michael, Finbarr
                  TRIGEN LIMITED, for all designates States except US;
                  DEADMAN, John, Joseph, for US only; SPENCER, John, for
                  US only; GREENIDGE, Paulette, Angela, for US only;
                  GOODWIN, Christopher, Andrew, for US only; KAKKAR,
                  Vijay, Vir, for US only; SCULLY, Michael, Finbarr, for
                  US only
                  HARRISON GODDARD FOOTE
                  English
                  English
                  Patent
                  NUMBER
                                    KIND
                                              DATE
                  WO 2002057273 A1 20020725
                  AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                  CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                  IL IN IS JE KE KG KE KR KZ LO LK LE LS LT LU LV MA MD
                  MG MK MN MW MK MZ NO NZ OM PH PL PT RO RU SD SE SG SI
                  SK SL TJ TM TN TR TT TO UA UG US UD VN YU DA ZM ZW GH
                  GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD
                  RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
                  NL PT SE TH BE BUICE OG CI CM GA GN GQ GW ML MR NE SN
                  T \subseteq T \subseteq
                  WO 2002-GED24
                                       A 20020113
                  GB 2001-0101537.9
                                          20010120
                  US 1001-60/267,172
                                          20010206
 Compounds, useful as protease inhibitors, of the formula (I): Where: Ar
 ring system, for example a kenzene ring, and may be substituted by one
 or more moieties
 in addition to "X and "LJ; X is a functional group which is a
 hydrogen-bond accepto:,
```

e.g. a nitro or boronate group BY/sp>1</sp>Y/sp>2</sp>; L is a linker,

rreferably (CR<sp>5</sp>6</sp>:-S-; U is a molety containing a

APPLICATION INFO.:

sterils.

sterols.

ACCESSION NUMBER:

PATENT ASSIGNEE(S):

LANGUAGE OF FILING:

LANGUAGE OF PUBL.:

PATENT INFORMATION:

DESIGNATED STATES

APPLICATION INFO .:

is a ring or

PRIORITY INFO.:

ABEN

DOCUMENT TYPE:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PRIORITY INFO.:

ABEN

ABFR

T.133

AGENT:

```
amino, carboxamido, hydroxylamino, or imidazolyl, or an N-substituted
      analoque
      thereof.

    L'invention concerne des composés utilisés comme inhibiteurs de

ABFR
      protease representes par la formule (I). Dans cette formule, Ar
      represente un novau ou un système dyplique, par exemple, un noyau
      menzenique,
      et peut etre substitue par au moins une fraction en plus de X et LJ; X
      represente un groupe fonctionnel accepteur de liaison hydrogene,
      par exemple, un groupe nitro ou boronate BY(sp-10/sp>Y0sp-20/sp-; L
      represente
      un liant, de preference (CEKsp>5K/sp>ESp>6M/sp>)-3-; Z represente
      une fraction contenant un atome d'azote basique mais ne contenant pas de
      residu d'acide amine, et contenant de preference amidino,
      quanidino, amino, carboxamido, hydroxylamino, ou imidazolyl, cu un
      analogue
      de beux-di substitue par un N.
      ANSWER 13 OF 100 FOTFULL COPYRIGHT 1002 Univentio
ACCESSION NUMBER: 2001047582 PCTFULL ED 20000709 EW 200225
                       EMPANDABLE STENT WITH SLIDING AND LOCKING RADIAL
TITLE (ENGLISH):
                       ELEMENTS
TITLE (FRENCH):
                       EXTENSEUR DILATABLE COMPORTANT DES ELEMENTS DE
                       COULISSEMENT ET DE VERROUILLAGE RADIAL
INVENTOR(S):
                       STEINKE, Thomas, A.; KOENIG, Donald, H.
                     MD3, INC., for all designates States except US;
PATENT ASSIGNEE(S):
                       STEINKE, Thomas, A., for US only; KOENIG, Donald, H.,
                       for US only
AGENT:
                      ALTMAN, Daniel, E.
LANGUAGE OF FILING:
                     English
LANGUAGE OF FUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBEE.
                                        KIND DATE
                       WO 2002047582 A2 20020620
                       AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
DESIGNATED STATES
                       CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE
                       GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
                       LT LU LV MA MD MG MK MN MW MX MC NO NZ PH PL PT RO RU
                       SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG U3 U2 VN YU
                       DA DW GH GM KE LS MW MD SD SL SD TZ UG DM DW AM AZ BY
                       KG KZ MD PU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE
                       IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML
                       MF NE SN TD TG
PRIORITY INFO:: US DODG 00:771
                                           A 20011.111
                       US 2000-09/739,552
                                          20/01214
ABEN
      The present invention provides a lumen support stent with a clear
      through-lumen
      for use in a body lumen. The stent is formed from at least one series of
      sliding and
      locking radial elements and at least one ratcheting mechanism comprising
      articulating element and a plurality of stops. The ratcheting mechanism
      the-way sliding of the radial elements from a collapsed diameter to an
      explanded
      diameter, but inhibits radial recoil from the empanded diameter.
ABFR
      L'invention concerné un extenseur de support concu pour etre
      mis en application dans une lumière anatomique et comportant un passage
      depourvu d'obstacle. Cet extenseur est constitue par au moins
      une serie d'elements de coulissement et de verrouillage
```

nitrogen atom but not containing an amino acid residue, preferably

basic

amidino, quanidino,

radial et par au moins un mecanisme d'encliquetage comprenant un element d'articulation et une pluralité de putées. Ce mécanisme d'encliquetage permet à ces elements de coulisser dans un sens radial unique depuis un diametre d'affaissement à un diametre de dilatation, mais empeché le retrecissement

1139 ANSWER 14 OF 100 POSFULL SUPPYFIGHT 1:00 Univertic

radial depuis le diametre de dilatation.

ACCESSION NUMBER: 210: 44736 PUTFULL ED 20020624 EW 210223

TITLE (ENGLISH): DIA MOSIS AND TREATMENT OF DISEASE TITLE (FRENCH): DIA GNOSTIC ET TRAITEMENT DE MALADIE

INVENTOR(S): TAZI-AHNINI, Bachid; BAVIK, Claes; WARD, Simon; DUFF,

Gordon; CORK, Michael

PATENT ASSIGNEE(S): MOLECULAR SKINCARE LIMITED, for all designates States

except US; TAZI-AHNINI, Rachid, for US only; BAVIK, Class, for US only; WARD, Simon, for US only; DUFF, Gordon, for US only; CORK, Michael, for US only

AGENT: KHOO, Chong-Yee

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE
Wo 2002044736 A2 20020606

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BE BY BZ CA CH CN CO CR

CU CC DE DK DM D3 EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP RE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MM MZ NO M2 OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT T3 UA UG US UC VN YU ZA ZM ZW GH GM KE L3 MW M3 SD SL SZ T2 UG ZM ZW AM AZ BY KG KZ M0 RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL

PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD

TG

APPLICATION INFO.: WD 2001-GB5303 A 20011130 PRIORITY INFO.: GB 2000-0029879.4 20001207

ABEN We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an

individual.

ABFR L'invention concerne un methode de diagnostic d'une maladie, ou de susceptibilite a une maladie, associée à une adhésion celule-cellule anormale entre des cellules épithéliales, la methode consistant à détecter, chez un individu, une mutation dans un acide nucleique codant pour une proteine d'adhésion, une protease, ou un inhibiteur de protease.

L139 ANSWER 15 OF 100 POTFULL COPYRIGHT 2002 Univentie

ACCESSION NUMBER: 2000039997 POTFULL ED 20020610 EW 200221

TITLE (ENGLISH): ACE: MODULATING COMPOUNDS AND METHODS OF USE THEREOF TITLE (FRENCH): COMPOSES MODULANT ACE: ET PROCEDES D'UTILISATION

ASSOCIES

INVENTOR(S): ACTEM, Susan, L.; OCARM, Timothy, D.; GOULD, Alexandra,

E.; DALES, Natalie, A.; GUAN, Bing; BROWN, James, A.; PATANE, Michael; KADAMBI, Vivek, J.; SOLOMON, Michael;

STRINKER-KEONGRAD, Alain

PATENT ASSIGNEE(S): MILLENNIUM FHAFMACEUTITALS, INC., for all designates

States except US; ACTON, Susan, L., for US only; CCAIN, Tim.thy, D., for US only; GOULD, Alexandra, E., for US only; DALES, Natalie, A., for US only; GUAN, Bing, for

US inly; BROWN, Tames, A., for US only; PATAME,

Michael, for US only; KADAMBI, Vivek, J., for US only;

```
SCLOMON, Michael, for US only; STRICKER-KRONGRAD,
                       Alain, for US only
AGENT:
                       HANLEY, Elizabeth, A.
                       English
LANGUAGE OF FILING:
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                        KIND DATE
                       W0 L000034997 AJ 0000523
                       AE AG AL AM AT AU AC BA BB BG BR BY BZ CA CH ON CO CR
DESIGNATED STATES
                       CU OU DE DK DM DU EU EE ES FI GB GD GE GH GM HR HU ID
                       IL IN IS IF HE HIGHER HALLS LT LU LV MA MD
                       MG MK MN MW MX MU NO NO DM PH PL PT RO RU SD SE SG SI
                       SK OL TJ TM TR TT TO UA UG US UZ VN YU ZA ZW GH GM KE
                       LE MW MZ DD SE SC TO UG DW AM AD BY KG KZ MD RU TJ TM
                       AT BE CHOR DE DK ES FI FR GB GR IE IT LU MC NL PT SE
                       TR BE BU OF DG OF CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:
                       W0 2001-U345703 A 20011031
                                          20001101
                      US 2000-04/704,216
PRIORITY INFO.:
                       US 2001-04/871,382
                                              20010529
                       US 2001-69/371,741
                                             20011019
ABEN
      ACE 2 modulating compounds for the treatment of body disorders are
      disclosed. Methods of using the compounds and pharmaceutical
      compositiosh containing the compounds are also claimed.
ABFR
      L'invention concerne des composes modulant ACE-2, destines au traitement
      de problemes de poids. L'invention concerne egalement des procedes
       d'utilisation de des composes et des compositions pharmaceutiques
      contenant lesdits composes.
L139
      ANSWER 16 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002029062 PCTFULL ED 20020627 EW 200215
                      CYTOKINE PROTEINS
TITLE (ENGLISH):
                      PROTEINES CYTOKINE
TITLE (FRENCH):
                      FAGAN, Richard, Joseph; PHELFS, Christopher, Benjamin;
INVENTOR(S):
                       GUTTERIDGE, Alex
                      IMPHARMATICA LIMITED, for all designates States except
PATENT ASSIGNEE(S):
                       US; FAGAN, Richard, Joseph, for US only; PHELPS,
                       Christopher, Benjamin, for US only; GUTTERIDGE, Alex,
                       for US only
AGENT:
                       MERCEP, Christopher, Faul
LANGUAGE OF FILING:
                       English
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                       KIND DATE
                       ......
                       WO 2002029062 AD 20020411
                       AE AG AL AM AT AU AJ BA BB BG BF BY BJ CA CH CN CO CR
DESIGNATED STATES
                       CU CO DE DK DM DO EC EE ES FI GB GD GE GH GM HE HU ID
                       IL IN IS JE HE KG KE KE KE LC LK LE LS LT LU LV MA ME
                       MG MK MN MW MX MD NO ND PH PL PT RO RU SD SE SG SI SK
                       SE TU TM TE TT TO UA NO US UZ VN YU DA DW GH GM KE ES
                       MW MC SD SL SZ TC UG CW AM AZ BY KG KC MD RU TC TM AT
                       BE OH OY DE DK ED FI FF GB GR IE IT LU MO NL PT SE TR
                       BE BU OF OG OI OM GA GN GQ GW ML ME NE BN TD TG
APPLICATION INFO .:
                     WC .:001-GB4412
                                           A 20011004
                      GB 2000-0004283.4
                                             .:0001004
PRIORITY INFO.:
      This invention relates to havel proteins, termed the CC1 and CC2
      polypeptides, herein identified as sytckines and to the use of these
      proteins and nucleic acid sequences from the encoding genes in the
      diagnosis, prevention and treatment of disease.
ABFR
      La presente invention concerne de nouvelles proteines, denommees
      polypeptides CC1 et CC2, identifices commo etant des cytokines, ainsi
       que l'utilisation de des proteines et de sequences d'acide nucleique de
```

genes codants dans le diagnostic, la prevention et le traitement de maladie.

1139 ANSWER 17 OF 100 EUROPATFULL COPYRIGHT 1000 WILA

GRANTED PATENT - ERTEILTES FATENT - BREVET DELIVAE

994848 EUROPATFULL EW 200201 FS PS AGCESSION NUMBER:

SELECTIVE FACTOR MA INHIBITORA CONTAINING A FUSED TITLE:

AZEPINONE STRUCTURE.

SELEKTIVE INHIBITOREN DES FAKTORS X, EINE

AZEPINONSTRUKTUR ENTHALTEND.

INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE

STRUCTURE D'AZERINONE CONDENSEE.

STARBURGUGH, Robert, M., 2544 Belmont Canyon Road, INVENTOR(S):

Belmont, CA 94002, US

COR THERAPEUTICS, INC., 1156 East Grand Avenue, Suite 80, PATENT ASSIGNEE(S):

South San Francisco, CA 94080, US

PATENT ASSIGNEE NO: 1193.100

Doireau, Marc et al., Cabinet Ores 6, avenue de Messine, AGENT:

7500% Paris, FR

AGENT NUMBER: 44325

OTHER SOURCE: BEFB1002001 EP 0994893 B1 0063

Wila-EPS-2002-H01-T1 SOURCE:

DOCUMENT TYPE:

Patent Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R

GB; F GF; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

FATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE FATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

INVENTOR:S;:

KIND DATE PATENT NO \_\_\_\_\_ B1 20020102 EP 994393 'OFFENLEGUNGS' DATE:
APPLICATION INFO.: EP 1393-939911 19930811
PRIORITY APPLN. INFO.: US 1997-82316 19970811
US 1997-907779 19970811
RELATED DOC. INFO.: WD 98 US16704 980811 INTAKE
WD 9907730 990218 INTPNR 20000426

REFERENCE PAT. INFO.: WO 97-05160 A

REF. NON-PATENT-LIT.: J A FOBL ET AL.: "Dual metalloprotease inhibitors. II.

Effect of substitution and stereochemistry on

benzazepinone based mercaptoacetyls" BIOORGANIC AND

MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 15, 1994, pages 1795-1800, KP000196070 Amsterdam J A FOBL ET AL.: "Dual metalloprotease inhibitors. 6. Incorporation of bicyclic

and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors" JOURNAL OF MEDICINAL AND

PHARMACEUTICAL CHEMISTRY., vol. 39, 1996, pages 494-502,

XP000743701 EASTON US

ANSWER 18 OF 100 EMPOPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVEE

3220-4 ACCESSION NUMBER: EUROPATFULL EW 200233 FS PS

ANTIOMAGULANI PERTIDYL-ARGININE ALDEHYDE DERIVATIVES. TITLE:

ANTIFCAGULIEREND WIRKENDE PEPTIDYL-ARGININ ALDEHYD

PERIMATE.

DERIVES DE PEPTIDYL-ARGININE ALDEHYDE ANTICOAGULANTS. BAJUNG, Sandor, Derek u. 16/a, H-1916 Budapest, HU;

JUHA. 2, Attila, Petnehazy u. 13, H-1139 Budapest, HU;

BARABAS, Eva, Pusztaszeri ut 6, H-1025 Budapest, HU;

FEHER, Andras, Tuzko u. 6, H-1118 Budapest, HU; SZABO, Gapriella, Vaci ut 8, H-1132 Budapest, HU; SZELL, Erzsebet, Heves u. 64, H-1106 Budapest, HU; VEGHELYI, Iren, Lahanz u. 6/b, H-1921 Budarest, HU; LAVINH, Emilia, Frankovins M. u. 33, H-1151 Budapest, HU; KASZAS, Eva, Nyar v. 69, H-1045 Budapest, HU; LANGO, Jurset, Amfiteatrum 1. 11, H-1031 Budapest, HU; MURAVOSIK, Imre, Mester u. 38, H-1095 Budapest, HU; SZEKHR, Agnes, Deak F. u. 81, H-1041 Budapest, HU; TASCHLER, Zsuzsanna, Amfiteatrum u. 27, H-1031 Budapest, HU; TOTH, Gabor, Veres P. u. 74, H-1163 Budapest, HU; MDHAI, Isuzsanna, Baratka u. 48, H-1173 Budapest, HU; SZALKAY, Anna Maria, Szoedliget u. 10, H-1151 Budapest, MAKK, Klara, Liget u. 26, H-2623 Kismaros, HU GYOGYGDERKUTATO INTEZET KFT., Berlini u. 47-49, H-1045 PATENT ASSIGNEE(S): Budapest, HU PATENT ASSIGNEE NO: 1663100 AGENT: Beszedes, Stephan G., Dr., Patentanwalt, Muenchener Strasse 80a, 85221 Dachau, DE AGENT NUMBER: 1931 OTHER SOURCE: BEPB3002057 EP 0922054 B1 0025 SOURCE: Wila-EPS-2002-H33-T1 DOCUMENT TYPE: Patent Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R DESIGNATED STATES: GF; F IE; R IT; R LI; R LU; R MC; R NL; R FT; R SE PATENT INFO.PUB.TYPE: EFB1 EUFOPAEISCHE PATENTSCHRIFT (Internationale Anmeldung) PATENT INFORMATION: PATELT NO KIND DATE EP 900054 Bl 20020814 19990616 'OFFENLEGUNGS' DATE: EP 1997-925210 19970605 APPLICATION INFO.: PRIORITY APPLN. INFO.: HU 1996-9601526 19960605 WO 97-HU28 970605 INTAKE WO 9746574 971041 INTAKE RELATED DOG. INFO.: WO 9746576 971211 INTPNR REFERENCE PAT. INFO.: EP 19539 A EP 479489 US 4703036 A L139 ANSWER 19 OF 100 IFIPAT COPYRIGHT 2002 IFI 10203477 IFIPAT; IFIUDB; IFICDB AN TITLE: COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS Kosoglou; Teddy, Jamison, PA, US INVENTOR(3): Erss; Rudyard J., Flemington, NJ, US Strony; John T., Lebanon, NJ, US Veltri; Enrico P., Princeton, NJ, US PATENT ASSIGNEE(S): Schering Corporation AGENT: SCHEFING-PLOUGH CORPORATION PATENT DEPARTMENT (K-6-1, 1930), 2000 GALLOPING HILL FOAD, KENILWORTH, NJ, 0703340530, US NUMBER PK DATE U. .: 0002147134 A1 20021610 PATENT INFORMATION: 20020125 APPLICATION INFORMATION: U.S. 1002-56630 NUMBER DATE \_ :- :- - -:- :- - :- - :- - :-V3 2001-264275P20010136 (Provisional: UU 2001-264396P20010126 (Provisional)

US .001-264600P20010126 Provisional: US []]]1-324123P2001092. (Provisional)

FAMILY INFORMATION: ys M002147184 20021010

POCUMENT TYPE:

Utility

Patent Application - First Publication

FILE SEGMENT: CHEMICAL APPLICATION

NUMBER OF CLAIMS:

4.5

Ab The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

CLMN 48

L139 ANSWER 20 OF 100 USPATFULL

ACCESSION NUMBER: 2001:63240 USPATFULL

TITLE:

Pharmaceutical preparation for treating klood

ccaqulation disorders

INVENTOR(S):

Turecek, Peter, Klosterneukurg/Weidling, Austria

Schwarz, Hans-Feter, Vienna, Austria

Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S):

Baxter Aktiengesellschaft, Vienna, Austria (non-U.S.

corporation)

NUMBER KIND DATE \_\_\_\_\_ PATENT INFORMATION: US 6224862 B1 20010501 APPLICATION INFO.: US 2000-521219 20000308 (9)

APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1999-245339, filed on 5 Feb

1999 Division of Ser. No. US 1998-165745, filed on 6 Oct 1998, now patented, Pat. No. US 6039945 Division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb 1999

NUMBER DATE ERIORITY INFORMATION: AT 1996-513 19960320 AT 1996-1573 19960920 AT 1996-1673 19960920 DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
FRIMARY EXAMINER: Weddington, Kevin E.

LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe

NUMBER OF CLAIMS: 4

1

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s) LINE COUNT: 1454

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 21 OF 100 FOTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 20010W3290 FCTFULL ED 20020822

TITLE (ENGLISH):

-BOMP-7 AS MARKER FOR DIAGNOSIS OF BREAST CANCER

TITLE (FRENCH):

BOMP 7 EN TANT QUE MARQUEUR POUR LE DIAGNOSTIC DU

CANCER DU SEIN

INVENTOR(S):

BOYD, Robert, Simon; STAMPS, Alasqair, Craig; TERRETT,

Jonathan, Alexander; TYSON, Kerry, Louise

PATENT ASSIGNEE(S): OXFORD GLYCOSCIENCES (UK) LTD.; BOYD, Robert, Simon; STAMPS, Alasdair, Graig; TERRETT, Conathan, Alexander;

TYSCN, Kerry, Louise

PATENT INFORMATION: NUMBER

KIND DATE WO 0.401063090 A1 20010830

DESIGNATED STATES

AE AJ AL AM AT AU AZ BA BB BG BE BY BZ CA CH CN CR CU GZ DE DK DM DZ EE E3 FI 35 GD JE 3H 3M HR HU ID IL IX IS TO KE HIS KO KR KI LO IN IR IS IT LU LV MA MD MI MK MN: MW MX MO NO NO PL PT RO RU SD SE SG SI SK SL TA TM THE TT TZ MA MG MS MZ MN YM ZA DW GH GM KE LS MW MD SD SE GD TZ MG ZW AM AC BY HG KZ MD RU TJ TM AT BE CH CY DE DE ES FI FR GB GR IE IT LU MO NL PT SE TR BF B' OF OG DI OM GA GN OW ML MR NE SN TO TG

APPLICATION INFD.: PRICRITY INFO.: W0-0001-GB/34 A 00010001 GB 2000-0004576.5 20000225

The present invention provides the use of a protein found in breast ABEN cancer cell membranes, known as BCMP 7, in the diagnosis, screening, treatment and prophylaxis of breast cancer, as well as compositions comprising BCMP 7, including vaccines and antibodies that are immunospecific for BUMP 7.

La presente invention concerne l'utilisation d'une proteine presente ABFR dans des membranes collulaires de cancer du sein, connue en tant que BCMP 7, dans le diagnostic, le criblage, le traitement et la prophylaxie du cancer du sein. L'invention concerne egalement des compositions contenant BCMP 7 et des vaccins et anticorps immunospecifiques a BCMP 7.

L139

ANSWER 22 OF 100 POTFULL COPYRIGHT 2000 Univentie

ACCESSION NUMBER: 2001062085 PCTFULL ED 20020822

TITLE (ENGLISH):

PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND

USES THEREFOR

TITLE (FRENCH):

FORMES PROTEGEES D'AGENTS PHARMACOLOGIQUEMENT ACTIFS ET

UTILISATIONS CORRESPONDANTES

INVENTOR(S):

LAI, Ching-San; WANG, Tingmin; VASSILEV, Vassil, P.

MEDINON, INC. PATENT ASSIGNEE(S):

DOCUMENT TYPE:

PATENT INFOFMATION:

Patent

KIND DATE NUMBER WO 2001062085 Al 20010830

DESIGNATED STATES

AE AG AL AM AT AU AC BA BB BG BR BY CA CH CN CR CU CE DE DK DM DZ EE E3 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MM MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG 2W AM AZ BY KG KX MD KU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA ON GW ML MR NE 3N TO TG

APPLICATION INFO.:

WO 0001-US5977 A 00010003 US 0000-09/515,043 00000005

PRIORITY INFO.:

In accordance with the present invention, there are provided conjugates ABEN of dithipparbamates "" $\overline{\text{DC}}$ ") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., unti-inflammatory agents) which cause a much lower incidence of side-eftwats due to the protective effects imparted by modifying the pharma clogically active agents as described herein.

La presente invention se rapporte a des conjugues de dithiocarbamates ABFF. ("DC") et a des agents pharmacclogiquement actifs (par exemple, des AINS). Lesdits conjugues formissent une nouvelle classe d'agents pharmacologiquement actifs 'pa: exemple, d'agents anti-inflammatcires) qui providuent une arganition kien moindre d'effets secondaires en raison des effets protecteurs conferes par la modification des agents pharmabologiquement actifs decrits di-descus.

ANSWER 23 OF 100 POTFULL COPYRIGHT 2002 Univentic ACCESSION NUMBER: 2001057210 POTFULL ED 20020827

TITLE \*ENGLISH:: USE OF DENDROASPIN AS A VEHICLE FOR NON-DENDROASPIN DIMAINS UTILISATION DE DENDROASPINE EN TAKT QU'EXCIPIENT POUR TITLE (FRENCH): DIMAINES EXEMPTS DE DENDROASPINE INVENTOR:S;: II, Kinjie; HARKAR, Vijay, Vir TRIGEN LIMITED PATENT ASSIGNEE(S): DOCUMENT TYPE: Patent PATENT INFORMATION: FIND DATE NUMBER \_\_\_\_\_ W0 130:057:10 A2 . 010809 AE AG AL AM AT AU AC BA BB BG BR BY BC CA CH CN CR CU DESIGNATED STATES DE DE DE DE DE DE ES FI GE GD GE GH GM HE HU ID IL IN IS JP KE KG KP KR KD LC LK LR LS LT LU LV MA MD MG MK ME: MW MX ME NO NE PL PT RO BU SO SE SG SI SK SL TE TM TH TT TZ WA WG WE VIN YW DA ZW GH GM KE LS MW MZ SD SL 32 TO UG OW AM AC BY MG MO MO BU TU TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG OI CM GA GH GW ML MR NE BH TD TG APPLICATION INFO.: W0 2001-GB439 A 20010205 PRIORITY INFO.: GB 2000-0002625.2 20000205 The use of dendroaspin as a scaffold for one or more non-wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-binding amino acid sequence other than RGD which contains aspartic acid (D) or glutamic acid (E). ABFR L'invention concerne l'utilisation de dendroaspine en tant que structure pour au moins un domaine de dendroaspine qui n'est pas du type sauvage, la structure de dendroaspine etant modifiée du fait que le motif endagene RGD a ete elimine ou remplace (i) par une sequence d'acides amines ne possedant pas d'activité de liaison aux integrines ou (ii) par une sequence d'acides amines se liant aux integrines qui differe de RGD et renferme de l'acide aspartique (D) ou de l'acide glutamique (E). L133 ANSWER 24 OF 100 POTFULL COPYRIGHT 2000 Univention ACCESSION NUMBER: 2001049675 PCTFULL ED 20020827 DIHYDROBENGORYRANS, DIHYDROBENZOTHIOPYRANS, AND TITLE (ENGLISH): TETRAHYDROQUINGLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS TITLE (FRENCH): DIHYDROBENCOPYRAINES, DIHYDROBENZOTHIOPYFANNES ET TETRAHYDROQUINOLINES DESTINES AU TRAITEMENT DES TEOUBLES INDUITS PAR COX 0 ROGIER, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, INVENTOR(S): John, J. PATENT ASSIGNEE(S): PHARMACIA CORPORATION; ROGIEF, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, John, J. DOCUMENT TYPE: Patent PATENT INFORMATION: KIND DATE NUMBER WO 1,001049678 Al 20010712 AL AM AT AU AJ BA BB BG BR BY CA CH CN CU CJ DE DK EE DESIGNATED STATES ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR HZ LC LK LE LD LT LU LY MD MG ME MN MW MM NO NO PL PT RO EN SD SE SG SI SK SL TJ TM TR TT UA UG US US VN YU SW GH GM KE LS MW ME SD SL DE TE UG EW AM AZ BY KG KE ME AU TU TM AT BE CHOY DE DR ES FI FR GB GR LE IT LU MO NU PT SE TH SE BU OF OG UI CM GA GN GW ML MR NE SN TD TGAPPLICATION INFO.: W0 1 000-0034525 A 00061219 PRIORITY INFO.: U8 2 00-60/174,281 00000103 ABEN A class of dihydrobenzopyrans, dihydrokenzothiopyrans, tetrahydroguinolines, tetrahydronaphthalenes, and analogs thereof, is

described for use in treating cyclockygenase-2 mediated disorders.

Compounds of particular interest are defined by Formula (I. wherein X, A1, A2, A3, A4, R, R'', R1 and R2 are as described in the specification. ABFR L'invention concerne une categorie de dihydrokenzopyrannes, dihymropenzothiopyrammes, tetranydroquinolines, tetranydronaphthalenes, et leurs analoques, destines a etre utilises dans le traitement des troubles induits par la byplooxygenase-2. Les composes presentant un interet particulier sont representes par la formule (1), ou X, Al, A2, A3, A4, R, R'', R1 et R2 sont tels que definis dans le descriptif.

ANSWER 25 OF 100 POTFULL COPYRIGHT 2002 Univentia L139

ACCESSICN NUMBER: 2001021661 POTFULL ED 2 0020620

TITLE (ENGLISH): BIVALENT INHIBITOR OF FVIIA/TF, FXA COMPLEX TITLE (FRENCH): INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa
INVENTOR(S): FRESKGAARD, Per-Dla; JAKOBSEN, Palle
PATENT ASSIGNEE(S): NOVO NORDISK A/S; FRESKGAARD, Per-Dla; JAKOBSEN, Palle

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE 

Wolld01021661 A1 00010309 AE AG AL AM AT AU AZ BA EB BG BR BY BZ CA CH CN CE CU DESIGNATED STATES

CO DE DK DM DZ EE ES FI OB OD GE GH SM HR HU ID IL IN IS JE KE KG KE KE KE LO LK LE LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT SO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA DW GH GM KE LS MW MZ SD

SL SE TE UG EW AM AS BY KG KE MD FU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

CI CM GA GN GW ML MP NE 3N TD TG

Wo 2000-DK516 A 20000919 APPLICATION INFO.: DK 1999-PA 1999 01333 19990920 US 1999-60/159,773 19991015 PRIORITY INFO.:

ABEN A novel bivalent serine protease inhibitor (I) of coagulation factor VIIa and factor Xa comprises: (i) a first serine protease inhibitor binding to factor VIIa; (ii) a linker monety; and (iii) a second serine protease inhibitor bunding to factor Xa. Also claimed are a method for inhibiting the two different serine protesses factor VIIa and factor Xa simultaneously and selectively when the two serine proteases becomes localised on the membrane protein tissue factor. The compounds and method are useful for prevention or treatment of FVIIa/TF-related diseases or disorders such as deep venous thrombosis, arterial thrombosis, post surgical thrombosis, coronary artery bypass graft (CABG), percutaneous transdermal coronary angioplastry (PTCA), stroke, tumbur metastasis, inflammation, septic chock, hypotension, AFDS, pulmonary embolism, disseminated intravascular coagulation (DIC), vascular restenosis, platelet deposition, myocardial infarction, angregenesis, or the prophylactic treatment of mammals with atherosclerotic vessels at risk for thrombosis.

ABFR

ANSWER 26 OF 100 POTFULL COPYRIGHT 1002 Univentio L139

ACCESSION NUMBER: 2001021259 FCTFULL ED 20020820

TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED

DISCRDERS

TITLE (FRENCH): PROCEDES ET COMPOSITIONS DE TRAITEMENT DES PATHOLOGIES

APPARENTEES AUX PLAQUETTES

INVENTOF(3): HANSON, Stephen, R. PATENT ASSIGNEE(3): EMORY UNIVERSITY

DCCUMENT TYPE: Patent

PATENT INFORMATION:

FIND DATE NUMBER Wo 1001021259 A2 0/010329

AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC DESIGNATED STATES

NI PT SE

WG 2000-US25791 A 21000921 APPLICATION INFO.:

PRIORITY INFO.: US 1999-60/154,929 19995931

ABEN The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-populative events, including embelism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmadeutical preparations comprising such agents are privided.

ABFR

1139 ANSWER 27 OF 100 FOTFULL COPYRIGHT 1001 University

ACCESSION NUMBER: 0.01020163 POTFULL ED 0.02080 )
TITLE (ENGLISH): METHODS AND COMPUSITIONS FOR TR

METHODS AND COMPUSITIONS FOR TREATING PLATELET-RELATED

DISCREERS USING MPL PATHWAY INHIBITORY AGENTS

PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES TITLE (FREMCH):

LIES AUX PLAQUETTES AU MOYEN D'AGENTS INHIBITEURS DE TRAJET DE MEL

INVENTOR, S): INVENTOR(S): HAMSON, Stephen, R. PATENT ASSIGNEE(S): EMDRY UNIVERSITY

DOCUMENT TYPE: Patent

PATENT INFORMATION:

KIND DATE NUMBER WD 0001001163 A2 00010309

AU CA JP AT BE CH CY DE DK ES FI FE GB GR IE IT LU MC DESIGNATED STATES

NL PT SE

APPLICATION INFO:: WO 0000-U826005 A 00000901 PRIORITY INFO:: US 1999-60/154,929 19990901

ABEN The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations

comprising such agents are provided.

ABFR

L139 ANSWER 28 OF 100 POTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 2001010892 PCTFULL ED 20020928

TITLE (ENGLISH): FVIIA ANTAGONISTS
TITLE (FRENCH): ANTAGONISTE DU EVIIA
INVENTOR(S): DENNIS, Mark, S.
PATENT ASSIGNEE(S): GENENTECH, INC.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

ETAG CKIN NUMBER .....

WO 2001010890 A2 20010015 AF AG AL AM AT AU AL BA BB BG BR BY BZ CA CH CN CR CU DESIGNATED STATES

CO DE DK DM DO EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KP KZ LC LK LR LS LT LU LV MA MD MG MK M: MW MM MA NO NA PL PT PO PU SD SE SG SI SK SL TJ TM TH TT TZ WA WG WZ VN YW ZA ZW GH GM KE LS MW MZ SD SL

SO TO UG OW AM AC BY KG HO MD HU TU TM AT BE CH CY DE DE ES FI FE GB GP IE IT LU MC NL PT SE BF BJ CF CG CI

CM GA GN GW ML MR NE SN TD TG

WO 2000-US21396 A 20000804 US 1999-60/147,627 19990806 APPLICATION INFO .: PRIORITY INFO.:

UR 1999-60/147,627 19990806 UR 1999-60/150,315 19990803

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIK to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FWIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides

pharmaceutical commissitions comprising the novel compounds as well as

their use in diagnostic, therapeutic, and prophylastic methods.

ABFR

1139 ANSWER 29 OF 100 FOTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 2101009334 PITFULL ED 20000808 TITLE (ENGLISH: BASB118 POLYPEPTIDE AND POLYNUGI BASBII8 POLYPEPTIDE AND POLYMUCLECTIDE FROM MORAMELLA CATARRHALIS POLYPEPTIDE BASBIIS ET POLYNUOLEOTIDE DE MORAMELLA TITLE (FRENCH): CATARRHALIS INVENTOR'S: THOMMARD, Johlle PATENT ASSIGNEE(S): SMITHKLINE BEECHAM BIOLOGICALS S.A.; THONMARD, Joelle DOCUMENT TYPE: Patrit PATENT INFORMATION: KIND NUMBER DATE -----W0 1001009334 A1 00010208 AE AG AL AM AT AU AN BA BB BG BR BY BZ CA CH CN CF CU DESIGNATED STATES CZ DE DK DM DZ EE ES FI OS GD GE GH GM HR HU ID IL IN IS JE KE KG KE KR KI LO LK LE LS LT LU LV MA MD MG MK MN MW MM MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TRITTITO UA UGIUS UN VII YU DA EW GHIGMIKE LS MW ME SD SL SE TO UG OW AM AC BY KG KE MD RU TU TM AT BE OH OY DE DK ES FI FR GB GR IE IT LU MO NL PT SE BF BJ OF OG CI CM GA GN GW ML MR NE 3N TD TG APPLICATION INFO:: Wo 0000-EP7340 A 200000731 PRIORITY INFO:: GB 1999-9918008.1 19990803 The invention provides BASBIIN polypeptides and polynucleotides encoding BASB118 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. ABFF. ANSWER 30 OF 100 POTFULL COPYRIGHT 2002 Univention L139 ACCESSION NUMBER: 2001007918 PCTFULL ED 20020828 TITLE (ENGLISH): CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES ALLO ANTICOPPS CATALYTIQUES DU FACTEUR VIII KAVERI, Srinivas; LACROIM-DESMAZES, Sebastien; TITLE (FRENCH): INVENTOR(S): KAZATCHKINE, Michel PATENT ASSIGNEE(S): INSTITUT MATIONAL DE LA SANTE ET LE LA RECHERCHE MEDICALE (INSERM); BAYER PHARMA; KAVERI, Srinivas; LACHOIX DESMAZES, Sebastien; KAZATCHKINE, Michel DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE \_\_\_\_\_ Wo 2001007918 A1 20010201 AE AG AL AM AT AU AC BA BB BG BR BY BZ CA CH CN CR CU DESIGNATED STATES CO DE DK DM DO BE ES FI GB GD GE GH GM HE HU ID IL IN IS JE KE KG KE KE KZ LC LK LE LS LT LU LV MA MD MG MK MN MW MX MZ NO MZ PL PT PO PU SD SE SG SI SK SL TJ TM TRUTT TO UA UG US UZ VM YU DA ZW GH GM KE LS MW MO SD SL M2 TO UG ZW AM AD BY KG KO MD FU TJ TM AT BE OH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MF NE SN TO TG APPLICATION INFO.: WO 2000-EP6870 A 000000718 PRIORITY INFO.: EP 1999-99401841.4 19990721 The present invention relates to a method of determining the presence of ABEN catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said datalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo antibody-datalysed Factor

The present invention relates to a method of determining the presence of datalytic anti-Factor VIII allo-antibodies dapable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said datalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo antibody-datalysed Factor VIII degradation inhibitor; and to a pharmaleutical composition comprising said datalytic anti-Factor VIII allo-antibodies which are dapable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-matalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-datalysed Factor

VIII degradation innibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-anticodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharma seutical composition comprising said anti-Factor VIII allo-antibody catalysed Factor VIII degradation inmibitor.

ABFR

L139 ANSWER 31 OF 100 POTFULL COPYRIGHT 100% Univentic

ACCESSION NUMBER: 1911031349 PUTFULL ED 20121828
TITLE (ENGLISH): FVIIA ANTAGONISTO
TITLE (FRENCH): ANTAGONISTES DE FVIIA

INVENTOR(3): DEMNIS, Mark, S.; EIGENBROT, Charles; LAZARUS, Robert,

A.

PATENT ASSIGNEE(S): GENERITECH, INC.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE ----Wo 2001001749 AC 20010111

AE AG AL AM AT AU AC BA BB BG BR BY BZ CA CH CN CR CU DESIGNATED STATES

> CO DE DE DE DM DO EE ES FI GB GD GE GH GM HE HU ID IL IN IS JP KE KG KP KR KO LC LK LR LS LT LU LV MA MD MG MK MY MW MM MZ NO NO PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TO UA UG UZ VN YU DA ZW GH GM KE LS MW MZ SD SL SE TE UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE

> DK ES F1 FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US18284 A 20000630 PRIORITY INFO.: US 1999-60/142,211 19990702

This invention provides novel compounds which prevent or block a FVIIa ABEN mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (EVII) and/or block the association of FVII or FVIIa with a peptide commound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as

their use in diagnostic, therapeutic, and prophylactic methods.

ABFR

ANSWER 32 OF 100 PCTFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 2001001150 PCTFULL ED 20020828

TITLE (ENGLISH):

DIAGNOSTIC TEST FOR THROMBOTIC OR THROMBOEMBOLIC

DISEASE

TITLE (FRENCH):

EMAMEN DIAGNOSTIQUE POUR LA THROMBOSE OU LA

THROMBOEMBOLIE

INVENTOR(S): MORRIS, Timothy, A.

PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; MORRIS,

Timothy, A.

DOCUMENT TYPE:

Patent

PATENT INFOFMATION:

KIND DATE NUMBER

DESIGNATED STATES

WO J001001150 AF J0010104 AE AG AL AM AT A' AC BA BB BG BF BY BZ CA CH CN CU CZ

DE DE DE EE ES FI GB GE GE GH GM HR HU IL IL IN IS JP HE EG HE KR HI IN LE LE LS IT LU LV MD MG MK MN MW MX

ME NO NO PL PT NO PU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU DA ZW GH GM FE LS MW MZ SL SL SZ TZ UG OW AM AD BY KG KO MO RU TO TM AT BE OH OY DE DK ES FI FR (B GR IE IT LU MU NL PT SE BF BJ OF CG DI CM GA GN

YW ML MA NE SN TD TG

APPLICATION INFO:: WO ..0(0-US17977 A 20000630 PRIORITY INFO:: US .999-66/141,734 19991630

ABEN Thrombotic or thromboembolic disease is detected or monitored by

determining the presence or amount B in a physiological sample.

ABFR

ANSWER 33 OF 150 EUROPATFULL COPYRIGHT 2000 WILA L139

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1074-42 EURDPATFULL EW 200106 FS 03

Catalytic anti-factor VIII allocantifodies. TITLE:

Hatalytische gegen Faktor VIII spezifische

Allbuntikberper.

Jatalytic anti-factor VIII allo-antibodies.

Kaveri, Srimivas, 15, rue Lucien et Edouard Gerber, INVENTOR(S):

92149 Malakoff, FR;

Ladroix-Desmazes, Sebastien, 33, rue de St-Cloud, 92410

Ville D'Avray, FR;

Kazatohkine, Michel, I, rue Le Goff, 75005 Paris, FR

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE PATENT ASSIGNEE(S):

MEDICALE (INSERM), 101, rue de Tolbiac, 75654 Paris

Cedex 13, FR;

Bayer Pharma, 13, rue Jean Jaures, 92807 Puteaux Cedex,

FR

PATENT ASSIGNEE NO: 243490; 1666151

Fortal, Gerard et al., Cabinet Beau de Lomenie 158, rue AGENT:

de l'Universite, 75340 Paris Cedex 07, FR

48943 AGENT NUMBER:

BEPAL001012 EP 1074842 A1 0020 OTHER SOURCE:

Wila-EPZ-2001-H06-T2a SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: A AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; P. GR; P. IE; P. IT; R. LI; P. LU; P. MC; P. NL; P. PT; R.

SE; R AL; R LT; P LV; R MK; R RO; R SI

PATENT INFO.PUB.TYPE: EPAI EUROPAEISCHE FATENTANMELDUNG

FATENT INFORMATION:

PATENT NO KIND DATE

-----EP 1074842 A1 20010207

'OFFENLEGUNGS' DATE:

20010207

APPLICATION INFO.: EP 1999-401841

19990721

ANSWER 34 OF 100 EUPOPATFULL COPYRIGHT 2002 WILA L139

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVEE

ACCESSION NUMBER: 833848 EUROPATFULL EW 200137 FS PS STA R

FACTOR IX BINDING PERTIDES, DERIVED FROM FACTOR VIII AND TITLE:

THEIR USE AS INHIBITORS OF BLOOD COAGULATION.

FAKTOR IX BINDENDE PEPTIDE ABGELEITET VON FAKTOR VII UND

THRE VERWENDUNG ALS INHIBITOFEN DER BLUTGERINNUNG.

PEFTIDES LIANT LE FACTEUR IX DERIVES DU FACTEUR VIII ET LEUR UTILISATION COMME INHIBITEURS DE LA COAGULATION DU

DANG.

INVENTOR(S): MEMTENS, Koenraad, Domela Nieuwenhuislaan 14, 2314 ES

Leiden, NL;

LENTING, Petrus Johannes, Stoombootweg 8, 1035 TW

Amsterdam, NL

FATENT ASSIGNEE(S): Stichting Sanguin Bloedvoorziening, Plesmanlaan 125,

1006 CK Amsterdam, NL

1530 30 PATENT ASSIGNEE NO:

Emulaers, Theodorus A.H.J., Ir. et al., Vereeniade AGENT:

Postius 87930, 2508 DH Den Haaq, NL

AGENT NUMBER: 11191

CTHER SCURCE: BEPB2001041 EP 0833849 B1 0017

SOURCE: Wila-EPS-2001-H37-T1 DOCUMENT TYPE:

LANGUAGE:

DESIGNATED STATES:

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT Internationale

Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch R AT; R BE; R CH; R DE; R CK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MG; R ML; R PT; R SE

Arme.dunst

PATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_

EE 3:334 % B1 2001691. 'OFFENLEGUNGS' DATE: APPLICATION INFO.:

PRIORITY APPLN. INFO.: EP 1895-201554

RELATED DOG. INFO.:

19980415 EF 1396-417727 19960612 1995081.. W0 96-NL236 960612 INTAK: W0 9641816 961227 INTERNE WO 9041816 961227 INTENR REFERENCE PAT. INFO.: WO 90-15015 A WO 96 000 REF. NON-PATENT-LITE:

Wo 96 00572 A

REF. NON-PATENT-LIT.: COURMAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 10, 11 March 1894, MD US, pages 7150 7155, XP000017254 P. LENTING ET AL: "Identification of a binding site for blood coaquiation factor IXa on the light chain of human factor VIII" cited in the application ANNUAL REPORT DR KARL LANDSTEINER FOUNDATION, AMSTERDAM NL, pages 1-2, MP003017355 J. VAN DE LOO ET AL: "Identification and characterization of the binding site of a murine monoclonal antibody that inhibits factor VIII function" cited in the application NATURE, vol. 312, pages 337-342, XP002017256 G. VEHAR ET AL: "Structure of human factor VIII" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 3, 25 January 1990, MD US, pages 1484-1489, MP000017057 F. WALKER ET AL: "Identification of the binding site for activated protein C on the light chain of factors V and VIII" JOURNAL OF BIOLOGICAL CHEMISTRY 071 (4). 1996. 1935-1940. ISSN: 0021-9258, 26 January 1996, MP002017258 LENTING P J ET AL: "The sequence Glu-1911-Lys-1818 of human blood coaquiation factor VIII

L139 ANSWER 35 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER:

INVENTOR(S):

TITLE:

692025 EUROPATFULL EW 200142 FS PS STA R YEAST CELLS ENGINEERED TO PRODUCE PHEROMONE SYSTEM PROTEIN SURROGATES, AND USES THEREFOR.

comprises a binding site for activated factor IX."

HEFE ZELLEN SO KONSTRUIERT, DASS SIE PROTEINSURROGATE DES PHEROMENSYSTEMS PRODUZIEREN UND ANWENDUNGEN DAFUER. CEMBULES DE LEVURE TRAITEES FOUR PRODUIRE DES SUBSTITUTS DE PROTEINES DU SYSTEME DE PHEFOMONES, ET LEUFS EMPLOIS. FOWLKES, Dana, Merriman 90 Green Street, Apartment 2,

New York, NY 10012, US;

BROACH, Jim 360 East 88th Street, Apartment 2A, New

York, NY 10128, US;

MANFREDI, John 666 Greenwich Street, Apartment 556, New

York, NY 10014, US;

KLEIN, Christine 666 Greenwich Street, Apartment 556,

New York, NY 10014, US;

MURPHY, Andrew, J., 17 Windsor Place, Montolair, NJ

07143, 03;

PANE, Joremy, 197 Route RW, Palisades, NY 10964, US; TRMEHEART, Joshua, 212 South Broadway, Stuth Nyack, NY

10960, 00

PATENT ASSIGNEE(S):

(dagus Pharmaceutical Corroration, 7th floor, 180 Varisk

Street, New York, NY 10128, US

PATENT ASSIGNEE NO:

1860060 AGENT:

Price, Vincent Andrew et al., FRY HEATH & SPENCE The Old

College 53 High Street, Horley Surrey RH6 7BN, 3B

AGENT NUMBER: 7 - 513

BEPB: 001051 EP 0692025 B1 0069 CTHER SOURCE:

SOURCE: Wila EPS-2001-H41-T1

POGUMENT TYPE: Pitent

Armeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE: PESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

FATENT INFO.PUB.TYPE: EP51 EUROPAEISCHE PATENTSCHRIFT 'Intérnationale

Anmeldung:

PATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_ EP 642025 B1 2001.017 19960117 'OFFENLEGUNGS' DATE: 19940323 EF 1994-912292

APPLICATION INFO.:

19930331 19940131 PRIORITY APPLN. INFO.: US 1993-41431 US 1994-190328

FELATED DCC. INFO.:

W0 94-US3143 940323 INTAKE WO 9423025 941013 INTENE

REFERENCE PAT. INFO.: WD 90-05244 A

FEF. NON-PATENT-LIT.: 3CIENCE vol. 250, October 1990, LANCASTER, PA US pages 121 123 KLIM KING ET AL. 'Control of yeast mating signal transduction by a mammalian beta2-adrenergic receptor and Gs alpha subunit' CELL vol. 66, 20 September 1991, CAMBRIDGE, NA US pages 1197 - 1296 D. J. LEW ET AL. 'Isolation of three novel human cyclins by rescue of Gl cyclin (Cln) function in yeast' CELL vol. 65, 17 May 1991, CAMBRIDGE, NA US pages 691 - 699 YUE KIONG ET AL. 'Human D-type cyclin' PROCEEDINGS OF THE MATIONAL ACADEMY OF SCIENCES OF USA vol. 89, October 1992, WASHINGTON US pages 9410 - 9414 M. WITHEWAY ET AL. 'Dominant negative selection of heterologous genes: Isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell eyelm arrest' JOURNAL OF CELLVIAR BIOCHEMISTRY vol. 18B, February 1994 page 224 J. MANFREDI ET AL. 'Autocrine stimulation of yeast through human G-coupled receptors' A. KOFF ET AL.,: 'HUMAN CYCLIN E, A NEW CYCLIN THAT INTERACTS WITH TWO MEMBERS OF THE CDC2 GENE FAMILY' CELL vol. 66, 1991, pages 1217 - 1228 D.A. HUGHES ET AL.,: 'COMPLEMENTATION OF BYEL IN FISSION YEAST BY MAMMALIAN MAP KINASE REQUIRES COEMPRESSION OF FAF KINASE' NATURE vol. 364, 1993, pages 394 - 352

L139 ANSWER 36 OF 100 MEDLINE DUPLICATE 2

ACCESSION NUMBER: 2002040323 MEDLINE

DOCUMENT NUMBER: 21619700 PubMed ID: 11769093

TITLE: [Research on synthetic peptides of biological interest].

Szintetikus peptidek a gyogyszerkutatasban.

AUTHOR: Bajusz S

CORPORATE SOURCE: Gyoxysuerkutato Intenet Kft., Budapest, Pf. 82.-1325. SOURCE: ACTA PHARMACEUTICA HUNGARIGA, (2001) 71 (1) 13-24.

Journal code: 0414322. ISSN: 0001-6659.

PUB. COUNTRY: Hungary Journa

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Hundarian

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200101

ENTRY DATE: Entered STN: 20020124

> Last Updated on STN: 20020129 Entered Medline: 20020125

Research on synthetic peptides at the Institute for Drug AΒ Research (IDR) is exemplified by an overview of the projects that resulted în significant résults. The first synthesis of cxytopin, a pituităry

hirmone, in 1953 launched the research on synthetic peptides all over the world. This synthesis was reproduced by Bodanszky at the IDR in 1954, then, after sime improvements, the process was presented to Richter to produce synthetic oxytocin for therapeutic purposes. Significant result was the first synthesis of the 33-memmer whole molecule of human ACTH, another pituitary hormone. A short SAE study on luteinizing nirmone-releasing hormone (LHRH) led to an interesting analog, Cit-8-LHRH, and somewhat later, to the D-Dit-6-LHRH analogues, of which SE-75 become marketed under the name Cetrorelix. Studies in the brain peptides, enkephalins, resulted in GYKI-14,238, the first analog that showed analgesic activity upon systemic administration and whose human efficacy could also be proven during clinical examination. Significant results were also achieved in the research on anticoagulant peptides. The first highly potent peptide aldehyde inhibitor of thrombin, GYKI-14,166, was identified at the IDE as well as its stable analog, GYKI-14,766. This compound was selected for detailed preclinical study, licensed to Eli Lilly Company, got the generic name efegatran, and entered clinical trials. The first non-covalent peptide inhibitor of thrombin, GYKI-14,525, was also identified at the IDR. Thus IDR really provided the prototype of original thrombin inhibitors in the mid 70's, and analogues were prepared in many laboratories through two decades. IDR's current research program's objective includes a quest for peptide originals that can inhibit both thrombin and factor Xa in solution and also within plasma clots in which these enzymes are entrapped. Structures with such inhibitory profile were identified among the efegatran-related alpha-hydroxy acid and ethoxycarbonyl-amino acid derivatives. The follow-up molecules are even more promising as antithrombotics, and may also be useful for treatment of disseminated intravascular coagulation, an often fatal syndrome, so we continue working on this project.

L139 ANSWER 37 OF 100 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 2000:953223 PROMT

Tick Anticoaqulant Peptides Have Inhibitory Activity. TITLE:

Blood Weekly, (9 Nov 2000) . SOURCE:

ISSN: 1065-6073.

Charles W. Henderson Newsletter PUBLISHER:

DOCUMENT TYPE: LANGUAGE: English

WORD COUNT: 412

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

2000 NOV 9 - (NewsEx.com) --AΒ

THIS IS THE FULL TEXT: COPYRIGHT 2000 Charles W. Henderson

Subscription: \$995.00 per year. Published weekly. P.O. Box 930409, Birmingham, AL 35283-0409.

L139 ANSWER 38 OF 100 USPATFULL

ACCESSION NUMBER: 2000:174602 USPATFULL

TITLE: Pharmaceutical preparation for treating blood

ccagulation disorders

INVENTOR(S): Turesek, Feter, Klosterneuburg/Weidling, Austria

Schwarz, Hans-Peter, Vienna, Austria

Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S.

derporation)

NUMBER KIND DATE PATENT INFORMATION: US 6165974 20001.26 APPLICATION INFO.: US 1999-245339 19990205 (9) RELATED APPLN. INFO.: Division of Ser. No. US 1998-165745, filed on 6 Oct 1998, now patented, Pat. No. US 6039945 which is a

division of Ser. No. US 1997+821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb: 1949

		NUMBER.	PATE
PRICRITY	INFORMATION:	AT 1990-518	19960320
		AT 1994-1573	19960904
		AT 1996-1673	199(092)
516 011145115	mun n	A Part of the Land	

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Weddington, Kevin E. LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 1.9 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There is disclosed a pharmaceutical preparation for treating blood roagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Ka as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 39 OF 100 USPATFULL

ACCESSION NUMBER: 2000:101870 USPATFULL

TITLE: Pharmaceutical preparation for treating blood

coaqulation disorders

INVENTOR(S): Turedek, Peter, Klosterneuburg/Weidling, Austria

Schwarz, Hans-Peter, Vienna, Austria

Eikl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S.

corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6099837		20000808	
APPLICATION INFO.:	US 1999-244762		19990205	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-165745, filed on 5 Oct 1998 which is a division of Ser. No. US 1997-821763,

filed on 20 Mar 1997, now patented, Pat. No. US 5866122

	NUMBER DATE			
PRIORITY INFORMATION:	AT 1996-518 19960320 AT 1996-1573 19960904			
	AT 1996-1673 19960920			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINEF:	Weddington, Kevin E.			
LEGAL REPRESENTATIVE:	Foley & Lardner			
NUMBER OF CLAIMS:	16			
EXEMPLARY CLAIM:	1			

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 1533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There is disclosed a pharmaceutical preparation for treating blood coaggilation disorders which comprises purified prothrombinase factors, in rarticular purified prothromkin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1139 ANSWER 40 OF 100 USPATFULL

2000:34192 USPATFULL ACCESSION NUMBER:

TITLE: Pharmaceutical preparation for treating klood

coagilatiin disorders

INVENTORIS: Turesek, Feter, Klostern-Auburg/Weidling, Austria

Schwarz, Hans-Peter, Vienna, Austria

Eikl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S.

misporation)

NUMBER HIND DATE -- -----

PATENT INFORMATION: US 6/39945 .00000321 APPLICATION INFO:: US 1998-185745 .19981006 (9)

RELATED APPLN. INFD.: Division of Ser. No. US 1997-381763, tiled on 20 Mar

1997, now patented, Pat. No. US 53661.2

NUMBER DATE \_\_\_\_\_

PRIORITY INFORMATION: AT 1996-518 19960320 AT 1996-1573 19960320 AT 1996-1673 19960320

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E. LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 13 EXEMPLARY CLAIM:

NUMBER OF DEAWINGS: % Drawing Figure(s); % Drawing Page(s) LINE COUNT: % Drawing Figure(s); % Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There is disclosed a pharmaceutical preparation for treating blood coaquiation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

ANSWER 41 OF 100 POTFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 2000052034 PCTFULL ED 20020515

INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND TITLE (ENGLISH):

COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS

INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET TITLE (FRENCH):

COMPOSITIONS DE TRAITEMENT D'INFECTIONS VIRALES

INVENTOR(S): SHAPIRO, Leland
PATENT ASSIGNEE(S): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF FUBL: English

LANGUAGE OF FUBL.:

DOCUMENT TYPE: Patent

PATENT INFOFMATION:

NUMBER KIND DATE -----

Wo 2000052034 A2 U0000908 AE AL AM AT AU AZ BA BB BG BE BY CA CH CN CE CZ DE DK DESIGNATED STATES

OM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG BE KO LO LK DE LS DT DU DV MA MD MG ME MN MW MX NO NZ

PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ UN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY HIS HI MO RU TJ TM AT BE OH BY DE DK E. FI FR GB GR IE

IT L' MO MIL ET SE BE BJ OF OG OI OM GA GN GW ML MR NE SN TD TG

WC 1/1011-U35558 A 20000303 APPLICATION INFO.: US 1999-61/123,167 19990305 US 1999-60/137,795 19990603 PRIORITY INFO.:

A nivel method of treating and preventing viral infection is provided.

ABEN In particular a method

of blooking viral infection facilitated by a serine proteclytic (SP)

activity is disclised, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound having a serine protease innihitory or ser; in activity. Among compounds are α 1-antitrypsin (AAT), peptide derivatives from the carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such compounds. The preferred viral infections include retroviral infection such as human immunideficiency virus (HIV) infection. L'invention concerne une nouvelle methode de traitement et de prevention d'une infection virale. L'invention concerne, en particulier, une methode destinee a combattre une infection virale favorisee par une activite de serine proteolytique (SP), consistant a administrer a un sujet scuffrant ou susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace d'un compose presentant une activite d'inhibition de serine protease ou serpin. Parmi les composes se trouvent l'antitrypsine %alpha; l (AAT), des derives peptidiques de l'extremite carboxyterminale de l'AAT, et des composes synthetiques artificiels imitant l'action de ces composes. Farmi les infections virales preferees se trouvent les infections retrovirales telles que l'infection du virus de l'immunodeficience humaine (VIH). ANSWER 42 OF 100 PCTFULL COPYRIGHT 2002 Univentio ACCESSION NUMBER: 2000051625 PCTFULL ED 20020515 TITLE (ENGLISH): INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF HERPES VIRUSES TITLE (FRENCH): INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT DE VIRUS DE L'HERPES SHAPIFO, Leband INVENTOR(S): PATENT ASSIGNEE(S): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND DATE WO 0000051625 A1 00000908 AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DESIGNATED STATES DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KE KZ LC LK LE LS LT LU LV MA MD MG MK MIN MW MK NO NZ PL PT RO RU SD SE SG SI 3K SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE L3 MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FF GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG Wo 11000-US5557 A 20000393 APPLICATION INFO.: US 1999-60/123,167 19990305 US 1999-60/153,942 19990915 PRIORITY INFO.: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blicking a viral infection facilitated by a serine proteolytic

ABFR

(SP: activity is disclosed,

which involves administering to a subject suffering or about to suffer from a viral infection a

therapeutically effective amount of a substance having serine protease inhibitory activity or serpin

activity. Among the substances found to be useful are %alpha; l-antitrypsin (AAT), peptide

derivatives from the carroxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviriuae family. ABFR L'invention concerne de nouvelles compositions et methodes de traitement et de prevention d'une infection virale. L'invention concerne une methode visant a bloquer une infection virale favorisee gar une activité protéclytique de serine (SP), consistant à administrer a un sujet souffrant ou susceptible de soutfrar d'une infection virale une quantité therapeutiquement efficace d'une substance presentant une activité d'inhibition de serine protease cu serpin. Parmi les substances utiles se trouvent l'antitrypsine α l (AAT), des derives peptidiques de l'extremite carboxyterminale de l'AAT et des medicaments synthetiques imitant l'action de des substances. L'invention est particulierement appropriée dans le dépistage d'une infection virale a mediation de membres de la famille des Herpesviridae. ANSWER 43 OF 100 POTFULL COPYRIGHT 2000 Univentio 2000051623 POTFULL ED 20020515 ACCESSION NUMBER: INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND TITLE (ENGLISH): COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET TITLE (FRENCH): COMPOSITIONS DE TRAITEMENT DES ETATS CLINIQUES DUS AU BIONYDE D'AZOTE INVENTOR(S):
PATENT ASSIGNEE(S): INVENTOR(S): SHAPIRO, Leland THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND DATE NUMBER **W**O 1000051633 A2 00000908 AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DESIGNATED STATES DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI 3K SL TJ TM TR TT TZ UA UG UZ VM YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MO NL PT SE BE BU OF OG OI OM GA GN GW ML ME NE SN TD TG A 20000303 APPLICATION INFO.: WO 2000-US5556 US 1999-60/123,167 19990305 US 1999-60/156,523 19990929 PRIORITY INFO.: A novel method of treating and preventing diseases is provided. In ABEN particular, compositions and methods of blocking diseases associated with aberrant levels of mitric oxide and facilitated by a serine proteclytic (SP) activity are disclosed, which consist of administering to a subject a therapelitically effective amount of a compound having a serine protease innihitory activity. Among effective compounds are α l-antitrypein and synthetic drugs mimicking some or all of the actions of α .-antitrypsin. ABER L'invention concerne une nouvelle methode de traitement et de prevention de maladies.

L'invention concerne en particulier des compositions et des methodes

destinees a bloquer des

maladies associees a des niveaux anormaux de monoxyde d'azote et favorisées par une activite

proteolytique de serine 'SP', consistant 4 administrer a un sujet une quantite therapeutiquement

efficase d'un compose presentant une activite d'inhibition de serine

protease. Parmi les composes

efficaces se trouvent l'antitrypsin# α let des medicaments

synthetiques imitant certaines cu

toutes les actions de l'antitrypsine α l.

L139 AMSWER 44 OF 100 FOTFULL COPYRIGHT 2000 Univention

ACCESSION NUMBER: 200005:450 POTFULL ED 2:020515 TITLE (ENGLISH):

MITE PROTEIN PROTEINE D'ACARIEN TITLE (FRENCH):

INVENTOR(S): MATTSSON, Jens
PATENT ASSIGNEE(S): STATENS VETERINAERMEDICINSKA ANSTALT; MATTSSON, Jens
LANGUAGE OF FUBL: English

LANGUAGE OF FUBL.: DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE Wo 2000050450 Al 00000331

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CC DE DESIGNATED STATES

DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TO UA UG UB UZ VNI YU ZA ZW GH GM KE LB MW BD SL SZ TZ UG ZW AM AN BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR

GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW

ML MR NE SN TD TG

APPLICATION INFO.: WO 7000-SE346
PRIORITY INFO.: SE 1999-9900674-4 A 20000222 19990025

The present invention relates to a novel major mite antigen, which according to the invention

has been isolated and sequenced for the first time. More specifically, said antigen is a protein

originating from the mite i(Sarcoptes scable)). Thus, the invention relates to said antigen as well

as to the encoding nucleic acid as defined in the claims. Further, the invention also relates to

advantageous uses of the novel protein and/or functional fragments thereof, e.g. in immunological

testing, such as in ELISA methods, as well as in the preparation of vaccines.

ABFR La presente invention concerne un nouvel antigene acarien majeur qui selon la presente

invention a ete isble et sequence pour la première fois. De manière plus specifique, ledit antigene

est une proteine issue de l'acarien i (Sarcoptes scabiei.) L'invention concerne par consequent ledit

antigene ainsi que l'acide nucleique de codage tel qu'il est defini dans les revendications. En

outre, l'invention concerne egalement les utilisations interessantes de la nouvelle proteine et/ou

de ses fragments fonctionnels, par exemple dans les analyses immunologiques telles que les procedes

ELIJA, ainsi que dans la preparation de vaccins.

ANSWER 45 OF 100 POTFULL COPYRIGHT 2000 Univentic 1000139310 POTFULL ED 21020515 ACCESSION NUMBER:

TITLE PENGLISH:: RUBREDOMIN FUSION PROTEINS, PROTEIN EMPRESSION SYSTEM

AND METHODA

TITLE 'FRENCH': PROTEINES HYBRIDES DE RUBREDOXINE, SYSTEME ET METHODES

D'EMPRESSION DE PROTEINE

INVENTOR"S : PRZYBYLA, Alan; MENCN, Nanda

THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.; PATENT ASSIGNEE(S): PRZYBYLA, Alan; MENGN, Nanda

LANGUAGE OF PUBL.: DOCUMENT TYPE: PATENT INFORMATION:

,

English Patent

KIND NUMBER. DATE 

WD 2000039310 A1 2000070€

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DESIGNATED STATES DY DM BE ES FI 9B 3D 3E 9H 3M HR HU ID IL IN IS JP KE

KO KO KE KE LO LK LE LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL 3Z TZ UG ZW AM AZ BY KG KW MĐ RƯ TƯ TM AT BE CH CY DE DK ES FI FR GB

GR IE IT LU MO NL PT SE BF BJ OF GG OI OM GA GN GW ML

ME NE SN TO TG

A 19991229 Wo 1999-US31176 APPLICATION INFO .: PRIORITY INFO.: US 1998-60/114,034 19931229

A recombination fusion protein is presented which comprises rubredoxin ABEN as the fusion partner.

The fusion protein optionally includes an intervening spacer region between the rubredoxin

constituent and the fused polypeptide of interest that can contain a proteolytic cleavage site for

release of the polypeptide of interest. The fusion protein can contain one or more sites for

affinity purification. The invention also includes methods and materials for making and using the

rubredoxin fusion protein. Also provided are antigenic compounds and compositions, including

vaccines, comprising a rubredoxin as a carrier molecule linked to an antigen or hapten.

AEFF. Cette invention a trait a une nouvelle proteine hybride de recombinaison comprenant de la

rubredoxina comme partenaire de fusion. Cette proteine hybride peut, eventuellement, comprendre une

region d'espacement intervenante entre le constituant rubredoxine et le polypeptide fusionne etudie,

pouvant comporter un site de clivage proteolytique pour la liberation dudit polypeptide. Cette

proteine hybride peut contenir un ou plusieurs sites pour purification par affinite. L'invention

concerne egalement des methodes et des substances permettant de produire et d'utiliser la proteine

hybride rubredoxine. Elle porte, en outre, sur des composes et des compositions antigeniques,

notamment des vaccins, renfermant la rubredoxine comme molecule porteuse liee a un antigene ou a un haptene.

ANSWER 46 OF 100 POTEVILL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 2000030646 POTFULL ED 20020515

TITLE (ENGLISH): HETEROSYGLIC COMPOUNDS REGULATING CLOTTING COMPOSES HETEROCYCLIQUES REGULANT LA COAGULATION TITLE (FRENCH):

JAKOBSEN, Palle: HDFNEMANN, Anne, Marie: PERSSON, Egon INVENTOR( $\mathcal{Z}$ ):

PATENT ASSIGNEE(S): NOVO NORDISK A/S

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION:

> NUMBEE. FIND DATE W1 2000131646 A1 20000602

AF AL AM AT AU AZ BA BB BG BR BY CA CH CN CF CU CZ DE DESIGNATED STATES DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KE KZ EG IK IE IB IT EU IV MA MD MG MK MN MW MX

```
MI MZ PL PT RO RU SD SE 83 SI SK SL TJ TM TR TT TZ VA
                       UB UZ MN YU ZA ZW GH BM HE LS MW SD SL SZ TZ UG ZW AM
                       AL BY MG KZ MO RU TU TM AT BE CH CY DE DK ES FI FR GB
                       GA TE IT LU MO NU PT SE BF BU OF OG CI CM GA GN GW ML
                       MR NE AN TO TO
                                            A .9991123
                      Wu 1994-DK646
                       DR 199--PA 1999 11560 19981126
     The invention relates to the use of heterographic compounds with formulas
       :I) and (II), and
      pharmaceutical acceptable salts thereof, for the manufacture of a
      pharmaceutical preparation for
       treatment of coagulation-related diseases. The compounds are inhibitors
       of TF-FVIIa activity and
       thus show anticoagulant activity. The invention also relates to methods
       of treatment. The invention
       furthermore relates to novel compounds with the formula (I) or (II).
       La presente invention concerne l'utilisation de composes heterocycliques
       representes par les
       formules (I) et (II), et de leurs sels acceptables sur le plan
      pharmaceutique, dans la fabrication
      dune preparation pharmaceutique destinee au traitement des maladies
      lieus a la coagulation. Ces
      composes sont des inhibiteurs de l'activité de TF-FVIIa et ont par
      consequent une activité
      anticoagulante. En outre, cette invention concerne des methodes de
      traitement, ainsi que de nouveaux
      composes representes par les formules (I) ou (II).
      ANSWER 47 OF 100 FOTFULL COPYRIGHT 2000 Univention
ACCESSION NUMBER: 2000015653 PCTFULL ED 20020515
                      FACTOR VIIa INHIBITORS
                       INHIBITEURS DU FACTEUR VIIa
                      SAFAR, Pavel; SAFAROVA, Alena; WILDGOOSE, Peter
                      AVENTIS PHARMA DEUTSCHLAND GMBH
                       English
                       Patent
                                                   DATE
                       NUMBER
                                         KIND
                       WO 0000015658 A1 20000323
                       AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
                       DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
                       KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO
                       NO PL PT RO RU SO SE SG SI SK SL TJ TM TR TT UA UG UZ
                       VN YU DA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG
                       KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT
                       LU MC NL PT SE BE BJ CF CG CI CM GA GN GW ML MR NE SN
                       TU TS
                                            A 19990902
                       WO 1999-EP6449
                       EP 1998-93117506.0
                                              19980915
      The present invention relates to novel compounds, their preparation,
      pharmaceutical compositions containing the compounds which have a strong
      antithrombotic effect
      through reversible inhibition of activated blood coagulation factor VIIa
      L'invention porte sur de nouveaux composes, leur preparation, leurs
      utilisations, et sir des
      preparations pharmaceutiques les contenant presentant une forte activite
      antithrombotique en tant
      gu'inhibiteurs reversible du facteur VIIa d'activation de la coaquiation
      au sang (F/IIa).
```

APPLICATION INFO::

PRIGRITY INFO.:

ABEN:

ABFR

1.139

TITLE (ENGLISH): TITLE (FRENCH):

PATENT ASSIGNEE(S): LANGUAGE OF FUBL.:

PATENT INFORMATION:

DESIGNATED STATES

APPLICATION INFO .:

their use and

ANSWER 48 OF 100 FOTFULL COPYRIGHT 2002 Univentic

ACCESSION NUMBER: 2100004392 POTFULL ED 20020515

PRICRITY INFO .:

ABFR

1139

INVENTOR(3):

DOCUMENT TYPE:

TITLE (ENGLISH): ARRAYS OF PROTEINS AND METHODS OF USE THEREOF

TITLE (FRENCH): GROUPEMENTS DE PROTEINES ET PROCEDES D'UTILISATION DE

CEUK-CI

INVENTOR(S): WARNER, Peter; AULT-RICHE, Dana; NOCK, Steffen; ITIN,

Christian

PATENT ASSIGNEETS): CYDMYM, INC.

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

We 1000004382 A1 20000127

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DESIGNATED STATES

> HE ES FI GB GD SE GH GM HR HU ID IL IN IS JP KE KG KP KE KO LO LK LE LS LT LU LV MD MG MK MN MW MX NO NO PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU MA OW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

> NL PT SE BE BU OF OG CI CM GA GN GW ML MR NE SN TD TG

WO 1999-US15971 A 19990714 APPLICATION INFO.: บร 1998-09/115,455 19950714 PRIORITY INFO.:

ABEN Frotein arrays for the parallel, i(in vitro) screening of bicmolecular

activity are provided.

Methods of using the protein arrays are also disclosed. On the arrays, a

plurality of different

proteins, such as different members of a single protein family, are

immobilized on one or more

organic thin films on the substrate surface. The protein arrays are

particularly useful in drug

development, proteomics, and clinical diagnostics.

ABFR. L'invention concerne des groupements de proteines permettant de mettre

en ceuvre un criblage

r(in vitro) en parallele d'activite biomoleculaire. Des procedes

d'utilisation des groupements de

proteines sont egalement decrits. Dans les groupements, plusieurs

proteines differentes telles que

des membres differents d'une seule famille de proteines, sont

immobilisees sur un ou plusieurs films

minces organiques a la surface du substrat. Les groupements de proteines

sont particulierement

utiles dans le developpement de medicaments, la proteomique et le

diagnostic clinique.

ANSWER 49 OF 100 EUROPATFULL COPYRIGHT 2002 WILA L139

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 987274 EUROPATFULL EW 200012 FS OS

Factor VIIa Inhibitors. TITLE: Faktor VIIa Inhibitore.

Inhibiteurs du facteur VIIa.

Safar, Pavel, 12431 N. Forest Lake Way, Tucson AZ 85737, INVENTOR(S):

US;

35737, US;

Safarova, Alena, 12431 N. Forest Lake Way, Tucson AZ

Wildgoose, Peter, Hintergasse 13, 61440 Oberursel, DE PATENT ASSIGNEE(S): Hoethat Marion Roussel Deutschland GmbH, Brueningstrasse

50, 65929 Frankfurt am Main, DE

PATENT ASSIGNEE NO: 2370630

BHPA. 000020 EP 0387274 Al 0029 OTHER SOURCE:

Wila-EFZ-2000-H12-Tla SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Verseffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R

GE; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R

SE; R AL; R LT; R LV; R MK; R RO; R SI

PATENT INFO. PUB. TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

KIND DATE PATENT NO 

A1 .1000314 EP 987274

2000/312 'OFFENLEGUNGS' DATE:

1998/915 EP 1998-117506 APPLICATION INFO.:

ANSWER 50 OF 100 EUROPATFULL COPYRIGHT 1000 WILA

GRANTED PATENT - ERTEILTES FATENT - BREVET DELIVEE

EUROPATFULL EW 200010 FS PS 863871 ACCESSION NUMBER: ANTICOAGULANT PERTIDE ALDEHYDE DERIVATIVES. TITLE:

PEPTID-ALDEHYDDEFIVATE ALS ANTIKOAGULIERENDE MITTEL.

DERIVES D'ALDEHYDE PEPTIDIQUES ANTICOAGULANTS.

BAJUSZ, Sandor, Derek u. 16/a, H-1916 Budapest, HU; INVENTOR(S):

JUHASZ, Attila, Fetnehazy u. 23, H-1139 Budapest, HU; BARAHAS, Eva, Pusztaszeri ut 6, H-1025 Budapest, HU; FEHER, Andras, Tuzko u. 6, H-1118 Budapest, HU; SMABD, Gabriella, Vaci ut 8, H-1130 Budapest, HU; SZELL, Erzsebet, Heves u. 64, H-1106 Budapest, HU; VEGHELYI, Iren, Labanc u. 6/b, H-1021 Budapest, HU; LAVICH, Emilia, Frankovics M. u. 33, H-1150 Budapest,

KASZAS, Eva, Nyar u. 69, H-1045 Budapest, HU;

LANGO, Jousef, Amfiteatrum u. 11, H-1031 Budapest, HU; MORAVCSIK, Imre, Mester u. 38, H-1095 Budapest, HU; SIEKER, Agnes, Deak F. u. 81, H-1041 Budapest, HU;

TASCHLER, %sumsanna, Amfiteatrum u. 27, H-1031 Budapest,

TOTH, Gabor, Veres P. u. 74, H-1163 Eudapest, HU; MOHAI, Zsuzsanna, Baratka u. 48, H-1173 Budapest, HU; SZALKAY, Anna, Maria, Szoedliget u. 10, H-1151 Budapest,

MAKK, Klara, Liget u. 26, H-2623 Kismaros, HU

PATENT ASSIGNEE(S): GYOGYSZERKUTATO INTEZET KFT., Berlini u. 47-49, H-1045

Budapest, HU

1668100 PATENT ASSIGNEE NO:

AGENT:

Beszedes, Stephan G., Dr. et al., Patentanwalt Postfach

11 68, 85201 Dachau, DE

AGENT NUMBER: 1932

OTHER SOUFCE: BEPB2000011 EP 0863871 B1 0019

SOURCE:

Wila-EPS-2000-H10-T1

DOCUMENT TYPE:

Patent LANGUAGE:

DESIGNATED STATES:

Anmeldung in Englisch; Veroeffentlichung in Englisch R AT; R BE; R CH; R DE; R DK; F ES; P FI; R FR; R GB; R

GR; F IE; R IT; F LI; R LU; F MC; F NL; R PT; R SE PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE EP 863871 B1 20000308

'OFFENLEGUNGS' DATE:

19980916 APPLICATION INFO.: EP 1997-905209 19970605 19960605

FRICRITY APPLN. INFO.: HU 1996-1527 RELATED DCC. INFO.:

WC 97-EU27 WC 9746523 970805 INTAF2 971211 INTENE

REF. NON-PATENT-LIT.: JONES D.M. ET AL.: "Design and synthesis of thrombin inhibitors" LETT.PEPT.3CI., vol. 2, no. 3/4, 1995, pages 147-154, MP002041031 SHUMAN F.T. ET AL.:

"Utrusture-Astivity Study of Tripertide Thrombin Inhibitors Using Alpha-Alkyl Amino Acids and other

Conformationally Constrained Amino Acids" J.MED.CHEM., vol. 38, 1995, pages 4446-4453, XP002041032 BAJUSŽ S. ET

AL.: "Active Site-Directed Thrombin Innibitors:

Alpha-Hydrixyacyl-prolyl-arginals. New Crally active Stble Analigs of D-Fne-Pro-Arg H" BIODRGANIC & MEDICAL

OHEMISTRY, vol. 3, no. 8, 1495, pages 1079-1089,

MP302041033 rited in the application

1139 ANSWER 51 OF 100 EUROPATFULL COPYRIGHT 1:02 WILA

GRANTED PATENT - ERTEILTES (ATEN) - BEEVET DELIVEE

530371 EURCPATFULL EW 200051 FS PS ACCESSION NUMBER:

IMIDADO(1,5A) PYRIDINE DERIVED SERINE PROTEASE TITLE:

INHISITORS.

AUS IMIDADD-(1,5A)-FYRIDIN STAMMENDE INHIBITOREN VON

SERINPROTEASEN.

INHIEITEURS DE SERINE PROTEASE DERIVES DE

IMIDAGO(1,5A) PYRIDINE.

OTTENHEYM, Henricus Carl Joseph, Gagelveld 5, 6596 CC INVENTOR(S):

Milsheek, NL;

ADANG, Antin Egbert Feter, Le Sage ten Broeklaan 77,

9615 CR Eindhoven, NL;

FETERS, Jacobus Albertus Maria, Meerval 23, 5345 DB Oss,

Akzo Nobel N.V., Velperweg 76, 6824 BM Arnhem, NL PATENT ASSIGNEE(S):

200754 PATENT ASSIGNEE NO:

Hogenbirk, Marijke et al., P.O. Box 20, 5340 BH Oss, NL AGENT:

AGENT NUMBER: 96941

BEPB2000040 EP 0830371 BI 0019 OTHER SOURCE:

Wila-EPS-2000-H51-T1 SOURCE:

E-DOUMEN'T TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: P AT; P BE; P CH; P DE; P DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

FATENT INFOFMATION:

PATENT NO KIND DATE

\_\_\_\_\_ B1 20001220 EP 830371 19980325

'OFFENLEGUNGS' DATE: APPLICATION INFO.:

19960529 EP 1996-919638 PRIORITY APPLN. INFO.: EF 1985-201448 19950602 RELATED DOC. INFO.: WO 96-EP2098 960529 INTAKS

WO 9639470 REFERENCE PAT. INFO.: EP 335483 A

REF. NON-PATENT-LIT.: LIEBIGS ANNALEN DER CHEMIE, no. 9, September 1983,

WEINHEIM DE, pages 1623-1637, MP002014819 C KLEIN ET

961205 INTPNE

AL.: "Umwandlung von omega-Guanidino- und

omega-Ureido-alpha-aminosaeuren in alpha-Ketosaeuren und

derer heterocyclische Folgeprodukte " cited in the application TETRAHEDRON, vol. 48, no. 24, 12 June 1992, OMFORD GB, pages 5191-5198, MPD02014820 R GONZALEZ-MUNIZ

ETT AL.: "Synthesis of 2-substituted 8-amino-3-

excindelizidine-2-carpoxylic acid derivatives as peptide

conformation mimetics"

1139 ANSWER 52 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET IELIVAE

ACCESSION NUMBER: 5.1963. EURCEATFULL EW 200021 FS PS

IMPROVED INHIBITORS OF THROMBIN. TITLE: VERBEUSERTE THROMEININHIEITOREN.

INHIBITEURS AMELICRES DE THROMBINE.

MARA MAMORE, John, M., 17 Highland Street, Concord, MA INVENTER Set

01742, US;

JABLEMSKI, Jo-Ann, M., 9 Summer Street, Middleborough,

MA 01346, US;

BOURDON, Paul, R., 17 1/1 Vinal Avenue, Sommerville, MA

02.43, VS

PATENT ASSIGNEE:S: BIOGEM, INC., 14 Cambridge Center, Cambridge

Massichusetts 32142, US

PATENT ASSIGNEE NO: 1049451

VOSSIUS & PARTNER, Postfach %6 07 67, %1634 Muencher, DE

AGENT NUMBER: 100311

BEFBL000029 EP 0529031 B1 0026

SOURCE:

AGENT:

Wila-EPS-2000-H21-T1

DOCUMENT TYPE:

OTHER SOURCE:

Patent

LANGUAGE:

Anmeldung in Englisch; Verbeffentlichung in Englisch DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IT; R LI; R LU; R MC; R NL; R SE

FATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldung)

: NOITAMRORNI THETAR

'OFFENLEGUNGS' DATE:

HIND DATE PATENT NO \_\_\_\_ EP 509031 B1 20000524 19930303 APPLICATION INFO.: EP 1992-905748 19920203
PRIORITY APPLN. INFO.: US 1991-652929 19910208
RELATED DOC. INFO.: WO 92-US836 920203 INTAKZ
WO 9213952 920820 INTPNR
PEFERENCE PAT. INFO.: EP 19589 A EP 118280
WO 91-02750 A

WO 91-02750 A

PEF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, (Easton, PA, US), J.M. MAFAGANORE et al.: "Design and characterization of Hirulogs: A novel class of Bivalent peptide inhibitors of thrombin" pages 7095-7101, see abstract, page 7099, left hand column, lines 21-23 Scand. J. Haematol., vol. 31, 1983, (Ocpenhagen, DK), G.F. HANDELAND et al.: "Simplified assay for antithrombin III activity using chromogenic peptide substrate", pages 427-436, see abstract; page 435, left-hand column, paragraphs 2-3

L139 ANSWER 53 OF 100 USPATFULL

DUPLICATE 3

ACCESSION NUMBER: 1999:33980 USPATFULL Inhibitirs of factor Xa

TITLE: INVENTOR(S):

Brunck, Terence Kevin, San Diego, CA, United States Webb, Thomas Roy, Encinitas, CA, United States

PATENT ASSIGNEE(5):

Fipka, William Charles, San Diego, CA, United States Corvas International, Inc., San Diego, CA, United

States (U.S. corporation)

NUMBER KIND DATE PATENT INFOFMATION: US 5383077 19990316 APPLICATION INFO.: US 1993-163964 19931015 (8) RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-991204, filed

on 15 Dec 1992, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cemilia J. ASSISTANT EXAMINER: Lukton, David LEGAL REPRESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS: 13 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure s:; 3 Drawing Page s:

LINE COUNT:

1521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds, their salts and compositions related thereto having

autivity against mammalian factor Xa are displosed.

The novel compounds include peptide aldenyue analogues

naving substantial potency and specificity as inhibitors of

mammalian factor Xa are further disclosed. The

sympounds are thought useful as inhibitors of factor

xa in vitro or as a therapeutic agent for the prevention and

treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also

displised.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 54 OF 100 USPATFULL

ACCESSION NUMBER: 1999:15493 USPATFULL

TITLE: Pharmaceutical preparation for treating blood

coagulation disorders

Turecek, Peter, Weidling, Austria INVENTOR(3):

Schwarz, Hans-Peter, Vienna, Austria

Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

NUMBER KIND DATE \_\_\_\_\_\_ PATENT INFORMATION: US 5866122 19990202 APPLICATION INFO:: US 1997-821763 19970320

19970320 (8)

NUMBER PATE PRIORITY INFORMATION: AT 1996-518 19960320 AT 1996-1573 19960904 AT 1996-1673 19960920

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINEF: Weddington, Kevin E. LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 45 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 3 Drawing Page(s) LINE COUNT: 1609

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEMING IS AVAILABLE FOR THIS PATENT.

ANSWER 55 OF 100 POTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 19999066918 PCTFULL ED 20020515

TITLE (ENGLISH): THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF

DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR

DISCRIBE DE DITHICCARBAMATES ET COMPOSITIONS U'
INVENTOR S: LAI, Ching-San; VASSILEV, Vassil
PATENT AGSIGNEE(S): MEDINOX, INC.; LAI, Ching-San; VASSILEV, Vassil
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent TITLE (FRENCH):

METHODES THERAPEUTIQUES UTILISANT DES DERIVES DE BISULFURE DE DITHIGCARBAMATES ET COMPOSITIONS UTILISEES

PATENT INFORMATION:

NUMBER KIND F'AT'E \_\_\_\_\_ WO 9966918 Al 19991229

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK

```
EE ES FI 3B 3D GE GH 3M HR HU ID IL IN IS JP KE K3 KP
                        KR KE LO LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
                        PT RD RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
                        YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
                        MD RU TU TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
                        MO NU PT SE BE BU OF OG OF OM GA GN GW ML MR NE SN TD
                        Τ.;
                                              A 19990622
                       WD 1999-US14237
                       US 1998-09/103,639
                                                 19980623
      The present invention provides a novel dithiocarkamate disulfide dimer
       useful in various
       therapeutic treatments, either alone or in combination with other active
       agents. In one method, the
       disulfide derivative of a dithiocarbamate is coadministered with an
       agent that inactivates (or
       inhibits the production of) species that induce the expression of nitric
       oxide synthase to reduce
       the production of such species, while, at the same time reducing nitric
       oxide levels in the subject.
       In another embodiment, free iron ion levels are reduced in a subject by
       administration of a
       disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions,
       for example, in subjects
       undergoing anthracycline chemotherapy. In another embodiment, cyanide
       levels are reduced in a
       subject by administration of a disulfide derivative of a dithiocarbamate
       so as to bind cyanide in
       the subject. In a further aspect, the present invention relates to
       compositions and formulations
       useful in such therapeutic methods.
       La presente invention porte sur un nouveau dithiocarbamate bisulfure
       dimere utilise dans divers
       traitements therapeutiques, soit seul, soit en combinaison avec d'autres
       agents actifs. Selon un
       procede, le derive de bisulfure d'un dithiocarabamate est administre
       conjointement avec un agent qui
       desactive (ou inhibe la production) d'especes induisant l'expression de
       la synthase de l'oxyde
       nitrique de facon a reduire la production de ces especes tout en
       reduisant, en meme temps, les taux
       d'oxyde nitrique chez le sujet. Selon une autre realisation, on reduit
       chez un sujet les taux d'ions
       ferriques libres en administrant un derive de bisulfure d'un
       dithiocarbamate de facon a pieger des
       ions ferriques libres, par exemple, chez des sujets soumis a une
       chimiotherapie a l'anthracycline.
       Selon une autre realisation, on reduit les taux de cyanure chez un sujet
       en administrant un derive
       de bisulfure de dithiocarbamate de facon a fixer le cyanure chez le
       sujet. La presente invention
       porte egalement sur des compositions et des formulations utilisées dans
       ces procedes therapeutiques.
      ANSWER 56 OF 100 PCTFULL COPYFIGHT 2002 Univention
ACCESSION NUMBER: 1999048878 PCTFULL ED 20020515
                    HETEROTYCLIC COMPOUNDS REGULATING CLOTTING COMPOSES HETEROCYCLIQUES REGULATEURS DE COAGULATION
                       PERSSON, Egon; JAKOBSEN, Palle; WORSAAE, Helle
PATENT ASSIGNEE(S): NEVO NORDISK A/S LANGUAGE OF PUBL.: English
                        Patent
```

APPLICATION INFO.:

PRIORITY INFO.:

ABEN

ABFR

L139

TITLE (ENGLISH): TITLE (FRENCH):

INVENTOR(s):

DOCUMENT TYPE:

PATENT INFORMATION:

NUMBER KIND DATE WC 9948878 Al 19990930

```
AE AL AM AT AU AZ BA BB BG BR BY CA CH QN CU CZ DE DK
DESIGNATED STATES
                       EE ES FI GB 3D 3E 3H 3M HR HU ID IL IN IS JP KE KG KP
                       KR KZ LC LK LR LS IT LU LV MD MG MK MN MW MX NO NZ PL
                       PT RO RU SI SE SO SI SK SL TU TM TR TT UA UG UZ VN YU
                       ZA ZW GH GM KE LS MW SD SL SZ UG ŹW AM AZ BY KG KZ MD
                       RU TJ IM AT BE CH CY DE DK ES FI FA GB GR IE IT LU MC
                       MI PT SE BE BU DE DG CI OM GA GN GW ML ME NE SM TO TO
                       WI 4999-DK138 A 19990317
APPLICATION INFD.:
                       DM 1998-0413/98
                                              19998324
PRICRITY INFO.:
                       DM 1995-0464/98
                                              19980402
                       DK 1998-PA 1998 01559 19981126
ABEN
      The use of compounds of general formula (I) as factor VII-tissue factor
      inhibitors as well as
      novel benzoaxin derivatives are disclosed. The compounds of general
       formula (I) and pharmateutical
      acceptable salts thereof have been shown to be inhibitors of factor
      VIIa-tissue factor activity. The
       compounds show anticoagulant properties. The compounds are useful for
       the treatment of deficiencies
       of blood clotting factors or the effects of inhibitors to blood clotting
       factors. Methods for
       inhibiting clotting activity are disclosed.
      L'invention se rapporte a l'utilisation de composes representes par la
ABFR
      formule (I) en tant
      qu'inhibiteurs du complexe facteur VII-facteur tissulaire ainsi qu'a de
      nouveaux derives
      benzoxazines. On a montre que les composes representes par la formule
      (I) et leurs sels
      pharmaceutiquement acceptables sont des inhibiteurs de l'activite du
      facteur VIIa-facteur
      tissulaire. Ces composes possedent des proprietes anticoagulantes.
      Lesdits composes s'averent utiles
      au traitement des anomalies des facteurs de coagulation sanquine ou des
      effets d'inhibiteurs sur les
      facteurs de coaquiation sanquine. L'inventior se rapporte egalement a
      des procedes d'inhibition de
      l'activité de coaquiation.
      ANSWER 57 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999040907 PCTFULL ED 20020515
                      METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE
TITLE (ENGLISH):
                      FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
TITLE (FRENCH):
                      PROCEDES D'APPORT REGULE DE DISULFURE DE CARBONE DANS
                      LE TRAITEMENT D'ETATS INFLAMMATOIRES
INVENTOR(\mathcal{S}):
                       LAI, Thing-San
                      MEDINOX, INC.; LAI, Ching-San
PATENT ASSIGNEE(S):
LANGUAGE OF PUBL .:
                      English
DOCUMENT TYPE:
                      Patent
PATENT INFORMATION:
                       NUMBER
                                         KIND
                                                  DATE
                       W0 3940907 Al 19990819
                       AL AM AT AU AZ BA BB BG BE EY CA CH CN CU CZ DE DK EE
DESIGNATED STATES
                       ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
                       K3 DC LK LR LS LT LU LV MD MG MK MN MW MX NO NO PL PT
                       RO BU SD SE SG SI SK SL TJ TM TF TT UA UG US UZ VN YU
                       ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD EU TJ
                       TM AT BE CHICY DE DR ES FI FR GB GR IE IT LU MC NL PT
                       SE BE BU DE OG DI OM DA GN GW ML MR NE SN TD TG
APPLICATION INFO.:
                      WO 1399-U32679
                                           -A 19990208
                      US 1998-61/074,741
PRICRITY INFO.:
                                              19980213
      In accordance with the present invention, it is described for the first
ABEN
       time that CS2 is
       capable of directly innihiting the activity of NF4kappa; B, without the
      need for any other active
```

```
effect of, for example,
      pyrrolidine mithipdarmamate and other dithipdarbamates on NF4kappa; B may
       simply be attributed to CS2
      released upon i(in vivo) hydrolysis of dithiocarbamates rather than as a
      result of the action of the
      garental compound per se. Dithiodarpamates may therefore be considered
       is pro-drugs for 182 for the
       treatment of inflammatory conditions mediated via NFAkappa; B pathways.
       Thus, in additionable with the
      present invention, there are provided methods for the treatment of
       inflammatory conditions mediated
      by NF4kappa; B pathways, as well as novel compositions useful for such
      methods.
ABFR
      Selon la presente invention, in decrit pour la première fois que du
      disulfure de carbone 332
      meut inhiber directement l'activite de NEgkappa; B (facteur nucleaire
       Rappa B) sans que la presence
      d'autres agents ne soit necessaire. Un en à deduit, par consequent, que
      l'on rouvait attribuer
      l'effet inhibiteur sur le facteur NFSkappa; B, par exemple du
      dithiocarbamate de pyrrolidine et
      d'autres dithiocarbamates, plutot au CS2, libere lors d'une hydrolyse
      i(in vivo) de
      dithiocarbamates, qu'au resultat de l'action du compose parenteral en
      lui-meme. On peut donc
      considerer des dithiocarbamates comme des promedicaments de CS2, dans le
      traitement d'etats
      inflammatoires induits par des mecanismes d'action du facteur
      NFκ B. Ainsi, selon l'invention,
      on decrit des procedes de traitement d'états inflammatoires induits par
      des mecanismes d'action du
      facteur NFκ B, de meme que des nouvelles compositions utiles dans
      de tels procedes.
      ANSWER 58 OF 100 ECTFULL COPYRIGHT 2002 Univentio
L139
ACCESSION NUMBER: 1999040787 PCTFULL ED 20020515
                      MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED
TITLE (ENGLISH):
                      THERAPEUTIC METHODS EMPLOYING SAME
                      AGENTS MODIFIES, ACTIFS SUR LE PLAN PHARMACOLOGIQUE, ET
TITLE (FRENCH):
                      PROCEDES THERAPEUTIQUES AMELIORES ET METTANT EN GEUVRE
                      CES AGENTS
INVENTOF(S):
                      LAI, Ching-San
PATENT ASSIGNEE(S):
                     MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF FUBL.:
                      English
                      Patent
DOCUMENT TYPE:
PATENT INFORMATION:
                      NUMBER
                                        KIND
                                                 DATE
                       WO 9940787 Al 19990819
                       AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CC DE DK EE
DESIGNATED STATES
                       ES FI GE GD GE GH GM HR HU ID IL IN IS JP KE EG KP KR
                       HZ IC LE LE LS LT LU LV MD MG ME MN MW ME NO NE EL PT
                       RO RU SI SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
                       IN GH GM KE LS MW 3D SI UG IW AM AZ BY KG KI MD EU TJ
                       TM AT BE CH CY DE DK E3 FI FR GB GR IE IT LU MC NL PT
                       THE BF BJ OF OG OI OM GA GN GW ML MR NE SN TD TG
                      WG 1939-US2679 A 19990208
APPLICATION INFO.:
                      US 1998-60/074,694
                                              19980213
      In accordance with the present invention, there are provided midified
      forms of
      pharmacologically active agents (e.g., anti-inflammatory agents) which
      provide increased prolonged
      circulating levels of the active agent, thereby allowing administration
      of reduced levels of the
```

agents to be present. It is assumed, therefor, that the inhibitory

agent to the recipient. This not only reduces the cost of drug, it also reduces the level to which

the recipient is exposed to potentially harmful agents. Invention

compounds provide a new class of

pharmacologically active agents which cause a much lower incidence of side effects due to the

benefits obtained by modifying the pharmacologically active agents as described herein.

Selon la presente invention, des formes modifiées d'agents actifs sur le ABFF. colan charmacologique

(par exemple des agents anti-inflammatcires) apportent des

concentrations direulatoires accrues/a

effet prolonge de l'agent actif, permettant ainsi d'administrer des concentrations reduites de cet

agent a un receveur, ce qui diminue non seulement le cout du medicament mais equlement la

concentration en agents potentiellement nocifs, a laquelle le receveur est empose. Les composes de

l'invention constituent une nouvelle classe d'agents actifs, sur le plan pharmacologique, provoquant

une frequence moins grande d'effets secondaires, par suite de l'effet benefique obtenu par

modification pharmacologique de ces agents actifs.

ANSWER 59 OF 100 POTFULL COPYRIGHT 2002 Univention

ACCESSION NUMBER: 1999027962 PCTFULL ED 20020515

TITLE (ENGLISH):

USE OF A FIBRINGGEN RECEPTOR-ANTAGONIST FOR PREVENTING

DISSEMINATED INTRAVASCULAR COAGULATION

TITLE (FRENCH):

UTILISATION O'UN ANTAGONISTE DU RECEPTEUR DU

FIBRINGGENE FOUR LA PREVENTION DE LA COAGULATION

INTRAVASCULATRE DISSEMINEE

INVENTOR(S): WIEMANN, Gundula
PATENT ASSIGNEE(S): WIEMANN, Gundula
LANGUAGE OF PUBL:

LANGUAGE OF PUBL.:

German Patent

DOCUMENT TYPE: PATENT INFORMATION:

NUMBER KIND DATE

Wo 9927962 Al 19990610

DESIGNATED STATES

CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

NL PT SE

APPLICATION INFO.: WO 1998-EP7833 A 19981302 PRIORITY INFO.: DE 1997-197 53 393.3 19971302

The present invention relates to the use of fibrinogen ABEN

receptor-antagonists for preventing

disseminated intravascular coaquilation (DIC) related to sepsis or

systemic inflammatory response

syndrome (SIRS) in humans.

La presente invention concerne l'utilisation d'antageniste du recepteur ABFE du fibrinogene pour la

prevention de la chagulation intravasculaire disseminée (DIC) en relation avec la septicemie ou le

syndrome de reaction inflammatoire systemique (SIRS) chez l'homme.

ANSWER 60 OF 100 POTFULL COPYRIGHT NOW Univentic L139

ACCESSION NUMBER: 1999017784 FOTFULL ED 20020515

TITLE (EMGLISH):

TREATING OCCLUSIVE PERIPHERAL VASCULAR DISEASE AND COROMARY DISEASE WITH COMBINATIONS OF HEPARIN AND AN

ADENDOIDE AZ AGONIST, OF WITH ADENOSINE

TITLE (FRENCH):

TRAITEMENT DE LA VASCULOPATHIE FERIPHERIQUE OBLITERANTE ET LE LA CORCNAPITE AU MOYEN DE CONBINAISONS D'HEPARINE ET D'UN AGONISTE AZ ADENDSINE, DU AU MOYEN D'ADENOSINE

INVENTOR(S): BARRON, Hal, V.; BOTVINICK, Elias
PATENT ASSIGNEE'S: REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION
LANGUAGE OF PUBL: English

```
DOCUMENT TYPE:
PATENT INFORMATION:
```

Patent

KIND NUMBER DATE W0 9917784 Al 19990415 DESIGNATED STATES AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE EX FI 3B 3N 3E 3H 3M HR HT ID IL IS JP KE KG KP KR KZ IN LK IR IS IT IU WY MO MU MK MW MW MW NO NZ PI PT RO RU SD SE SG SI SK SL TJ TM TH TT UA UG VO WW YU ZW GH SM KE LS MW SD SZ UG ZW AM AR BY KG KZ MD RU TJ TM AT BE OH BY DE DU ES FI FR GB GR IE IT LU MO NU PT SE BF BI OF OG DI OM GA GN GW ML MR NE SN TD TG WD 1998-USB1153 APPLICATION INFO .: A 19981007 US 1997-08/946,196 13971007 US 1998-09/167,816 19981007

PRIORITY INFO.:

Compositions and methods for treatment of occlusive peripheral vascular ABEN disease and coronary

disease are disclosed. The compositions and methods allow treatment of diseases associated with

population of coronary vessels, for example, by promoting growth of new blood vessels, i(i.e.),

angingenesis and/or by recruitment of collaterals. The methods involve the co-administration of an

adenosine A2 receptor agonist, i(e.g.) adenosine, and heparin and/or a heparin-like substance over a

period of several days. In particular, this invention is applicable to improving collateral coronary

circulation in patients suffering from myocardial infarction.

ABFF: Cette invention concerne des compositions et des procedes permettant de traiter la

vasculopathie peripherique obliterante et la coronarite. Les compositions et les procedes permettent

de traiter des maladies associées à l'occlusion des vaisseaux coronaires, par exemple, au moyen de

l'activation de la croissance de nouveaux vaisseaux sanguins (d'est-a-dire par angiogenese et/ou par

recrutement d'arteres colluterales). Le procede consiste a coadministrer un agoniste du recepteur Al

adenosine, par exemple de l'adenosine et de l'heparine et/ou une substance similarre a l'heparine

sur une periode de plusieurs jours. D'une manière plus specifique, cette invention peut s'appliquer

pour ameliorer la circulation des arteres coronaires collaterales chez des patients atteints d'infarctus du myocarde.

L139 ANSWER 61 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTAMMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER:

TITLE:

EUROPATFULL EW 199919 FS OS 915154

Yeast cells engineered to produce pheromone system

protein surrogates, and uses therefor.

Hefe Zellen so konstruiert, dass sie Proteinsurrogate des Pheromonsystems produzieren und Anwendungen dafuer. Cellules de levure traitées pour produire des substituts de proteines du système de pheromones, et leurs emplois. Fowlkes, Dana Merriman, 90 Green Street, Apartment 2,

New York, NY 10012, US;

Broach, Jim, 360 East 38th Street, Apartment 2A, New

York, NY 10128, US;

Manfredi, John, ééé Greenwich Street, Apartment 55é, New

York, NY 10014, US:

Klein, Christine, 666 Greenwich Street, Apartment 556,

New York, MY 10014, US;

INVENTOR(S):

Murphy, Andrew J., 17 Windsor Place, Montolair, NJ

07043, US; Paul, Jeremy, 197 Route 9W, Palisades, MY 10964, US; Trueneart, Joshua, 212 South Broadway, South Nyack, NY

1096 , YS

PATENT ASSIGNEE S): Cadus Pharmaceuticals, Inc., 7th floor, 180 Varick

Street, New York, NY 10014, US

PATENT ASSIGNEE NO: 1361561

Frice, Vincent Andrew et al, FEY HEATH & SPENCE The Old AGENT:

College 53 High Street, Horley Furrey RH6 7BN, GB

AGENT NUMBER: 795.3

ESP1999034 EF 0915154 A1 990513 OTHER SOURCE:

Wila-EPZ-1994-H19-Tla SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MG; R NL; R PT; R SE

PATENT INFO. PUB. TYPE: EPA! EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_ EP 915154 A1 19990510 'OFFENLEGUNGS' DATE: 19990512 EP 1998-202997 APPLICATION INFO .: 19940323 PRIORITY APPLN. INFO.: US 1993-41431 19930331 US 1994-190328 19940131

RELATED DOC. INFO.: EP 692025 DIV

ANSWER 62 OF 100 EUROPATFULL COPYRIGHT 2002 WILA L139

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 634830 EUROPATFULL EW 199924 FS PS

INHIBITORS OF THROMBOSIS. TITLE: INHIBITOREN GEGEN THROMBOSE. INHIBITEURS DE LA THROMBOSE.

VLASUK, Seorge Phillip, 3024 Garboso Street, Carlsbad, INVENTOR(S):

CA 93009, US;

WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA

92024, U3;

PEARSON, Daniel Andrew, 149 Beals Road, Bedford, NH

03110, US;

ABELMAN, Matthew Mark, 873 Stevens Avenue, 3312, Solana

Beach, CA 92075, US

CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San FATENT ASSIGNEE(3):

Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501390

AGENT: Irvine, Jonquil Claire et al, J.A. KEMP & CO. 14 South

Square Gray's Inn, London WC1R SLX, GB

AGENT NUMBER: 7418.1

EPB1999035 EP 0684830 B1 990616 OTHER SOURCE:

SCURCE: Wila-EPS-1999-H24-T1

DECUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Verbeffentlichung in Englisch P AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R DESIGNATED STATES:

IE; PIT; PLI; PLU; PMC; RNN; PPT; RSE

PATENT INFO.PUB.TYPE: EPB1 EUROPAELSCHE PATENTSCHRIFT (Internationale

Anmeldung)

PATENT INFOFMATION:

	PATENT NO	KIND	DATE
	EP 8:4530	Б1	19990610
'OFFENLEGUNGS' DATE:			199512Cm
APPLICATION INFO.:	EP 1994-90968		19940214
PRICRITY APPLM. INFO.:	US 1993-17125		19933212

US 1994-195995 19940311

W0 94-US1612 940214 INTAKZ W0 9417817 940818 INTPNR 940818 INTPNA

REFERENCE PAT. INFO.: WD 93-1477 A - WO 93-19756 A

US 4394065 A

ANSWER 63 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVEE

6647-6 ACCESSION NUMBER: EUFOPATFULL EW 194912 FS PS

ARGININE METO-AMIDE ENDYME INHIBITORS. TITLE:

INHIBITOREN DES ARGININ-KETGAMID-ENZYMS.

CETO-AMIDE D'ARGININE COMME INHIBITEURS ENZYMATIQUES. WEBB, Thomas, Roy, 2250 Colony Terrace, Encinitas, CA INVENTOR(S):

92024, US;

MILLER, Todd, Anthony, 1710 South El Camino Real, E-208,

Encinitas, CA 92024, US;

VLASUK, George, Phillip, 3024 Garboso Street, Carlsbad,

CA 92009, US;

ABELMAN, Matthew, Mark, 873 Stevens Avenue, 3312, Solana

Beach, CA 92075, US

CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San FATENT ASSIGNEE(S):

Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501290
AGENT: 1501290
Viering, Jentschura & Partner, Postfach 22 14 43, 80504

AGENT NUMBER: 100645

EPB1999017 EP 0664786 B1 990324 OTHER SOURCE:

Wila-EPS 1999-H12-T1 SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale

Anmeldungi

FATENT INFORMATION:

RELATED DOG. INFC.:

PATENT NO KIND DATE EP 664786 B1 19990324

19950803 'OFFENLEGUNGS' DATE: APPLICATION INFO.: EP 1885-88500 19921016
PRIORITY APPLN. INFO.: US 1892-962301 19921016
RELATED DOC. INFO.: WO 93-US10015 931018 INTAKE
WO 9403941 940428 INTPNR

REFERENCE PAT. INFO.: EP 195010 A WO 92-11850 A

WO 92-12140 A US 3966701 A US 4161922 A US 4473745 A US 4171299 A US 5221752 A

REF. NON-PATENT-LIT.: J. AM. CHEM. SOC., vol.112, 1990 pages 7053 - 7054 N.

FUSETANI, 3. MATSUNAGA 'Cyclotheonamides, Potent

Thrombin Inhibitors from a Marine Sponge'

L139 ANSWER 64 OF 100 MEDILINE DUPLICATE 4

ACCESSION NUMBER: 2000014:45 MEDLINE

DOCUMENT NUMBER: 20014045 PubMed ID: 10543068

Incorporation of noncoded amino abids into the N-terminal TITLE:

domain 1-47 of hirudin yields a highly potent and selective

thromkin inhibitor.

De Filiggis V; Russo I; Vindigni A; Di Cera E; Salmaso S; AUTHOR:

Fontana A

CRIBI Biotechnology Center and Department of Pharmaceutical GORPORATE SOURCE:

Sciences, University of Padua, Italy.

HL49413 'NHLBI) CONTRACT NUMBER:

HL59141 (NHLBI)

SCURCE: PROTEIN SCIENCE, 1999 35t, 9 (13) 2213-7.

Jaurnal code: 9211750. ISSN: 0961-8368.

PUB. CHUNTRY: United States

DOCUMENT TYPE: Journal; Article; @JOURNAL ARTICLE.

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200000

ENTRY PATE: Entered STN: 20010229

Last Updated on STN: 20100229

Entered Medline: 20000211

Hirudin is an anticoagulant polypeptide isolated from a medicinal leech that inhibits throme in with extraordinary potency (Kd = 0.2-1.0 pM) and selectivity. Hirudin is composed of a compact N-terminal region (residues 1.47, cross-linked by three disulfide bridges) that binds to the active site of thrombin, and a flexible C-terminal tail (residues 48-64) that interacts with the expsite I of the enzyme. To minimize the sequence of hirudin able to bind thrombin and also to improve its therapeutic profile, several N-terminal fragments have been prepared as potential antipragulants. However, the practical use of these fragments has been impaired by their relatively poor affinity for the enzyme, as given by the increased value of the dissociation constant (Kd) of the corresponding thrombin complexes (Kd = 30-400 nM). The aim of the present study is to obtain a derivative of the N-terminal domain 1-47 of hirudin displaying enhanced inhibitory potency for thrombin compared to the natural product. In this view, we have synthesized an analogue of fragment 1-47 of hirudin HM2 in which Vall has been replaced by tert-butylglycine, Ser2 by Arg, and Tyr3 by beta-naphthylalanine, to give the BugArgNal analogue. The results of chemical and conformational characterization indicate that the synthetic peptide is able to fold efficiently with the correct disulfide topology (Cys6-Cys14, Cys16-Cys28, Cys22-Cys37), while retaining the conformational properties of the natural fragment. Thrombin inhibition data indicate that the effects of amino acid replacements are perfectly additive if compared to the singly substituted analogues (De Filippis V, Quarzago D, Vindigni A, Di Cera E, Fontana A, 1998, Biochemistry 37:13507-13515), yielding a molecule that inhibits the fast or slow form of thrombin by 2,670- and 6,818-fold more effectively than the natural fragment, and that binds exclusively at the active site of the enzyme with an affinity (Kd, fast = 15.4 pM, Kd, slow = 220 pM) comparable to that of full-length hirudin (Kd, fast = 0.2 pM, Kd, slow = 5.5 pM). Moreover, BugArgNal displays absolute selectivity for thrombin over the other physiologically important serine proteases trypsin, plasmin, factor Xa, and tissue plasminogen activator, up to the highest concentration of inhibitor tested (10 microM).

L139 ANSWER 65 OF 100 USPATFULL DUPLICATE 5

ACCESSION NUMBER: 1999:39504 USPATFULL

PATENT ASSIGNEE(S):

Inhibitors of factor Xa

INVENTOR(3):

TITLE:

Brunck, Terence Kevin, San Diego, CA, United States

Webk, Thomas Roy, Encinitas, CA, United States

Ripka, William Charles, San Diego, CA, United States

Corvas International, Inc., San Diego, CA, United

States (U.S. corporation)

PATENT INFORMATION: US 5739112 19980414
APPLICATION INFO.: US 1995-465115 19950605 (8)
RELATED APPLN. INFO:: Cintinuation of Ser. No. US 1993-168964, filed on 15
Dec 1993 which is a continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cecilia J. ASSISTANT EXAMINER: Luxton, David

LEGAL REPRESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS:

EMEMPLARY CLAIM:

NUMBER OF DEAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT. Novel compounds, their salts and compositions related thereto having

activity against marmalian factor Xa are disclosed.

The nevel compounds include peptide aluehyde analogues

naving substantial potency and specificity as inhibitors of

mammalian factor Xa are further disclosed. The

compounds are thought useful as inhibitors of factor

Xa in vitro or as a therapeutic agent for the prevention and treatment of conditions: characterized by abnormal thrombosis in

mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 66 OF 100 PUTFULL COPYRIGHT 1002 Univention L139

ACCESSION NUMBER: 1948085483 PCTFULL ED 20020814

TITLE (ENGLISH:

CONJUGATES OF DITHICCARBAMATES WITH PHARMACCLOGICALLY

ACTIVE AGENTS AND USES THEREFOR

TITLE (FRENCH):

CONJUGUES DE DITHIOCARBAMATES COMPRENANT DES AGENTS

PHARMACOLOGIQUEMENT AUTIFS ET UTILISATIONS DESDITS

CONJUGUES

INVENTOR(3):

LAI, Ching-San

PATENT ASSIGNEE(S):

MEDINOX, INC.; LAI, Ching-San

LANGUAGE OF FUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER KIND DATE \_\_\_\_\_

WO 9855453 A1 19981210

DESIGNATED STATES

AL AM AT AU AZ BA BB BG BP BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LE LS LT LU LV MD MG MK MN MW MX NO NU PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG DW AM AD BY KG KZ MD RU TJ TM AT BE CH CY DE DK E3 F1 FR GB GR IE IT LU MU NL FT SE BF

BJ OF OG CI OM GA GN ML ME NE SN TD TG

APPLICATION INFO .:

WO 1998-US10095 A 19980519

PRIORITY INFO.:

US 1997-8/869,158 19970604

In accordance with the present invention, there are provided conjugates of nitria oxide

scavengers (e.g., dithiocarbamates, or DC) and pharmacologically active agents (e.g., NSAIDs).

Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory

agents) which cause a much lower incidence of side-effects due to the protective effects imparted by

modifying the pharmacologically active agents as described herein. In addition, invention conjugates

are more effective than unmodified pharmacologically active agents because cells and tissues

contacted by the pharmacologically active agent(s) are protected from the potentially damaging

effects of nitric oxide overproduction induced thereby as a result of the do-production of mitric

oxide shavenger (e.4., dithipparbamate), in addition to free

pnarmapslogically active agent, when invention conjugate is cleaved.

L'invention concerne des conjugues d'accepteurs de monoxyde d'azote ABFR dithid carbamates ou DC,

par exemple: et des agents pharmacologiquement autifs 'AINS, par

actifs 'agents anti-inflammatoires, par exemple- qui ont une incidence d'effets secondaires peaucoup maindre en raison de l'effet de protection produit par la modification de des agents pharmacologiquement aptifs. En outre, les conjugues de l'invention sont plus efficaces que les adents pharmacologiquement actifs puisse que des cellules ou des tissus places au contact desdits agents sont protèges contre les effets potentiellement déteriorants de la surproduction de monoxyde d'azote ainsi induite par la diproduction d'accepteurs de monoxyde d'azote (des dithiocarpamates, car exemple), a laquelle s'a oute celle d'un agent libre pharmacologiquement actif lorsque le conjugue est clive. AMSWER 67 OF 100 POTFULL COPYRIGHT 2002 Univention ACCESSION NUMBER: 1995011066 PCTFULL ED 20020514 POLYDITHIOCAREAMATE-CONTAINING MACROMOLECULES AND THE TITLE (ENGLISH): USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TITLE (FRENCH): MACROMOLECULES CONTENANT DU POLYDITHIOCARBAMATE, ET LEUR UTILISATION DANS DES APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES INVENTOR(3): LAI, Ching-San MEDINOX, INC.; LAI, Ching-San PATENT ASSIGNEE(S): LANGUAGE OF FUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: KIND NUMBEE. DATE WO 9811066 A1 19930319 DESIGNATED STATES AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV ME MG MK MN MW MM NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW GH KE LS MW SD SE UG 2W AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML ME NE SN TD TG APPLICATION INFO .: Wo 1997-US15324 A 19970828 19960910 PRIORITY INFO.: US 1996-60/025,967 US 1997-8/399,087 19970723 In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as derebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiccarbamates are linked to the surface of a macromolecule (e.g., albumin protein) either ky using pross-linking reagents or by non-specific binding to produce polydithiocarkamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or insubition of formation (either directly or indirectly) of species which induce the expression of inducible nitric cxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In accordance with yet another aspect of the present

l'invention donnent une nouvelle dategorié d'agents pharmacologiquement

exemple. Les conjugues de

ABEN

invention, magnetic resonance imaging methods have seen developed for the measurement of serebral and cardias blood flow and infarct volume in isonemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a madrimolequie as contrast agents. L'invention concerne une nouvelle classe de medicaments destines au ABFR traitement therapeutique de certains troubles, tels qu'une apoplexie ou d'autres accidents causes par une ischemie cu une reperfusion. Des dithiccarbamates sont lies a la surface d'une madrimolecule (par exemple, une proteine d'albumine), soit au moyen de reactifs reticules, soit par liaison non specifique, de facon a produire des compositions contenant des macromolecules de polygithiccarbamate, qui representent une nouvelle classe de medicaments servant au traitement therapeutique de certains troukles, tels qu'une apoplexie ou d'autres accidents causes par une ischemie ou une reperfusion. Dans un autre mode de realisation, des procedes therapeutiques combinatoires ont ete elakores pour inactiver ou inhiber in vivo (soit directement soit indirectement) la formation d'especes induisant l'expression de synthase d'oxyde nitrique inductible et pour reduire le niveau d'oxyde nitrique produit en consequence de l'empression de synthase .ND. Dans un autre mode de realisation, des procedes d'imagerie par resonance magnetique ont ete mis au point pour mesurer le debit sanguin du cerveau et du coeur et le volume de l'infarctus lors de troubles ischemiques ou de crise cardiaque. De tels procedes ont recours a des complexes contenant du fer d'une composition renfermant un dithipparhamate et une macromplecule comme agents de contraste.

L139 ANSWER 68 OF 100 ACCESSION NUMBER: TITLE (ENGLISH):	1998005333 PCTFULI USE OF BETA-SHEET	ED 2002051 MIMETICS AS	
TITLE (FRENCH):	UTILISATION DE MIN INHIBITEURS DE PRO INHIBITEURS DE FAC	TEASE ET DE	
INVENTOR(S):	Kim; OGBU, Cyprian Hwa-Ok; BOATMAN, F	n, Okwara; EG Patrick, Doug trick; BABU,	icola; McMILLAN, Michael, UCHI, Masakatsu; KIM, las, Jr.; UEBAN, Jan; Suresh; FERGUSON, Mark,
PATENT ASSIGNEE(3):	McMILLAN, Michael, Masakatsu, KIM, Hw	Kim; OGBU, wa-Ok; BOATMA Joseph, Pat	el; QABAR, Maher, Nicola; Cyprian, Okwara; EGUCHI, N, Patrick, Douglas, Jr.; rick; BABU, Suresh; topher, Todd
LANGUAGE OF FUBL.: DOCUMENT TYPE: PATENT INFORMATION:	2		
	NUMBER	KIND DA	TE 
	WO 9805333	Al 199302	12

DESIGNATED STATES

AL AM AT AM BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH HU IL IS OP KE KG KP KR KZ LO LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO BU SO SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD BU TJ TM AT BE CH DE DK ES FI FR

```
3B GR IE IT LU MO NL PT SE BF BJ OF OG CI CM GA GN ML MR NE SN TD T3
                                          A 19970805
APPLICATION INFO.:
                       WO 1997-US13692
                       US 1996-8/692,420 19960805
PRIORITY INFO.:
                                               .9961002
                        WS 1996-9/725,073
                       vs 1997-8/797,915
                                               19970210
                                               .9973519
                        US 1997-60/040,067
      'beta'-sheet mimetics and methods relating to the same are disclosed.
ABEN:
      The 'reta'-sneet mimetics
      have utility as protease and kinase inhibitors, as well as inhibitors of
       transcription factors.
      Methods of the invention include administration of a 'beta'-sheet
      mimetic, or use of the same for
       the manufacture of a medicament for treatment of a variety of conditions
       associated with the
       targeted protease, kinase and/or transcription factor.
       L'invention concerne des mimetiques de feuillets beta et des procedes
ABFR
      les concernant. Les
       mimetiques de feuillets beta sont utiles comme innibiteurs de protease
       et de kinase ainsi que comme
       inhibiteurs de facteurs de transcription. Des procedes de l'invention
       comprennent l'administration
       d'un mimetique de feuillets beta ou l'utilisation dudit mimetique pour
       fabriquer un medicament
       destine au traitement d'une variete d'états pathologiques associes a la
       protease, a la kinase et/ou
       au facteur de transcription cibles.
      ANSWER 69 OF 100 POTFULL COFFRIGHT 2002 Univention
ACCESSION NUMBER: 1998001438 PCTFULL ED 20020514
TITLE (ENGLISH):
                      AMIDINOINDOLES, AMIDINOADOLES, AND ANALOGS THEREOF AS
                       INHIBITORS OF FACTOR Ka AND OF THROMBIN
TITLE (FRENCH):
                       AMIDINOINDOLES, AMIDINOADOLES ET LEURS ANALOGUES
                       AGISSANT EN TANT QU'INHIBITEURS DU FACTEUR Ka ET DE LA
                       THROMBINE
INVENTOR(S):
                       DOMINGUEZ, Colia; HAN, Q1; DUFFY, Daniel, Emmett; PARK,
                       Jeongsook, Maria; QUAM, Mimi, Lifen; ROSSI, Karen,
                       Anita; WEXLER, Ruth, Richmond
PATENT ASSIGNEE(S):
                       THE DU PONT MERCK PHARMACEUTICAL COMPANY
LANGUAGE OF FUBL.:
                       English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                                                  DATE
                       NUMBEE
                                         KIND
                        ......
                       WO 9801428 Al 19980115
                       AM AU AZ BR BY CA CN CZ EE HU IL JE KG KR KZ LT LV MD
DESIGNATED STATES
                       MK NO NE PL RO EU SG SI SK TJ TM UA VN AM AZ BY KG KZ
                       MD RU TU TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC
                       NL PT 3E
                       W0 1997-US11325 A 19970630
US 1996-8/676,766 19960708
APPLICATION INFO .:
                       US 1997-60/049,519 19970813 idation decrei
PRIORITY INFO.:
      The present application describes amidinoundoles, amidinoazoles, and
ABEN
      analogs thereof of formula
       (I): wherein W, W1, W2, and W3 are selected from CH and N, provided that
      one of WI and W2 is
       C'C(:NH/NH2) and at mist two of W, Wl, W2, and W3 are N and one of Ja
      and Ib is substituted by
      - [CH2:n-Z-A-B, which are useful as inhibitors of factor Ma or thrombin.
       La presente demande concerne des amidincindoles, des amidinoazoles et
ABFR
      leurs analogues repondant
      a la formule (T), cu W, Wl, W2 et W3 sont choisis parmi CH et N, a
      condition que l'un des elements
      W. et W2 scit CCCTMH(NH2), que deux au plus des elements W, W1, W2 et
      W3 scient N, et que l'un des
```

elements Ja et Jb soit substitue par - (CH2)n-Z-A-B, et pouvant etre utiles en tant qu'inhibiteurs du fasteur Ma ou de la thrombine.

L139 ANSWER 73 OF 113 POTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1998000442 POTFULL ED 20020514

TITLE (ENGLISH): SERINE PROTEASE INHIBITORS

TITLE "FRENCH:: INHIBITEURS DE LA SERINE PROTEAME

INVENTOR'S:: DEADMAN, John, Joseph; ELGEMPY, Said; GREEN, Donovan;

SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr; GOODWIN, Enristopher, And:ew; KAKKAR, Vijay, Vir

THROMBOSIS RESEARCH INSTITUTE; DEADMAN, John, Joseph; PATENT ASSIGNEE(S):

ELGENDY, Said: GREEN, Donovan; SKORDALAMES, Emmanuel; SIULLY, Michael, Finbarr; 300DWIN, Christopher, Andrew;

KAKKAR, Vijay, Vir

English LANGUAGE OF FUBL : DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WD 9800442 Al 19980108

DESIGNATED STATES AL AM AT AU AZ BA BB BG BR EY CA CH CN CU CZ DE DK EE

ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MM NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UB UB VN YU ZW GH KE LS MW SD SO UG ZW AM AS BY KG KZ MD RU TU TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

GN ML MR NE SN TD TG

WO 1997-GB1574 A 19970611 APPLICATION INFO.: PRIORITY INFO.: GB 1996-9613719.5

19960629

Bifunctional serine protease inhibitors and methods of preparing

boron-containing peptides are

provided. The serine protease inhiitors comprise a catalytic

site-directed moiety, which binds to

and inhibits the active site of a serine protease, and an exesite

associating moiety, which are

joined by a connector molety. The datalytic site directed molety and the

expsite associating molety

are capable of binding simultaneously to a molecule of the serine

protease.

ABFF. L'invention concerne des inhibiteurs bifonctionnels de la serine

protesse et des procedes de

preparation de peptides contenant du bore. Ces inhibiteurs comprennent

une fraction catalytique

dirigee qui se lie au site actif d'une serine protease et l'inhibe, et

une fraction se liant a un

exosite, des deux fractions etant reunies par une fraction de couplage.

La fraction dirigen

catalytique et la fraction se liant a un exosite sont capables de se

lier simultanement a une

molecule de la serine protease.

L139 ANSWER 71 OF 100 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 818744 EUROPATFULL EW 199843 FS OS

TITLE: Process for selecting candidate drug compounds.

Verfahren zur Auswahl von Kandidat-Drogenverbindungen. Procede de selection des compositions medicamenteuses

patentielles.

Young, Stephen Clinton, 3 Cranbourne Road, Heaton Moor, INVENTOR'S::

Stockport, Cheshire SF4 4DL, GB;

Murray, Christopher, I Wheatfield Close, Titherington,

Maddlesfield, Cheshire SK10 2TT, GB

PATENT ASSIGNEE S.: Proteus Molecular Design Limited, Béechfield House, Lyme

906234 PATENT ASSIGNEE NO:

Green Business Park, Macclesfield, Cheshire SKI1 3JL, GB

Cockbain, Julian, Ir., Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Vistoria Street, London EC4V

4EL, GB

AGENT NUMBER: 52841

AGENT:

OTHER SOURCE: ESP1998004 EP 0818744 A2 980114

Wila-EPZ-1945-H03-T2a SIMECE:

DECUMENT TYPE: Patent

Anneldung in Englisch; Verteffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: RAT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; P IE; F IT; F LI; R LU; R MC; R NL; F PT; F SE

PATENT INFO.PUB.TYPE: EFA2 EUROPAEISCHE PATENTANMELDUNG

FATENT INFORMATION:

PATENT NO KIND DATE \_\_\_\_\_\_ A2 19980114 EF 313744 'OFFENLEGUNGS' DATE: 19380114 APPLICATION INFO.: EF 1997-304412 19970624 PRIORITY APPLN. INFO.: GE 1996-14302 19960708 GB 1996-16562 19960807

L139 ANSWER 72 OF 100 EUFOPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

703933 EUFOFATFULL EW 199841 FS PS ACCESSION NUMBER:

FACTOR VII-DERIVED PEPTIDES. TITLE:

FARTOR VII-PEPTIDE. PEPTIDES DERIVES DU FACTEUR VII.

STEPHENS, Ross Wentworth, Silurveien 19, N-0380 Oslo, INVENTOR(S):

OFNING, Lars, Thomas Heftyes gate 47B, N-0267 Oslo, NO; SAKAPIASSEN, Kjell Steina:, Kygd Alle 33B, N-0262 Oslo,

NO

NYCOMED IMAGING AS, Nycoveien 1-2, 0401 Cslo 4, NO PATENT ASSIGNEE(S):

PATENT ASSIGNEE NO: 1564564

Matthews, Derek Peter et al, Frank B. Dehn & Co., AGENT:

European Patent Attorneys, 179 Queen Victoria Street,

London EC4V 4EL, GB

AGENT NUMBER: 60131

OTHER SOURCE: EPB1998055 EP 0703923 R1 931007

Wila-EPS-1993-H41-T1 SOURCE:

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE:

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUFOPAEISCHE PATENTSCHEIFT (Internationale

Anmeldung)

PATENT INFOFMATION:

PATENT NO KIND DATE \_\_\_\_\_ EP 703923 B1 19931007 'OFFENLEGUNGS' DATE: 19960403 EF 1994-918437 APPLICATION INFO.: 19940617 PRIORITY APPLN. INFO.: GB 1993-12601 19930813 GB 1994-9335 19940510 940617 INTAKZ WD 94-GB1315 WD 9500541 950105 INTPNR

RELATED DOC. INFO.:

REFERENCE FAT. INFO.: EP 446797 A WO 90-03390 A

W0 93-09804 A

1139 ANSWER 73 OF 100 WRIDS (C) 2002 THOMSON DERWENT

Addession NUMBER: 1998-594555 [50] WPIDS

DOC. NO. SPI: 01938-178350 New di aza syslis **peptide** mimetis Xa/prothrombinase complex, useful for tréating e.g. angina and as diagnistic agents. DERWENT CLASS: INVENTOR(S): B02 B13 B04 MCARBOROUGH, R M; SU, T; ZHU, B PATENT ASSIGNEE'S : CORT-U: DUR THERAPEUTICS INC COUNTRY DIUNT: PATENT INFORMATION: PATENT NO KIND DATE WEEK LA EG Wo 9646627 Al 19981022 (199850)\* EN 72 RW: AT BEICH CY DE DK EA ES PI FR GBIGH GM GF. IE IT KE LS LU MC MW NL OA PT SD SE SE UG ZW W: AL AM AT AU AL BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KE KZ LC LK LR LS LT LU LV MD MG MK MN MW MM NO NO PL PT RO RU SO SE SG SI SK SL TJ TM TR TT UA UG UZ WN YU ZW AU 9865963 A 19981111 (199912) EP 977773 Al 20000209 (200012) EN R: AT BE CHICY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE MK 9909143 A1 20000201 (200123) NZ 500352 A 20011026 (200176) US 6369063 B1 20020409 (200227) JP 2002514214 W 20020514 (200236) 82 APPLICATION DETAILS: APPLICATION DATE PATENT NO KIND Wo 9844627 Al Wo 1998-US7160 19980413 AU 1998-63963 19980413 EP 1998-914658 19980113 AU 9363763 A EP 977773 A1 WD 1998-US7160 19980413 MX 9909143 A1 NC 500352 A MK 1999-9143 19991006 NZ 1998-500352 19980413 WO 1998-US7160 19980413 US 6363063 B1 Provisional US 1997-72094P 19970414 US 1998-58821 19980413 JP 1998-544068 19980413 JP 2002514214 W WO 1998-US7160 19980413 FILING DETAILS: PATENT NO PATENT NO KIND \_ \_ \_ .... AU 9868963 A Based on WO 98466.7 EP 977773 Al based on WO 98466.7 NO 50031.1 A Based on WO 98466.7 JP 2002514214 W Based on WO 98466.7 PRIORITY APPLN. INFO: US 1997-72094P 19970414; US 1998-58821 199804.3 1498-594955 [50] WPIDA Al: AB WO 9846627 A UPAB: 194812.7

1998-504656 [50] WPID:

WO 9840617 A UPAB: 1908-1217

Diama dyclic peptide minetic analogues of formula (I), their valto and optical isomers are new. R: = H, alkyl, sycloalkyl, 1-3C alkylacyl, 1-3C alkyl-cycloalkyl or aryl; E: =H; or E: E: = carbocyclic ring; m =0 2; n =0-6; R, p, s = -1; q = 0 3; r,t = 0-4; A = R3, NR3R4, N(R5,C =NP0)NR3R7, C:=NR6)NR3R8, N(R5)C(=NR6)R7, C:=NP6/R8 or SC(=NR0)NR3R8; R3-R6 = H, OH, alkyl, aryl or 1-4C alkylaryl; R7 = H, alkyl, aryl or 1-4C alkylaryl; R8 =

H, alkyl, aryl or 1-40 alkylaryl; or R8+R6 = 5-6 membered ring; 2 = bond, s, so, d, soinh, NHSDL, CDP, CDNH, 1-60 alkyl, 3-80 cyclialkyl, 2-60 alkenyl, 2-6: alkenylaryl, aryl or a fell membered heterocyclic ring system dentaining 1-4 of M, D or S; D = pind, CO, 302, 100, NR9S02 or NR+30; R+ = H, OH, al-yl, aryl or 1-40 al-ylaryl; E = bond, cycloal-kyl, aryl or i 5-10 membered heteropyclic ring system containing 1-4 of N, 0 or S : S = as A, provided that if G is Ri, then E must contain at least one N; E = pond, cycloalwyl, 3-60 alwenyl, 1-60 alwenylaryl, aryl or 5-10 membered heteropyplic ring containing 1-4 of M, C or S; T = R28, MR28R29, N RFF: D(#NRS1)NRL+R31, D(#NRS1)N R28)(R83 , N REC)D(#NS1)R32, D(\*NRS1)R33 or  $80^{\circ}$  =NR31\*NR28R33; Ru8+R31 = H, OH, alkyl, aryl or 1-40 alkylaryl; R32 = H, alkyl, aryl or 1-40 alkylaryl; or 830+830 or 832+831 = 5-6 membered ring; R33 = H, alkyl, aryl or 1 40 alkylaryl; or R33+R31 = 5-6 membered ring; X, Y = 0 or H2; W = H, B(OR16)OR17, OOZ or a cyclic boronyl group of formula (a) or (b); R16, B17 = H, 1-30 alkyl or aryl; Z = H, CDORIE, COMPIR, DE3, CF20F3 or a heterocyclic group of formula (c) or (d); R18,  $\mathrm{Ri}^{2}$  + H, alkyl, aryl or 1-40 alkylaryl; U, V = 0, 3, N or NH, provided that at least one is NH; R20  $\approx$  H, alky1, 2-60 alkeny1, 0-60 alkylary1, 2 60 alkenylaryl, 0-60 alkylheterocyclo, 2-60 alkenylheterocyclo, CF3 or CF2CF3; C = S, S0, S00, D or NEC1; R21 = H, 1-60 alkyl or benzyl; C =CH(F22) (CH2)dCH(F23); C(F24) \*C(F25); o-phenylene substituted by F24 and F25; or 6-100 heterocyclic ring substituted by F24 and F25 and containing 1-4 of N, S or O; d = 0-2; R22, R23 = H, alkyl, aryl, alkylaryl, C00526, CONFIGERY, CN or CF3; R24, R25 = H, aikyl, aryl, alkylaryl, 1-4C alkoxy, halb, Not, NR26R27, NR36CDR37, DR26, OCOR36, COOR26, CONR26R27, CN, CF3, SOUNREGRET or alkyl-ORE6; RE6, RE7 = H, alkyl, 1-3C alkylaryl or aryl; unless specified otherwise, alkyl moleties have 1-60 and cycloalkyl moleties 3-80.

 $\label{eq:USE} {\tt USE} = ({\tt I}) \mbox{ are potent and highly selective } {\tt inhibitors} \mbox{ of } {\tt factor} \mbox{ Xa} \mbox{ or } {\tt factor} \mbox{ Xa}$ 

/prothrombinase complex and are potent and specific inhibitors of blood coagulation in mammals. (I) are useful for treating unstable or refractory angina, myocardial infarction, transient ischaemic attacks, thrombotic or embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restencess or reperfused coronary arteries, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy (all claimed). (I) are also useful for inhibiting the coagulation of biological samples (claimed) and as diagnostic agents.

L139 ANSWER 74 OF 100 WRIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1998-594554 [50] WPIDS

DOC. NO. CPI: 01998-178349

TITLE: New dr aga cyclic peptide mimetic

analogues - are selective inhibitors of

factor Xa or factor

Xa/prothrombinase complex, useful for treating

e.g. angina and as diagnostic agents.

DERWENT CLASS: B02 B03 B04

INVENTOR(S): SCARBOROUGH, F M; SU, T; IHU, B LATENT ASSIGNEE S.: CORT M: COR THERAFEUTICS INC

COUNTRY COUNT: 53

PATENT INFORMATION:

RW: AT BE CHICY DE DY MA ES FI FRIGBIGH GM GRITE IT KE LS LU MC MW NL OA PT SD SE SZ "HI ZW

W: AL AM AT AU AZ BA BB B3 BR BY CA CH CN CU CZ DE DK EE ES FÎ GB GE 3H 3M HU ID IL IS JP KE K3 KP KR KZ LO LK LR LS LT LU LV MD MG MK MN MW MM NO NZ PL PF RC HU SD SE 33 DI SK SL TJ TM TR TT UA UG UZ VN YU ZW AU 9868462 A 19981111 (199912)

AU 9063462 A 19951111 (199912) EP 907770 Al 20000209 (200012) EM

R: AT BE CHICY DE DK ES FI FR GB GR IE IT LI LU MO NL PT SE

US 6.04143 B1 10010920 200118) MK 3-09133 A1 10000201 200123)

JP 3101513226 W 20011120 200204) 83

NO 500353 A #0020201 200214)

#### APPLICATION DETAILS:

PATENT NO K	IND	APPLICATION	DATE
WD 9846626	Al	WD 1998-US7159	13980413
AU 9363962	A	AU 1993-6896.	19980413
EP 377770	A1	EF 1998-914697	19980413
		พอ 1998-ช37159	13330413
US 6204268	Bl Frovisional	US 1997-6932LP	19970414
		US 1998-59565	19930413
MM 9909138	A1	MM 1999-9138	19391006
JF 2001523226	W	JP 1998-544067	19930413
		<b>W</b> ⊝ 1998-US7159	19980413
NZ 500353	Α	NZ 1998-500353	19930413
		<b>W</b> O 1998-US7159	13980413

#### FILING DETAILS:

PAT	ent no i	(INL)			PAS	CN TNET
AU	9868962	А	Based	on	WO	9846626
EF	377772	Al	Based	on	$W \odot$	9846626
JF	2001523226	5 W	Based	on	WO	9346626
NC	500353	A	Based	on	WO	99466336

PRIORITY APPIN. INFO: US 1997-69322P 19970414; US 1998-58565

19980413

AN 1998-394554 [50] WPIDS

AB WO 9846626 A UPAB: 19931217

Diaza cyclic peptide mimetic analogues of formula (I) and their salts and optical isomers are new. Rl = H, alkyl, cycloalkyl, 1-30 alkylaryl, 1-30 alkyl-cycloalkyl or aryl; E2 =H; or R1+R2 = carbocyclic ring; m = 0-2; n = 0-6; k, p, s = 0-1; q = 0-3; r, t = 0-4; A= R3, NR3R4, N(R5)C(=NR6)NR3R7, C(=NR6)NR3R8, N(R5)C(=NR6)R7, C(=NR6)R8 or SC(=NR6)MR3R8; R3-R6 = H, OH, alkyl, aryl or 1-4C alkylaryl; R7 = H, alkyl, aryl or 1-40 alkylaryl; or R7+R5 or R7+R6 = 5-6 membered ring; R8 = H, alkyl, aryl or 1-40 alkylaryl; or R8+R6 = 5-6 membered ring; Q = bond, alkyl, cycloalkyl, 2-60 alkenyl, 2-60 alkenylaryl, aryl or a 5-10 membered heterocyclic system containing 1-4 of N, O or S; D = bond, CO, 302, OCO, NEBSON or NEBCO; FR = H, OH, alkyl, aryl or 1-40 alkylaryl; X, Y = 0 or HD; K = 0RDS or NF29F30; R28-R30 = H, alkyl, 0-3C alkylaryl, 0-3C alkyl-cycloalkyl, 0.30 alkyl heterocycle; or R19+R30 = 5-10 membered heterocyclic ring system containing 1-4 of N, C or S; E = bond, 3-3C cycloalkyl, aryl or a 5-10 membered heterocyclic ring system containing 1.4 of N , C or S ; G = as for A, provided that if G is R3, then E must contain at least one N; W  $\odot$  H, B(OR16)OR17, CO2 or a cyclic boronyl group of firmula (a) or (b); E17, E16 = H, 1-30 alkyl or aryl; Z = H, E00E18, CONRIBER, 3F3, CF2CF3 or a heterocyclic group of formula (c) or (d); R18, R13 = H, alkyl, aryl or 1-40 alkylaryl; U, V = 0, S, N or NH, provided that at least one is NH; R10 = H, alkyl, 2~6C alkenyl, 0~6C alkylaryl, 2-60 alkenylaryl, (-60 alkylheterocyclo, 2-60 alkenylheterocyclo, CF3 cr CF20F3; T = 3, SO, SO2, O or NR21; R21 = H, alkyl or benzyl; L =CH k22)(CH2)dCH(R23); C'R24)=C(R25); c-phenylene substituted by R24 and

R25; or 6-100 heterocycle substituted by R24 and R25 and containing 1-4 of N, S or O; d = 3-2; R22, R23 = H, alkyl, aryl, alkylaryl, 000R26, CDMR28R27, CM or CF9; R24, R25 = H, alkyl, aryl, alkylaryl, 1-40 alkoxy, nalo, ND2, NR26R27, NR26COF27, OR26, DCOR26, CDDR26, CDNR26R27, CN, CF3, SD2NR26R27 or alkyl-DR26; R26, R27 = H, alkyl, 1-3C alkylaryl or aryl; unless specified otherwise alkyl moleties have 1-6C and cycloalkyl mointies 3-80.

USE - (I) are potent and highly selective inhibitors of

### factor Xa or factor Xa

sprothrombinase complex and are potent and specific inhibitors of plind coagulation in mammals. (1) are useful for treating unstable or refractory angina, myodardial infarction, transient isonaemic attacks, thrombotic or embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis or reperfused coronary arteries, deep venous thrombosis, rulmonary embolism, myodardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coadulopathy (all claimed). (I) are also useful for inhibiting the coadulation of biological samples (claimed) and as diagnostic agents. Dwg.0/0

L139 ANSWER 75 OF 100 MEDLINE DUPLICATE 6

ACCESSION NUMBER: 1998123583

MEDLINE

DOCUMENT NUMBER:

98128583 PubMed ID: 9454596

TITLE:

Discovery of a novel, potent, and specific family of factor

Ma inhibitors via combinatorial chemistry.

AUTHOF:

Ostrem J A; al-Obeidi F; Safar P; Safarova A; Stringer S K; Patek M; Cross M T; Spoonamore J; LoCascio J C; Kasireddy P; Thorpe D S; Sepetov N; Lebl M; Wildgoose P; Strop P

CORPORATE SOURCE: Selectide Corporation, Tutson, Arizona 85737, USA..

gim.ostrem@hmrag.com

SOURCE:

BIOCHEMISTRY, (1993 Jan 27) 37 (4) 1053-9. Journal code: 0370623. ISSN: 0006-2960.

PUB. COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199803

ENTRY DATE:

Entered STN: 19980319

Last Updated on STN: 20000303 Entered Medline: 19980306

A series of low molecular weight peptide inhibitors of AB factor Xa, unrelated to any previously described, was identified by screening a combinatorial peptide library composed of L-amino acids. The minimal inhibitory sequence is a tripeptide, L-tyrosinyl-L-isoleucyl-L-arginyl, which competitively inhibits the hydrolysis of small chromogenic substrates by factor Xa but binds in an orientation which prevents a productive nucleophilic attack by serine 195 of the datalytic triad on the carbonyl carbon of the carkoxyterminal arginine. The initial leads identified in an octamer combinatorial peptide library ranged in potency from 4 to 15 microM. These peptides were modified into peptide m:metics with a great-Fr than 1000-fold increase in potency while retaining unusual selectivity for factor Xa over the related serine proteases thromkin, factor VIIa/tissue factor, plasmin, activated protein C, kallikrein, and trypsin. One of the most potent analogues, SEL 2711, with a Ki of 0.003 microM for factor Xa and 40 microM for thrombin, is active in in vitre and ex vivo chaquiation assays, suggesting the potential application of these inhibitors in anticcagulant therapy.

```
L139 ANSWER 76 OF 100 POTFULL COPYRIGHT 2002 Univention
ACCESSION NUMBER: 1997046576 POTFULL ED 20020514
                       ANTICHAGULANT PERTIDYL-ARGININE ALDEHYDE DERIVATIVES
TITLE : ENGLISH:
                       DERIVES DE PEPTIDYL-ARGININE ALDEHYDE ANTICOAGULANTS
TITLE "FRENCH:
INVENTOR(S):
                       BATUSE, Sssndor; JUHASE, Attila; BARABAS, Eva; FEHER,
                       Andress; SNABD, Babriella; SNELL, Erzsebet; VESHELYI,
                        Iren; LAVICH, Emilia; KASIAS, Eva; LANGO,
                        Jafrar34; zset; MORAVCSIK, Imre; SZEKER, Agnes;
                        TASCHLER, Esuzsanna; TOTH, Gssbor; MOHAI, Zsuzsanna;
                        STALKAY, Anna Mssria; MAKK, Klasna
PATENT ASSIBNEE S):
                        GYDGYSZERKUTATO INTEZET MFT.; BAJUSZ, Sssndor; JUHASZ,
                        Attila; BARABAS, Eva; FEHER, Andress; SZABO, Jabriella;
                        SHELL, Erzsebet; VEGHELYI, Iren; LAVICH, Emilia;
                        HASSAS, Eva; LANGO, J¾ zsef; MOFAVOSIK, Imre;
                        SCEKEE, Agnes; TASCHLEE, Isuzsanna; TOTH, Gssbor;
                        MOHAI, Zsudsanna; SDALKAY, Anna Mssria; MAKK, Klssra
LANGUAGE OF PUBL.:
                        English
DOCUMENT TYPE:
                        Patent
PATENT INFORMATION:
                        NUMBER
                                          KIND
                                                   DATE
                         WC 9746576 Al 19971211
                        AL AM AT AU AZ BE BG BE FY CA CH ON CZ DE DK EE ES FI
DESIGNATED STATES
                        GB GE HU IL IS JP KE KG KP KR KZ LK LE LS LT LU LV MD
                        MG MK MN MW MK NO NE PL PT RO RU SD SE SG SI SK TJ TM
                        TE TT UA UG US UZ VN GH KE LS MW SD SZ UG AM AZ BY KG
                        KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU
                        MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
                        WO 1997-HU28
                                             A 19970605
APPLICATION INFO .:
PRIORITY INFO.:
                       HU 1996-P 96 01526
                                              19960605
ABEN
       The invention relates to new peptidyl-arginine aldehyde derivatives of
       general formula (I):
       Q-D-Xaa-Pro-Arg-H, wherein Q represents an acyl group of formula
       Q'-0-CO-, where Q' represents an
       alkyl group with 1-3 carbon atoms, D-Xaa represents 3-cyclobuty1-D-
       alanyl- or
       B-cyclo-pentyl-D-alanyl- group, Pro stands for L-prolyl- group, and Arg
       stands for L-argin; l- group,
       and acid-addition salts thereof formed with an organic or inorganic acid
       and pharmaceutical
       compositions containing the same. The compounds of formula (I) have
       valuable therapeutic,
       particularly anticoagulant, properties together with inhibiting platelet
       functions and thrombosis
      development.
ABER
      L'invention concerne des nouveaux derives de peptidyl-arginine aldehyde
       de formule generale (I)
       Q-D-Xaa-pro-Arg-H, et leurs sels d'addition d'acide formes avec un acide
       organique ou inorganique.
       Dans ladite formule (I), Q represente un groupe acyle de formule
       Q'-0-00-, ou Q' represente un
       groupe alkyle a 1 a 3 atomes de carbone, DoXaa represente un groupe
       Proyolobutyl-Dralamyl- ou
       3-cyclo-pentyl-D-alanyl-, Pro represente un groupe L-propyl-, et Arg un
       groupe L-arginyl-. Elle
       porte aussi sur des compositions pharmaceutiques les contenant. Les
       composes de formule (I)
       presentent des proprietes therapeutiques precieuses, en particulier
       anticcagulantes, inhibent les
       fonctions des plaquettes et le développement de la thrombose.
     ANSWER 77 OF 100 POTFULL COPYRIGHT 2002 Univention
ACCESSION NUMBER: 1997046523 POTFULL ED 20020514
TITLE (ENGLISH): ANTICOAGULANT PEPTIDE ALDEHYDE DERIVATIVES
TITLE (FRENCH): DERIVES D'ALDEHYDE PEPTIDIQUES ANTICOAGULANTS
```

BAJUSZ, Sssndor; JUHASZ, Attila; BARABAS, Eva; FEHER, INVENTOR'S: Andress; SCABO, Gapriella; SZELL, Erzseket; VEGHELYI, Iren; LAVICH, Emilia; KASZAS, Eva; LAMGO, J&fras34;zsef; MURAVOSIK, Imre; SZEKER, Agnes; TASCHLER, Isuzsanna; TOTH, Isskor; MOHAI, Isuzsanna; SZALKAY, Anna, Masria; MAKK, Klasra WYDDYGZERKUTATO INTEZET HET.; BAJUSZ, Sasndor; JUHASZ, PATENT ASSIGNEE'S: Attila; BARABAS, Eva; FEHER, Andrass; SZABD, Subriella; SZELL, Errseket; VEGHELYI, Iren; LAVICH, Emilia; MASJAS, Eva; LANGO, J¾ zsef; MOSAVCSIF, Imre; SZEKER, Adnes; TASCHLER, Zsuzsanna; TOTH, Gasbor; MCHAI, Zsunsanna; SIALKAY, Anna, Mssria; MAKK, Klasra LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent PATENT INFORMATION: NUMBER KIND  $\Gamma A T E$ .... WO 9746523 Al 13971211 AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI DESIGNATED STATES GE GE HU IL IS JE KE KG KP KE KZ LK LE LS LT LU LV MD MG MK MN MW MX NO NO PL PT RO RU SD SE SG SI SK TJ TM TE TT UA UG US UZ VN GH KE LS MW SD SZ UG AM AC BY KG KZ MD RU TU TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SM TD TG A 19970605 WO 1997-HU27 APPLICATION INFO .: HU 1996-P 96 01527 19960605 PRIORITY INFO.: This invention relates to new peptide aldehyde derivatives of general ABEN formula (I): P-Xaa-Pro-Arg-H, wherein Xaa represents a 2-cycloheptyl-2-hydroxyadetyl 2-cyclopentyl-2-hydroxyacetyl group, Pro represents an L-prolyl residue and Arg represents an L-arginyl residue, their acid-addition salts formed with an organic or inorganic acid and pharmaceutical compositions containing the same. The compounds of general formula (I) of the invention have valuable therapeutic, particularly anticoaquiant, antiplatelet and antithrombotic, properties. L'invention concerne des neuveaux derives d'aldehyde peptidiques de ABFR formule generale (I) In-Xaa-Pro-Arg-H, et leurs sels d'addition d'acide formes avec un acide organique ou inorganique. Pans ladite formule (I), Kaa represente un groupe 2-cycloheptyl-2hydroxyacetyl ou u-cyclopentyl-2-hydroxyacetyl, Pro represente un reste L-prolyl et Arg represente un reste L-arginyl. L'invention porte aussi sur des compositions pharmaceutiques contenant des derniers. Les composes de formule generale (I) presentent des proprietes therapeutiques presieuses, notamment unticoaquiantes, untiplaquettaires et antithrobontiques. ANSWER 78 OF 100 POTEULL COPYRIGHT 2002 Univertio 1997043436 POTFULL ED 20020514 ACCESSION NUMBER: A PROCESS FOR PRODUCING A RECOMBINANT POLYREPTIDE TITLE (ENGLISH): INVOLVING THE ADDITION OF AN INHIBITOR OF METAL-DEPENDENT FROTEASES OR CHYMOTRYESINS TO THE CELL MULTURE MEDIUM PROCEDE POUR PRODUIRE UN POLYPEPTIDE RECOMBINE TITLE (FRENCH): COMPRENANT L'ADDITION D'UN INHIBITEUR DE PROTEASES METAL-DEPENDANTES DU DE CHYMOTRYPSINES AU MILIEU DE CULTURE CELLULAIRE ADAMSON, Lars; WALUM, Erik; DIMELIUS, Johan; LIMA LIE, INVENTOR SE:

Kristina

PATENT ASSIGNEE S.: PHARMACIA & UPJOHN AB; ADAMSON, Lars; WALUM, Erik; DIMELIUS, Johan; LIMA LIE, Kristina LANGUAGE OF PUBL.: DOCUMENT TYPE: English Patent PATENT INFORMATION: NUMBER KIND DATE WO 9743436 Al 19971120 AL AM AT AU AC BA BB BG BR BY CA CH CN CU CZ DE DK EE DESIGNATED STATES ES FI 3B 3E HV IL IS JP KE KG KP KR KZ LC LK LR LS LT LT LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT WA WG WS WZ VN YW GH HE LS MW SD SZ WG AM AZ BY KG KZ MD KU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MO NL PT SE BF BJ OF OG CI CM GA GN ML MR NE SN TD TG A 19970513 WD 1997-SE783 APPLICATION INFD.: US 1996-60/018,874 19960509 PRIORITY INFO.: The present invention relates to a process for reducing the detrimental ABEN influence of certain proteases on recombinant human protein and polypeptide molecules, by adding an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium. The invention also relates to a cell culture medium for cultivating cells expressing and secreting a biologically active recombinant human polypeptide containing an inhibitor of metal-dependent proteases or chymotrypsins, or a combination thereof. The invention further relates to use of recombinant factor VIII which has been produced in a cell culture medium according to the present process for the manufacture of a medicament for administration to a patient having the symptoms of hemophilia A. Also, the invention relates to a method for treatment of hemophilia A by administration of a therapeutically effective amount of recombinant factor VIII which has been produced in a cell culture medium according to the present process. ABFF Procede pour reduire l'influence nocive de certaines proteases sur les molecules de proteines et de polypeptides humains recombines, par l'adjonction d'un inhibiteur de proteases metal-dependantes ou de chymotrypsines au milieu de culture cellulaire. L'invention concerne egalement un milieu de culture cellulaire pour cultiver des cellules exprimant et secretant un polypeptide humain recombine, biologiquement actif et contenant un inhibiteur de proteases metal-dependantes ou de chymotrypsines, ou une combinaison des deux. L'invention porte en outre sur l'utilisation du facteur recombine VIII produit dans un milieu de culture conforme au procede decrit, pour la fabrication d'un medicament pouvant etre administre a un patient presentant les symptomes de l'hemophilie A. Une methode de traitement de l'hemophilie A comprehant l'administration d'une quantite therapeutiquement active de facteur recombine VIII produit dans un milieu de fulture conforme au procede decrit est egalement proposée. ANSWER 79 OF 100 POIFULL COPYRIGHT 2002 Univention 1139 ACCESSION NUMBER: 199701880 PCTFULL ED 20020514

COMBINATIONAL THERAPEUTIC METHODS EMPLOYING MITRIC

OXIDE SCAMENGERS

TITLE 'ENGLISH):

```
ENTRAINEURS DE MONOMYDE 2'AZOTE
INVENTOR'S::
                       LAI, Ching-San
                       MEDINOX, INC.; LAI, Ching-San
PATENT ASSIGNEE(S:
LANGUAGE OF PUBL.:
                       English
DOCUMENT TYPE:
                        Patent
PATENT INFORMATION:
                       NUMBER
                                           KIND
                                                    DATE
                       WD 9013835 AI 19970529
DESIGNATED STATES
                       AL AM AT AU AZ BA BB BG BE BY CA CH CN CU CZ DE DK EE
                        ES FI GB GE HU IL IS UP KE KG MP KR KZ LO LK LR LS LT
                        LU LV MD MG MK MN MW MX ND NZ PL PT RO RU SD SE SG SI
                        SK TJ TM TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ
                        BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE
                       IT LU MO NL PT SE BE BU OF OG OI CM GA GN ML ME NE SN
                       TI TS
                       WO 1996-US18124
APPLICATION INFO.:
                                             A 13361112
PRICRITY INFO.:
                       US 1995-8/561,594
                                               19951121
     In accordance with the present invention, there are provided
      combinational therapeutic methods
      for the in vivo inactivation or inhibition of formation (either directly
      or indirectly) of species
      which induce the expression of nitric oxide synthase, as well as
      reducing nitric oxide levels
      produced as a result of .No synthase expression. In contrast to the
      inhibitory approach described in
      the prior art (i.e., wherein the function of the enzymes responsible for
      nitric oxide production is
      inhibited), the present invention employs a combination of inactivation
      (or inhibition) and
      scavenging approach whereby the stimulus of nitric oxide synthase
      expression is inactivated, or the
      production thereof is inhibited, and overproduced nitric oxide is bound
      in vivo to a suitable nitric
      oxide scavenger. The resulting complexes render the stimulus of nitric
      oxide synthase expression
      inactive (or inhibit the production thereof), and nitric oxide harmless.
      The resulting complexes are
      eventually excreted in the urine of the host. Further in accordance with
      the present invention,
      there are provided compositions and formulations useful for carrying out
      the above-described
      methods.
ABFR
      Methodes therapeutiques combinees d'inactivation ou d'inhibition de
      formation (soit directe
      soit indirecte) d'especes encourageant l'expression de la monoxyde
      d'azote synthase, et la reduction
      des niveaux de monoxyde d'anote produits du fait de l'expression de la
      monoxyde d'azote synthase.
       Schtrairement a la methodo par inhibition decrite dans les procedes
      existants precedemment
      (d'est-a-dire, lorsque la fonction des enzymes responsables pour la
      production de monoxyde d'azote
      est inhibee), la presente invention emploie une combinaison
      d'inactivation (ou d'inhibation) et
      d'entrainement par laquelle le stimulus de l'expression de minoxyde
      d'aucte synthase est inactive,
      tu sa production est inhibat, et le surplus de monoxyde d'azote est lie
      in vivo a un entraineur de
      minexyde d'azete adapte. Les complexes ainsi produits rendent le
      stimulus d'expression du monoxyde
      d'accte synthase inactif cu inhibent sa production), et rendent le
      monoxyde d'azote inoffensit. Les
      complexes ainsi produits font finălement éxpretes dans l'urine de
```

METHODES THERAPEUTIQUES COMBINEES EMPLOYANT LES

TITLE FRENCH:

l'hote. Sont decrites egalement des compositions et preparations utiles a la mise en deuvre des procedes debrits plus haut.

ANSWER 90 OF 100 EUROPATFULL COPYRIGHT 2002 WILA 1139

GRANTED PATENT - ERTEILTES FAIRNT - BREVET DELIVRE

EUROPATFULL EW 199730 FS PS 50246-ACCESSION NUMBER:

ACTIVATABLE FIBRINGLYTIC AND ANTI-THROMBOTIC PROTEINS. TITLE:

AKTIMIERBARE FIBRIMOLYTISCHE UND ANTITHROMBOTISCHE

PROTEINE.

PROTEINES FIBRINGLYTIQUES ET ANTITHROMBOTIQUES

ACTIVABLES.

DAWSON, Keith Martyn, 30 Barnards Hill, Marlow, Bucks INVENTOR(S):

SL7 PME, GF;

EDWARDS, Richard Mark, 7 Ludlow Drive, Thame, Oxon CX9

3X3, G5;

FURNAL, Joan Mabel, 6 Margaret Road, Oxford OX3 8NG, GB

PATENT ASSIGNEE(S): BRITISH BICTECH PHARMAJEUTICALS LIMITED, Watlington

Road, Cowley Oxford, OM4 SLY, GB

PATENT ASSIGNEE NO: 97061.5

Walls, Alar James et al, British Biotech Pharmaceuticals AGENT:

Ltd., Watlington Road, Oxford OX4 5LY, GB

AGENT NUMBER: 37214

OTHER SOURCE: EPB1997047 EP 0502968 B1 970703

SOURCE:

Wila-EPS-1997-H30-T1

DOCUMENT TYPE:

Patent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: DESIGNATED STATES:

R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

KIND DATE

IT; R LI; R LU; R NL; R SE

FATENT INFO. PUB. TYPE: EPB1 EUFOPARISCHE FATENTSCHRIFT (Internationale

Anmeldung)

PATENT NO

PATENT INFORMATION:

			-1	
	ΕP	500968		B1 19970723
'OFFENLEGUNGS' DATE:				19920316
APPLICATION INFO.:	$\Xi F$	1991-900	851	19901.507
FRIORITY APPLN. INFO.:	G5	1989-277	122	19891307
FELATED DOC. INFO.:	WΟ	90-GB191	_	301207 INTAKZ
	CM	9109113		910627 INTPNR
FEFERENCE PAT. INFO.:	EP	211299	А	EP 227938
	ΞF.	292009	А	EF 297882
	ΞF	304013	A	EF 319944

EP 323143 A EP 330700 We 89 01036 A EP 338941 A WO 90-10081 A WO 89-06239 A WO 90-13640 A Wc 91-09297 A

FEF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, American Chemical Society, D.J. Davidson et al.: "plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens", pages 3585-3590 Chemical Abstracts, vol. 103, 1985, Columbus, Ohio, US); J.Y. Chang: "Thrombin specificity. Requirement for apolar aming acids adjacent to the thrombin cleavage site of polymeptiede substrate", see page 412 Archives of Biconemistry and Biophysics, vol. 271, no. 2, June 1989, Adademic Press, Inc.; T. Whitefilet-Smith et al.: "Expression of human plasminogen oDNA in a baculovirus vestor-infested insect sell system", pages 390-399 Pros. Natl. Acad. Sci. USA, vel. 79, Cotober 1982; T. Miyata et al.: "Plasminogen Tochiq:: inactive plasmin resulting from replacement of alamine 600 by threonine in the active site", pages 61:2-61:6

Α Α Α L139 ANSWER 81 OF 100 WPIDS (d) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1997-340137 [31] WPIDS

DOC. NO. CPT: C1997-109336

TITLE: New peptide analogues derived from imidazolyl-koronic

acid - useful as trypsin-like serine protease inhibitors,

especially for treatment of thrombosis or as

anticoadulants.

DERWENT CLASS: 503

INVENTOR S:: CACCIOLA, J; DOMINGUEZ, C; FEVIG, J M

PATENT ASSIGNEE(S): (DUPO) DUPONT MERCK FHARM CO

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG
US 5639739 A 19970617 (199731)\* 12

### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5639739	А	us 1995-409573	19950324

PRIORITY APPLN. INFO: US 1995-409573 19950304

AN 1997 340537 [31] WPIDS

AB US 5639739 A UPAB: 19970731

Imigazolyl-substituted boronic acid derivative peptide analogues of formula (I) and their salts are new. Rl = CO CH((CH2)nR4)-NR5R6, CO-CR8R9-(CH2)p-R4 or CO-CR8R9-W-(CH2)r-R4; R2 = CH2-C(R12)2-aryl or (1-aryl-(3-6C) sycloalkyl)-methyl; R3 = H; or EIRÁN CHE3-CO = 1-(E1)-pyrrolidin-2-ylcarbonyl; E4 = aryl or 3-8C cycloalkyl; R5 = H or - (alkyl)-aryl; R6 = COE7, COGE7, COMESE7, SOZE7 or SOONESET; R7 = alkyl or (alkyl) -aryl; R8, R9 = H, alkyl, aryl or (alkyl)-aryl, or  $8.8 + 8.9 \approx 3.70$  cycloalkyl;  $8.12 \approx 1.50$  alkyl or 1.50perfluoroalkyl; aryl = phenyl (optionally substituted by 1-3 of F, Cl, Br, I, alkyl, methylenedioxy, ND2, CF3, S(0)r-alkyl, CN, OH, NH2, mono- or di-alkylamino, NHCO-alkyl, (CH2)p-COO-alkyl and phenyl); T = NH2; Y1,Y2 = OH, or BY172 = a cyclic ester derived from pinanediol, pinacol, 1,2 ethanediol, 1,2 or 1,3 -propanediol, 2,3-butanediol, 1,2-drisopropylethanediol, 5,6-decanediol or 1,2-dicyclohexylethanediol; n = 0 or 1; p = 0-3; r = 0-2; s = 1-4; t = 1-3; alkyl moleties have 1-4C unless specified otherwise.

USE - (I) inhibit trypsin-like serine proteases e.g. Factors II, X, VII, XII, kallikrein, tissue plasminogen activators, urokinase-like plasminogen activator, plasmin, complement system enzymes, acrosin (required for fertilisation) or pancreatic trypsin, especially thrombin, factor X and factor VII. They are useful for treatment of aberrant proteolysis e.g. consumptive coagulopathy, inflammation, pancreatitis, hereditary angioedema or especially thrombosis (including arterial thrombosis associated with myocardial infarction and other clotting disorders); and as anticoagulants in the processing of blood for therapeutic or diagnostic purposes or for the production of blood products or fragments. (I) are especially used for treatment of thrombosis by inhibiting trypsin-like serine proteases of the coagulation cascade. The desage of (I) is 0.12-15 mg/kg, orally, parenterally or intravenously.

ADVANTAGE - (I) have potent trypsin-like protease inhibiting activity i.e. Fi values of a 20 nM for inhibition of the human blood coagulation proteases thrombin, Factor Xa and Factor VIIa; and may be effective against plotting disorders against which conventional anticoagulants (e.g. herarin) are ineffective. Dwg. 3/0

ACCESSION NUMBER: 1999002699 MEDLINE

DOCUMENT NUMBER: 98002688 PubMed ID: 9341205

TITLE: New inhibitors of thrombin and other trypsin-like

proteases: nydrogen bonding of an aromatic cyano group with a kackbone amide of the Pl binding site replaces binding of

a kasic side chain.

AUTHOR: Lee S L; Alexander R S; Smallwood A; Trievel R; Mersinger

L; Weber P C; Kettner C

CORPORATE SOURCE: Chemical and Physical Sciences, DuPont Merck Pharmaceutical

Company, P. O. Box 40500, Wilmington, Delaware 19880-0500,

3.4

SOURCE: BIJCHEMISTRY, (1997 Oct 28) 36 (43) 13180-6.

Tournal bode: 0370603. ISSN: 0006-2960.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: PDB-1AUJ ENTRY MONTH: 199711

ENTRY DATE: Entered STN: 19971224

Last Updated on STN: 10000303 Entered Medline: 19971117

Highly effective thrombin inhibitors have been obtained by preparing boronic acid analogues of m-cyano-substituted phenylalanine and its incorporation into peptides. The cyano group enhances binding by several orders of magnitude. For example, Ab-(D)Phe-Pro-boroPheOH binds to thrombin with a Ki of 320 nM and the Ki of Ac-(D)Phe-Pro-boroPhe(m-CN)-DH is 0.79 nM. Protein crystal structure determination of trypsin complexed to H-(D)Phe-Pro-boroPhe(m-CN)-OH indicates that the aromatic side chain is bound in the Pl binding site and that the cyano group can act as a Hebond acceptor for the amide proton of Gly219. Enhanced binding for inhibitors containing the m-cyano group was observed for coagulation factor Xa and for the factor VIIa.tissue factor complex (Ki values of Ac-(D)Phe-ProboroPhe(mCN) -OH are 760 and 2.3 nM, respectively]. This result is consistent with the sequence homology of these two enzymes in the Pl binding site. Two enzymes lacking the strict homology in the Pl binding site, pancreatic kallikrein and chymotrypsin, did not exhibit significantly enhanced binding.

1139 ANSWER 83 OF 100 EMBASE COPYFIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 8

ACCESSION NUMBER: 97147964 EMBASE

DOCUMENT NUMBER: 1997147964

TITLE: Feptide argininol 'inverse substrates' of anisic acid:

Novel inhibitors of the trypsin-like serine proteinases.

AUTHOR: Lynas J.F.; Walker B.

COFFOFATE SOURCE: B. Walker, Centre Peptide/Protein Engineering, School of

Riology/Biochemistry, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, United

Fingdom. brian.walker@qub.ac.uk

SCURCE: R:corpanic and Medicinal Chemistry Letters, (1997) 7/9

(1133-1138). Refs: 14

ISSN: 0960-894K CODEN: BMCLE8

PUBLISHER IDENT.: \$ 1960-994X(97)00174-1

COUNTRY: United Mingdom
DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Bicchemistry

037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

AB Peptides containing a C-terminal argininol residue linked, via an ester bond, to anisid acid have been synthesized as putative inhibitors of trypsin-like serine proteinases. The most potent analogue, Boo-Ile-Slu-Sly-Arg-.P3I.- CH2-O -CC-C6H4-CMe, that was

modelled on a known recognition sequence for the clotting enzyme factor Xa, was found to inactivate the protease with a second-order rate constant of .apprx. 4.5 x 105 M-1.min-1.

L139 ANSWER 64 OF 100 MEDLINE

ACCESSION NUMBER: 97404031 MEDLINE DIGUMENT NUMBER: 97404031 PubMed ID - PubMed II: 9282115

TITLE: Current status on new anticcaquiant and antithrombotic

drugs and devices.

CIMMENT: Gamment in: Surr Srin Pulm Med. 1997 Jul;3/4::265-7

AUTHOR: - Walenda J M; Fareed J

CORPORATE SOURCE: Loycla University Medical Center, Department of Pathology,

Maywood, IL 60153, USA.

CURRENT OPINION IN PULMONARY MEDICINE, (1997 Jul) 3 (4) SOURGE:

291-302. Ref: 96

Journal code: 9503765. ISSN: 1070-5297.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

English LANGUAGE:

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199709

ENTRY DATE: Entered STN: 19971013

> Last Updated on STN: 19971013 Entered Medline: 19970926

Several new drugs for the management of thromboembolic disorders have AΒ recently become available. Low-molecular-weight heparins are being evaluated for the prophylaxis of medical and surgical deep venous thrombosis and pulmonary embolism; for the treatment of pre-existing thrombosis; and for cases of coronary syndrome (unstable angina, myocardial infarction), thrombotic and ischemic stroke, interventional cardiology, pregnancy, cancer, and transplantation-associated thrombosis. A chemically synthesized heparin pentasaccharide, which has purely antifactor Xa activity and does not induce thrombocytopenia, is also in clinical trial. Thrombin inhibitors, such as hiradin and argatroban, are a practical anticoagulant substitute where heparin cannot be used. They are also useful for the management of coronary syndrome and as adjunct therapy. The antiplatelet agent ticlopidine and its analogue, clopidogrel, which does not produce blood dyscrasia, are effective for the secondary prevention of thrombotic stroke and the management of combined arterial thrombotic syndromes. Glycoprotein-targeting antibodies, synthetic derivatives, and peptides (some of which are orally bicavailable) have added a new dimension to the management of arterial thrombosis and high-risk patients having angioplasty. Plasma-derived agents, such as antithrombin III, are available for the management of thrombophilia and disseminated intravascular coaquiation. Compression devices and the foot pump, alone and in combination with pharmacologic agents, have been used successfully. Combination therapy using various agents in different proportions have also been found useful. Although there is much enthusiasm in this quickly developing area and clinical trials are demonstrating the antithrombotic efficacy of the new drugs, safety considerations require additional clinical validation. Long-term outcomes and costs also need to be addressed objectively.

ANSWER 85 OF 100 POTFULL DOPYRIGHT 2002 Univention ACCESSION: NUMBER: 1996038470 POTFULL ED 20020814

IMIDAZO(1,5a)PYRIDINE DERIVED SERINE PROTEASE TITLE 'ENGLISH:

INHIBITORS

TITLE (FRENCH): INHIBITEURS DE SERINE PROTEASE DERIVES DE

IMIDAZD[1,5A]PYRIDIME

OTTEMHEYM, Henricus, Carl, Joseph; ADANG, Anton, INVENTOR S): Equert, Peter; PETERS, Jacobus, Albertus, Maria PATENT ASSIGNEE'S: AKZC NOBEL N.V.; OTTENHEYM, Henricus, Carl, Joseph;

```
ADANG, Anton, Egbert, Peter; PETERS, Jacobus, Albertus,
                       Marīa
LANGUAGE OF FUBL.:
                       Berman
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                         KIND DATE
                       WD 9838470
                                          A1 19961205
                       AU BR CA CH CZ HU JE KR MM NO MZ EL RU SG TR US AT BE
DESIGNATED STATES
                       CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.:
                      WD 1996-EP2298 A 19960529
                      AT 1995-95201448.4
PRIORITY INFO.:
                                            19950602
     The invention relates to an imidazo[1,fa]ryridine derived serine
ABEN
       protease inhibitor comprising
       a unit having general formula (I) wherein Rl is hydrogen, lower alkyl or
       an acyl group; R2 is
       hydrogen or lower alkyl; R3 and R4 are independently hydrogen, lower
       alkyl or together form
       =CH-NESE6, E5 and E6 being lower alkyl. The compounds are serine
       protease inhibitors and can be used
       for the treatment and prophylaxis of thrombosis and thrombin-associated
      diseases.
ABFR
       Cette invention concerne un inhibiteur de serine protease derive de
       imidazo[1,5a]pyridine,
       lequel inhibiteur comprend une unite correspondant a la formule generale
       (I) ou Rl represente
      hydrogene, alkyle inferieur ou un groupe acyle; R2 represente hydrogene
       ou alkyle inferieur; R3 et
       E4 representent independamment hydrogene, alkyle inferieur ou forment
       ensemble = CH-NR5R6, R5 et R6
       representant un alkyle inferieur. Ces composes sont des inhibiteurs de
       serine protease et peuvent
       etre utilises dans le traitement et la prevention de thromboses et de
      maladies associees a la
      thrombine.
     ANSWER 86 OF 100 POTFULL COPYRIGHT 2002 Univentic
T.133
ACCESSION NUMBER: 1996030035 PCTFULL ED 20020514
TITLE (ENGLISH):
                       'beta'-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF
                      BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS
TITLE (FRENCH):
                      IMITATEURS DE FEUILLETS 'beta' ET LEUR EMPLOI COMME
                       INHIBITEURS DE FEPTIDES OU DE PROTEINES BIOLOGIQUEMENT
                      ACTIFS
                       KAHN, Michael
INVENTOR(S):
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; KAHN, Michael LANGUAGE OF PUBL.: Frolish
LANGUAGE OF PUBL.:
                      English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                         KIND DATE
                       Wd 9630035 Al 19961003
                       AL AM AT AU AZ BB BG BR EY CA CH CN CZ DE DK EE E3 FI
DESIGNATED STATES
                       GB GB HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG
                       ME MN MW ME NO NE PL PT FO RU SD SE SG SI SK TJ TM TR
                       TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD
                       RU TU TM AT BE CH DE DE ES EI FR GB GR IE IT LU MC NL
                       PI SE BE BI OF OG OI OM GA GN ML MR NE SN TD TG
                       WC 1996-US4044
                                            A 19960325
APPLICATION INFO .:
                       vs 1995-8/419,518
                                               19950324
PRICRITY INFO.:
                       TS 1993-8/149,006
                                              19981027
      There are disclosed 'beta'-sheet mimetics and methods relating to the
ABEN
       same for imparting in
```

stabilizing the 'beta'-sheet structure of a peptide, protein or

'beta'-sheet mimetics are ocvalently attached at the end or within the

molecule. In one aspect, the

protein. The 'beta'-sheet mimetics have utility as inhibitors of one or more of proteases, kinases, CAAM, peptides pinding to SH2 domains and MHC-I and/or MHC-II presentation of peptides to T cell receptors in Warm-planded animals. La presente invention concerne des mimetiques de feuillets 'beta' et des prinedes s'y rarportant rermettant de communiquer ou stabiliser la structure en feuillets 'beta' d'un reptide, q'une priteine ou d'une molecule. Cans l'une des variantes, les mimetiques de fauillets 'heta' sont fixes par covalence a l'extremite du peptide ou de la proteine, ou entre ses extremites. Ces imitateurs de feuillets 'keta' conviennent comme inhibiteurs d'une ou plusieurs proteases, kinases, CAAM, de peptides se liant a des domaines SH2 et de la presentation MHC-I et/ou MHC-II de peptides a des recepteurs de cellules T chez les animaux a sang chaud. ANSWER 87 OF 100 POTFULL COPYRIGHT 2002 Univention ADDESSION NUMBER: 1996025427 POTFULL ED 20020514 SERINE PROTEASE INHIBITORS TITLE (ENGLISH): INHIBITEURS DE SERINES PROTEASES TITLE (FRENCH): GREEN, Denovan, St. Clair; ELGENDY, Said, Mohammed, INVENTOR(S): Arwr, Ahmed; PATEL, Gueta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph ELLEFMAN PHAFMACEUTICALS LIMITED; GREEN, Donovan, St. PATENT ASSIGNEE(S): Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph LANGUAGE OF PUBL.: English Patent DOCUMENT TYPE: PATENT INFORMATION: NUMBER KIND \_\_\_\_\_ Wo 9825427 Al 19960822 AU CA JP NZ US AT BE CH DE DK ES FR GB GR IE IT LU MC DESIGNATED STATES NL PT SE APPLICATION INFO.: WO 1996-GB352 A 19960215 PRIORITY INFO.: GB 1995-9502985.6 19950216 Peptide inhibitors of serine proteases, especially thrombin, in which the P1-P2 natural amide linkage is replaced by another bond. Exemplary thrombin inhibitors are of the formula: X-(aa3) (aa2)-'psi'-(aa1)-Z wherein X is H or a substituent on the N-terminal amino group, aad is a hydrophobic amino acid such as Phe, aa2 is Pro, aal is Arg or an Arg analogue such as methoxyproryldlycyl, 2 is -200H or a heteriatom acid group, such as boronate, in a derivative of either, and 'PSI' is a non-amide linkage, typically containing up to 5 in-unain atoms, such as -Coll-, -CH20-, NHCO- ir -CH2-CH2-. On decrit des inhibiteurs peptidiques de serines proteases, notamment la ABFF. thrombine, dans lesquels la liaison amide naturelle Pl-P2 est remplacee par une autre liaisin. A titre d'exemple, on decrit des inhibiteurs de thrombine possedant la formule X-/aa3x-laa2 -'PSI'- xal)-Z dans laquelle X represente H ou un su:stituant sur le groupe amino N-terminal, aa3 represente un adidé amine nydrophobe tel que Phe, aa2 representé Pro, aa1 represente Arg ou un analoque de Arq tel que

length of the peptide or

```
methowypropylglycyle, 2 represente -000H ou un groupe acide
      d'hetersatomes, tel qu'un boronate, ou
       un dérive de l'un ou de l'autre, et 'PSI' représenté une liaison non
      amide, contenant typiquement
       jusqu'a 8 atomes en chaine, tels que -002-, -0H2D-, NHOD- ou -0H2-0H2 .
     ANSWER 66 08 100 POTFULL COPYRIGHT 2002 Univention
ACCESSION NUMBER: 1996010636 POTFULL ED 20020514
                      ALPHA-1-AUTITEYESIN AND ANTITHEOMBINE-III VARIANTS
TITLE (ENGLISH):
TITLE (FRENCH):
                      VARIANTES DE L''alpha'-1-ANTITRYESINE ET DE
                       L'ANTITHROMBINE III
                      HOPKINS, Faul, C., F.; CARRELL, Robin; CROWTHER,
INVENTOR(3):
                      Damian; STONE, Stuart
                      PPL THERAPEUTICS (SCOTLAND) LTD.; HOPKINS, Paul, C.,
PATENT ASSIGNEE(S):
                      R.; CARRELL, Robin; CROWTHER, Damian; STONE, Stuart
LANGUAGE OF FUBL.:
                       English
DOCUMENT TYPE:
                       Fatent
PATENT INFORMATION:
                       NUMBER
                                        KIND
                                                 DATE
                       ____
                       Wo 9610639 Al 19960411
                       AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE
DESIGNATED STATES
                       HU IS JE KE KG KE KE KZ LK LR LT LU LV MD MG MN MW MX
                       NO NO PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ
                       VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU
                       MC NL PT SE BE BJ CF CG CI CM GA GN ML MR NE SN TD TG
                      WO 1995-GB2155 A 19950912
APPLICATION INFO.:
PRIORITY INFO.:
                      GB 1994-9419804.1
                      GB 1995-3502138.2
                                              19940930
                                              19950203
      Serine protease inhibitors (serpins) are provided which: (a) are
ABEN
      substantially incapable of
      inhibiting activated protein C; (b) do not require activation by
      heparin; and (c) comprise a target
      sequence capable of interacting with the proteolytic active site of
      thrombin thereby to inhibit the
      proteolytic activity of thrombin. Preferred serpins are muteins or
      variants of 'alpha'l-antitrypsin,
      modified by inclusion of a thrombin-specific target sequence derived
      from antithrombin-III (AT-III).
      Such serpins have the specificity and irreversibility of action of
      AT-III, but do not have to be
      co-administered with heparin.
      On decrit des inhibiteurs de serine protease (serpines) qui: a) sont en
ABER
      pratique incapables
      d'inhiber la proteine C activee, b) n'exigent pas d'activation par
      l'heparine, et c) comprennent une
      sequence dible pouvant interagir avec le site actif proteolytique de la
      thrombine pour inhiber
      l'activité proteolytique de cette dernière. Les serpines preferées sont
      des muteines ou des
      variantes de l''alpha'-l-antitrypsine, modifiees par l'inclusion d'une
      sequence dible, specifique de
      la thrombine, derivee de l'antithrombine-III (AT-III). Ces serpines
      presentent la specificité et
      l'irreversibilite propres a l'action de l'AT-III, mais elles n'exigent
      pas d'etre co-administrees
      avec de l'heparine.
1139 ANSWER 69 OF 100 POTFULL COFFEIGHT 2002 Univention
ACCESSION NUMBER: 1998014373 POTFULL ED 20020814
TITLE (ENGLISH):
                      RECOMBINANT PRODUCTION OF BIOLOGICALLY ACTIVE PERTIDES
                      AND PROTEINS
                    PRODUCTION PAR RECOMBINAISON DE PEPTIDES ET PROTEINES
TITLE (FRENCH):
                      BIOLOGIQUEMENT ACTIFS
INVENTOR'S:: WILLIAMS, Jon, I.; PIERCE, James, C.; ANDERSON, G.,
```

Mark; KARI, Prasad PATENT ASSIGNEE S.: MAGAININ PHARMACEUTICALS, INC. LANGUAGE OF PUBL.: English DOCUMENT TYPE: Pater.t. PATENT INFORMATION: NUMBER KIND DATE Wei 9804373 A2 19960215 AU DA JE KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL DESIGNATED STATES PT 3E APPLICATION INFO.: WD 1995-US10219 A 19950726 US 1994-8/282,030 PRIORITY INFO.: 19940729 ABEN The present invention relates to the recombinant production of amphiphilic peptides with biologically and therapeutically significant activities. In one emcodiment, this invention relates to recombinantly producing an amphibhilic peptide by providing a protease-deficient microbial host transformed with an expression vector containing DNA that encodes the amphiphilic peptide under the control of a regulatory sequence operable in the microbial host and expressing the amphiphilic peptide in the transformed microbial host. In another embodiment, this invention relates to providing an E. coli protease-deficient K-12 cell transformed with a vector that expresses a cleavable fusion. protein comprising at least part of a carbohydrate binding protein and the amphiphilic peptide in the cell, expressing the fusion protein in the cell, and cleaving the fusion protein to obtain the amphiphilic peptide substantially free of carbohydrate binding protein residues. The biologically active amphiphilic peptide so produced can be further treated chemically or enzymatically to obtain a chemically distinct amphiphilic peptide with improved biological and therapeutic properties. ABFR L'invention concerne la production par recembinaison de peptides amphiphiles qui presentent des activites biologiques et therapeutiques significatives. Une variante de dette invention conderne la production par recombinaison d'un peptide amphiphile, qui consiste a produire un hote microbien presentant une deficience en protease, transforme a l'aide d'un vecteur d'expression contenant un ADN codant de peptide amphiphile sur commande d'une sequence regulatrice qu'on peut activer dans l'hote microbien, et a exprimer de peptide amphiphile dans l'hote microbien transforme. Une autre variante de l'invention consiste a prendre une cellule K-12 d'E. coli, presentant une deficience en protease, transformee a l'aide d'un vecteur qui exprime une proteine de fusion qu'on peut douper et qui comprend au moins une partie d'une proteine se liant a un glucide et le peptide amphiphile present dans la cellule, a exprimer cette proteine de fusion dans la cellule et a la couper pour donner un peptide amphiphile pratiquement depourvu de residu de la

proteine se liant a un glucide. Le peptide amphiphile biologiquement actif ainsi obtenu peut alors etre traite par voie chimique ou enzymatique, ce qui permet d'obtenir un peptide amphiphile chimiquement different dote de propriétes biologiques et therapeutiques amelionees. ACCESSION NUMBER: 1996000541 POTFULL ED 20020514

TITLE 'ENGLISH): AN EXTERNAL URINARY CATHETER AND A HOSE CONNECTOR FOR

donnection therewith

TITLE FRENCH : CATHÈTER ENTERNE POUR LES UMINES ET RACCORD DE CONDUITE

DESTINE A CE CATHETER

INVENTOR 'S::

JENSEN, Thomas, Dam

PATENT ASSIGNEE'S: COLUPLAST A/S; JENSEN, Thomas, Dam

LANGUAGE OF PUBL.: English DOGUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE 

W0 9600541 A1 19960111

AM AT AU BB BG BR BY CA CH ON CZ DE DK DK EE ES FI FI DESIGNATED STATES

GB GE HU IS JE KE KG KE KR KS LK LR LT LU LV MD MG MN MW MX NO NO PL PT RO RU SO SE SG SI SE TJ TM TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MO NL PT SE BF BJ OF OG OI OM GA GN ML MR NE SN TD

TG

APPLICATION INFO.: WC 1995-DK234 A 19950612 PRIORITY INFO.: DK 1994-774/94 19940629 19940629

ABEN An external catheter comprises a sheath essentially formed as a shaft and a constricted

drainage tube part (1) integrated therewith for connection with a nose

connector (5) which is

connected to a draining bose. In order to facilitate the mounting of the

drainage tube part (1) on

the hose connector (5), an end portion of the drainage tube part at the

orifice thereof is divided

into at least two sections (2-3).

AEFF: Un catheter externe bour les urines comprend une gaine venue d'une piece avec une partie

resserree (1) formant un tube de drainage, ce systeme etant raccorde par un raccord (5) a une

conduite de drainage. Pour faciliter le montage de la partie resserree (1) formant un ture de

drainage sur le raccord (5), une portion terminale du tube de drainage au niveau de son prifice est

divisee en deux sections (2-3) au moins.

L139 ANSWER 91 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 489070 EUROPATFULL EW 199617 FS PS

NOVEL INHIBITORS OF THROMBIN. TITLE: NEUE THROMBININHIBITOREN.

NOUVEAUX INHIBITEURS DE THROMBINE.

INVENTOR(S): MARAGANOFE, John, M., 34 Patrick Road, Tewksbury, MA

01376, US;

FENTON, John, W., II, P.O. Box 37 Route 66, Maiden

Bridge, NY 12115, US;

KLINE, Toni, 47 Hayes Street, Cambridge, MA 02139, US

PATENT ASSIGNEE(S): BIOGEN, INC., 14 Cambridge Center, Cambridge

Massachusetts 02142, US;

HEALTH RESEARCH INCORPORATED, 66 Hackett Boulevard, 3rd

Floor, Albany NY 12209, US

1149451; 522424 PATENT ASSIGNEE NO:

VISSIUS & PARTNER, Postfach 96 07 67, D-91634 Muenchen, AGENT:

AGENT NUMBER: 1-01311

1003.1 EPE1996025 EP 0489070 B1 980424 OTHER SOURCE:

SIURCE: Wila-EPS-1996-H17-T1

∴lla~E Patent DOCUMENT TYPE:

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE:

R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R PESIGNATED STATES:

LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT \*\* Internationale

Armeldung

PATENT INFORMATION:

\_\_\_\_\_\_ HE 489070 B1 19960424

'OFFENLEGUNGS' DATE: APPLICATION IMFO.:

PRIORITY APPLN. INFO.: US 1989-398482

RELATED DOG. INFO.:

F.EF. NON-PATENT-LIT.:

PATENT NO KIND DATE 19920610 E.E. 1990-912754 19900917 19390818 US 1990-549388 19300706 900817 INTAKS 910307 INTPNE WO 30-U34642 WO 9102750 REFERENCE PAT. INFO.: EE 276014 A EE 291992 A EP 341607 A EP 291931 EP 333356 A EP 357242

WO 79-00638 A Chemical Abstracts, volume 107, no. 11, 14 September 1987, (Columbus, Ohio, US), Krstenansky, John L. et al.: "Anticoaquiant peptides. Nature of the interaction of the C-terminal region of hirudin with a noncatalytic hinding site on thrombin", see page 733, abstract 47113c, & J. Med. Chem. 1987, 30(3), 1688-169 Chemical Abstracts, volume 103, no. 19, 9 May 1988, (Columbus, Ohio, US), Owen, Thomas J. et al.: "N-Terminal requirements of small peptide anti-coagulants based on hirudin", see page 701, abstract 167961z, & J. Med. Them. 1988, 31(5), 1009-101 The Journal of Biological Chemistry, Vol. 264, No. 15, May 1989 John M. Maraganore

et al.: "Anticoagulant Activity of Synthetic Hirudin Peptides" Thrombosis and Haemostasis, Vol. 63, No. 2, 1990 John L. Krstenansky et al.: "Development of MDL 08,050, a Small Stable Antithrombin AgentBased on a Functional Domain of the Leech Protein, Hirudin" Blood, Mol. 75, No. 2, January 1990 Joseph A. Jakubowski et al.: "Inhibition of Coagulation and Thrombin-Induced Platelet Activities by a Synthetic Dodecapeptide Modeled

on the Carboxy-Terminus of Hirudin"

L139 ANSWER 92 OF 100 ADISALERTS COPYRIGHT 2002 (ADIS)

ACCESSION NUMBER: 1996:39037 ADISALERTS

DOCUMENT NUMBER:

300416693

TITLE:

Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Ma in experimental

thrombosis

ADIS TITLE: Bivalirudin, CVS 995, desirudin:

pharmacodynamics.; Antithrombotic effects, comparison with tick anticoaqulant peptide and madroparin calcium; Animal

AUTHOR:

Biemond B J; Friederich P W; Levi M; Vlasuk G P; Buller H R; et al

CORPORATE SOURCE: University of Amsterdam, Amsterdam, The Netherlands; Corvas International, San Diego, California, USA

SCURCE:

Circulation (Jan 1, 1996), Vol. 93, pp. 153-160

DOCUMENT TYPE:

(Ar.imal)

REFERENCE:

Antithrombotics (Summary): Alert nc. 2, 1996

FILE SEGMENT: Summary LANGUAGE: English WORD COUNT: 655

1139 ANSWER 93 OF 100 MEDLINE

DUPLICATE 9

DOGUMENT NUMBER:

ADCESSION NUMBER: 96049146 MEDLINE DOCUMENT NUMBER: 96049146 PubMed ID: 7562983

TITLE:

Pertide-derived transition state analogue innibitors of

thrombin; synthesis, activity and selectivity.

Jetter M; Peters C A; Visser A; Grootenhuis P D; van Nispen AUTHOR:

3 W; Ottenneigm H C

CORPORATE SOURCE:

N.V. Organon, Oss, The Netherlands. BIOGREANIE AND MEDICINAL CHEMICTRY, 11995 Aug 3 8

1099-114.

Journal come: 9413298. ISSN: 1968-0896.

EMGLAND: United Mingdom PUB. COUNTRY:

POGUMENT TYPE: Journal; Article; JOURNAL ARTICLE

LANGUAGE: English

FILE SEGMENT: Pribrity Tournals

199818 ENTRY MONTH:

Entered STM: 19960124 ENTRY DATE:

Last Updated on STN: 19960124 Entered Medline: 19951318

A5 In a study to compline the transition state analogue concept with the principle of catalytic site spanning, a series of peptide -derived transition state analogue (TSA) inhibitors of thrombin has been synthesized and tested. In the sequence H-D-Phe-Pro-Arg-Sly-OH (D) the Arg-Sly amide bond has been replaced by three classes of transition state analogues, being the ketomethylene, the hydroxyethylene and the hydroxymethylene amide bond replacements. Compound 10a, in which the amide bond has been replaced by the ketomethylene group, was found to be the most potent thrombin inhibitor of the series studied. Subsequently, penta- and hexapeptide sequences with good affinity for thrombin were developed, i.e.  $H-D-Phe-Pro-Arg-Gl\gamma-Phe-OH$  (16) and H-D-Phe-Pro-Arg-Gly-Phe-Lys-OH (26). In these sequences the Arg-Gly amide bond was then replaced by the ketomethylene group. The resulting compounds 43a and 47a, respectively, were evaluated in vitro as inhibitors of thrombin and factor Xa. Compound 47a was found to be the most potent thrombin inhibitor of the series studied (Ki = 29 nM). The combination of the transition state analogue concept and the principle of peptide elongation (tetrapeptide---hexapeptide) yields thrombin inhibitors of high potency and selectivity. The

L139 ANSWER 94 OF 100 MEDLINE DUPLICATE 10

ACCESSION NUMBER: 95369143 MEDLINE

DOCUMENT NUMBER: 95369143 PubMed ID: 7641602

Novel antithrombotic drugs in development. TITLE:

Verstraete M; Zoldhely: P AUTHOR:

CORPORATE SOURCE: Center for Molecular and Vascular Biology, University of

effects of these two alterations reinforce each other indicating a synergistic effect. This might be rationalized by entropy factors.

Leuven, Belgium.

DRUGS, (1995 Jun) 49 (6) 856-84. Ref: 229 SOURCE:

Journal code: 7600076. ISSN: 0012-6667.

New Zealand PUB. COUNTRY:

Journal; Article; (JOURNAL ARTICLE) DOCUMENT TYPE:

General Roview; (REVIEW)

/REVIEW, ACADEMIC)

LANGUAGE: English

FILE SEGMENT: Priority (Sournals)

199509 ENTRY MONTH:

Entered STN: 19950930 ENTRY DATE:

> Last Updated on STN: 19950930 Entered Mealine: 19950920

Flatelet activation plays a critical role in thromboembolic disorders, and ΑВ aspirin remains a keystone in preventive strategies. This remarkable efficacy is rather unexpected, as aspirin selectively inhibits platelet aggregation mediated through activation of the arachidonic-thromboxane pathway, but not platelet aggregation inquoed by agenosine diphosphate 'ADP:, collagen and low levels of thrombin. This apparent paradox has stimulated investigations on the effect of aspirin on eigosancidindependent effects of aspirin on cellular signalling. It has also

fostered the search for antiplatelet drugs inhibiting platelet aggregation at other levels than the abetylation of platelet byplo-oxygenase, such as thromkowane synthase inhibitors and thrombowane receptor antaginists. The final step if all platelet agonists is the functional expression of glycoprotein (GP) II:/IIIa on the platelet surface, which ligates fibrinogen to link platelets together as part of the aggregation process. Agents that interact between 3911r/IIIa and fibrinogen have been developed, which plack @PIIb/IIIa, such as monoclonal antibodies to GPIIn FIIIa, and natural and synthetic peptides disintegrins containing the Arg-Gly-Asp (AGP) recognition sequence in fibrinogen and other adhesion madromolecules. Also, some non-peptide EGD mimetres have been developed which are brally active prodrugs. Stable analogues of pristacyclin, some of which are orally active, are also available. Thrombin has a pivotal role in both platelet activation and fibrin generation. In addition to natural and recombinant human antithrombin III, direct antithrombin III-independent thrombin inhibitors have been developed as recombinant hirudin, hirulog, argatroban, borbarginine derivatives and single stranded DNA pligonupleatides (aptames). Direct thrombin inhibitors do not affect thrombin generation and may leave some 'escaping' thrombin molecules unaffected. Inhibition of factor Xa can prevent thrombin generation and disrupt the thrombin feedback loop that amplifies thrombin production.

L139 ANSWER 95 OF 100 DUPLICATE 11 MEDLINE

ACCESSION NUMBER: 97022654 MEDLINE DOCUMENT NUMBER: 97022654 PubMed ID: 8869014

DOCUMENT NUMBER: 97022654 PubMed ID: 8589014
TITLE: New developments in antiplatelet and antithrombotic

AUTHOR: Verstraete M

CORPORATE SOURCE: Center for Molecular and Vascular Research, University of

Leuven, Belgium.

EUROPEAN HEART JOURNAL, (1995 Nov) 16 Suppl L 16-23. Ref: SOURCE:

Journal code: 8006263. ISSN: 9195-668X.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

English LANGUAGE:

Priority Journals FILE SEGMENT:

ENTRY MONTH: 199701

ENTRY DATE: Entered STN: 19970138

> Last Updated on STN: 19970128 Entered Medline: 19970103

Several agents which inhibit platelet aggregation (aspirin, ticlopidine, AΒ dipyridamole), and anticpagulants (vitamin K antagonists, unfractionated heparin, low molecular weight keparins and keparinoids) are in clinical use. The search for more effective antiaggregating agents has resulted in the development of clopidogrel, a chemical analogue of tiplopidine with minimal bone-marrow suppressing effects, thromboxane synthase inhibitors and receptor klockers, and antagonists of platelet receptor glycoproteins Ib and IIb/IIIa. In addition there is increasing therapeutic experience with chimeric monoclonal antibodies against the platelet receptors, glycoprotein IIk/IIIa, and, to a minor extent, with synthetic peptides or non-peptide inhibitors against the same receptors. Although new anticoagulants

have become available, their efficacy has only been tested in animal models of thrombosis: tissue factor pathway inhibitor,

factor Xa inhibitors (recombinant tick

anticcagulant peptide, antistasin, natural pentasaccharide and DM-9085, recombinant thrombomodulin and recombinant protein C have been tested in this manner. Considerable clinical progress has been made with direct thrombin inhibitors, such as recombinant hirudin and hiruled which appear to be effective antithremmettic agents in patients.

There is also clinical experience with argatropan, an arginine derivative which is a competitive antagonist to thrombin. However, PPACK, a tripeptide synthetic compound which irreversibly blocks the active catalytic site of thrombin, has not been investigated in the clinical setting.

1139 ANSWER 96 OF 100 EURIHAIFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

RB9942 EURDEATFULL EW 195944 FS OS STA B ACCESSION NUMBER: Aprotinin analogues and process for the production TITLE:

therest.

Aprotinin-Analoge und Verfahren zu ihrer Herstellung. Analogues d'aprotinin et procede pour leur production. Norris, Ejeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK; Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm,

D(80)

NOVO-NORDISK A/s, Novo Alle, DK-2880 Bagsvaerd, DK PATENT ASSIGNEE(S):

1099510 PATENT ASSIGNEE NO:

AGENT: Brown, John David et al, FORRESTER & BOEHMERT

Widenmayerstrasse 4/I, D-3000 Muenchen 22, DE

AGENT NUMBER: 118811

ESP1989046 EP 0339942 A2 891101 OTHER SOURCE:

Wila-EPZ-1989-H44-T1 SOURCE:

DOCUMENT TYPE: Fatent

Anmeldung in Englisch; Veroeffentlichung in Englisch LANGUAGE: 

LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EFAZ EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

INVENTOR(3):

PATENT NO KIND DATE BF 339947 A2 19891102 19891102 'OFFENLEGUNGS' DATE: EF 1989-304122 APPLICATION INFO.: 19890425 PRIORITY APPLN. INFO.: DE 1988-0254 19880436

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

339942 EUROPATFULL EW 199412 FS PS STA B ACCESSION NUMBER:

TITLE: Aprotinin analogues and process for the production

thereof.

Aprotinin-Analoge und Verfahren zu ihrer Herstellung. Analogues d'aprotinin et procede pour leur production. Norris, Kjeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK; INVENTOR(3):

Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm,

10K

FATENT ASSIGNEE(S): NOVO NORDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK

PATENT ASSIGNEE NO: 2.31781

Thalspe-Madsen, Kine Birgit et al, c/o Novo Nordisk A/S AGENT:

Novo Alle, DK-2380 Bagsvaerd, DK

AGENT NUMBER: 61421

CTHER SOURCE: EPB1994021 EP 0339942 B1 940323

SOURCE: Wila-EPS 1994-H12-T1

DOCUMENT TYPE: Patent

Anmeldung in Englisch; Verbeffentlichung in Englisch LANGUAGE: RAT; RBE; RCH; RDE; RES; RFR; RGB; RGR; RIT; R DESIGNATED STATES: LI; F LU; R NL; F SE

PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

PATENT INFORMATION:

PATENT NO KIND DATE EP 339942 B1 19949323

'DFFENLEGUNGS' DATE: 19991102 APPLICATION INFO.: EP 1989-304122 19890425 PRIORITY APPLN. INFO.: DK 1988-2254 19880426 REFERENCE PAT. INFO.: EP 132732 A EP 238993 A EP 244627 A EP 307594 A

REF. NOW-PATENT-LIF.: SCIENCE, vol. 135, 13th March 1987, pages 1370-1373; C.B. MARKS et al.: "Mutants of bovine pandreatic trypsin inhibitor lacking systeines 14 and 35 can fold properly" BIOCHEMISTRY, vol. 16, no. 8, 19th April 1977, pages 1531-1541, The American Themical Society; N.H. Tan et al.: "Synthesis and characterization of a pancreatic Trypsin inhibitor nomploque and a model inhibitor"

DUFLICATE 12 L139 ANSWER 97 OF 100 MEDLINE

ACCESSION NUMBER: 94355559 MEDLINE

DOCUMENT NUMBER: 94355559 FubMed ID: 8075312
TITLE: Synthetic peptides and peptidomimetics as substrates and

inhibitors of thrombin and other proteases in the blood

coagulation system.

AUTHOR: Claeson G

CORPORATE SOURCE: Thrombosis Research Institute, London, UK.

BLOOD COAGULATION AND FIBRINGLYSIS, (1994 Jun) 5 (3) SOURCE:

411-36. Ref: 214

Journal code: 9192551. ISSN: 0357-5235.

PUB. COUNTRY: ENGLAND: United Kingdom DOCUMENT TYPE: Journal; Article; (JOURN. General Review; (REVIEW)

Journal; Article; (JOURNAL ARTICLE)

(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals Priori 199410

ENTRY MONTH:

ENTRY DATE: Entered STN: 1994:013

> Last Updated on STN: 20000303 Entered Medline: 19941006

The synthesis of peptides as imitations of the thrombin cleavage ΑE site of fibrinogen has led to sequences with affinity for the enzyme. These peptides were first developed as chromogenic and fluorogenic substrates for thrombin. The same idea was also used to generate peptide substrates for other serine professes in blood coagulation and fibrinolysis. Amidolytic methods based upon the substrates have revolutionized assays of proenzymes, enzymes, cofactors and inhibitors in research as well as in clinical laboratories. Like peptidomimetics based only on Arg (FI of the natural substrate) or Arg analogues, these amino acid sequences also have been developed as active site directed inhibitors of thrombin and of factor Xa. A further interesting development is the synthesis of bivalent thrombin inhibitors which, like hirudin, bind to the thrombin active centre as well as to its anionic exosite. Recently, also, it has been shown that the positively charged side chain of Pl Arg is not an absolute necessity for binding a peptide to the artive site of thrombin. Several of the new thrombin inhibitors show interesting properties for pharmaceutical development and some of them are on clinical trials.

L139 ANSWER 98 OF 100 WRIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1993-320447 [40] WPIDS

DOG. NO. CPI: C1993-142581

TITLE: Human factor X to human factor Xa conversion inhibition

for treating thrombosis - by contacting with reagent hinding scalid acid alpha-2 linked to galactose or galactosamine residues, or cleaving glycosylation

moieties e.g. neuraminidase.

DERWENT CLASS: E74 D16

DERWENT (CLASS: INVENTOR(S):

SINHA, U; WILF, D L GORTHN: COR THERAPEUTIES INC PATENT ASSIGNEE S:

COUNTRY COUNT: 4 ì

# PATENT INFORMATION:

PAC	TENT NO	KIND DATE	WEEK	I.A	P 3				
WO	9316763	Al 1993091	30 1199340	, * EN	34				
	RW: Al BE	E CH DE DK E3	I FR GB GR	IE IT	LU MC	NL CA	PT SE		
	W: AT AC	J BB BG BR CA	CH DE DK	ES FI	GB HT	JP KP	KR LK	LU MG M	MW NL
	ND NZ	Z PL PT ŘO RU	SD SE US	VN:					
AU	9239.71	A 1993101	1 -139407	)					
ΞP	831E01	Al 199501.	4 :199506	) EN					
	h: AT BE	E CH DE DK E:	FE GB GE	IE IT	LI L'I	MC NL	PT SE		
JΡ	J75077696	W 1995083	(199543	)	3				
ΕP	531501	A4 1995121	7 (199627)	)					
ΙL	105064	A 1997041	5 (199726	)					
ΑU	∂∂1074	B 199708:	1 (199742	)					
ΑU	4745304	A 1998021	.2 (199814	)					
US	5798332	A 1998080	(199841)	)					
ΑU	717123	B 2000031	6 (200024	)					
EΡ	631501	B1 2000083	30 (200042	) EN					
	F: AT BE	E CH DE DK ES	FR GB GR	IE IT	LI LU	MC NL	PT SE		
US	6117836	A 2000097	2 (200046	)					
DE	n9329333	E 7000100	5 (200057	)					

## APPLICATION DETAILS:

PATENT NO	KIND	AFPLICATION	DATE
WO 9318732 AU 9339177 EP 631501	Al A Al	WO 1993-US:203 AU 1993-39177 EP 1993-308307	19930311 19930311
JP 07507769	W	WO 1993-USC203 JP 1993-516612 WO 1993-USC203	19930311 19930311 19930311
EP 631501 IL 105064	A4 A	EP 1993-908307 IL 1993-105064	
AU 981074 AU 9745309	B A Div ex	AU 1993-39177 AU 1993-39177 AU 1997-45309	19930311
US 1798332	A Cont of	US 1992-854109 US 1994-300026	19920320 19940906
AU 717123	B Div ex	AU 1993-39177 AU 1997-45309	
EP 631501	B1	EP 1993-908307 Wo 1993-USCC03	19930311 19930311
US 6117836	A Cont of	US 1992-854109 WO 1993-US2203	19920320 19930311
DE 09329333	Div ex E	US 1994-302226 US 1994-307609 DE 1993-624333 EF 1993-305307 WO 1993-US2203	19940906 19941202 19930311 19930311 19930311

# FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU +339.77	A Hased or.	₩0 9318732
-EP-4315(1 -JP-17501769	Al Based on W. Based on	WC 9318733 Wr 9319782
AU + 81974	B Frevious Publ.	
AU 017123	Rased on	WD 9313792 Au 681074
Ad 1/123	B Div ex Previous Publ.	
EP +31501	Bl Based on	WD 9314792
US →117836	A Div ex	US 5798332

Based on W0 9319782 DE 69329333 E Based on EF 631531 Based on W0 9319782

PRIORITY APPLN. INFO: US 1992-854109 19920320; US 1994-302226 19940906; US 1994-307609 19941202

AN 1993-320447 [41] WPIDS

AB W0 9318782 A UPAB: 19931129

The inhibition comprises contacting human Factor X with a reagent capable of specifically binding sialic acid residues that are alpha2-6 linked to galactose or galactosamine residues (SA/Gal/GalNAc binding reagent) in an amt. and for a time sufficient to complex to Factor X.

The SA/Gal/GalNAs kinding reagent may be pref. a lectin, e.g. Sambucus nigra agglutinin (SNA), an antibody or a peptide derived from Faster IXa/VIIIa or tissue fastor/Factor VIIa.

Fref. a complex comprises a SA/Gal/GalNAc binding reagent and human Factor  $X_{\star}$ 

Pref. preventing or treating (i) thrombosis, (ii) inflammation, (iii) restenses or (iv) complications of transplantation in a human subject comprises administering a SA/Gal/GalNAc binding reagent.

Eref. inhibition comprises contacting human Factor X with (i) a glycosylation moleties cleavable reagent from the Factor X, or (ii) a reagent capable of binding to the glycosylation moleties of the activation peptide of Factor X, or (iii) soluble

analogue(s) of SA/Gal/GalNac, and the contact is under conditions which may normally, in the absence of the soluble analogue, effect the conversion of Factor X to Factor Xa.

Pref. inhibition in a living organism comprises administering as inhibitor of glycosylation.

USE - The inhibition may be used for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin e.g. restenosis and inflammation. They may also be used for inhibition of Factor X activation in cardiopulmonary by-pass, in harvesting organs, in prepn. of blood prods, or samples, in transport and implantation of organs and in treatment of adult respiratory distress syndrome. The reagents may also be used for producing antibodies which may be used to monitor therapy. Dwg.0/1

L139 ANSWER 99 OF 100 MEDLINE

ACCESSION NUMBER: 90036406 MEDLINE

DOCUMENT NUMBER: 90036406 PubMed ID: 8509406

TITLE: The inhibition of the enzymic activity of blood coagulation

and fibrinolytic serine proteases by a new leupeptin-like inhibitor, and its structural analogues, isolated from

DUPLICATE 13

Streptomyces griseus.

AUTHOR: Chi C W; Liu H Z; Liu C Y; Chibber B A; Castellino F J

CORFORATE SOURCE: Department of Chemistry and Biochemistry, University of

Notre Dame, Indiana 46556.

CONTRACT NUMBER: HL-13423 (NHLBI)

HL-19982 (NHLBI)

Jaurnal code: 0151115. ISSN: 0021-3320.

PUB. COUNTRY: Japan

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198912

ENTRY DATE: Entered STN: 19900323

Last Updated on STM: 21000303 Entered Medline: 19891201

AB A group of leupeptin analogues was found in Streptomyces griseus strain 254, isolated from a soil sample from Fujian Province, China. The inhibitors excreted in the culture filtrate were purified by adsorption on macroporous resin, followed by sequential ion exchange

chromatography on DEAE-52 bellulose, CM-32 bellulose and affinity chromatography with immobilized trypsin. The preparation thus obtained was further purified by preparative HPLC. Several major components were found and characterized, which possessed different innibitory properties toward trypsin. Based upon amino abid and mass spectrophotometric analysis, these peptides were placed in four major structural categories, viz., R-Val-Val-argininal, R-Leu-Leu-argininal, R-Ile-Ile-argininal and F-Inr-Thr-argininal, this latter component representing a newly identified leupeptin analogue. The structural variability of the R-group was partly responsible for the multiplicity of the peaks obtained with HPLD. All peptides displayed varying degrees of innibitory activity toward proteases involved in blood coaquiation and fibrinolysis, including plasmin, factor Xa, activated protein C and thrombin. Among these peptide inhibitors, the molecule containing threonine showed the strongest inhibitory activity.

L139 ANSWER 100 OF 100 BABS COPYRIGHT 2002 BEILSTEIN CDS MDLI

ACCESSION NUMBER: 6056113 BABS

TITLE:

Feptide Argininal "Inverse Substrates" of Anisic Acid:

Novel Inhibitors of the Trypsin-like Serine

Proteinases

AUTHOF(S):

Lynas, John F.; Walker, Brian

SOURCE:

Bisorg.Med.Chem.Lett. (1997), 7(9), 1133-1138

CODEN: BMCLE8

DOCUMENT TYPE:

Journal English

LANGUAGE: SUMMARY LANGUAGE:

English

6056113 BABS AN

Peptides containing a C-terminal argininol residue linked, via AB an ester bond, to anisic acid have been synthesized as putative inhibitors of trypsin-like serine proteinases. The most potent analogue, Boc-Ile-Glu-Gly-Arg-\$Q-(CH2-0)-CO-C6H4OMe, that was modelled on a lnown recognition sequence for the clotting enzyme factor Xa, was found to inactivate the protease with a second-order rate constant of ca. 4.5x10-5% M--1%.min--1%.

= $\cdot$ >